# Predictive role of vital parameters for the outcomes of systemic inflammation and the role of TRP channels in pharmacological modulation of body temperature

Doctoral (PhD) thesis

**Zoltán Rumbus, MD**

Department of Thermophysiology, Institute for Translational Medicine

Medical School, University of Pécs, Pécs, Hungary

Doctoral School Leader: Erika Pintér MD, PhD, DSc

Program Leader: Péter Hegyi MD, PhD, DSc

Supervisor: András Garami MD, PhD



Doctoral Council and Habilitation Committee of Medical and Pharmaceutical Sciences of the University of Pécs

**PÉCS, 2024**

# Table of contents

# List of abbreviations

A1 ankyrin-1

AP acute pancreatitis

APACHE acute physiology and chronic health evaluation

CI confidence interval

ES estimated logit mortality rate

i.p. intraperitoneal(ly)

i.v. intravenous(ly)

KO knockout

LOS length of hospital stay

MA metabolic acidosis

$NH_4Cl$ ammonium chloride

s.c. subcutaneous

SDM(s) standardized difference(s) in means

SE standard error

SIRS systemic inflammatory response syndrome

$T_b$ body temperature

TRP transient receptor potential

V1 vanilloid-1

WT wild type

# I. Introduction

## I/1. Impact of body temperature and blood pH on outcomes of systemic inflammation

I/1.1. Sepsis and acute pancreatitis: two distinct manifestations of systemic inflammation

Systemic inflammation is a complex, generalized pathophysiological process, which can be clinically manifested in numerous forms, including systemic inflammatory response syndrome, sepsis, severe sepsis, septic shock, and multiple-organ dysfunction and failure (Bone, et al., 1992). This response describes an inflammatory process independent of its cause, and can result from infections, as well as from noninfectious causes (e.g., trauma, burns, acute pancreatitis).

When the underlying origin of the systemic inflammatory response is infection, it is termed sepsis. The definition and clinical criteria of sepsis has changed over the past three decades (Bone, et al., 1992; Levy, et al., 2003; Singer, et al., 2016), and based on the latest consensus (Singer, et al., 2016), it is defined as evidence of infection plus life-threatening organ dysfunction. Sepsis constitutes a global burden for medical care with an estimated 31 million cases per year worldwide (Fleischmann, et al., 2016). The incidence of sepsis has remained considerable (Esteban, et al., 2007; Vincent, et al., 2014; Walkey, Lagu, & Lindenauer, 2015) and it is associated even nowadays with high mortality rates (Vincent, et al., 2014). Moreover, it also increases the risk of mortality for 5–8 years after the septic event (Cuthbertson, et al., 2013).

Acute pancreatitis (AP) is initially a sterile inflammation of the pancreas most commonly triggered by noninfectious causes such as bile stones or excessive use of alcohol. The incidence of AP increases worldwide, and it is one of the most common gastrointestinal causes for hospitalization with significant morbidity and mortality in the US (Lee & Papachristou, 2019). Although the mortality rate in mild and moderate AP is low, this value is still unacceptably high (30%) in its severe form (Parniczky, et al., 2016).

I/1.2. Association between body temperature and mortality in sepsis

Sepsis is often associated with changes of deep body temperature ($T_b$), which can be manifested as fever or hypothermia in experimental animals (Romanovsky, et al., 2005; Romanovsky & Szekely, 1998; Saper, Romanovsky, & Scammell, 2012), as well as in human patients (Cunha, 2012; Kushimoto, et al., 2014; Romanovsky & Szekely, 1998). Due to its frequent occurrence in systemic inflammation, deep $T_b$ is regularly measured as one of the vital signs in the clinical praxis. In fact, many diagnostic and prognostic scoring systems of sepsis e.g., acute physiology and chronic health evaluation II (APACHE II), systemic inflammatory response syndrome (SIRS), include an abnormal deviation of $T_b$ from the normal range (Bone, et al., 1992; Knaus, Draper, Wagner, & Zimmerman, 1985; Le Gall, Lemeshow, & Saulnier, 1993; Opal, 2005; Singer, et al., 2016). Usually $T_b$s below 36.0°C or above 38.0°C are considered equally pathological (Beverly, Walter, & Carraretto, 2016), which values are in accordance with the criteria of the systemic inflammatory response syndrome (Proud, 1953; Singer, et al., 2016). Based on experimental data from animal

studies, Romanovksy and colleagues (Romanovsky, et al., 2005; Romanovsky & Szekely, 1998) proposed that hypothermia and fever can both develop as two distinct adaptive mechanisms in sickness syndrome. The latter characteristically occurs at the beginning of an infection, representing an active fight against the pathogen, while the former is usually associated with progressed stage or severity of the disease and it aims to secure the vital systems of the host (Romanovsky, et al., 2005; Romanovsky & Szekely, 1998). The two adaptive strategies can develop sequentially (e.g., early phase fever followed by late phase hypothermia) as the severity of the disease progresses (Romanovsky & Szekely, 1998), but hypothermia can be also one of the initial developing events in animal models of endotoxin shock (Fonseca, et al., 2016), moreover, septic patients admitted to intensive care unit develop hypothermia more frequently in the early than in the late stages of their stay (Fonseca, et al., 2016). Despite the distinct pathological background of fever and hypothermia in systemic inflammation, both the increase and the decrease of $T_b$ are evaluated commonly as equally severe signs in the clinical praxis (Beverly, et al., 2016). This can be, at least in part, due to the standpoint that fever and hypothermia both represent an adaptive (though different) biological response to infection (Romanovsky & Szekely, 1998). Accordingly, beneficial effects have been shown for elevated $T_b$ on the clinical outcome of sepsis in clinical trials (Bryant, Hood, Hood, & Koenig, 1971; Megged, Yinnon, Raveh, Rudensky, & Schlesinger, 2006), although no association between fever and disease severity was also reported (Kushimoto, et al., 2013). Therapeutic (i.e., induced) hypothermia has also been shown to improve the outcome of sepsis in human studies (Blair, Henning, Hornick, & Cowley, 1964; Villar & Slutsky, 1993), but in case of spontaneously occurring

hypothermia usually a positive association with mortality rate was found (Clemmer, et al., 1992; Drewry, Fuller, Skrupky, & Hotchkiss, 2015; Kushimoto, et al., 2013). The definite association of $T_b$ and mortality rate in a large study population has remained unknown.

I/1.3. Blood pH and the outcomes of acute pancreatitis

The inflammatory response is accompanied by changes in vital parameters, including $T_b$, heart rate, and respiratory rate. The changes in blood pH are also common in systemic inflammation (White, et al., 2018). Changes in acid-base balance significantly alter the release of inflammatory mediators which can affect the outcome of systemic inflammation. The bicarbonate production is one of the most important functions of the pancreas, which is required to maintain its constant "milieu intérieur," thereby to prevent premature activation of pancreatic proteases (Hegyi & Petersen, 2013; Pallagi, Hegyi, & Rakonczay, 2015; Pallagi, et al., 2011). When pancreatic bicarbonate production is challenged by local or systemic acid load (i.e., metabolic acidosis, MA), the resulting lower pH can facilitate pancreatic enzyme activation and deteriorate cell damage (Reed, et al., 2011). Furthermore, animal experiments in rats showed that injection of acidic contrast solution either into the pancreatic duct or into the vein significantly increased the severity of acute AP (Bhoomagoud, et al., 2009; Noble, Romac, Vigna, & Liddle, 2008). Beside an external acid load, the pancreatic pH balance can be also compromised by tissue injury such as AP, which can lead to acidification of local tissues, thus deteriorate cell damage (Behrendorff, Floetenmeyer, Schwiening, & Thorn, 2010). The luminal pH of the main pancreatic duct

was also lower in human patients with AP compared to controls (Takacs, Rosztoczy, Maleth, Rakonczay, & Hegyi, 2013), suggesting that the development of AP is accompanied by a decrease of local pH. Multiple mechanisms have been implicated in AP which can lead to MA, including direct mechanisms such as the loss of bicarbonate-rich pancreatic juice via pancreatic fistula or drainage (Rice, Ismail, & Pillow, 2014), as well as indirect ones through lactic acidosis which can sequentially occur in AP due to shock, sepsis, cardiovascular failure, or upper gastrointestinal bleeding (Zhan, Guo, Yang, Li, & Li, 2015). However, the interaction between AP and systemic pH is still not fully clarified.

Acidosis is often considered as a marker of disease severity, viz., a by-product of systemic dysregulation, and as such it is a proven prognostic factor in the assessment of critically ill patients (Vincent & Moreno, 2010). Despite the fact that scoring systems, which are used to help the diagnosis and the assessment of the progression of AP, include the changes in systemic pH balance of the patients (e.g., APACHE II and Ranson scores), clinical trials aiming to reveal a correlation between the acid-base status and the outcome of AP are scarce. To our knowledge, the sole published human study, which aimed to directly answer this question showed that changes in the parameters of systemic acid-base status can predict mortality in AP (Sharma, et al., 2014). On the contrary, the necessity of arterial blood gas sampling was questioned in patients with AP in another human study (Ward, Gilbert, Mulchandani, & Garrett, 2008). With regards to the results obtained in experimental animals, a detailed analysis of the correlation between systemic pH and the outcome of AP would be of utmost importance, because it could establish blood pH as a predictor of the severity and the outcome of the disease and, arguably, identify acidosis as a therapeutic target in AP.

## I/2. Transient receptor potential (TRP) channels in pharmacological modulation of body temperature

### I/2.1. The thermal effects of TRP vanilloid-1 (V1) antagonists

TRP channels are multimodal ion channels that act as sensors of chemically toxic and physical stimuli (Chen, Mu, Zhu, Mukherjee, & Zhang, 2020). Total of 28 different TRP channel proteins are known in mammals, which can be divided into seven subfamilies based on amino acid sequence homology: TRPA (Ankyrin), TRPC (Canonical), TRPM (Melastatin), TRPML (Mucolipin), TRPN (NO-mechano-potential, NOMP), TRPP (Polycystin), TRPV (Vanilloid). The TRPV1 channels are expressed throughout the thermal shell and core including neural and non-neural tissues (Caterina, et al., 1997; Miller, Jones, Chauhan, & Anderson, 1990; Schicho, Florian, Liebmann, Holzer, & Lippe, 2004; Starowicz, Cristino, & Di Marzo, 2008; Szallasi, et al., 1995; Tominaga, et al., 1998), and their thermoregulatory role was proposed long years (Jancso-Gabor, Szolcsanyi, & Jancso, 1970). In the 1990s, number of pharmaceutical companies have started developing TRPV1 antagonists (Holzer, 2008; Y. Lee, et al., 2015). During the in-vivo testing of TRPV1 antagonists, an unexpected adverse effect on $T_b$, hyperthermia, were repeatedly observed in animal studies and human clinical trials alike. Usually, when studying the TRPV1-antagonizing property of compounds, pharmaceutical companies use capsaicin, low extracellular pH, and heat (> 42°C) stimuli to activate this channel. It is now known that TRPV1 antagonists can affect these three modes differentially (for review, see Blumberg, Pearce, & Lee, 2011; Romanovsky, et al., 2009). Upon systemic administration many

TRPV1 antagonists cause hyperthermia in a variety of laboratory animal species (Garami, et al., 2020). However, not all TRPV1 antagonists are equal as far as their ability to cause hyperthermia (Watabiki, et al., 2011). Some TRPV1 antagonists have been shown to be hyperthermic in several mammalian species, whereas others cause hyperthermia only in particular species. Intriguingly, some TRPV1 antagonists (e.g., A-1165901, A-425619, AMG7905, and AMG8562) cause hypothermia instead of hyperthermia (Garami, Pakai, et al., 2018; Lehto, et al., 2008; Mills, et al., 2008). And yet other compounds appear to affect $T_b$ regulation in a species-specific fashion.


I/2.2. Ammonium chloride-induced hypothermia


Ammonium chloride ($NH_4Cl$) is a systemic and urinary acidifying agent that can be used in the treatment of metabolic alkalosis (Doxiadis, Goldfinch, & Holt, 1953; Martin & Matzke, 1982; Sellers & Kast, 1945). As an expectorant, it is also a common ingredient of many cough mixtures, which explains why the excessive consumption of such over-the-counter medications can lead to MA (MacRury, Neilson, & Goodwin, 1987; Wong, et al., 2001) that was also observed in subjects receiving $NH_4Cl$ in other types of medicines (Relman, Shelburne, & Talman, 1961; Sleisenger & Freedberg, 1951; Wood, 1955). Extending its application areas, more recently, the use of $NH_4Cl$ was implicated in COVID-19 (Baker, Williams, Tropsha, & Ekins, 2020; Siami, et al., 2021).

The oral and/or parenteral administration of $NH_4Cl$ is often used to induce systemic (extracellular) acidosis in animal models (Celotto, et al., 2016; Galicek, Seow, & Lingard,

1981; Nowik, Kampik, Mihailova, Eladari, & Wagner, 2010; Rothe & Schimek, 1984; Rumbus, et al., 2018) and in human experiments (Edge, et al., 2015; Kleger, et al., 2001; Reaich, Channon, Scrimgeour, & Goodship, 1992; Tizianello, De Ferrari, Gurreri, & Acquarone, 1977). Although interspecies differences, for example, between rats and mice, were demonstrated in the response to the same $NH_4Cl$-loading protocol (Nowik, et al., 2010; Stauber, et al., 2005), $NH_4Cl$ administration has been widely used to study the effect of MA associated with different conditions, such as physical exercise (Bento, Fagian, Vercesi, & Gontijo, 2007; Edge, et al., 2015; Jara, Felsenfeld, Bover, & Kleeman, 2000; Lane & Adams, 1993) and iron metabolism (Coe, et al., 1975; Daher, et al., 2022).

In 1988, Gordon showed that the systemic administration of $NH_4Cl$ leads to hypothermia in mice (Gordon, 1988). This finding can explain why its overconsumption was also associated with hypothermia in case of a human patient (MacRury, et al., 1987). However, the molecular mediators of the $NH_4Cl$-induced hypothermia have remained largely unknown. Our literature search did not reveal any studies that aimed to clarify the underlying mechanisms of this thermoregulatory phenomenon.

TRPV1 and TRPA1 channels are temperature-sensitive members of the TRP channel family, for the reason that in vitro they can be activated by noxious heat and cold, respectively (Romanovsky, et al., 2009; H. Wang & Siemens, 2015). In addition to thermal signals, they can be both activated by ligand agonists and by changes in pH, hence they function as polymodal receptors (Bamps, Vriens, de Hoon, & Voets, 2021; Holzer, 2011), especially on primary afferent neurons where they are often co-expressed (Huang, Li, Dhaka, Story, & Cao, 2012; Kobayashi, et al., 2005). Their thermosensor function has been well

established in pain sensation (Bamps, et al., 2021; Julius, 2013; Kashio & Tominaga, 2022), however, neither of them was found to serve as a thermosensor for the thermoregulation system in rodents (de Oliveira, et al., 2014; Steiner, et al., 2007). It was proposed that their activation by agonists other than temperature (by protons for TRPV1 and by sulfides for TRPA1) contributes to the regulation of deep $T_b$ (Garami, Pakai, et al., 2018; Olah, et al., 2021). Interestingly, both channels can be activated by $NH_4Cl$ (Dhaka, et al., 2009; Fujita, et al., 2008) and also by low pH (de la Roche, et al., 2013; Jordt, Tominaga, & Julius, 2000; Tominaga, et al., 1998; Wang, Chang, Allgood, Silver, & Liman, 2011). However, to our best knowledge, the contribution of the TRPV1 or TRPA1 channel to the thermal response to $NH_4Cl$ has not been investigated yet.

In the present work, we studied whether $NH_4Cl$ induces hypothermia also in rats in addition to mice to exclude the possibility of a mouse-specific effect, and whether the blockade of TRPV1 and TRPA1 channels influences the $NH_4Cl$-induced hypothermia by using genetic deletion of the channels. To avoid chronic compensatory mechanisms, which may develop for the function of a knocked out gene, we also used pharmacological inhibition of TRPV1 and TRPA1 in genetically unaltered animals.

## II. Aims

The goal of the current work is to investigate the predictive role of vital parameters for the outcomes of systemic inflammation in human patients as well as to identify a potential pharmacological target for the modulation of $T_b$ in animal experiments and human patients. The following main topics will be discussed in this thesis:

1. We studied the role of changes in $T_b$ and blood pH as vital signs in the prediction of outcomes in two different manifestations of systemic inflammation (in sepsis and in AP) with meta-analysis. Regarding fever, different clinical trials came to controversial results in sepsis, while clinical trials aiming to reveal a correlation between the acid-base status and the outcomes of AP are scarce. We hypothesized that the increase and the decrease of $T_b$ or blood pH from the normal range predicts the clinical outcomes in systemic inflammation differently.

2. Based on animal studies, nonthermal activation by protons is involved in thermoregulatory responses to TRPV1 antagonists. Therefore, we also aimed to examine the thermal effect of TRPV1 antagonists in humans using meta-analysis of clinical trials.

3. Previously, it has been shown that $NH_4Cl$ causes hypothermia in mice. In order to exclude the possibility that the $NH_4Cl$-induced hypothermic response is specific only to mice, we aimed to detect $NH_4Cl$-induced hypothermia in rats as well. Although TRPV1 and TRPA1 channels can be activated by $NH_4Cl$, the contribution of these channels in the thermal response to $NH_4Cl$ has not been investigated yet. Thus, we

studied the role of TRPV1 and TRPA1 channels in $NH_4Cl$-induced hypothermia using genetic deletion and pharmacological blockade of either channel in rodents.

# III. Materials and Methods

## III/1. Predictive role of body temperature and blood pH for the outcomes of systemic inflammation in humans

III/1.1. Body temperature and mortality in sepsis

### III/1.1.1. Search strategy

A search of the PubMed, EMBASE, and Cochrane Controlled Trials Registry databases was performed with using the following Medical Subject Headings and search terms (from inception to February 2016): sepsis OR bacteremia OR "septic syndrome" AND ("body temperature" OR fever OR hypothermia OR normothermia OR hyperthermia) AND (mortality OR survival). We restricted our search to original human studies published in English without time period limitations. Publications reporting immunosuppressive conditions (e.g., cancer, transplantation, HIV infection) were not included in the analysis. As a specific example, in the EMBASE database, which identified the highest number of articles, the term "sepsis OR bacteremia OR "septic syndrome" AND ("body temperature" OR fever OR hypothermia OR normothermia OR hyperthermia) AND (mortality OR survival) NOT (cancer OR immunosuppressive OR aids OR hiv OR transplantation)" was entered, and then the following filters were selected: humans, English, article, article in press, conference abstract, conference paper, major clinical study, case control study, clinical trial, cohort analysis, comparative study, controlled clinical trial, controlled study, cross-sectional study, double blind procedure, medical record review, multicenter study,

observational study, outcomes research, phase 3 clinical trial, prospective study, randomized controlled trial, retrospective study. Our meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (Shamseer, et al., 2015). The analysis was based on the Participants, Intervention (prognostic factor), Comparison, Outcome model: in septic population, we aimed to assess the predictive role of $T_b$ deviations on the mortality ratio. No review protocol has been registered for the current meta-analysis.

### III/1.1.2. Study selection and data extraction

The titles and abstracts of the publications from the literature search were screened and the full text of potentially eligible articles was obtained. We included studies in which both the $T_b$ values and the mortality ratios were reported for the same group(s) of patients with systemic inflammation accompanied by suspected or confirmed blood infection. From all included articles we extracted the sample size, the reported mean $T_b$ value of the patients with its standard error (SE), and the mortality ratio within the group during 28–30 days in most cases. To analyze the influence of fever, normothermia, and hypothermia on the mortality ratio in sepsis we separated the collected data into three study groups based on the mean $T_b$ of the patients.

*III/1.1.3. Statistical analysis*

We have used event rates (mortality rates) as effect size data. Studies were grouped by $T_b$ as low (up to 36.0°C; n = 890), medium (36.1 to 38.0°C; n = 3,904) and high (above 38.0°C; n = 6,040) and forest plots in the three groups were used to describe mortality. Selection of the $T_b$ groups was based on the SIRS criteria (Bone, et al., 1992; Singer, et al., 2016). Another grouping was conducted by mortalities, these were split into quartiles and the means of $T_b$s were compared by investigating the presence or absence of overlaps in the 95% confidence intervals (CI), just like in case of the grouping by $T_b$.

Between-study heterogeneity was tested with Q homogeneity test (P values of less than 0.05 were considered as indicators of significant heterogeneity) and with $I^2$ statistical test, where $I^2$ is the proportion of total variation attributable to between-study variability (an $I^2$ value of more than 50 was considered as indicating considerable heterogeneity). These two values were used to model selection purposes as well (fixed vs random). The tests revealed considerable heterogeneity in the overall study population (Q = 809.509; $I^2$ = 89.25) and also in all three $T_b$ groups, in particular Q = 270.447; $I^2$ = 85.58 in the high, Q = 373.357; $I^2$ = 90.63 in the medium, and Q = 36.843; $I^2$ = 70.14 in the low $T_b$ group. Consequently, we applied the random effect model in our forest plot and meta-regression analyses.

Publication bias was tested by inspecting the funnel plot. Meta-regression was performed to assess the overall effect of $T_b$ to mortality. Except for the Pearson correlation analysis for which Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) was used, all analyses were performed with the Comprehensive Meta-Analysis software (Biostat, Inc., Engelwood, MJ, USA).

III/1.2. Blood pH and outcomes of acute pancreatitis

*III/1.2.1. Search strategy*

Our meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (Moher, Liberati, Tetzlaff, Altman, & Group, 2009; Olah, et al., 2018). The analysis was based on the Patients, Intervention (or indicator), Comparison, Outcome model: in patients with AP, we aimed to assess the predictive role of the change in pH status (as assessed by blood pH, bicarbonate concentration, base excess, or base deficit) on disease severity (indicated by clinical scores), length of hospital stay (LOS), and mortality ratio. This meta-analysis has been registered with PROSPERO (CRD42017055396). A search in the PubMed, EMBASE, and Cochrane Controlled Trials Registry databases was performed from inception to January 2017 using the following terms: "pancreatitis AND (mortality OR survival OR severity) AND ("arterial pH" OR "blood pH" OR "systemic pH" OR "base deficit" OR "base excess" OR bicarbonate OR HCO3- OR "anion gap" OR acidosis OR alkalosis OR acid-base)." We restricted our search to original human studies published in English without time period limitations. A manual search of the reference lists of relevant full-text articles was conducted to identify further potentially eligible articles.

*III/1.2.2. Study selection and data extraction*

The titles and abstracts of the publications from the literature search were screened and the full text of potentially eligible articles was obtained. We included studies in which blood pH or a related parameter (e.g., base excess, base deficit, or bicarbonate) and severity scores or LOS or mortality ratios were reported for the same group(s) of patients with AP. From all included articles we extracted the sample size, the reported mean pH or its related parameter for the studied patient groups with the corresponding SE or deviation, as well as the severity score, LOS, and mortality ratio within the group. To analyze the influence of the change in acid-base status on the severity and the outcome of AP, in each study we assigned the patient groups as a lower pH group and as a higher pH group, irrespective from the original basis for grouping used by the authors of the study. We used mortality ratio of the AP patients groups as the primary outcome. Regarding secondary outcomes, we used two commonly applied severity indices (i.e., APACHE II and Ranson scores) and the LOS. The APACHE II score estimates intensive care unit mortality based on laboratory values and vital signs, while Ranson score estimates mortality of patients with pancreatitis, based on initial and 48-hour lab values.

*III/1.2.3. Statistical analysis*

We used logit transformation of event rates for mortality ratios and standardized mean difference (SMD) for LOS and severity scores as the effect size data. The secondary

outcomes were compared between the lower and higher pH groups (see above) within each study, and then the estimated pooled mean values were calculated. The relevant studies were compared with standard meta-analysis tools (e.g., forest plot) in case of each outcome.

Between-study heterogeneity was assessed by $I^2$ statistical test, where $I^2$ is the proportion of total variation attributable to between-study variability (an $I^2$ value of more than 50 was considered as indication of considerable statistical heterogeneity). The selection of patients, study design, and the used methods showed variability among the studies included in our analyses, which also resulted in statistical heterogeneity. Since the lack of statistical significant results on these heterogeneity tests could be also due to the lack of power because of the small number of studies eligible for the analyses, we used the random effect model in case of each forest plot, similarly to our earlier meta-analysis (Rumbus, et al., 2017). Publication bias was assessed by funnel-plot analysis, Egger's test and Duval and Tweedie trim and fill method. Publication bias plots were used to assess whether studies with small sizes could have been missed in our analyses, however, due to the design of these tests they do not allow to firmly rule out the possibility that some papers missed the inclusion criteria of our search.

As a different statistical approach to reveal a correlation between systemic pH and mortality in moderate and severe forms of AP, we performed meta-regression analysis of those studies in which both blood pH and mortality rate were reported within the same patient group. The meta-analyses were performed with Comprehensive Meta-Analysis (version 3.3; Biostat, Inc., Engelwood, MJ, USA) and Stata (version 11.1; StataCorp, College Station, TX, USA) software.

**III/2. The role of TRP channels in pharmacological modulation of body temperature**

III/2.1. Relationship between body temperature and pH: TRPV1 antagonists induced thermal changes

*III/2.1.1. Search strategy*

We used standard meta-analysis tools, in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (Moher, et al., 2009). This analysis was registered with PROSPERO (CRD 42018095220).

*III/2.1.2. Study selection and data extraction*

We included the studies that reported deep $T_b$ values in both TRPV1 antagonist-treated and placebo groups at least at two time points: (i) at shortly before the drug (or placebo) administration and (ii) at 3 h after the time of administration. Studies for which all the necessary information could not be obtained were excluded from the analysis. In certain cases, we had to make limited assumptions or simplifications, as explained in (Garami, et al., 2020). For each included study, we calculated the change in deep $T_b$ as a difference between the $T_b$ values at 3 h after the drug (placebo) administration vs. at the time of administration (0 h). We then calculated the difference between the $T_b$ changes induced by

a drug and those induced by placebo (difference in means); we considered the latter difference to represent the thermal effect of the drug in our meta-analysis.

### *III/2.1.3. Statistical analysis*

For all doses, the differences in means were standardized (based on variances) to obtain standardized differences in means (SDMs). The SDMs with 95% confidence intervals (CIs) were used as primary measures of effect size and are presented as a "forest plot". We considered each TRPV1 antagonist to be either mode-nonselective (ABT-102, AZD1386, and V116517) or mode-selective (NEO6860). To characterize the nonselective group, SDMs for the corresponding antagonists were weighted based on sample size and inversed variance.

## III/2.2. The roles of TRPV1 and TRPA1 in $NH_4Cl$-induced hypothermia in rodents

### *III/2.2.1. Animals*

Experiments were conducted in adult male rats and mice under protocols approved by the Institutional Animal Use and Care Committee of the University of Pecs (registration no.: BA02/2000-13/2021) and in accordance with the directives of the National Ethical Council for Animal Research and those of the European Communities Council (86/609/EEC). One hundred and ten Wistar rats and thirty-seven C57BL/6 mice were obtained from the Laboratory Animal Centre of the University of Pecs. In addition, mice

with ($^{-/-}$ aka knockout, KO) or without ($^{+/+}$ aka WT) a homozygous targeted mutation in the *Trpv1* gene (KO: n = 21; WT: n = 14) or in the *Trpa1* gene (KO: n = 24; WT: n = 16) were also obtained from the Laboratory Animal Centre of the University of Pecs, where they were bred and kept as described in details elsewhere (Bolcskei, et al., 2005; de Oliveira, et al., 2014). Mice from these strains were also used in previous studies aiming to investigate the thermoregulatory function of TRPA1 (de Oliveira, et al., 2014; Olah, et al., 2021) and TRPV1 (Garami, et al., 2017; Garami, Pakai, et al., 2018). The animals were housed in polycarbonate cages kept in temperature-controlled rooms on a 12 h light/dark cycle (lights on at 5:00 A.M.). The ambient temperature was maintained at 24-25°C and humidity at 30–40%. Standard rodent chow and tap water were available ad libitum. Animals were extensively habituated to the experimental setup, as described elsewhere (Garami, et al., 2011; Romanovsky, Ivanov, & Shimansky, 2002). At the time of the experiments, the mice and rats weighed 25 ± 1 and 328 ± 3 g, respectively.

### *III/2.2.2. Surgeries*

Animals were anesthetized with intraperitoneal (i.p.) administration of a ketamine–xylazine cocktail (81.7 and 9.3 mg/kg for mice, 55.6 and 5.5 mg/kg for rats, respectively), and they received antibiotic protection intramuscularly (gentamicin, 6 mg/kg). To prevent intra- and postoperative hypothermia, during the surgery mice were kept on a heating pad (PECO Services Ltd., Brough, United Kingdom), and then they were allowed to recover from anesthesia in a temperature-controlled chamber (model MIDI F230S; PL Maschine

Ltd., Tarnok, Hungary) set to 31°C. Each rat and mouse was implanted with an i.p. catheter, additionally rats assigned to experiments with pharmacological antagonists were also implanted with an intravenous (i.v.) catheter during the same surgery. The i.p. and i.v. catheter implantations have been widely used in thermoregulation experiments, and the animals tolerated these interventions well (Garami, et al., 2017; Garami, Pakai, et al., 2018; Keringer, et al., 2022; Olah, et al., 2021). These preimplanted catheters were used for the non-stressful administration of substances to conscious animals in our experiments. In case of a bolus injection (i.p. or i.v.), the handling of the animal and the puncture of the abdominal wall with the needle would have resulted in pain and stress-induced hyperthermia (for review, see Romanovsky, et al., 2005), which could interfere with our results. All experiments were performed 3-5 days after the surgery.

For the non-stressful i.p. administration of the substances during the experiment, a polyethylene (PE)-50 catheter filled with pyrogen-free saline was implanted into the peritoneal cavity of each mouse and rat, similarly as in previous studies (Garami, et al., 2017; Garami, Pakai, et al., 2018). In brief, through a small midline incision on the abdomen, the internal end of the catheter was fixed to the left side of the abdominal wall with a suture, while the external end of the catheter was tunneled under the skin to the nape, where it was exteriorized and heat-sealed. The surgical wound was sutured in layers. The catheter was flushed with 0.1 ml of saline on the day after the surgery and every other day thereafter.

I.v. catheter implantation was performed in rats assigned to treatment with a TRPV1 or a TRPA1 antagonist. As described before (Garami, et al., 2017), the i.v. catheter was implanted during the same surgery as the i.p. catheter. A small longitudinal incision was

made on the ventral surface of the neck, left of the trachea. The left jugular vein was exposed, freed from its surrounding connective tissue, and ligated. A silicone catheter (with inner and outer diameter of 0.5 and 0.9 mm, respectively) was filled with heparinized (10 U/ml) saline, then it was inserted into the left jugular vein, passed into the superior vena cava, and secured in place with ligatures. The free end of the catheter was knotted and exteriorized at the nape. The skin wound was sutured. The catheter was flushed with heparinized saline on the day following the surgery and every other day thereafter.

### III/2.2.3. Thermocouple thermometry

The mice and the rats were placed in cylindrical confiners and equipped with copper-constantan thermocouples (Omega Engineering, Stamford, CT, USA) to measure colonic temperature (a form of deep $T_b$). The colonic thermocouple was inserted beyond the anal sphincter (10 and 3 cm deep for rats and mice, respectively); fixed to the base of the tail with adhesive tape; and plugged into a data logger device (Cole-Palmer, Vernon Hills, IL, USA) connected to a computer. Animals in their confiners were then placed into a biochemistry incubator (model BJPX-Newark; Biobase; Jinan, China). As the expected $T_b$ change was hypothermia, the ambient temperature was set to 25°C, which is slightly subneutral for rats and mice in this setup. The preimplanted i.p. and i.v. catheter (when present) was connected to a PE-50 extension, which was prefilled with the substance of interest and connected to a syringe placed in an infusion pump (model 975; Harvard Apparatus Inc., Holliston, MA, USA).

*III/2.2.4. Drugs and drug administration*

$NH_4Cl$ was purchased from VWR Chemicals (Leuven, Belgium). On the day of an experiment, $NH_4Cl$ was freshly dissolved in sterile water to achieve final concentrations of 32.1, 220 or 280 mg/ml. For the i.p. administration of $NH_4Cl$ to mice, the working solution (32.1 mg/ml) was infused (10 ml/kg) over 16 minutes to deliver $NH_4Cl$ at 321 mg/kg (~6 mmol/kg). In rats, the working solutions (220 and 280 mg/ml) were infused (1 ml/kg) over 5 minutes to deliver $NH_4Cl$ at 220 and 280 mg/kg (ca. 4 and 5 mmol/kg), respectively. The decreased dose of $NH_4Cl$ in the rats compared to mice was necessary, because rats were more sensitive to the effect of the same $NH_4Cl$-loading protocol on protein expression than mice (Nowik, et al., 2010). Control animals were infused with sterile water. All infusion rates and volumes were selected with the goal to minimize the stress and discomfort of the animals that may originate from the substance administration procedure itself. Similar i.p. infusion rates as in the present experiments were successfully applied in our previous studies for non-stressful administration of substances to mice (Garami, et al., 2017) and rats (Pakai, et al., 2018).

AMG 517, a highly potent TRPV1 antagonist (Garami, et al., 2010), and A967079, a highly potent TRPA1 antagonist (Chen, et al., 2011), were purchased from Tocris (Bristol, UK). A stock solution of AMG 517 (1 mg/ml) was prepared with 10% dimethyl sulfoxide (DMSO) and 10% Tween-80 in saline, aliquoted, and stored at -80°C. On the day of the experiment, the stock was diluted to give a working solution of AMG 517 at 210 µg/ml in 10% DMSO and 10% Tween-80 in saline. A stock solution of A967079 (10 mg/ml) was prepared with polyethylene glycol 400 (PEG 400), aliquoted, and stored at -80°C. On the

day of the experiment, the stock was diluted with PEG 400 and saline to give a working solution of A967079 at 5 mg/ml in 80% PEG 400 in saline. For the i.v. administration, the working solution of AMG 517 or A967079 (210 μg/ml or 5 mg/ml, respectively) was infused (1 ml/kg) over 10 minutes to deliver AMG 517 and A967079 at 210 μg/kg and 5 mg/kg, respectively. Both antagonists were infused i.v. to the rats 20 minutes before the i.p. infusion of $NH_4Cl$. Control rats were infused with the vehicle of the antagonist of interest. The efficacies of AMG 517 and A967079 administered i.v. at similar doses and rates as in the present experiments were shown in previous studies (Garami, et al., 2010; McGaraughty, et al., 2010).

To study the effect of AMG 517 on $NH_4Cl$-induced hypothermia in mice, we used a drug dose and administration model that was successfully applied earlier (Wanner, et al., 2012). The working solution (or its vehicle) was injected subcutaneous (s.c.) as a bolus to deliver AMG 517 at a dose of 210 μg/kg just before setting up the mice for the experiment (i.e., ~120 minutes before the administration of $NH_4Cl$). Then, the mice were allowed to accommodate to the experimental conditions for ~2 hours before they received the non-stressful, i.p. infusion of $NH_4Cl$ (321 mg/kg) through a preimplanted catheter. The 2-hour latency until the $NH_4Cl$ infusion was needed to reduce the stress-induced hyperthermia resulting from the needle prick associated with the s.c. injection of AMG 517 (or its vehicle). Because of the long (31 h) half-life of AMG 517 in rodents (Doherty, et al., 2007), the effect of the drug could be reasonably expected at the time of $NH_4Cl$ infusion even with this latency.

The drug administration procedures in the different experiments are summarized in Table 1.

**Table 1** Summary of drug administration procedures in the experiments
(Rumbus, et al., 2024)

| Species (strain) | Pretreatment | | | NH$_4$Cl | Figure number |
| | Drug | Dose (mg/kg) and route | Time prior NH$_4$Cl (min) | I.p. dose (mg/kg) | |
|---|---|---|---|---|---|
| Rat (Wistar) | N/A | | | 220; 280 | 12 |
| Mouse (*Trpv1*$^{-/-}$ and $^{+/+}$) | N/A | | | 321 | 13 |
| Mouse (C57BL/6) | AMG 517 | 0.21  s.c. | -120 | 321 | 14 |
| Rat (Wistar) | AMG 517 | 0.21  i.v. | -20 | 280 | 15 |
| Mouse (*Trpa1*$^{-/-}$ and $^{+/+}$) | N/A | | | 321 | 16 |
| Rat (Wistar) | A967079 | 5  i.v. | -20 | 280 | 17 |

N/A, not applicable

### III/2.2.5. Blood pH measurements

One hour after the i.p. administration of NH$_4$Cl, the animals were anesthetized with ketamine-xylazine cocktail, and then blood samples were collected by cardiac puncture with a heparinized syringe. The pH of the blood samples was measured by a pH meter (model OP-211/2; Radelkis Ltd., Budapest, Hungary) within 1 minute after collection. After the blood withdrawal, the animals were euthanized with sodium pentobarbital (100 mg/kg, i.p.).

### III/2.2.6. Data processing and analysis

Data on deep T$_b$ and on blood pH were compared by ANOVA, as appropriate. ANOVA was followed by the Student-Newman-Keuls post hoc test as in our earlier study (Keringer, et al., 2022). Sigmaplot 11.0 (Systat Software, San Jose, CA, USA) software was

used for statistical analyses. Differences were considered significant when $p < 0.05$. Data are presented as mean $\pm$ SE.

# IV. Results

## IV/1. Predictive role of body temperature and blood pH for the outcomes of systemic inflammation in humans

IV/1.1. Body temperature and mortality in sepsis

### IV/1.1.1. Study selection

The flow chart of the study selection is presented in Figure 1. Until February 29, 2016 the electronic literature search identified altogether 6,083 studies from the PubMed, EMBASE, and Cochrane databases. After enabling filters for human studies and English language, 762 articles remained, which were screened on title and abstract for inclusion criteria. In 720 studies $T_b$ or mortality rate was not suitably reported in the septic patients, these were also excluded, as a result 42 full-text publications were found eligible for statistical analysis which included data from a total of 10,834 septic patients.

**Figure 1.** Flow chart of study selection and inclusion in our meta-analysis (Rumbus, et al., 2017).

*IV/1.1.2. Incidence of mortality in septic patients with fever, normothermia, and hypothermia*

As a rude approach, first we performed a common (Pearson) correlation analysis between $T_b$ and mortality rate of all septic patients. A weak negative linear correlation was found ($y = -0.0909x + 3.6902$; $R2 = 0.2794$), which suggests an association between $T_b$ and mortality in sepsis. This method, however, did not allow us to weight the collected data

according to the size of the studied populations, thus a detailed meta-analysis was needed. We divided the studies into three groups based on the $T_b$: fevbrile (defined as $T_b > 38.0°C$), normothermic ($T_b = 36.0-38.0°C$), and hypothermic ($T_b < 36.0°C$).

First, we investigated the incidence of mortality in fever associated with sepsis. We found 29 studies (Aceng, Byarugaba, & Tumwine, 2005; Arons, et al., 1999; Asiimwe, Abdallah, & Ssekitoleko, 2015; Bryant, et al., 1971; Clemmer, et al., 1992; Diekema, et al., 2003; Gozel MG, 2012; Harkness & Braun, 1989; Heffner, Horton, Marchick, & Jones, 2010; Hodgin & Sanford, 1965; Hoeboer, et al., 2012; Hung, et al., 2005; Kang, et al., 2012; Kirov, et al., 2001; Kushimoto, et al., 2013; Lee, et al., 2012; Marfin, Sporrer, Moore, & Siefkin, 1995; Megged, et al., 2006; Molina, et al., 2013; Neuberger, et al., 2015; Pittet, et al., 1996; Rhodes, et al., 1999; Schortgen, et al., 2012; Seguin, et al., 2012; Song, et al., 2012; Su, et al., 2012; Swenson, Hedrick, Popovsky, Pruett, & Sawyer, 2007; Taylor, Wills, Courval, & Molyneux, 1998; Weinstein, Murphy, Reller, & Lichtenstein, 1983), in which the authors reported fever (defined as $T_b > 38.0°C$) in sepsis. From these studies, 40 groups of septic patients could be separated and included in the analysis with the random effect model. The meta-analysis of the mortality rates in the septic patients with fever revealed an average event rate of 22.2% (95% CI, 19.2-25.5%; Z = -13.4331) (Figure 2). This percentage was significantly (P = 0.000) lower than the 50% chance of mortality, which could be regarded as a random outcome.

| Study name and subgroup | Mortality rate | Lower limit | Upper limit | Deaths / cases | Mortality rate and 95% CI | Relative weight |
|---|---|---|---|---|---|---|
| Green 2014 grp 2 | 0.085 | 0.045 | 0.154 | 9 / 110 | | 2.36 |
| Kushimoto 2013 grp 3 | 0.162 | 0.117 | 0.220 | 32 / 197 | | 3.01 |
| Kang 2012 grp 1 | 0.128 | 0.086 | 0.187 | 22 / 172 | | 2.87 |
| Seguin 2012 grp 1 | 0.190 | 0.148 | 0.240 | 53 / 278 | | 3.16 |
| Seguin 2012 grp 2 | 0.150 | 0.089 | 0.241 | 13 / 87 | | 2.55 |
| Lee 2012 grp 1 | 0.258 | 0.209 | 0.314 | 69 / 267 | | 3.21 |
| Schortgen 2012 grp 2 | 0.343 | 0.256 | 0.442 | 34 / 99 | | 2.94 |
| Aceng 2005 grp 1 | 0.192 | 0.106 | 0.321 | 10 / 52 | | 2.32 |
| Aceng 2005 grp 2 | 0.118 | 0.054 | 0.239 | 6 / 51 | | 1.98 |
| Kirov 2001 grp 1 | 0.500 | 0.225 | 0.775 | 5 / 10 | | 1.34 |
| Rhodes 1999 grp 2 | 0.071 | 0.010 | 0.370 | 1 / 14 | | 0.65 |
| Arons 1999 grp 1 | 0.350 | 0.305 | 0.398 | 143 / 409 | | 3.32 |
| Taylor 1998 grp 1 | 0.110 | 0.059 | 0.197 | 9 / 83 | | 2.32 |
| Taylor 1998 grp 2 | 0.160 | 0.095 | 0.257 | 13 / 81 | | 2.53 |
| Clemmer 1992 grp 2 | 0.260 | 0.217 | 0.309 | 90 / 348 | | 3.26 |
| Asiimwe 2015 grp 1 | 0.300 | 0.232 | 0.378 | 45 / 150 | | 3.07 |
| Gozel 2012 grp 1 | 0.370 | 0.310 | 0.434 | 85 / 230 | | 3.22 |
| Hoeboer 2012 grp 1 | 0.300 | 0.184 | 0.450 | 13 / 44 | | 2.42 |
| Hoeboer 2012 grp 2 | 0.200 | 0.107 | 0.342 | 9 / 45 | | 2.23 |
| Hoeboer 2012 grp 3 | 0.330 | 0.129 | 0.621 | 4 / 12 | | 1.39 |
| Molina 2013 grp 1 | 0.286 | 0.170 | 0.439 | 12 / 42 | | 2.37 |
| Neuberger 2015 grp 1 | 0.235 | 0.163 | 0.326 | 24 / 103 | | 2.85 |
| Song 2012 grp 1 | 0.060 | 0.040 | 0.089 | 22 / 366 | | 2.90 |
| Song 2012 grp 2 | 0.240 | 0.169 | 0.329 | 26 / 108 | | 2.88 |
| Su 2012 grp 2 | 0.431 | 0.276 | 0.601 | 14 / 33 | | 2.32 |
| Diekema 2003 grp 2 | 0.200 | 0.176 | 0.227 | 186 / 929 | | 3.37 |
| Heffner 2010 grp 1 | 0.250 | 0.173 | 0.347 | 24 / 95 | | 2.83 |
| Heffner 2010 grp 2 | 0.140 | 0.088 | 0.216 | 16 / 116 | | 2.69 |
| Hung 2005 grp 1 | 0.150 | 0.064 | 0.315 | 5 / 33 | | 1.78 |
| Marfin 1995 grp 2 | 0.008 | 0.001 | 0.118 | 0 / 60 | | 0.38 |
| Megged 2006 grp 1 | 0.183 | 0.104 | 0.301 | 11 / 60 | | 2.40 |
| Megged 2006 grp 2 | 0.026 | 0.004 | 0.164 | 1 / 38 | | 0.68 |
| Swenson 2007 grp 1 | 0.129 | 0.103 | 0.160 | 70 / 541 | | 3.25 |
| Bryant 1971 grp 1 | 0.310 | 0.213 | 0.427 | 22 / 70 | | 2.73 |
| Bryant 1971 grp 2 | 0.270 | 0.199 | 0.355 | 33 / 124 | | 2.97 |
| Hodgin 1965 grp 1 | 0.440 | 0.256 | 0.642 | 10 / 23 | | 2.04 |
| Hodgin 1965 grp 2 | 0.480 | 0.338 | 0.625 | 21 / 44 | | 2.54 |
| Weinstein 1983 grp 3 | 0.287 | 0.241 | 0.338 | 96 / 334 | | 3.27 |
| Weinstein 1983 grp 4 | 0.225 | 0.143 | 0.336 | 16 / 71 | | 2.62 |
| Pittet 1996 grp 1 | 0.350 | 0.267 | 0.443 | 39 / 111 | | 2.99 |
| **Overall** | 0.222 | 0.192 | 0.255 | | | |

0.00    0.50    1.00

**Figure 2.** Forest plot analysis of mortality rate using random-effects model in septic patients with fever (body temperature above 38.0°C; n = 6,040) (Rumbus, et al., 2017).

Next, we analyzed the mortality ratios of patients who developed neither fever nor hypothermia in association with sepsis, therefore this population could be regarded as normothermic ($T_b$ = 36.0-38.0°C). From the 25 studies, in which normal $T_b$ was reported in the septic patients (Asiimwe, et al., 2015; Bernard, et al., 1997; Carl, Grossman, Behnke, Sessler, & Gehr, 2010; Drewry, Fuller, Bailey, & Hotchkiss, 2013; Drewry, et al., 2015; DuPont HL, 1969; Green, Ariathianto, Wong, Aboltins, & Lim, 2014; Hung, et al., 2005; Kang, et al., 2012; Kirov, et al., 2001; Kushimoto, et al., 2013; Marfin, et al., 1995; Memis, Karamanlioglu, Turan, Koyuncu, & Pamukcu, 2004; Molina, et al., 2013; Neuberger, et al., 2015; Pestana, et al., 2007; Rhodes, et al., 1999; Sarmin, Ahmed, Bardhan, & Chisti, 2014; Sawyer, et al., 2015; Schortgen, et al., 2012; Su, et al., 2012; Villar & Slutsky, 1993; Weinstein, et al., 1983; Young, et al., 2015), 36 subgroups of patients were separated, which were then analyzed with the random effect model. We found that the average mortality ratio was 31.2% (95% CI, 25.7-37.3%; Z = -5.7089) (Figure 3), which was higher than in the fever group. The mortality rate was significantly (P < 0.001) lower than 50% in this study population.

| Study name and subgroup | Mortality rate | Lower limit | Upper limit | Deaths / cases | Mortality rate and 95% CI | Relative weight |
|---|---|---|---|---|---|---|
| Sawyer 2015 grp 1 | 0.218 | 0.172 | 0.273 | 56 / 257 | | 3.42 |
| Sawyer 2015 grp 2 | 0.223 | 0.176 | 0.278 | 58 / 260 | | 3.42 |
| Green 2014 grp 1 | 0.211 | 0.109 | 0.368 | 8 / 38 | | 2.76 |
| Kushimoto 2013 grp 2 | 0.205 | 0.140 | 0.290 | 23 / 112 | | 3.24 |
| Drewry 2013 grp 1 | 0.281 | 0.153 | 0.458 | 9 / 32 | | 2.77 |
| Drewry 2013 grp 2 | 0.069 | 0.017 | 0.238 | 2 / 29 | | 1.79 |
| Yang 2013 grp 1 | 0.618 | 0.448 | 0.764 | 21 / 34 | | 2.90 |
| Yang 2013 grp 2 | 0.258 | 0.135 | 0.437 | 8 / 31 | | 2.72 |
| Kang 2012 grp 2 | 0.228 | 0.167 | 0.303 | 33 / 145 | | 3.32 |
| Schortgen 2012 grp 1 | 0.188 | 0.123 | 0.276 | 19 / 101 | | 3.18 |
| Pestana 2007 grp 1 | 0.316 | 0.149 | 0.549 | 6 / 19 | | 2.46 |
| Kirov 2001 grp 1 | 0.700 | 0.376 | 0.900 | 7 / 10 | | 1.89 |
| Rhodes 1999 grp 1 | 0.909 | 0.700 | 0.977 | 20 / 22 | | 1.77 |
| Memis 2004 grp 1 | 0.350 | 0.177 | 0.574 | 7 / 20 | | 2.53 |
| Memis 2004 grp 2 | 0.400 | 0.214 | 0.620 | 8 / 20 | | 2.57 |
| Bernard 1997 grp 1 | 0.370 | 0.309 | 0.435 | 83 / 224 | | 3.44 |
| Bernard 1997 grp 2 | 0.400 | 0.339 | 0.465 | 92 / 231 | | 3.45 |
| Villar 1993 grp 1 | 0.955 | 0.552 | 0.997 | 10 / 10 | | 0.73 |
| Villar 1993 grp 3 | 0.950 | 0.525 | 0.997 | 9 / 9 | | 0.73 |
| Asiimwe 2015 grp 2 | 0.230 | 0.172 | 0.300 | 38 / 167 | | 3.35 |
| Drewry 2015 grp 2 | 0.249 | 0.208 | 0.295 | 95 / 381 | | 3.47 |
| Molina 2013 grp 2 | 0.048 | 0.016 | 0.138 | 3 / 63 | | 2.17 |
| Neuberger 2015 grp 2 | 0.168 | 0.132 | 0.212 | 56 / 336 | | 3.43 |
| Sarmin 2014 grp 1 | 0.670 | 0.566 | 0.760 | 59 / 88 | | 3.25 |
| Sarmin 2014 grp 2 | 0.140 | 0.088 | 0.216 | 16 / 116 | | 3.15 |
| Su 2012 grp 1 | 0.333 | 0.218 | 0.472 | 17 / 51 | | 3.06 |
| Su 2012 grp 3 | 0.067 | 0.025 | 0.165 | 4 / 60 | | 2.39 |
| Young 2015 grp 1 | 0.139 | 0.106 | 0.180 | 48 / 346 | | 3.41 |
| Young 2015 grp 2 | 0.137 | 0.105 | 0.178 | 47 / 344 | | 3.41 |
| Carl 2010 grp 1 | 0.523 | 0.417 | 0.627 | 44 / 85 | | 3.28 |
| Carl 2010 grp 2 | 0.683 | 0.558 | 0.786 | 42 / 62 | | 3.13 |
| Hung 2005 grp 2 | 0.420 | 0.226 | 0.643 | 8 / 19 | | 2.55 |
| Hung 2005 grp 4 | 0.260 | 0.155 | 0.403 | 12 / 47 | | 2.96 |
| Marfin 1995 grp 1 | 0.595 | 0.442 | 0.731 | 25 / 42 | | 3.01 |
| DuPont 1969 grp 1 | 0.220 | 0.055 | 0.577 | 2 / 9 | | 1.62 |
| Weinstein 1983 grp 2 | 0.417 | 0.317 | 0.525 | 35 / 84 | | 3.27 |
| **Overall** | 0.312 | 0.257 | 0.373 | | | |

0.00        0.50        1.00

**Figure 3.** Forest plot analysis of mortality rate using random-effects model in septic patients with normothermia (body temperature between 36.1 and 38.0°C; n = 3,904) (Rumbus, et al., 2017).

Then, we examined the incidence of mortality in hypothermic ($T_b < 36.0$°C) septic patients. We identified 11 studies (Arons, et al., 1999; Bro-Jeppesen, et al., 2015; Clemmer,

et al., 1992; Diekema, et al., 2003; Drewry, et al., 2015; DuPont HL, 1969; Gozel MG, 2012; Hung, et al., 2005; Kushimoto, et al., 2013; Villar & Slutsky, 1993; Weinstein, et al., 1983), which included data on both $T_b$ and mortality in septic patients. From these, the patients could be divided in 12 subgroups, which served as the basis of the meta-analysis. The random effect model revealed that the average mortality rate was the highest, 47.3% (95% CI, 38.9-55.7; Z = 0.520491) in the hypothermic patients (Figure 4), which did not significantly differ from the 50% random chance (P = 0.603).

| Study name and subgroup | Mortality rate | Lower limit | Upper limit | Deaths / cases | Mortality rate and 95% CI | Relative weight |
|---|---|---|---|---|---|---|
| Bro-Jeppesen 2015 grp 1 | 0.360 | 0.266 | 0.466 | 31 / 86 | | 13.06 |
| Bro-Jeppesen 2015 grp 2 | 0.300 | 0.211 | 0.407 | 25 / 83 | | 12.68 |
| Kushimoto 2013 grp 1 | 0.404 | 0.312 | 0.503 | 40 / 99 | | 13.56 |
| Arons 1999 grp 2 | 0.700 | 0.550 | 0.816 | 31 / 44 | | 10.45 |
| Clemmer 1992 grp 1 | 0.620 | 0.449 | 0.765 | 21 / 34 | | 9.88 |
| Villar 1993 grp 2 | 0.670 | 0.336 | 0.891 | 6 / 9 | | 4.42 |
| Drewry 2015 grp 1 | 0.500 | 0.380 | 0.620 | 32 / 64 | | 12.41 |
| Gozel 2012 grp 2 | 0.875 | 0.266 | 0.993 | 3 / 3 | | 1.23 |
| Diekema 2003 grp 1 | 0.400 | 0.356 | 0.446 | 180 / 449 | | 15.89 |
| Hung 2005 grp 3 | 0.200 | 0.027 | 0.691 | 1 / 5 | | 2.11 |
| DuPont 1969 grp 2 | 0.400 | 0.100 | 0.800 | 2 / 5 | | 2.98 |
| Weinstein 1983 grp 1 | 0.950 | 0.525 | 0.997 | 9 / 9 | | 1.32 |
| **Overall** | 0.473 | 0.389 | 0.557 | | | |

0.00    0.50    1.00

**Figure 4.** Forest plot analysis of mortality rate using random-effects model in septic patients with hypothermia (body temperature up to 36.0°C; n = 890) (Rumbus, et al., 2017).

As a further statistical approach, we also performed a meta-regression analysis on the collected data. We found a significant (P < 0.001) negative linear correlation between $T_b$ and mortality rate (regression coefficient: -0.4318; 95% CI, -0.6699 - -0.1938) based on 51 studies included in the analysis (Figure 5).

**Figure 5.** Meta-regression analysis of the association between body temperature and mortality ratio in septic patients (n = 10, 834) (Rumbus, et al., 2017).

Last, we divided the patients into quartiles (Q1-Q4) of mortality ratios (Q1: 0-25, Q2: 26-50, Q3: 51-75, and Q4: 76-100%) and calculated the average $T_b$ for each mortality quartile. The weighted average $T_b$s were 38.1 (95% CI, 37.9-38.4°C), 37.8 (95% CI, 37.5-38.25°C), 37.6 (95% CI, 36.5-38.7°C), and 37.1°C (95% CI, 36.7-37.4°C) in the Q1, Q2, Q3, and Q4 groups, respectively. These results also indicate that in sepsis a higher $T_b$ is associated with better outcome, while a lower $T_b$ is related with higher risk of mortality. Of

note, the $T_b$s in Q1 and Q4 (i.e., in the groups with lowest and highest mortality, respectively) are clearly distinct from each other, as the 95% CIs do not overlap.

IV/1.2. Blood pH and outcomes in acute pancreatitis

*IV/1.2.1. Study selection*

The flow chart of the study selection is presented in Figure 6. Until January 2017 the electronic literature search identified altogether 1,076 studies from the PubMed, EMBASE, and Cochrane databases. After enabling filters for human studies and English language and removal of duplicates, 793 articles remained, which were screened on title and abstract for inclusion criteria. Full texts of the remaining 122 articles were reviewed in detail. In 109 studies pH parameters or outcomes were not suitably reported in the patients with AP, therefore these were also excluded. As a result, 13 full-text publications were found eligible for statistical analysis which included data from a total of 2,311 patients (De Campos, et al., 2008; Eachempati, Hydo, & Barie, 2002; Kaya, Dervisoglu, & Polat, 2007; Keskinen, et al., 2007; Lei, et al., 2013; Nair, Yadav, & Pitchumoni, 2000; Pupelis, Plaudis, Grigane, Zeiza, & Purmalis, 2007; Ranson, Rifkind, & Turner, 1976; Sharma, et al., 2014; Shen, et al., 2016; Shinzeki, et al., 2008; Zhan, et al., 2015; Zhu, Shi, & Sun, 2003).

**Figure 6.** Flow chart of study selection and inclusion (Rumbus, et al., 2018).

*IV/1.2.2. Reduction of blood pH is associated with higher mortality rate in AP*

First, we investigated the association between systemic (blood) pH status and our strongest endpoint, namely the mortality. Our meta-analysis revealed a logit event rate of -0.09 (95% CI, -0.79, 0.61), corresponding to an average mortality rate of 51.0% (95% CI, 31.5, 70.1) in the more acidotic patient groups, while in the patient groups with higher pH or bicarbonate level the logit event rate was -3.68 (95% CI, -4.81, -2.55), which corresponds

to an average mortality rate of 3.0% (95% CI, 1.2, 7.1) (Figure 7). The mortality ratios were

significantly different between the two groups (P < 0.001).



**Figure 7.** Forest plot of mortality rate using random-effects model in different systemic pH groups of patients with acute pancreatitis (AP). For each patient group, black circles and horizontal lines represent the estimated logit mortality rate (ES) and the corresponding confidence interval (CI), respectively. Lower ES corresponds with lower mortality rate and vice versa. Gray squares indicate the relative statistical weight of a given patient group. Open diamonds show the average ES and CI of patient groups with higher systemic pH (top), lower systemic pH (middle), and all patient groups (bottom) (Rumbus, et al., 2018).

*IV/1.2.3. Lower pH or bicarbonate concentration worsen the severity of AP*

We wanted to know whether the change in acid-base status can also predict the severity of AP as assessed by clinical scores. Thus, we studied the association between blood pH and clinical severity scores. We found two scores, the Ranson and the APACHE II scores, which were reported in sufficient number of studies for statistical analysis (De Campos, et al., 2008; Eachempati, et al., 2002; Kaya, et al., 2007; Keskinen, et al., 2007; Lei, et al., 2013; Nair, et al., 2000; Pupelis, et al., 2007; Ranson, et al., 1976; Sharma, et al., 2014; Shen, et al., 2016; Shinzeki, et al., 2008; Zhan, et al., 2015; Zhu, et al., 2003). Meta-analysis revealed that the estimated SMDs of the Ranson score (0.92, 95% CI, 0.58, 1.26) and the APACHE II score (1.38, 95% CI, 0.95, 1.81) were significant between the patient groups with lower pH or bicarbonate levels compared with less acidotic groups of patients (P < 0.001) (Figure 8A and B). These standardized values correspond to 1.60 (95% CI, 0.77, 2.42) higher Ranson score and 7.40 (95% CI, 5.05, 9.75) higher APACHE II score in the more acidotic patients with AP. The correlation found between lower blood pH and higher clinical scores could be expected as these scores also include blood pH (Vincent & Moreno, 2010), nevertheless, these results confirm the feasibility of our meta-analysis approach to reveal an interaction between systemic pH and the outcome of AP.

**A**



**Ranson score**

| study | SMD (95% CI) | % Weight |
|---|---|---|
| Lei et al (2013) | 0.60 (0.27, 0.93) | 40.63 |
| Zahn et al (2015) | 1.10 (0.56, 1.63) | 25.36 |
| Shinzeki et al (2008) | 1.00 (0.09, 1.92) | 11.62 |
| Eachempati et al (2002) | 1.25 (0.67, 1.84) | 22.39 |
| Overall  (I-squared = 39.0%, p = 0.178) | 0.92 (0.58, 1.26) | 100.00 |

NOTE: Weights are from random effects analysis

Standardized mean difference

**B**



**APACHE II score**

| study | SMD (95% CI) | % Weight |
|---|---|---|
| De Campos et al (2008) | 0.39 (-0.15, 0.93) | 11.51 |
| Lei et al (2013) | 0.63 (0.30, 0.96) | 13.01 |
| Shen et al (2016) | 1.10 (0.79, 1.41) | 13.12 |
| Keskinen et al (2007) | 1.16 (0.37, 1.96) | 9.48 |
| Zahn et al (2015) | 1.26 (0.72, 1.80) | 11.54 |
| Eachempati et al (2002) | 1.64 (1.03, 2.25) | 10.96 |
| Kaya et al (2007) | 1.91 (1.46, 2.36) | 12.22 |
| Shinzeki et al (2008) | 2.22 (1.26, 3.17) | 8.30 |
| Zhu et al 2003 | 2.62 (1.87, 3.37) | 9.85 |
| Overall  (I-squared = 84.0%, p = 0.000) | 1.38 (0.95, 1.81) | 100.00 |

NOTE: Weights are from random effects analysis

Standardized mean difference

**Figure 8.** Forest plot of (A) Ranson scores and (B) Acute Physiology and Chronic Health Evaluation (APACHE II) scores using random-effects model in different systemic pH groups of patients with acute pancreatitis. Here and in Figure 9, in each study the standardized mean difference (SMD) of

the outcome was calculated between the patient group with lower and higher pH. Black circles represent the SMD for each study, while the left and right horizontal arms of the circles indicate the corresponding 95% confidence intervals (CI) for the SMD for each study. The size of the gray box is proportional to the sample size of the study; bigger box represents larger sample size, thus bigger relative weight of the study, and vice versa. Circles close to zero represent smaller SMD between the lower and higher pH groups in the given study. A positive SMD means higher score (Figure 8) or longer hospital stay (Figure 9) in the patient group with lower pH compared to the patient group with higher pH. The diamond on the bottom represents the averaged SMD calculated from the SMDs of all the individual studies. The vertical dashed line is determined by the two vertical points of the diamond and indicates the value of the averaged SMD of all studies. The horizontal points of the diamond represent the 95% CI of the averaged SMD (Rumbus, et al., 2018).

### *IV/1.2.4. Acidosis is associated with longer hospitalization in AP*

Next, we analyzed the LOS in patients with AP by using the same grouping of acid-base status as we did for mortality and severity scores. For the meta-analysis, LOS was expressed as SMD between the patient groups. We found that this difference was significant between the more acidotic patient groups and the groups with higher pH or bicarbonate concentrations (0.89, 95% CI, 0.733, 1.043; P < 0.001) (Figure 9), which difference corresponds to 15.05 days (95% CI, 10.84, 19.19) longer LOS in the more acidotic AP patient group.

## Length of hospital stay



**Figure 9.** Forest plot analysis of the length of hospital stay using random-effects model in different systemic pH groups of patients with acute pancreatitis. For explanation, see the legend of Figure 8. SMD, standardized mean difference; CI, confidence interval (Rumbus, et al., 2018).

### IV/1.2.5. Meta-regression analysis

As a further statistical approach to determine a correlation between blood pH and mortality in the more progressed forms of AP, we also performed a meta-regression analysis on the collected data. For that, we used those study groups, in which pH and mortality rate was reported in moderately severe or severe manifestations of AP for the same patient groups (Lei, et al., 2013; Shen, et al., 2016; Zhu, et al., 2003). We found a significant correlation between pH and mortality rate with a regression slope of -55.4 (95% CI, -97.9, -12.9; P =

0.011) (Figure 10). The potential reason for statistical heterogeneity, as revealed in the forest plots, could not be evaluated in the meta-regression analysis because of the small number of eligible studies.



**Figure 10.** Meta-regression analysis of the association between blood pH and mortality rate in patients with moderately severe and severe forms of acute pancreatitis. The circles indicate estimated logit mortality rate calculated for each patient group. A lower calculated value corresponds with lower mortality rate and vice versa. The circle size is proportional to the precision of the estimated logit mortality rate. The solid black line represents the weighted regression line based on variance-weighted least squares (Rumbus, et al., 2018).

**IV/2. The role of TRP channels in pharmacological modulation of body temperature**

IV/2.1. Relationship between body temperature and pH: TRPV1 antagonists induced thermal changes. Meta-analysis of human clinical trials

All three antagonists in the mode-nonselective group caused hyperthermia, which was dose-dependent for those compounds that were administered at multiple doses, viz., ABT-102 and V116517 (Figure 11). The highest hyperthermic effect (SDM: 2.5; CI: 1.4-3.5) occurred in the group treated with the 86 μmol dose of ABT-102. The mean thermal effect of all doses of all mode-nonselective TRPV1 antagonists in the analyzed clinical trials was an SDM of 1.2 (CI: 0.9-1.6; P < 0.001). NEO6860, the only mode-selective TRPV1 antagonist that we were able to include in our analysis, did not cause hyperthermia at the dose used (1.2 mmol) but, instead, decreased the deep $T_b$ (SDM: -0.7; CI: -0.3 to -1.1; P < 0.001).

| Group | TRPV1 antagonist | Dose (µmol) | SDM | CI limits Lower | CI limits Upper | P value | Drug-placebo difference in deep $T_b$ SDM and CI | Relative weight |
|-------|------------------|-------------|-----|-------|-------|---------|-------------|-----------------|
| Non-mode-selective | ABT-102 | 2.9 | 0.0 | -0.8 | 0.8 | 1.000 | | 0.08 |
| | | 5.7 | 1.0 | 0.4 | 1.5 | 0.001 | | 0.10 |
| | | 11 | 0.9 | 0.3 | 1.6 | 0.005 | | 0.09 |
| | | 17 | 1.9 | 1.0 | 2.9 | 0.000 | | 0.07 |
| | | 23 | 1.0 | 0.7 | 1.8 | 0.035 | | 0.08 |
| | | 52 | 2.4 | 1.4 | 3.4 | 0.000 | | 0.07 |
| | | 86 | 2.5 | 1.4 | 3.5 | 0.000 | | 0.07 |
| | | 115 | 1.9 | 1.0 | 2.9 | 0.000 | | 0.07 |
| | AZD1386 | 225 | 0.8 | 0.4 | 1.3 | 0.000 | | 0.11 |
| | V116517 | 68 | 0.5 | -0.7 | 1.7 | 0.411 | | 0.06 |
| | | 226 | 0.9 | -0.3 | 2.1 | 0.137 | | 0.05 |
| | | 678 | 0.9 | -0.28 | 2.1 | 0.130 | | 0.05 |
| | | 1,357 | 1.5 | 0.2 | 2.8 | 0.022 | | 0.05 |
| | | 2,261 | 1.7 | 0.4 | 3.1 | 0.010 | | 0.05 |
| | All drugs | All doses | 1.2 | 0.9 | 1.6 | 0.000 | | 1.00 |
| Mode-selective | NEO6860 | 1,149 | -0.7 | -1.1 | -0.3 | 0.000 | | 1.00 |

**Figure 11.** Forest plot of the thermal effects of TRPV1 antagonists. For each antagonist dose, an SDM (a measure of the $T_b$ response) and CI were calculated as described in the text and are shown in the figure with a square and a horizontal bar, respectively. The area of the square is proportional to the sample size and inversed variance. The rhombus refers to the weighted mean SDM for the mode-nonselective group; the vertical diagonal of the rhombus points at the SDM value, whereas the horizontal diagonal represents the CI. Red symbols refer to mode-nonselective TRPV1 antagonists; the green square and bar refer to the selective antagonist NEO6860 (Garami, et al., 2020).

IV/2.2. NH$_4$Cl-induced hypothermia is attenuated by transient receptor potential channel vanilloid-1, but augmented by ankyrin-1 in rodents

*IV/2.2.1. Systemic administration of NH$_4$Cl causes hypothermia in rats*

First, we studied the thermal effect of NH$_4$Cl administered systemically (i.p.) to rats in order to exclude the possibility that the NH$_4$Cl-induced hypothermic response is specific only for mice. We found that the i.p. injection of NH$_4$Cl to the rats caused hypothermia, which was more pronounced at the higher dose (Figure 12). The colonic temperature of the rats started to drop promptly, already at 10 min after the injection of NH$_4$Cl at both doses. Compared to the baseline, the NH$_4$Cl-induced maximal mean ($\pm$ SE) decrease in deep T$_b$ was -0.4 $\pm$ 0.1°C at 20 min in case of 220 mg/kg and -0.8 $\pm$ 0.2°C at 30 min in case of 280 mg/kg. From that timepoint, the T$_b$ of the NH$_4$Cl-treated rats gradually increased and reached the T$_b$ level of the control (sterile water-treated) group by the end of the experiment. The T$_b$ of the sterile water-treated rats tended to increase, and then to decrease during the experiment after the i.p. infusion, but it did not differ significantly from the baseline at any timepoints. The initial increase in the T$_b$ could be caused by an unwanted stress response to sterile water infusion despite all of our efforts to minimize the discomfort associated with substance administration, while the gradual fall might have reflected ultradian T$_b$ rhythms in rats maintained at an ambient temperature of ~25°C, which is below the thermoneutral zone. Statistically, both doses of NH$_4$Cl had a significant effect as compared to controls (P < 0.001 for both), and a statistical difference was also present between the lower and the higher dose groups (P < 0.001). At 220 mg/kg, the NH$_4$Cl-induced decrease in deep T$_b$ was significant

compared to the control group between 20-50 min, while at 280 mg/kg, the $T_b$ was significantly lower than in controls between 20-90 min. The development of hypothermia in response to $NH_4Cl$ in rats is a novel finding of our study, especially considering that the effect occurred already at an i.p. dose of 220 mg/kg, which is almost 50% smaller than the threshold dose predicted earlier in mice (Gordon, 1988).



**Figure 12.** Dose-response curves. Changes in colonic body temperature in response to intraperitoneal (i.p.) administration of sterile water or ammonium chloride (doses indicated) in rats. Here and in Figures 13–17, n is the number of animals in each experimental group (Rumbus, et al., 2024).

*IV/2.2.2. NH₄Cl-induced hypothermia is augmented in mice genetically lacking*

*the TRPV1 channel*

After we showed that the hypothermic response to $NH_4Cl$ is not specific to mice only, we wanted to know if two of the most studied thermo-TRP channels, TRPV1 or TRPA1, are involved in this thermoregulatory response. In our first approach, we compared the hypothermic response to $NH_4Cl$ between $Trpv1^{-/-}$ and $Trpv1^{+/+}$ mice. Since the threshold i.p. dose of $NH_4Cl$ to trigger hypothermia in mice was above 300 mg/kg according to Gordon (Gordon, 1988), in our experiments we infused the mice i.p. with 321 mg/kg of $NH_4Cl$. As expected, at this dose $NH_4Cl$ caused a sudden drop in the colonic temperature of $Trpv1^{+/+}$ mice, which reached the biggest mean decrease of $-2.1 \pm 0.5°C$ at 30 min post-injection (Figure 13). Compared to the vehicle (sterile water), the deep $T_b$ of $NH_4Cl$-treated $Trpv1^{+/+}$ mice was markedly lower between 20-50 min post-injection ($P < 0.05$). In Trpv1$^{-/-}$ mice, $NH_4Cl$ also caused hypothermia compared to sterile water, which was significant between 20-70 min ($P < 0.05$) with a maximal mean decrease of $-4.0 \pm 0.4°C$ ($P < 0.001$). Interestingly, however, the hypothermic response to $NH_4Cl$ was much more pronounced in the $Trpv1^{-/-}$ mice than in their $Trpv1^{+/+}$ littermates (Figure 13). The intergenotype difference was significant ($P < 0.05$) between 20-60 min post-$NH_4Cl$ administration with a maximum of ~2.0°C difference between the groups at 40 min ($P < 0.001$).

Nevertheless, it should be noted that the $NH_4Cl$-induced hypothermia developed in both genotypes of the mice (though to a different extent), which suggests that it also involves TRPV1-independent mechanisms.

**Figure 13.** Colonic temperature responses of *Trpv1*[+/+] and *Trpv1*[-/-] mice to i.p. administration of $NH_4Cl$ (dose indicated) or sterile water (Rumbus, et al., 2024).

IV/2.2.3. *Pharmacological blockade of the TRPV1 channel exaggerates $NH_4Cl$-*

*induced hypothermia in mice and rats*

Our findings in the genetically modified mouse model clearly indicated a bigger hypothermic response in *Trpv1*[-/-] mice. However, it could not be excluded that the *Trpv1*[-/-] mice had developed chronic compensatory mechanisms for the absence of TRPV1, which could have influenced the results. To avoid the potential development of chronic compensation, we decided to use genetically unaltered animals (viz., C57BL/6 mice and

Wistar rats) and block their TRPV1 channels acutely by a pharmacological antagonist, AMG 517.

AMG 517 is a highly potent and selective, in itself hyperthermia-inducing TRPV1 antagonist (Gavva, et al., 2008), which has been tested in hypothermic conditions associated with severe systemic inflammation and with general anesthesia (Garami, et al., 2017; Wanner, et al., 2012). Similarly as in our earlier study (Wanner, et al., 2012), in the present experiments the efficacy of AMG 517 could be confirmed by the higher deep $T_b$ of the AMG 517-treated mice compared to vehicle-treated controls in the present experiments before $NH_4Cl$ administration (Figure 14a). As it could be expected based on our results obtained in $Trpv1^{+/+}$ mice, in the vehicle-pretreated C57BL/6 mice the hypothermic response to $NH_4Cl$ developed rapidly and it reached the biggest mean decrease of $-2.4 \pm 0.4°C$ at 30 min ($P < 0.001$ compared to sterile water) (Figure 14b). In the vehicle-pretreated mice, the $NH_4Cl$-induced decrease in deep $T_b$ was significant ($P < 0.05$) compared to the sterile water-treated group between 20 and 90 min post-injection. Pretreatment with AMG 517 exaggerated the hypothermic effect of $NH_4Cl$ to a maximal mean $T_b$ decrease of $-3.5 \pm 0.6°C$ at 40 min ($P < 0.001$) compared to vehicle pretreatment (Figure 14b). The biggest difference between the mean $T_b$ of the pretreatment groups was $1.6°C$ at 50 min post-$NH_4Cl$ injection ($P < 0.001$). In response to $NH_4Cl$, the deep $T_b$ of the AMG 517-pretreated mice was significantly lower than that of the vehicle-pretreated mice between 30 and 70 min ($P < 0.05$).

**Figure 14. a** Colonic temperature in responses to subcutaneous (s.c.) AMG517 (dose indicated) in mice. **b** Colonic temperature responses of mice to i.p. administration of $NH_4Cl$ (dose indicated) or sterile water after pretreatement at -120 minutes with an s.c. administration of AMG517 (dose indicated) or vehicle (Rumbus, et al., 2024).

We also wanted to confirm that the blockade of TRPV1 leads to the augmentation of $NH_4Cl$-induced hypothermia not only in mice, but also in rats. We administered the same dose (210 µg/kg) of AMG 517 to rats i.v. 20 min before the i.p. injection of $NH_4Cl$. As expected, AMG 517 caused prompt hyperthermia, which was present also at the time of the i.p $NH_4Cl$ injection (Figure 15a). After the injection of $NH_4Cl$, the deep $T_b$ of vehicle-pretreated rats started to decrease immediately and reached a mean maximal decrease of -$1.2 \pm 0.2°C$ at 30 min ($P < 0.001$) compared to sterile water injection; it was significantly ($P < 0.05$) different between the two i.p. treatment groups ($NH_4Cl$ vs. sterile water) between 20-100 min (Figure 15b). Importantly, in AMG 517-pretreated rats both the magnitude and the duration of the $NH_4Cl$-induced hypothermia was markedly exaggerated. The maximal mean $T_b$ fall of -$1.7 \pm 0.2°C$ developed at 40 min, and the $T_b$ of the $NH_4Cl$-treated rats remained lower than the $T_b$ of the sterile water-treated rats between 20-130 min ($P < 0.05$). Accordingly, the effect of $NH_4Cl$ on $T_b$ was significantly different between the i.v. pretreatment groups (AMG 517 vs. vehicle) from 40 to 70 and at 110 min post-$NH_4Cl$ injection (Figure 15b).

Similarly to our results with the genetic blockade of TRPV1, the $NH_4Cl$-induced hypothermia developed both with and without the pharmacological blockade of the TRPV1 channel (though to a different extent), which suggests the involvement of TRPV1-independent mechanisms.

**Figure 15. a** Colonic temperature in responses to intravenous (i.v.) infusion AMG517 (dose indicated) in rats. **b** Colonic temperature responses of rats to i.p. administration of $NH_4Cl$ (dose indicated) or sterile water after pretreatement at -20 minutes with an i.v. administration of AMG517 (dose indicated) or vehicle (Rumbus, et al., 2024).

*IV/2.2.4. The hypothermic response to NH₄Cl is attenuated in the absence of the*

*TRPA1 channel in mice*

Because TRPV1 and TRPA1 channels are often co-expressed (Fernandes, Fernandes, & Keeble, 2012; Huang, et al., 2012; Kobayashi, et al., 2005) and crosstalk between them was also reported (Patil, Jeske, & Akopian, 2010; Staruschenko, Jeske, & Akopian, 2010), after discovering the exaggeration of $NH_4Cl$-induced hypothermia in different models of TRPV1 blockade, we studied whether the TRPA1 channel also plays a role in this thermal response. Similarly as in the case of TRPV1, in our first approach we used mice genetically lacking the channel (*Trpa1$^{-/-}$*) and their WT littermates (*Trpa1$^{+/+}$*). As expected, the injection of $NH_4Cl$ (321 mg/kg, i.p.) caused marked hypothermia in *Trpa1$^{+/+}$* mice as compared to sterile water (Figure 16). In *Trpa1$^{+/+}$* mice, the biggest $NH_4Cl$-induced drop in $T_b$ (-2.8 ± 0.3C°) developed 30 min after the injection (P < 0.001), and the $T_b$ of $NH_4Cl$-tretaed mice was significantly lower than the $T_b$ of the sterile-water-treated group from 20 to 110 min post-injection (P < 0.05). In the *Trpa1$^{-/-}$* mice, however, the hypothermic response to $NH_4Cl$ was greatly attenuated: the biggest mean $T_b$ decrease was -2.5 ± 0.2°C at 20 min, and it was significantly (P < 0.05) lower than that of sterile water-treated mice only between 20 and 50 min (Figure 16). With regards to intergenotype difference, *Trpa1$^{+/+}$* mice had significantly lower deep $T_b$ than *Trpa1$^{-/-}$* mice between 40 and 100 min after the administration of $NH_4Cl$ with a maximal mean $T_b$ difference of 1.0°C at 70 min (P = 0.008).

It should be noted that although the NH$_4$Cl-induced hypothermia was markedly attenuated in the genetic absence of the TRPA1 channel, it was still present in the KO mice suggesting the contribution of TRPA1-independent mechanisms to the response.



**Figure 16.** Colonic temperature responses of *Trpa1*[+/+] and *Trpa1*[-/-] mice to i.p. administration of NH$_4$Cl (dose indicated) or sterile water (Rumbus, et al., 2024).

*IV/2.2.5. The hypothermic response to NH$_4$Cl is attenuated by the pharmacological blockade of the TRPA1 channel in rats*

Similarly as in the case of TRPV1, it was important to exclude the potential presence of chronic compensatory mechanisms that may have developed in the absence of the TRPA1 channel in the *Trpa1*[-/-] mice. For that, we used pharmacological blockade of the channel with

a highly potent and selective TRPA1 antagonist, A967079 (Chen, et al., 2011). However, we could not use the mouse experimental model that was applied in case of AMG 517, because the half-life of A967079 is relatively short, ca. 49 min (Chen, et al., 2011), thus the efficacy of the drug could have been questionable 2 hours after its s.c. administration, when $NH_4Cl$ could be injected to mice (for details, see Table 1). In addition, it was of crucial importance to test the contribution of the TRPA1 channel in another species than mice, because interspecies differences were demonstrated in the temperature-sensitivity of the channel as well as in its response to pharmacological agents (for review, see J. Chen & Hackos, 2015). Therefore, we studied the effects of i.v. administered A967079 on $NH_4Cl$-induced hypothermia in rats with a similar experimental design as in the case of AMG 517 (for details, Table 1). In accordance with previous studies (Chen, et al., 2011; de Oliveira, et al., 2014), A967079 did not have any meaningful effect on the colonic temperature of the rats before the i.p injection of $NH_4Cl$ or sterile water (Figure 17). On the contrary, when the same dose (5 mg/kg) of A967079 was infused 20 min before the i.p. injection of $NH_4Cl$, it markedly attenuated the hypothermic response. While the $T_b$ of $NH_4Cl$-treated rats was significantly ($p < 0.05$) lower at 20-150 min compared to sterile water injection after pretreatment with vehicle, in the A967079-pretreated rats the $NH_4Cl$-induced hypothermia was significant only between 10-90 min (Figure 17). In accordance, a statistically significant difference was also present between the two pretreatments groups in the $NH_4Cl$-treated rats between 40-120 min with a maximal difference of 0.7°C at 50 min (P = 0.003).

  In line with our results with the genetic blockade of TRPA1, the $NH_4Cl$-induced hypothermia was substantially attenuated, but still present after the pharmacological

inhibition of the TRPA1 channel suggesting the contribution of TRPA1-independent mediators to the response.



**Figure 17.** Colonic temperature responses of rats to i.p. administration of NH$_4$Cl (dose indicated) or sterile water after pretreatement at -20 minutes with an i.v. administration of A967079 (dose indicated) or vehicle (Rumbus, et al., 2024).

*IV/2.2.6. I.p. administration of NH$_4$Cl decreases the blood pH in rats and mice*

Last, we wanted to know how the applied doses of NH$_4$Cl affected the blood pH of the rats and the mice. In rats, the blood pH after i.p. administration of NH$_4$Cl was decreased at both doses (to 7.47 and 7.24) compared to sterile water treatment (pH = 7.51), however, the difference was significant only at the higher (280 mg/kg) dose (P < 0.001) (Figure 18).

The blood pH was also statistically different between two doses of $NH_4Cl$ ( P< 0.001). In mice, the i.p. injection of $NH_4Cl$ (321 mg/kg) resulted in substantial drop in blood pH in all genotypes compared to sterile water injection (P < 0.001) (Figure 18). The fall in the blood pH of the mice reached a similar extent in all genotypes ranging between 7.23-7.30 after the i.p. injection of $NH_4Cl$.



**Figure 18.** Blood pH of rats and $Trpv1^{+/+}$, $Trpa1^{+/+}$, $Trpv1^{-/-}$ and $Trpa1^{-/-}$ mice in response to i.p. administration of sterile water or $NH_4Cl$ (doses indicated; numbers of animals in parentheses) (Rumbus, et al., 2024).

# V. Discussion

In the present thesis, we investigated the predictive role of vital parameters ($T_b$ and blood pH) for the outcomes of two different manifestations of systemic inflammation and the role of TRP channels in pharmacological modulation of $T_b$. First, we revealed a clear association between $T_b$ and mortality in septic patients by using a detailed statistical approach which was based on an extensive literature search of previous human studies. Second, a strong association between blood pH and the outcome of AP was found with meta-analysis of human studies. Then, our meta-analysis of human-trial data has confirmed that the first-generation TRPV1 antagonists cause hyperthermia in humans, whereas the second-generation compounds may lack this effect. Finally, we showed that the i.p. administration of $NH_4Cl$ decreases deep $T_b$ in rats and mice, and genetic and pharmacological blockade of TRPV1 and TRPA1 channels modulates the hypothermic effect of $NH_4Cl$. Nevertheless, this hypothermic response occurred (to a different extent) in all of our experimental models, indicating that per se neither TRPA1 nor TRPV1 is essential for $NH_4Cl$-induced hypothermia.

In the first part of our work, we found that fever reduces, while hypothermia promotes mortality in septic patients as compared to normothermic subjects. From previous studies of septic patients only limited information was available to show an association between $T_b$ and mortality in a wide temperature range. While a worse outcome was consistently found to be related to hypothermia (Arons, et al., 1999; Clemmer, et al., 1992; Drewry, et al., 2015; Kushimoto, et al., 2013), those studies compared hypothermia with

fever (Arons, et al., 1999; Clemmer, et al., 1992) or with nonhypothermic (i.e., by merging febrile and normothermic) patients (Drewry, et al., 2015; Kushimoto, et al., 2013). In one study, no association was found between hypothermia and the clinical outcome of sepsis (Megged, et al., 2006). Regarding the role of fever, different clinical trials came to controversial results in sepsis. Several authors showed that a higher $T_b$ was beneficial (Bryant, et al., 1971; Mackowiak, Browne, Southern, & Smith, 1980; Megged, et al., 2006; Weinstein, et al., 1983), others that it was disadvantageous (Manthous, et al., 1995; Schortgen, et al., 2012), and a few found no association between fever and mortality (Kushimoto, et al., 2013; Young, et al., 2015). The discrepancy among the studies may result from the limited sample size used in the trials. Another explanation for not detecting significant association could be the insensitivity of the used statistical method. Indeed, when we first performed a commonly used regression analysis, the Pearson correlation, which did not allow us to weight the collected data for example for sample size, we found only a very weak negative correlation ($P = 0.047$) between $T_b$ and mortality ratio in sepsis. Thus, we applied more precise statistical tools (forest plot and meta-regression analyses).

In our analyses, we used a sizeable, heterogeneous population of septic patients (n = 10,834) with a wide range of $T_b$ (33.0–39.9°C). We showed that in sepsis, mortality rates are lower if fever is present and higher in cases of hypothermia as compared to the normothermic group. In addition, we demonstrated a strong negative correlation ($P = 0.0004$) between $T_b$ and mortality ratio with the help of meta-regression analysis. In our statistical approach, we also included a substantial number of septic patient groups with average $T_b$s within the normal range (n = 3,904). Furthermore, when we calculated the mean $T_b$s of septic patients

in the mortality quartiles, we found that it gradually decreased from the lowest to the highest quartile and it was significantly higher in the lowest (0–25%) than in the highest quartile (75–100%) of mortality (38.1 ± 0.1 vs 37.1 ± 0.2°C for mean ± standard error of the mean, respectively). Taken together the results from all of our statistical approaches, our data strongly suggest a predictive role of $T_b$ for the outcome of sepsis.

Sepsis continues to constitute a major challenge in critical care medicine (Esteban, et al., 2007; Fleischmann, et al., 2016; Vincent, et al., 2014; Walkey, et al., 2015). As a form of systemic inflammation, sepsis is frequently accompanied by abnormalities of $T_b$, like fever and hypothermia. In animal experiments, lower doses of endotoxin usually cause fever, whilst higher doses lead to the development of hypothermia (Pakai, Garami, Nucci, Ivanov, & Romanovsky, 2015; Rudaya, Steiner, Robbins, Dragic, & Romanovsky, 2005), indicating that the severity of the disease determines the change in $T_b$ and not the way around. Based on our statistical analyses of human studies, fever seems beneficial, but hypothermia rather disadvantageous for the organism regarding the outcome. However, it has to be noted that the current analysis does not allow us to conclude that the change of $T_b$ per se is responsible for the lower and higher mortality rates in fever and hypothermia, respectively. Instead of a cause-effect relationship, the abnormal $T_b$ should be rather regarded as a prognostic vital parameter of the severity and progress of the inflammation, and as such, as a warning sign, which can help clinicians to assess the outcome of to the infection. However, this association does not automatically imply that fever is always beneficial and hypothermia is harmful in sepsis (Table 2) (Rumbus & Garami, 2019). The causative relationship between the

thermoregulatory manifestations and the outcome in systemic inflammation could not be assessed in our study and it deserves discussion.

**Table 2.** Disease coping strategies in different premorbid conditions, thermoregulatory manifestations, and potential outcomes in different severities of sepsis (Rumbus & Garami, 2019).

| Infection severity | Premorbid condition | Copingstrategy | Deep body temperature | Predicted outcome | Effect on mortality |
|---|---|---|---|---|---|
| Mild | Healthy | Disease fighting | Fever | Pathogen clearance | Not applicable |
| Moderate | Healthy | Disease fighting | Fever | Pathogen clearance | ↓ |
| | | | Extreme fever | Organ failure, energy depletion | ↑ |
| | Comorbidities* or exhaustion† | Disease fighting | Fever | Organ failure, energy depletion | ↑ |
| | | Energy saving | Hypothermia | Disease tolerance†† | ↓ |
| Severe (e.g., septic shock) | Healthy | Energy saving | Hypothermia | Disease tolerance | ↓ |
| | Comorbidities or exhaustion | | Extreme hypothermia | Organ failure | ↑ |

Effects on mortality are marked as: ↓, decrease; ↑, increase. *E.g., pre-existing cardiovascular, pulmonary, neurological disease. †E.g., because of old age, starvation, prolonged systemic inflammation. ††The host's ability to tolerate the presence of the pathogen (for details, see Garami, Steiner, & Romanovsky, 2018).

With regards to the adaptive biological value of $T_b$ alterations in mammals, the development of fever in systemic inflammation is considered to indicate the activation of defense mechanisms of the body to fight the intruding agent (Romanovsky, et al., 2005; Romanovsky & Szekely, 1998; Saper, et al., 2012). By enhancing immune functions and accelerating the elimination of the microorganism from the body, at the onset of the

inflammation fever is an adaptive, beneficial thermoregulatory response, although it involves a higher energy cost (Romanovsky, et al., 2005; Romanovsky & Szekely, 1998; Saper, et al., 2012). Therefore, fever itself is assumed to have a direct, advantageous effect on the mortality ratio in systemic inflammation (e.g., sepsis), when it is affordable for the host. However, $T_b$ regulation should be considered in the framework of complex energy balance (Garami A, 2014), therefore, the beneficial value of fever as an energetically expensive defense response is doubtable when there is a risk of energy deficiency, which often develops as the severity of the disease further progresses. In support of that, the administration of antipyretics resulted in an increase of mortality rate of critically ill patients in prospective clinical trials (Lee, et al., 2012; Schulman, 2005). However, in severe sepsis or septic shock, the use of pharmacological antipyretics did not influence mortality (Bernard, et al., 1997; Mohr, et al., 2012), while fever control with external cooling decreased early mortality in human studies (Schortgen, et al., 2012).

Spontaneous hypothermia represents a distinct, adaptive mechanism to systemic inflammation in experimental animals (Liu, et al., 2012) and in septic patients (Fonseca, et al., 2016). It characteristically develops in severe cases of already progressed diseases, when—instead of actively coping with the microorganism—the organism attempts to increase survival by saving its energy resources (Romanovsky, et al., 2005; Romanovsky & Szekely, 1998). A recent study by Fonseca et al. (Fonseca, et al., 2016) revealed that spontaneous hypothermia is a transient, self-limiting, and nonterminal event in human sepsis, which underlies its biological value as an adaptive mechanism in the critically ill patients. According to this study, hypothermia can occur not only when systemic

inflammation becomes more severe. In the studies of our meta-analysis constantly monitored $T_b$ values were not reported, thus the effect of spontaneous nonterminal hypothermia itself on mortality rate could not be analyzed. On the other hand, the effect of a febrile episode before terminal hypothermia could not be analyzed for similar reasons. However, regarding mortality, a modulating effect of initial fever cannot be ruled out.

Although the results of our analysis showed that hypothermia is associated with higher mortality, it should be noted that we can not be sure how mortality ratio of the patients would have changed if hypothermia had not developed or if the patients were rewarmed. As of today, to our knowledge, the effect of rewarming vs non-rewarming on the mortality of septic patients with spontaneous hypothermia has not been compared in randomized controlled trials. Therefore, hypothermia in itself should not be regarded harmful for the body as the associated higher mortality rate of the septic patients is presumably due to their more severe clinical condition. We suggest that the difference between the mortality rates of febrile and hypothermic patients with sepsis is due to the different severity and progression of the inflammation and not due to $T_b$ itself. As a consequence, $T_b$ itself serves not as a detrimental factor, but instead, as an indicative predictor for the severity of the disease and as such for mortality in sepsis.

From a clinical perspective, our results highlight the importance of precise and regular measurements of deep $T_b$, since its abnormalities can help physicians - especially in critical care medicine - not only in the diagnosis, but also in the follow up of the progression, and in the prognosis of sepsis. Based on our findings, it would be worth to consider that hypothermia should be weighted differently than fever and not equally as currently used in

many scoring systems (e.g., SIRS, APACHE), since hypothermia indicates a more severe stage of sepsis, and therefore it is associated with worse clinical outcome. Regarding therapeutic interventions, the $T_b$ management of septic patients should be always carefully evaluated and perhaps guidelines could be established (e.g., for the initiation of antipyretic treatment) to improve the clinical outcome in sepsis.

Next, investigating another important vital parameter, the blood pH, our analyses showed that lower blood pH predicts higher mortality rate, longer LOS, and worsens the severity of AP. A significant negative correlation between blood pH and mortality rate in severe forms of AP was found with meta-regression analysis of human studies.

Although previous human studies indicated a link between MA and AP (Nair, et al., 2000; Sharma, et al., 2014; Shen, et al., 2016; Shinzeki, et al., 2008; Zhu, et al., 2003), we found only one, single-center prospective study which directly aimed to explore this correlation (Sharma, et al., 2014). Because of the scarcity of data available from targeted clinical trials, we aimed to clarify the association between MA and AP by systematic review of the current literature and by meta-analysis of the available data. By identifying 13 eligible studies for the analysis (Eachempati, et al., 2002; Kaya, et al., 2007; Keskinen, et al., 2007; Lei, et al., 2013; Nair, et al., 2000; Pupelis, et al., 2007; Ranson, et al., 1976; Sharma, et al., 2014; Shen, et al., 2016; Shinzeki, et al., 2008; Zhan, et al., 2015; Zhu, et al., 2003), we included 2,311 patients with AP in the analyses. In all of these studies, blood sample analysis was performed at admission or within 24 h thereafter, hence the blood pH parameters were determined with practically the same latency compared to the time when AP was diagnosed. Unavoidably however, the disease could progress to different stages in the different patients

before the diagnosis has been reached. There were huge differences between the protocols of the individual studies, but it is remarkable that no matter how the patients were grouped by the authors originally, the patient group with lower pH had always (with no exceptions) worse outcomes (mortality rate, LOS, severity scores) than the group with higher pH in AP, which suggests that in the early stages (viz., until the time of diagnosis) of AP acidosis is an important influencing factor of the outcome regardless from the actual progression of the disease. Unfortunately, the design of the studies did not allow to analyze the causative relationship between MA and AP. In most of the studies, the systemic pH status of the patients prior to or repeatedly after the diagnosis of AP was not reported, thus the dynamics in the changes of pH during the time course of AP could not be assessed in the current analysis, but it is notable that the average base deficit was markedly (4-8 fold) higher in populations of patients, who did not survive severe AP (Kaya, et al., 2007; Keskinen, et al., 2007). In the prospective trial by Sharma et al. (Sharma, et al., 2014), in those severe AP patients, who had a blood pH of less than 7.35, the mortality rate was nearly 10 times higher than in those patients whose pH was above this level (54 vs. 6.5%).

As limitations of our study, it should be mentioned that even though our meta-analysis showed a clear association between blood pH and the outcome of AP, since originally the patients were not divided into subgroups based on their blood pH by the authors, the independent effect of lower blood pH on the outcome and the cause-effect relationship between MA and AP could not be assessed. Because of the same reason and also to reduce the inter-study heterogeneity, in each of the analyzed studies we assigned one patient group as the lower pH group and the other one as the higher pH group. Since the

reported pH values differed substantially among the analyzed studies, the cut-off value between the lower and the higher pH groups was individually determined for each study. Consequently, in the present analysis we could not determine a specific cut-off pH value which would be detrimental for the outcome of AP. The most convincing method to obtain direct evidence for the role of acidosis as an independent risk factor in AP, determine a detrimental cut-off pH value, and gain insight into the cause-effect relationship in humans would be to conduct targeted clinical trials in which patients with AP are grouped based on their blood pH at admission and their acid-base status as well as the severity and the outcome of AP is continuously monitored. By collecting data of individual patients in such clinical trials, it would be possible to statistically analyze the direct (independent) effect of acid-base disturbances on AP. Until such or similar trials are conducted, we are restricted to use different (not so direct) approaches such as meta-analyses and animal experiments.

Secondly, we studied the role of TRP channels in the pharmacological modulation of $T_b$ by conducting meta-analysis of clinical trials and animal experiments (Garami, et al., 2020; Rumbus, et al., 2024). This was important because targeted modulation of $T_b$ may improve the outcomes of systemic inflammation.

Our meta-analysis of the human-trial data has confirmed that the first-generation TRPV1 antagonists cause hyperthermia in humans, whereas the second-generation compounds may lack this effect. In humans TRPV1 channels may modulate $T_b$ via pH and heat signals. The location of TRPV1 channels that sense $T_b$s (whether shell or core) to drive thermoeffector responses in humans is unknown and can be different from the location of the channels that are tonically activated by protons. Knowing that the skin plays a prominent

thermosensory role in all species, at least some TRPV1 channels that mediate thermal signals to drive thermoeffectors in humans can be speculated to be located in the skin.

Finally, in animal experiments, we revealed that the genetic and pharmacological blockade of the TRPV1 channel exaggerates the hypothermic effect of $NH_4Cl$. On the contrary, the hypothermic response to $NH_4Cl$ is attenuated by the genetic ablation and pharmacological inhibition of the TRPA1 channel. These findings suggest that TRPV1 channels are limiting regulators, whereas TRPA1 channels are potentiating signaling molecules of $NH_4Cl$-induced hypothermia.

The hypothermic effect of i.p. administered $NH_4Cl$ has been shown in mice long time ago (Gordon, 1988). However, it has remained unknown whether it also develops in other species and which receptors are involved in the $NH_4Cl$-induced hypothermic response. $NH_4Cl$ administration is often used to induce MA in rodents (Celotto, et al., 2016; Galicek, et al., 1981; Nowik, et al., 2010; Rothe & Schimek, 1984; Rumbus, et al., 2018). The mechanism of $NH_4Cl$-induced MA is consumption of bicarbonate during conversion of ammonia to urea nitrogen via the urea cycle (Matsumoto, et al., 2019). In severe cases of the $NH_4Cl$-induced MA, a fall in intracellular pH also developed (Tizianello, et al., 1977), although the intra- and extracellular pH levels did not always correlate in milder cases of acidosis (extracellular pH drop of 0.11-0.19) (Rothe & Schimek, 1984; Tizianello, et al., 1977). The different effects on pH can originate from the used species (rat vs. mouse), experimental model (in vitro vs. in vivo), and acid loading protocol (acute vs. chronic). In our experiments, $NH_4Cl$ decreased the blood pH to ~7.25 in rats and mice, which was

markedly lower than in the control animals, however, in this in vivo experimental design the intracellular pH could not be measured.

The decreased blood pH could potentially serve as a direct mechanism for the development of the hypothermia through the stimulation of the TRPV1-mediated acido-antithermogenic and acido-antivasoconstrictor reflexes that originate from trunk muscles and limit the increase in deep $T_b$ during physical exercise (for review, see Garami, et al., 2020). However, since the $NH_4Cl$-induced hypothermia was still detectable after genetic and pharmacological blockade of both the TRPV1 and the TRPA1 channels, it cannot be excluded that the hypothermic response to the decreased blood pH involved TRPV1- and TRPA1-independent mechanisms. Several acid-sensitive ion channels, other than TRPV1 and TRPA1, are expressed on primary sensory neurons, which are involved in a number of physiological and pathophysiological reactions to acidosis (for review, see Holzer, 2009). Whether any of these acid sensors contribute to the development of $NH_4Cl$-induced hypothermia remains subject for future studies. It is also possible, however, that the hypothermic effect of $NH_4Cl$ was triggered by mechanisms that are not related solely to the decreased blood pH, because the lower dose of $NH_4Cl$ caused hypothermia in rats, but it did not influence the blood pH significantly, which argues against a direct acid-induced effect. Unfortunately, the pH of the mice was not reported in the study by Gordon (Gordon, 1988). It should be also noted that although the acidosis clearly developed in the rats (at the higher dose) as well as in the mice of all genotypes in our experiments, the extent of decrease in blood pH was not very severe. The drop in blood pH was probably not sufficient to reach the proton activation threshold of the TRPV1 channel, because the half-maximal response

of the rat TRPV1 channel to protons occurs at a pH of ~5.78 in vitro (McIntyre, et al., 2001). However, the elevated proton concentrations could potentiate responses evoked by other agonists, resulting in increased activity of the channel (Tominaga, et al., 1998). With regards to the TRPA1 channel the pH activation is complex. It was demonstrated that weak acids activate rodent TRPA1, but this was due to intracellular acidosis and direct proton activation of the channel from the cytosolic side (Wang, et al., 2011; Wang, Chang, & Liman, 2010). Although protons can rapidly permeate through the membrane to induce an intracellular acidosis when the extracellular $H^+$ concentration is increased (Andersson, Chase, & Bevan, 2004), rodent TRPA1 failed to respond to extracellular acidosis, and protons even inhibited the channel in a later study (de la Roche, et al., 2013). Nevertheless, exclusively in humans, TRPA1 is an important (nociceptive) proton sensor (de la Roche, et al., 2013), which complicates the translation of results from animal experiments to humans. Moreover, in case of $NH_4Cl$ administration the intracellular pH level does not always correlate with the extracellular pH and an increased pH within the cell was also described instead of acidosis (for review, see Roos & Boron, 1981). Ammonia and intracellular alkalization were shown to activate both the TRPV1 and the TRPA1 channels (Dhaka, et al., 2009; Fujita, et al., 2008). Hence, the rapid inward diffusion of gaseous ammonia and the resulting intracellular alkalization could have also contributed to our results. It is known that systemic (i.v.) administration of $NH_4Cl$ leads to formation of ammonia, which can readily cross the blood-brain barrier (Rapoport & Thompson, 1974). This raises the possibility that activation of TRPA1 channels in thermoregulatory neurons in the brain triggered the hypothermic response, as shown earlier in case of another gasotransmitter, hydrogen sulfide (Olah, et al.,

2021), but the investigation of the exact molecular interaction between $NH_4Cl$ and TRP channels, as well as finding the site of the thermoregulatory action of $NH_4Cl$ were beyond the scope of the present study and remain subjects for future research.

The exaggeration of $NH_4Cl$-induced hypothermia by the blockade of TRPV1 channels was an unexpected novel finding. We can only speculate that $NH_4^+$ ions could inhibit TRPV1 channels located in the abdominal wall, which were shown to tonically suppress skin vasoconstriction and thermogenesis (Garami, et al., 2023). When these TRPV1 channels are blocked with genetic or pharmacological tools the hypothermia-counteracting effect is absent, hence the thermal response to $NH_4Cl$ becomes augmented. In support of this assumption, it was found that different quaternary ammonium ions blocked the TRPV1 channel from the intracellular surface with the bigger molecules becoming slower blockers (Jara-Oseguera, Llorente, Rosenbaum, & Islas, 2008). As an alternative theory, we showed earlier that acidosis-induced vasodilation of rat and mouse tail arteries are limited by non-neuronal TRPV1 channels in the vascular wall (Ivic, et al., 2016), thus it can be assumed that the blockade of these vasodilation-limiting TRPV1 channels could result in higher heat loss and exaggerated hypothermic response to $NH_4Cl$. It has to be noted, however, that the abovementioned action mechanisms of $NH_4Cl$ on TRPV1 channels remain hypothetical until directly tested in future experiments. As another limitation of our study, it should be mentioned that we used only male animals in our experiments, hence sex differences in the thermal response to $NH_4Cl$ could not be investigated. Nevertheless, our results can also serve as an encouraging basis for designing future studies, which are required to determine the

potential presence of sex differences in the development of $NH_4Cl$-induced hypothermia and its relation to TRPA1 and TRPV1 channels.

# VI. Conclusions

In the present work, we investigated the predictive role of two vital parameters, the $T_b$ and the blood pH, in an infectious (sepsis) and mainly noninfectious (AP) manifestation of systemic inflammation. The deviations of deep $T_b$ are strongly associated with mortality in sepsis. We revealed a strong negative correlation between the mortality ratio and deep $T_b$. In our meta-analysis, we included data from a total of 10,834 septic patients in a wide temperature range (between 33.0 and 39.9°C) thus the sample size and temperature range can be considered large enough to draw conclusions about the association of $T_b$ and mortality rate in sepsis. Furthermore, patients with the lowest mortality quartile have significantly higher deep $T_b$ than those who belong to the highest mortality quartile. Similar to the $T_b$, the correlation between blood pH and mortality showed significant negative correlation in AP. We also found that lower systemic pH predicts longer LOS, and worsens the severity of AP. Our findings suggest that systemic pH level should be closely monitored in patients with AP and normalization of the low pH of patients with AP should be considered in clinical settings.

In the second part of my work, we highlighted the importance of the nonthermal activation of TRPV1 and TRPA1 channels in thermoregulation with different methodological designs in humans and rodents. Our meta-analysis of human trials showed that the first-generation TRPV1 antagonists cause hyperthermia in humans, whereas the second-generation compounds may lack this effect. In our animal experiments we found that (i) i.p. administration of $NH_4Cl$ induces hypothermia in rats as well as in mice; (ii) TRPA1 channels contribute to the development of $NH_4Cl$-induced hypothermia in both mice and

rats; (iii) TRPV1 channels play a limiting function in this process. It can be hypothesized that activation of TRPA1 channels in thermoregulation-related brain nuclei are responsible for the induction of $NH_4Cl$-induced hypothermia, while TRPV1 channels on the periphery, possibly in abdominal muscles or vascular smooth muscle exert a limiting effect on the response although in itself neither of them is essential for the occurrence of the response. Our findings highlight the importance of the nonthermal activation of TRPV1 and TRPA1 channels in thermoregulation. Since $NH_4Cl$ is still used in clinical practice (e.g., as a diuretic, expectorant, and perhaps COVID-19 treatment), the present results warrant for regular $T_b$ monitoring and careful consideration of the treatment, especially in patients with TRPA1 and TRPV1 channel function disorders.

In systemic inflammation, the pharmacological modulation of $T_b$ may be beneficial in humans and animals, and TRPV1 and TRPA1 channels are probably good targets to modify $T_b$. However, future research is needed to clarify the pharmacological potential of these channels in this field.

## VII. Summary of new findings

1. In our meta-analysis we revealed a strong negative correlation between the mortality ratio and deep $T_b$ in sepsis. Patients with hypothermia have a higher predicted mortality rate than patients with fever. This finding emphasizes that hypothermia and fever should be weighted not equally as currently used in many scoring systems (e.g., SIRS, APACHE).

2. We also showed that lower blood pH or base excess is associated with higher mortality rate, elevated severity scores, and longer hospital stay in AP patients. Similar to hypothermia and fever in sepsis, acidosis and alkalosis should not be weighted equally as the APACHE II score does.

3. The mode-nonselective TRPV1 antagonists cause hyperthermia whereas NEO6860, the mode-selective TRPV1 antagonist, decreased the deep $T_b$. The hyperthermic effect of mode-nonselective TRPV1 antagonists is dose-dependent.

4. We described that the $NH_4Cl$-induced hypothermic response is not specific only for mice because the i.p. administration of $NH_4Cl$ decreases deep $T_b$ in rats as well.

5. TRPA1 channels contribute to the development of $NH_4Cl$-induced hypothermia in mice and rats whereas TRPV1 channels play a limiting function.

6. I.p. administration of $NH_4Cl$ decreases the blood pH in rats and mice. The drop in the blood pH of the mice reached a similar extent in *Trpv1*, *Trpa1* KO and WT mice.

## VIII. Acknowledgments

First of all, I would like to thank my supervisor, Dr Andras Garami for guiding me to conduct research work in the field of thermophysiology, and for the help and support he has given to me.

I would like to express my deep gratitude to Prof. Peter Hegyi, the leader of the Translational Medicine doctoral program and head of the institute for providing me the opportunity to fulfill my Ph.D. studies in the Department of Translational Medicine.

I would like to also thank all members of the research group at the Department of Thermophysiology for their help and professional advice during my research through all these years. I would not have been able to carry out my experimental work without the help of assistants, whose expertise has been invaluable throughout this project.

Finally, I cannot be grateful enough to my family for supporting me, my wife for encouraging me all the time with unconditional love and patience.

## IX. Appendix

**Publications related to the subject of the thesis**

- Number of publications related to the subject of the thesis: 5

- Number of publications not related to the subject of the thesis: 36

- Number of book chapters: 1

- Sum of all impact factors: 157.789

- Sum of impact factors from publications related to the topic of PhD thesis: 23.477

- All citations: 866

- Independent citations: 779

**Publications related to the topic of the PhD thesis**

**Rumbus, Z**., Fekete, K., Kelava, L., Gardos, B., Klonfar, K., Keringer, P., Pinter, E., Pakai, E., & Garami, A. Ammonium chloride-induced hypothermia is attenuated by transient receptor potential channel vanilloid-1, but augmented by ankyrin-1 in rodents. Life sciences, 2024;346, 122633. Advance online publication.
**IF: 5.2 Q1/D1          Total citations/Independent citations: 0/0**

Garami, A., Shimansky, Y. P., **Rumbus, Z**., Vizin, R. C. L., Farkas, N., Hegyi, J., Szakacs, Z., Solymar, M., Csenkey, A., Chiche, D. A., Kapil, R., Kyle, D. J., Van Horn, W. D., Hegyi, P., & Romanovsky, A. A. Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis. Pharmacology & therapeutics, 2020, 208, 107474.
**IF: 12.31 Q1/D1          Total citations/Independent citations: 90/84**

**Rumbus, Z**., & Garami, A. Fever, hypothermia, and mortality in sepsis: Comment on: Rumbus Z, Matics R, Hegyi P, Zsiboras C, Szabo I, Illes A, Petervari E, Balasko M, Marta K, Miko A, Parniczky A, Tenk J, Rostas I, Solymar M, Garami A. Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials. PLoS One. 2017;12(1):e0170152. DOI: 10.1371/journal.pone.0170152. Temperature (Austin, Tex.), 2018. 6(2), 101–103.

**Rumbus, Z.,** Toth, E., Poto, L., Vincze, A., Veres, G., Czako, L., Olah, E., Marta, K., Miko, A., Rakonczay, Z., Jr, Balla, Z., Kaszaki, J., Foldesi, I., Maleth, J., Hegyi, P., & Garami, A. Bidirectional relationship between reduced blood pH and acute pancreatitis: A translational study of their noxious combination. Frontiers in physiology, 2018; 9, 1360.
**IF: 3.201 Q2         Total citations/Independent citations: 11/5**

**Rumbus, Z.,** Matics, R., Hegyi, P., Zsiboras, C., Szabo, I., Illes, A., Petervari, E., Balasko, M., Marta, K., Miko, A., Parniczky, A., Tenk, J., Rostas, I., Solymar, M., & Garami, A. Fever is associated with reduced, hypothermia with increased mortality in septic patients: A meta-analysis of clinical trials. Plos one, 2017; 12(1), e0170152.
**IF: 2.766 Q1         Total citations/Independent citations: 110/100**

**Other publications, not related to the topic of the PhD thesis**

Bálint, A., Hanák, L., Hegyi, P., Szakács, Z., Eitmann, S., Garami, A., Solymár, M., Márta, K., **Rumbus, Z.,** & Komócsi, A. Increased risk of adverse events in patients with low-on clopidogrel platelet reactivity after percutaneous coronary intervention: A systematic review and meta-analysis. Cardiology journal, 2023;30(3), 391–400.
**IF: 2.9 Q2             Total citations/Independent citations: 3/1**

Garai, J., Radnai, B., Vámos, E., Kovács, D., Vántus, V. B., **Rumbus, Z.,** Pákai, E., Garami, A., Gulyás-Fekete, G., Agócs, A., Krekó, M., Zaman, K., Prókai, L., Őrfi, L., Jakus, P. B., & Lóránd, T. Synthesis and evaluation of a new class of MIF-inhibitors in activated macrophage cells and in experimental septic shock in mice. European journal of medicinal chemistry, 2023; 247, 115050.
**IF: 6.0 Q1             Total citations/Independent citations: 2/1**

Jávor, P., Hanák, L., Hegyi, P., Csonka, E., Butt, E., Horváth, T., Góg, I., Lukacs, A., Soós, A., **Rumbus, Z.**, Pákai, E., Toldi, J., & Hartmann, P. Predictive value of tachycardia for mortality in trauma-related haemorrhagic shock: a systematic review and meta-regression. BMJ open, 2022; 12(10), e059271.
**IF: 2.9 Q1             Total citations/Independent citations: 4/3**

Kelava, L., Nemeth, D., Hegyi, P., Keringer, P., Kovacs, D. K., Balasko, M., Solymar, M., Pakai, E., **Rumbus, Z**., & Garami, A. Dietary supplementation of transient receptor potential vanilloid-1 channel agonists reduces serum total cholesterol level: a meta-analysis of controlled human trials. Critical reviews in food science and nutrition, 2022; 62(25), 7025–7035.
**IF: 10.2 Q1/D1        Total citations/Independent citations: 10/10**

Keringer, P., Furedi, N., Gaszner, B., Miko, A., Pakai, E., Fekete, K., Olah, E., Kelava, L., Romanovsky, A. A., **Rumbus, Z.**, & Garami, A. The hyperthermic effect of central cholecystokinin is mediated by the cyclooxygenase-2 pathway. American journal of physiology. Endocrinology and metabolism, 2022; 322(1), E10–E23.

**IF: 5.1 Q1          Total citations/Independent citations: 4/3**

Kovács, D. K., Gede, N., Szabó, L., Hegyi, P., Szakács, Z., Faludi, B., Sebők, Á., Garami, A., Solymár, M., Kósa, D., Hanák, L., Rumbus, Z., & Balaskó, M. Weight reduction added to CPAP decreases blood pressure and triglyceride level in OSA: Systematic review and meta-analysis. Clinical and translational science, 2022; 15(5), 1238–1248.

**IF: 3.9 Q1/D1          Total citations/Independent citations: 5/5**

Lőrincz, A., Váradi, A., Hegyi, P., **Rumbus, Z.,** Tuba, M., Lamberti, A. G., Varjú-Solymár, M., Párniczky, A., Erőss, B., Garami, A., & Józsa, G. Paediatric partial-thickness burn therapy: a meta-analysis and systematic review of randomised cntrolled trials. *Life (Basel, Switzerland)*, 2022; *12*(5), 619.

**IF: 3.2 Q2          Total citations/Independent citations: 6/3**

Ruzsics, I., Matrai, P., Hegyi, P., Nemeth, D., Tenk, J., Csenkey, A., Eross, B., Varga, G., Balasko, M., Petervari, E., Veres, G., Sepp, R., Rakonczay, Z., Jr, Vincze, A., Garami, A., **Rumbus, Z.** Noninvasive ventilation improves the outcome in patients with pneumonia-associated respiratory failure: Systematic review and meta-analysis. Journal of infection and public health,  2022; 15(3), 349–359.

**IF: 6.7 Q1          Total citations/Independent citations: 7/7**

Garai, J., Krekó, M., Őrfi, L., Jakus, P. B., **Rumbus, Z.,** Kéringer, P., Garami, A., Vámos, E., Kovács, D., Bagóné Vántus, V., Radnai, B., & Lóránd, T. Tetralone derivatives are MIF tautomerase inhibitors and attenuate macrophage activation and amplify the hypothermic response in endotoxemic mice. Journal of enzyme inhibition and medicinal chemistry, 2021; 36(1), 1357–1369.

**IF: 5.756 Q2          Total citations/Independent citations: 3/1**

Martonosi, Á. R., Soós, A., **Rumbus, Z.,** Hegyi, P., Izsák, V., Pázmány, P., Imrei, M., Váncsa, S., Szakács, Z., Párniczky, A. Non-invasive diagnostic tests in cystic fibrosis-related liver disease: A diagnostic test accuracy network meta-analysis. Frontiers in medicine, 2021; 8, 598382.

**IF: 5.058 Q1          Total citations/Independent citations: 3/3**

Olah, E., **Rumbus, Z**., Kormos, V., Tekus, V., Pakai, E., Wilson, H. V., Fekete, K., Solymar, M., Kelava, L., Keringer, P., Gaszner, B., Whiteman, M., Keeble, J., Pinter, E., & Garami, A. The hypothermic effect of hydrogen sulfide is mediated by the transient receptor potential

ankyrin-1 channel in mice. Pharmaceuticals (Basel, Switzerland), 2021; 14(10), 992.
**IF: 5.215 Q1          Total citations/Independent citations: 9/3**

Olah, E., Poto, L., **Rumbus, Z.,** Pakai, E., Romanovsky, A. A., Hegyi, P., & Garami, A. POLAR study revisited: therapeutic hypothermia in severe brain trauma should not be abandoned. Journal of neurotrauma, 2021; 38(19), 2772–2776.
**IF: 4.869 Q1          Total citations/Independent citations: 3/2**

Toldi, J., Nemeth, D., Hegyi, P., Molnar, Z., Solymar, M., Farkas, N., Alizadeh, H., **Rumbus, Z**., Pakai, E., & Garami, A. Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials. Scientific reports, 2021; 11(1), 8051.
**IF: 4.997 Q1/D1          Total citations/Independent citations: 13/12**

Trimmel, B., Gede, N., Hegyi, P., Szakács, Z., Mezey, G. A., Varga, E., Kivovics, M., Hanák, L., **Rumbus, Z**., & Szabó, G. Relative performance of various biomaterials used for maxillary sinus augmentation: A Bayesian network meta-analysis. Clinical oral implants research, 2021; 32(2), 135–153.
**IF: 5.021 Q1/D1          Total citations/Independent citations: 26/25**

Erős, A., Soós, A., Hegyi, P., Szakács, Z., Erőss, B., Párniczky, A., Mezősi, E., **Rumbus, Z**., & Sarlós, P. Spotlight on transition in patients with inflammatory bowel disease: a systematic review. Inflammatory bowel diseases, 2020; 26(3), 331–346.
**IF: 5.325 Q1/D1          Total citations/Independent citations: 25/22**

Kerémi, B., Márta, K., Farkas, K., Czumbel, L. M., Tóth, B., Szakács, Z., Csupor, D., Czimmer, J., **Rumbus, Z.,** Révész, P., Németh, A., Gerber, G., Hegyi, P., & Varga, G. Effects of chlorine dioxide on oral hygiene - A systematic review and meta-analysis. Current pharmaceutical design, 2020;  26(25), 3015–3025.
**IF: 3.116 Q2          Total citations/Independent citations: 20/17**

Keringer, P., Farkas, N., Gede, N., Hegyi, P., **Rumbus, Z**., Lohinai, Z., Solymar, M., Ruksakiet, K., Varga, G., & Garami, A. Menthol can be safely applied to improve thermal perception during physical exercise: a meta-analysis of randomized controlled trials. Scientific reports, 2020; 10(1), 13636.
**IF: 4.38 Q1/D1          Total citations/Independent citations: 12/11**

Lukács, A., Máté, Z., Farkas, N., Mikó, A., Tenk, J., Hegyi, P., Németh, B., Czumbel, L. M., Wuttapon, S., Kiss, I., Gyöngyi, Z., Varga, G., **Rumbus, Z.,** & Szabó, A.The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis. BMC public health, 2020; 20(1), 691.
**IF: 3.295 Q1          Total citations/Independent citations: 26/26**

Csenkey, A., Jozsa, G., Gede, N., Pakai, E., Tinusz, B., **Rumbus, Z.**, Lukacs, A., Gyongyi, Z., Hamar, P., Sepp, R., Romanovsky, A. A., Hegyi, P., Vajda, P., & Garami, A.. Systemic antibiotic prophylaxis does not affect infectious complications in pediatric burn injury: A meta-analysis. PloS one, 2019; 14(9), e0223063.
**IF: 2.74 Q1/D1        Total citations/Independent citations: 32/31**

Bui, T. Q., Bui, Q. V. P., Németh, D., Hegyi, P., Szakács, Z., **Rumbus, Z.**, Tóth, B., Emri, G., Párniczky, A., Sarlós, P., & Varga, O. Epidermal growth factor is effective in the treatment of diabetic foot ulcers: meta-analysis and systematic review. International journal of environmental research and public health, 2019; 16(14), 2584.
**IF: 2.849 Q2        Total citations/Independent citations: 34/33**

Tinusz, B., Szapáry, L., Paládi, B., Tenk, J., **Rumbus, Z.**, Pécsi, D., Szakács, Z., Varga, G., Rakonczay, Z., Jr, Szepes, Z., Czimmer, J., Vincze, Á., Hegyi, P., & Erőss, B. Short-course antibiotic treatment is not inferior to a long-course one in acute cholangitis: a systematic review. Digestive diseases and sciences, 2019; 64(2), 307–315.
**IF: 2.751 Q1        Total citations/Independent citations: 14/13**

Tóth, B., Hegyi, P., Lantos, T., Szakács, Z., Kerémi, B., Varga, G., Tenk, J., Pétervári, E., Balaskó, M., **Rumbus, Z.**, Rakonczay, Z., Bálint, E. R., Kiss, T., & Csupor, D. The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta medica, 2019; 85(1), 24–31.
**IF: 2.687 Q1        Total citations/Independent citations: 83/76**

Keringer, P., & **Rumbus, Z.** The interaction between neurokinin-1 receptors and cyclooxygenase-2 in fever genesis. Temperature (Austin, Tex.), 2019; 6(1), 4–6.

Varjú, P., Gede, N., Szakács, Z., Hegyi, P., Cazacu, I. M., Pécsi, D., Fábián, A., Szepes, Z., Vincze, Á., Tenk, J., Balaskó, M., **Rumbus, Z.**, Garami, A., Csupor, D., & Czimmer, J. (2019). Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis. Neurogastroenterology and motility, 31(5), e13527.
**IF: 2.946 Q1        Total citations/Independent citations: 49/47**

Olah, E., Poto, L., Hegyi, P., Szabo, I., Hartmann, P., Solymar, M., Petervari, E., Balasko, M., Habon, T., **Rumbus, Z.**, Tenk, J., Rostas, I., Weinberg, J., Romanovsky, A. A., & Garami, A. Therapeutic whole-body hypothermia reduces death in severe traumatic brain injury if the cooling index is sufficiently high: meta-analyses of the effect of single cooling parameters and their integrated measure. Journal of neurotrauma, 2018; 35(20), 2407–2417.
**IF: 3.754 Q1        Total citations/Independent citations: 37/31**

Pakai, E., Tekus, V., Zsiboras, C., **Rumbus, Z.,** Olah, E., Keringer, P., Khidhir, N., Matics, R., Deres, L., Ordog, K., Szentes, N., Pohoczky, K., Kemeny, A., Hegyi, P., Pinter, E., & Garami, A. The neurokinin-1 receptor contributes to the early phase of lipopolysaccharide-induced fever via stimulation of peripheral cyclooxygenase-2 protein expression in mice. Frontiers in immunology, 2018; 9, 166.

**IF: 4.716 Q1        Total citations/Independent citations: 17/10**

Zsiborás, C., Mátics, R., Hegyi, P., Balaskó, M., Pétervári, E., Szabó, I., Sarlós, P., Mikó, A., Tenk, J., Rostás, I., Pécsi, D., Garami, A., **Rumbus, Z.,** Huszár, O., & Solymár, M Capsaicin and capsiate could be appropriate agents for treatment of obesity: A meta-analysis of human studies. Critical reviews in food science and nutrition, 2018; 58(9), 1419–1427

**IF:  6.704 Q1/D1      Total citations/Independent citations: 72/71**

Garai, J., Kanizsai, P., **Rumbus, Z.,** Toldi, J., Garami, A., Az akut szisztémás gyulladás kórélettana az alapkutatásoktól a klinikai vonatkozásig ANESZTEZIOLÓGIA ÉS INTENZÍV TERÁPIA 2017; 47 : 4 pp. 5-21. , 17 p

Mosztbacher, D., Farkas, N., Solymár, M., Pár, G., Bajor, J., Szűcs, Á., Czimmer, J., Márta, K., Mikó, A., **Rumbus, Z**., Varjú, P., Hegyi, P., & Párniczky, A. Restoration of energy level in the early phase of acute pediatric pancreatitis. World journal of gastroenterology, 2017; 23(6), 957–963.

**IF: 3.3 Q1          Total citations/Independent citations: 17/14**

Rostás, I., Pótó, L., Mátrai, P., Hegyi, P., Tenk, J., Garami, A., Illés, A., Solymár, M., Pétervári, E., Szűcs, Á., Párniczky, A., Pécsi, D., **Rumbus, Z.,** Zsiborás, C., Füredi, N., & Balaskó, M. In middle-aged and old obese patients, training intervention reduces leptin level: A meta-analysis. PloS one, 2017; 12(8), e0182801.

**IF: 2.766 Q1          Total citations/Independent citations: 33/33**

Szabó, I. L., Mátics, R., Hegyi, P., Garami, A., Illés, A., Sarlós, P., Bajor, J., Szűcs, A., Mosztbacher, D., Márta, K., Szemes, K., Csekő, K., Kővári, B., **Rumbus, Z.,** & Vincze, Á. PPIs prevent aspirin-induced gastrointestinal bleeding better than H2RAs. A systematic review and meta-analysis. Journal of gastrointestinal and liver diseases : JGLD, 2017; 26(4), 395–402.

**IF: 1.964 Q2          Total citations/Independent citations: 27/27**

Ivic, I ; Solymar, M ; Pakai, E ; **Rumbus, Z** ; Pinter, E ; Koller, A ; Garami, A. Transient receptor potential vanilloid-1 channels contribute to the regulation of acid- and base-induced vasomotor responses. Journal of vascular research 2017; 53 : 5-6 pp. 279-290. , 12 p.

**IF: 1.759 Q2          Total citations/Independent citations: 4/1**

Carletto, L., Troncoso, A., Rocha, A. C., **Rumbus, Z.,** Solymár, M., & Garami, A. "Science without Borders" program and Brazilian-Hungarian collaboration in thermoregulation. Temperature (Austin, Tex.), 2015; 2(4), 455–456.

Benkó, R., Undi, S., Wolf, M., Magyar, K., Tóvölgyi, Z., **Rumbus, Z**., & Barthó, L. P(2) purinoceptors account for the non-nitrergic NANC relaxation in the rat ileum. Naunyn-Schmiedeberg's archives of pharmacology, 2006; 373(4), 319–324.
**IF: 2.779 Q1          Total citations/Independent citations: 11/8**

Benko, R., Lazar, Z., Undi, S., Illenyi, L., Antal, A., Horvath, O. P., **Rumbus, Z.,** Wolf, M., Maggi, C. A., & Bartho, L. Inhibition of nitric oxide synthesis blocks the inhibitory response to capsaicin in intestinal circular muscle preparations from different species. Life sciences, 2005; 76(24), 2773–2782.
**IF: 2.512 Q1          Total citations/Independent citations: 22/18**

Lázár, Z., Benkó, R., Bölcskei, K., **Rumbus, Z**., Wolf, M., Holzer, P., Maggi, C. A., & Barthó, L. Actions of endothelin and corticotropin releasing factor in the guinea-pig ileum: no evidence for an interaction with capsaicin-sensitive neurons. Neuropeptides, 2003; 37(4), 220–232.
**IF: 2.153 Q1          Total citations/Independent citations: 14/13**


**Book chapter**

Garami A., Pakai E., **Rumbus Z.**, Solymar M. The role of PACAP in the regulation of body temperature. In: Reglodi and Tamas (ed) Pituitary adenylate cyclase activating polypeptide-PACAP, Current Topics in Neurotoxicity 11. Springer Nature, New York, 2016, 239–257.


**International oral and poster presentations**

**Zoltan Rumbus**, Peter Jakus, Emoke Oláh, Eszter Pákai, Petra Gáspár, Patrik Kéringer, Janos Garai, Tamas Loránd, Andras Garami: The involvement of the macrophage migration inhibitory factor in lipopolysaccharideinduced fever and hypothermia in mice. PPTR 7th International Conference on the Physiology and Pharmacology of Temperature Regulation, Split, October 7-12, 2018

**Rumbus Zoltan**, Jakus Peter, Olah Emoke, Pakai Eszter, Gaspar Petra, Keringer Patrik, Garai Janos, Lorand Tamas, Garami Andras. The mediators of systemic inflammation. Medical conference for PhD students and experts of clinical sciences. 2018. október 27. Pécs

Patrik Keringer, Eszter Pakai, Valeria Tekus, Csaba Zsiboras, **Zoltan Rumbus**, Emoke Olah, Nora Khidhir, Robert Matics, Laszlo Deres, Katalin Ordog, Nikolett Szentes, Krisztina Pohoczky, Agnes Kemeny, Peter Hegyi, Erika Pinter, Andras Garami: The role of neurokinin signalling receptor in the development of endotoxin fever. 16th Annual Conference of the Hungarian Neuroscience Society, Debrecen, January 17-18, 2019.

Patrik Keringer, **Zoltan Rumbus**, Alexandra Miko, Alexandra Csenkey, Petra Gaspar, Eszter Pakai, Emoke Olah, Nora Khidhir, Nora Furedi, Zoltan Horvath-Szalai, Csaba Zsiboras, Margit Solymar, Eva Polyak, Balazs Gaszner, Andras Garami: Acute effects of saccharin on the energetic homeostasis in rodents. PPTR 7th International Conference on the Physiology and Pharmacology of Temperature Regulation, Split, October 7-12, 2018

Andras Garami, Eszter Pákai, Patrik Kéringer, **Zoltan Rumbus**, Alexandra Mikó, Petra Gáspár, Emoke Oláh, Andrej A. Romanovsky: Transient receptor potential vanilloid-1 (TRPV1) channel antagonists as candidates of targeted body temperature modulation – an overview. PPTR 7th International Conference on the Physiology and Pharmacology of Temperature Regulation, Split, October 7-12, 2018

Emese Tóth, **Zoltán Rumbus**, László Potó, Áron Vincze, Gábor Veres, László Czakó, Emőke Oláh, Kata Márta, Alexandra Mikó, Zoltán Rakonczay Jr, Zsolt Balla, János Kaszaki, Imre Földesi, József Maléth, András Garami, Péter Hegyi. Vicious metabolic cycle in acute pancreatitis: from clinical observation to experimental confirmation. Jubilee meeting of the European Pancreatinc Club. Berlin. 2018. június 13-16.

Pakai Eszter, Tekus Valeria, Zsiboras Csaba, **Rumbus Zoltan**, Matics Robert, Deres Laszlo, Pohoczky Krisztina, Kemeny Agnes, Pinter Erika, Garami Andras. The involvement of the neurokinin-1 receptor in lipopolysaccharideinduced fever in mice 6th International Symposium on the Physiology and Pharmacology of Temperature Regulation. 2016. dec. 5-9.


**National oral and poster presentations**


**Rumbus Zoltán**, Jakus Péter, Oláh Emőke, Pákai Eszter, Erdélyi Attila, Kéringer Patrik, Garai János, Lóránd Tamás, Garami András: A makrofág migráció inhibitor faktor szerepe lipopoliszacharida indukálta lázban és hipotermiában egérben. Magyar Kísérletes és Klinikai Farmakológiai Társaság, Magyar Anatómus Társaság, Magyar Mikrocirkulációs és Vaszkuláris Biológiai Társaság, Magyar Élettani Társaság Közös Vándorgyűlése – FAMÉ 2019, Budapest, 2019. jún. 5-8.


**Rumbus Zoltán**, Tóth Emese, Pótó László, Vincze Áron, Veres Gábor, Czakó László, Oláh Eemőke, Márta Kata, Mikó Alexandra, Ifj. Rakonczay Zoltán, Balla Zsolt, Kaszaki János,

Földesi Imre, Maléth József, Hegyi Péter és Garami András. The deadly combination: acidosis and acute pancreatitis. Magyar Gasztroenterológiai Társaság 61. Nagygyűlése. 2019. június 1–4. Siófok

**Rumbus Zoltán**, Oláh Emőke, Pótó László, Hegyi Péter, Szabó Imre, Hartmann Petra, Solymár Margit, Petervári Erika, Balaskó Márta, Habon Tamás, Tenk Judit, Rostás Ildikó, Weinberg J, Romanovsky AA, Pákai Eszter, Kéringer Patrik, Garami András: A novel measure to assess the efficacy of therapeutic whole-body hypothermia in severe traumatic brain injury: the cooling index. Magyar Idegtudományi Társaság 16. Kongresszusa. 2019. január 17-18. Debrecen

Farkas Boglárka, Füredi Nóra, Garami András, **Rumbus Zoltán**, Kovács László, Reglődi Dóra. Possible protective role of oituitary adenylate cyclase-activating polypeptide in rat osteoarthritis- preliminary study. IBRO Workshop 2020 . Szeged 2020. január 29-30.

Kéringer Patrik, Erdélyi Attila, Oláh Emőke, Tékus Valéria, Solymár Margit, Pákai Eszter, **Rumbus Zoltán**, Kemény Ágnes, Gaszner Balázs, Pintér Erika, Garami András: A tranziens receptor potenciál ankyrin-1 szerepe hidrogén-szulfid által indukált hipotermiában. Magyar Kísérletes és Klinikai Farmakológiai Társaság, Magyar Anatómus Társaság, Magyar Mikrocirkulációs és Vaszkuláris Biológiai Társaság, Magyar Élettani Társaság Közös Vándorgyűlése – FAMÉ 2019, Budapest, 2019. június 5-8

Pákai Eszter, Kéringer Patrik, **Rumbus Zoltán**, Erdélyi Attila, Garami András Pécs A tranziens receptor potenciál vanilloid-1 ioncsatorna szerepe az energia homeosztázisban. Magyar Élettani Társaság Vándorgyűlése. 2019. június 5-8. Budapest

Keringer Patrik, Pakai Eszter, Tekus Valeria , Zsiboras Csaba, **Rumbus Zoltan**, Olah Emőke, Khidhir Nora, Matics Robert, Deres Laszlo, Ordog Katalin, Szentes Nikolett, Pohoczky Krisztina, Kemeny Agnes, Hegyi Peter, Pinter Erika, Garami Andras: The role of neurokinin signalling receptor in the development of endotoxin fever. Magyar Idegtudományi Társaság 16. Kongresszusa. 2019. január 17-18. Debrecen

Kéringer Patrik, Pákai Eszter, Tékus Valéria, Zsiborás Csaba, **Rumbus Zoltán**, Oláh Emőke, Khidhir Nóra, Mátics Róbert, Deres László, Ördög Katalin, Szentes Nikolett, Pohóczky Krisztina, Kemény Ágnes, Hegyi Péter, Pintér Erika, Garami András: A neurokinin-1 receptor szerepe az LPS-indukált láz kialakulásában. Magyar Élettani Társaság Vándorgyűlése, Szeged, 2018. jún. 27-30.

Garami Aandrás, Oláh Emőke, Kéringer Patrik, Csenkey Alexandra, Zsiborás Csaba, Gáspár Petra, Pákai Eszter, **Rumbus Zoltán**: Tranziens receptor potenciál vanilloid-1 (TRPV-1) ioncsatorna gátlók, mint a testhőmérséklet célzott modulációjának farmakológiai lehetőségei. 48. Membrán-Transzport Konferencia, Sümeg, 2018. máj. 15-18.

Olah Emőke, Bánki Eszter, Pakai Eszter, **Rumbus Zoltán**, Gaszner Balázs, Zsiborás Csaba, Hashimoto H, Tóth Gergő, Tamás Andrea, Reglődi Dóra, Garami András. Mechanisms of the hyperthermic response to pituitary adenylate cyclase-activating polypeptide in rodents FENS regional meeting Pécs. 2017. szept. 20-23.

Solymár Margit, Khidhir Nóra, Mikó Alexandra, Füredi Nóra, Pákai Eszter, Kéringer Patrik, Kovács Nóra, **Rumbus Zoltán**, Zsiborás Csaba, Garami András: A tranziens receptor potenciál vanilloid-1 csatorna és katabolikus neuropeptidek szerepe a korfüggő testtömeg változások kialakulásában patkányokban. Magyar Farmakológiai, Anatómus, Mikrocirkulációs és Élettani Társaságok Közös Tudományos Konferenciája, 2016. jún. 1-4.

Solymár Margit, Mikó Alexandra, Füredi Nóra, V. Obomate Tobins, Kéringer Patrik, Khidhir Nóra, Zsiborás Csaba, **Rumbus Zoltán**, Garami András: A tranziens receptor potenciál ankyrin-1 (TRPA1) csatorna szerepe hőterhelésben és endotoxin által kiváltott szisztémás gyulladásban. Magyar Farmakológiai, Anatómus, Mikrocirkulációs és Élettani Társaságok Közös Tudományos Konferenciája, 2016. jún. 1-4.

# X. References

Aceng, J. R., Byarugaba, J. S., & Tumwine, J. K. (2005). Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. *BMJ, 330*, 334.

Andersson, D. A., Chase, H. W., & Bevan, S. (2004). TRPM8 activation by menthol, icilin, and cold is differentially modulated by intracellular pH. *J Neurosci, 24*, 5364-5369.

Arons, M. M., Wheeler, A. P., Bernard, G. R., Christman, B. W., Russell, J. A., Schein, R., Summer, W. R., Steinberg, K. P., Fulkerson, W., Wright, P., Dupont, W. D., & Swindell, B. B. (1999). Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. *Crit Care Med, 27*, 699-707.

Asiimwe, S. B., Abdallah, A., & Ssekitoleko, R. (2015). A simple prognostic index based on admission vital signs data among patients with sepsis in a resource-limited setting. *Crit Care, 19*, 86.

Baker, N., Williams, A. J., Tropsha, A., & Ekins, S. (2020). Repurposing quaternary ammonium compounds as potential treatments for COVID-19. *Pharm Res, 37*, 104.

Bamps, D., Vriens, J., de Hoon, J., & Voets, T. (2021). TRP Channel cooperation for cociception: therapeutic opportunities. *Annu Rev Pharmacol Toxicol, 61*, 655-677.

Behrendorff, N., Floetenmeyer, M., Schwiening, C., & Thorn, P. (2010). Protons released during pancreatic acinar cell secretion acidify the lumen and contribute to pancreatitis in mice. *Gastroenterology, 139*, 1711-1720, 1720 e1711-1715.

Bento, L. M., Fagian, M. M., Vercesi, A. E., & Gontijo, J. A. (2007). Effects of NH4Cl-induced systemic metabolic acidosis on kidney mitochondrial coupling and calcium transport in rats. *Nephrol Dial Transplant, 22*, 2817-2823.

Bernard, G. R., Wheeler, A. P., Russell, J. A., Schein, R., Summer, W. R., Steinberg, K. P., Fulkerson, W. J., Wright, P. E., Christman, B. W., Dupont, W. D., Higgins, S. B., & Swindell, B. B. (1997). The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. *N Engl J Med, 336*, 912-918.

Beverly, A., Walter, E., & Carraretto, M. (2016). Management of hyperthermia and hypothermia in sepsis: A recent survey of current practice across UK intensive care units. *J Intensive Care Soc, 17*, 88-89.

Bhoomagoud, M., Jung, T., Atladottir, J., Kolodecik, T. R., Shugrue, C., Chaudhuri, A., Thrower, E. C., & Gorelick, F. S. (2009). Reducing extracellular pH sensitizes the acinar cell to secretagogue-induced pancreatitis responses in rats. *Gastroenterology, 137*, 1083-1092.

Blair, E., Henning, G., Hornick, R., & Cowley, R. A. (1964). Hypothermia in bacteremic shock. *Arch Surg, 89*, 619-629.

Blumberg, P. M., Pearce, L. V., & Lee, J. (2011). TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation. *Curr Top Med Chem, 11*, 2151-2158.

Bolcskei, K., Helyes, Z., Szabo, A., Sandor, K., Elekes, K., Nemeth, J., Almasi, R., Pinter, E., Petho, G., & Szolcsanyi, J. (2005). Investigation of the role of TRPV1 receptors

in acute and chronic nociceptive processes using gene-deficient mice. *Pain, 117*, 368-376.

Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M., & Sibbald, W. J. (1992). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest, 101*, 1644-1655.

Bro-Jeppesen, J., Kjaergaard, J., Wanscher, M., Nielsen, N., Friberg, H., Bjerre, M., & Hassager, C. (2015). Systemic inflammatory response and potential prognostic implications after out-of-hospital cardiac arrest: a substudy of the target temperature management trial. *Crit Care Med, 43*, 1223-1232.

Bryant, R. E., Hood, A. F., Hood, C. E., & Koenig, M. G. (1971). Factors affecting mortality of gram-negative rod bacteremia. *Arch Intern Med, 127*, 120-128.

Carl, D. E., Grossman, C., Behnke, M., Sessler, C. N., & Gehr, T. W. (2010). Effect of timing of dialysis on mortality in critically ill, septic patients with acute renal failure. *Hemodial Int, 14*, 11-17.

Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature, 389*, 816-824.

Celotto, A. C., Ferreira, L. G., Capellini, V. K., Albuquerque, A. A., Rodrigues, A. J., & Evora, P. R. (2016). Acute but not chronic metabolic acidosis potentiates the acetylcholine-induced reduction in blood pressure: an endothelium-dependent effect. *Braz J Med Biol Res, 49*, e5007.

Chen, Joshi, S. K., DiDomenico, S., Perner, R. J., Mikusa, J. P., Gauvin, D. M., Segreti, J. A., Han, P., Zhang, X. F., Niforatos, W., Bianchi, B. R., Baker, S. J., Zhong, C., Simler, G. H., McDonald, H. A., Schmidt, R. G., McGaraughty, S. P., Chu, K. L., Faltynek, C. R., Kort, M. E., Reilly, R. M., & Kym, P. R. (2011). Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. *Pain, 152*, 1165-1172.

Chen, Mu, J., Zhu, M., Mukherjee, A., & Zhang, H. (2020). Transient receptor potential channels and inflammatory bowel disease. *Front Immunol, 11*, 180.

Chen, J., & Hackos, D. H. (2015). TRPA1 as a drug target--promise and challenges. *Naunyn Schmiedebergs Arch Pharmacol, 388*, 451-463.

Clemmer, T. P., Fisher, C. J., Jr., Bone, R. C., Slotman, G. J., Metz, C. A., & Thomas, F. O. (1992). Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. *Crit Care Med, 20*, 1395-1401.

Coe, F. L., Firpo, J. J., Jr., Hollandsworth, D. L., Segil, L., Canterbury, J. M., & Reiss, E. (1975). Effect of acute and chronic metabolic acidosis on serum immunoreactive parathyroid hormone in man. *Kidney Int, 8*, 263-273.

Cunha, B. A. (2012). With sepsis: If fever is good, then hypothermia is bad! *Crit Care Med, 40*, 2926; author reply 2926-2927.

Cuthbertson, B. H., Elders, A., Hall, S., Taylor, J., MacLennan, G., Mackirdy, F., Mackenzie, S. J., Scottish Critical Care Trials, G., & Scottish Intensive Care Society

Audit, G. (2013). Mortality and quality of life in the five years after severe sepsis. *Crit Care, 17*, R70.

Daher, R., Ducrot, N., Lefebvre, T., Zineeddine, S., Ausseil, J., Puy, H., & Karim, Z. (2022). Crosstalk between acidosis and iron metabolism: data from in vivo studies. *Metabolites, 12*.

De Campos, T., Braga, C. F., Kuryura, L., Hebara, D., Assef, J. C., & Rasslan, S. (2008). Changes in the management of patients with severe acute pancreatitis. *Arq Gastroenterol, 45*, 181-185.

de la Roche, J., Eberhardt, M. J., Klinger, A. B., Stanslowsky, N., Wegner, F., Koppert, W., Reeh, P. W., Lampert, A., Fischer, M. J., & Leffler, A. (2013). The molecular basis for species-specific activation of human TRPA1 protein by protons involves poorly conserved residues within transmembrane domains 5 and 6. *J Biol Chem, 288*, 20280-20292.

de Oliveira, C., Garami, A., Lehto, S. G., Pakai, E., Tekus, V., Pohoczky, K., Youngblood, B. D., Wang, W., Kort, M. E., Kym, P. R., Pinter, E., Gavva, N. R., & Romanovsky, A. A. (2014). Transient receptor potential channel ankyrin-1 is not a cold sensor for autonomic thermoregulation in rodents. *J Neurosci, 34*, 4445-4452.

Dhaka, A., Uzzell, V., Dubin, A. E., Mathur, J., Petrus, M., Bandell, M., & Patapoutian, A. (2009). TRPV1 is activated by both acidic and basic pH. *J Neurosci, 29*, 153-158.

Diekema, D. J., Beekmann, S. E., Chapin, K. C., Morel, K. A., Munson, E., & Doern, G. V. (2003). Epidemiology and outcome of nosocomial and community-onset bloodstream infection. *J Clin Microbiol, 41*, 3655-3660.

Doherty, E. M., Fotsch, C., Bannon, A. W., Bo, Y., Chen, N., Dominguez, C., Falsey, J., Gavva, N. R., Katon, J., Nixey, T., Ognyanov, V. I., Pettus, L., Rzasa, R. M., Stec, M., Surapaneni, S., Tamir, R., Zhu, J., Treanor, J. J., & Norman, M. H. (2007). Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. *J Med Chem, 50*, 3515-3527.

Doxiadis, S. A., Goldfinch, M. K., & Holt, K. S. (1953). Alkalosis in infants; treatment by intravenous infusion of ammonium chloride. *Lancet, 265*, 801-804.

Drewry, A. M., Fuller, B. M., Bailey, T. C., & Hotchkiss, R. S. (2013). Body temperature patterns as a predictor of hospital-acquired sepsis in afebrile adult intensive care unit patients: a case-control study. *Crit Care, 17*, R200.

Drewry, A. M., Fuller, B. M., Skrupky, L. P., & Hotchkiss, R. S. (2015). The presence of hypothermia within 24 hours of sepsis diagnosis predicts persistent lymphopenia. *Crit Care Med, 43*, 1165-1169.

DuPont HL, S. W. (1969). Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958–1966. *Medicine (Baltimore). 48(4)*, 307–332.

Eachempati, S. R., Hydo, L. J., & Barie, P. S. (2002). Severity scoring for prognostication in patients with severe acute pancreatitis: comparative analysis of the Ranson score and the APACHE III score. *Arch Surg, 137*, 730-736.

Edge, J., Mundel, T., Pilegaard, H., Hawke, E., Leikis, M., Lopez-Villalobos, N., Oliveira, R. S., & Bishop, D. J. (2015). Ammonium chloride ingestion attenuates exercise-induced mRNA levels in human muscle. *PLoS One, 10*, e0141317.

Esteban, A., Frutos-Vivar, F., Ferguson, N. D., Penuelas, O., Lorente, J. A., Gordo, F., Honrubia, T., Algora, A., Bustos, A., Garcia, G., Diaz-Reganon, I. R., & de Luna, R. R. (2007). Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. *Crit Care Med, 35*, 1284-1289.

Fernandes, E. S., Fernandes, M. A., & Keeble, J. E. (2012). The functions of TRPA1 and TRPV1: moving away from sensory nerves. *Br J Pharmacol, 166*, 510-521.

Fleischmann, C., Scherag, A., Adhikari, N. K., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., Reinhart, K., & International Forum of Acute Care, T. (2016). Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations. *Am J Respir Crit Care Med, 193*, 259-272.

Fonseca, M. T., Rodrigues, A. C., Cezar, L. C., Fujita, A., Soriano, F. G., & Steiner, A. A. (2016). Spontaneous hypothermia in human sepsis is a transient, self-limiting, and nonterminal response. *J Appl Physiol (1985), 120*, 1394-1401.

Fujita, F., Uchida, K., Moriyama, T., Shima, A., Shibasaki, K., Inada, H., Sokabe, T., & Tominaga, M. (2008). Intracellular alkalization causes pain sensation through activation of TRPA1 in mice. *J Clin Invest, 118*, 4049-4057.

Galicek, J., Seow, F., & Lingard, J. M. (1981). The effect of chronic acid/base disturbances on renal amino acid clearances in the rat. *Aust J Exp Biol Med Sci, 59*, 383-391.

Garami, A., Ibrahim, M., Gilbraith, K., Khanna, R., Pakai, E., Miko, A., Pinter, E., Romanovsky, A. A., Porreca, F., & Patwardhan, A. M. (2017). Transient receptor potential vanilloid 1 antagonists prevent anesthesia-induced hypothermia and decrease postincisional opioid dose requirements in rodents. *Anesthesiology, 127*, 813-823.

Garami, A., Pakai, E., McDonald, H. A., Reilly, R. M., Gomtsyan, A., Corrigan, J. J., Pinter, E., Zhu, D. X. D., Lehto, S. G., Gavva, N. R., Kym, P. R., & Romanovsky, A. A. (2018). TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development. *Acta Physiol (Oxf), 223*, e13038.

Garami, A., Pakai, E., Oliveira, D. L., Steiner, A. A., Wanner, S. P., Almeida, M. C., Lesnikov, V. A., Gavva, N. R., & Romanovsky, A. A. (2011). Thermoregulatory phenotype of the Trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis. *J Neurosci, 31*, 1721-1733.

Garami, A., Shimansky, Y. P., Pakai, E., Oliveira, D. L., Gavva, N. R., & Romanovsky, A. A. (2010). Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. *J Neurosci, 30*, 1435-1440.

Garami, A., Shimansky, Y. P., Rumbus, Z., Vizin, R. C. L., Farkas, N., Hegyi, J., Szakacs, Z., Solymar, M., Csenkey, A., Chiche, D. A., Kapil, R., Kyle, D. J., Van Horn, W. D., Hegyi, P., & Romanovsky, A. A. (2020). Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis. *Pharmacol Ther, 208*, 107474.

Garami A, S. M. (2014). Body temperature: Its regulation in framework of energy balance. *Temperature (Austin). 1(1):*, 28–29.

Garami, A., Steiner, A. A., Pakai, E., Wanner, S. P., Almeida, M. C., Keringer, P., Oliveira, D. L., Nakamura, K., Morrison, S. F., & Romanovsky, A. A. (2023). The neural pathway of the hyperthermic response to antagonists of the transient receptor potential vanilloid-1 channel. *Temperature (Austin), 10*, 136-154.

Garami, A., Steiner, A. A., & Romanovsky, A. A. (2018). Fever and hypothermia in systemic inflammation. *Handb Clin Neurol, 157*, 565-597.

Gavva, N. R., Treanor, J. J., Garami, A., Fang, L., Surapaneni, S., Akrami, A., Alvarez, F., Bak, A., Darling, M., Gore, A., Jang, G. R., Kesslak, J. P., Ni, L., Norman, M. H., Palluconi, G., Rose, M. J., Salfi, M., Tan, E., Romanovsky, A. A., Banfield, C., & Davar, G. (2008). Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. *Pain, 136*, 202-210.

Gordon, C. J. (1988). Thermoregulatory responses in mice following acute administration of principal nitrogenous excretory substances. *Pharmacol Biochem Behav, 31*, 699-703.

Gozel MG, E. A., Bodur H, Eren SS. (2012). Risk factors for mortality in patients with nosocomial gram-negative bacteremia. *Turkiye Klinikleri J Med Sci., 32(6)*, 1641–1647.

Green, J. E., Ariathianto, Y., Wong, S. M., Aboltins, C., & Lim, K. (2014). Clinical and inflammatory response to bloodstream infections in octogenarians. *BMC Geriatr, 14*, 55.

Harkness, R. E., & Braun, V. (1989). Inhibition of lipopolysaccharide O-antigen synthesis by colicin M. *J Biol Chem, 264*, 14716-14722.

Heffner, A. C., Horton, J. M., Marchick, M. R., & Jones, A. E. (2010). Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department. *Clin Infect Dis, 50*, 814-820.

Hegyi, P., & Petersen, O. H. (2013). The exocrine pancreas: the acinar-ductal tango in physiology and pathophysiology. *Rev Physiol Biochem Pharmacol, 165*, 1-30.

Hodgin, U. G., & Sanford, J. P. (1965). Gram-negative rod bacteremia. An analysis of 100 patients. *Am J Med, 39*, 952-960.

Hoeboer, S. H., Alberts, E., van den Hul, I., Tacx, A. N., Debets-Ossenkopp, Y. J., & Groeneveld, A. B. (2012). Old and new biomarkers for predicting high and low risk microbial infection in critically ill patients with new onset fever: a case for procalcitonin. *J Infect, 64*, 484-493.

Holzer, P. (2008). The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. *Br J Pharmacol, 155*, 1145-1162.

Holzer, P. (2009). Acid-sensitive ion channels and receptors. *Handb Exp Pharmacol*, 283-332.

Holzer, P. (2011). Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. *Pharmacol Ther, 131*, 142-170.

Huang, D., Li, S., Dhaka, A., Story, G. M., & Cao, Y. Q. (2012). Expression of the transient receptor potential channels TRPV1, TRPA1 and TRPM8 in mouse trigeminal primary afferent neurons innervating the dura. *Mol Pain, 8*, 66.

Hung, M. N., Chen, S. Y., Wang, J. L., Chang, S. C., Hsueh, P. R., Liao, C. H., & Chen, Y. C. (2005). Community-acquired anaerobic bacteremia in adults: one-year experience in a medical center. *J Microbiol Immunol Infect, 38*, 436-443.

Ivic, I., Solymar, M., Pakai, E., Rumbus, Z., Pinter, E., Koller, A., & Garami, A. (2016). Transient receptor potential vanilloid-1 channels contribute to the regulation of acid- and base-induced vasomotor responses. *J Vasc Res, 53*, 279-290.

Jancso-Gabor, A., Szolcsanyi, J., & Jancso, N. (1970). Stimulation and desensitization of the hypothalamic heat-sensitive structures by capsaicin in rats. *J Physiol, 208*, 449-459.

Jara-Oseguera, A., Llorente, I., Rosenbaum, T., & Islas, L. D. (2008). Properties of the inner pore region of TRPV1 channels revealed by block with quaternary ammoniums. *J Gen Physiol, 132*, 547-562.

Jara, A., Felsenfeld, A. J., Bover, J., & Kleeman, C. R. (2000). Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. *Kidney Int, 58*, 1023-1032.

Jordt, S. E., Tominaga, M., & Julius, D. (2000). Acid potentiation of the capsaicin receptor determined by a key extracellular site. *Proc Natl Acad Sci U S A, 97*, 8134-8139.

Julius, D. (2013). TRP channels and pain. *Annu Rev Cell Dev Biol, 29*, 355-384.

Kang, M. J., Shin, T. G., Jo, I. J., Jeon, K., Suh, G. Y., Sim, M. S., Lim, S. Y., Song, K. J., & Jeong, Y. K. (2012). Factors influencing compliance with early resuscitation bundle in the management of severe sepsis and septic shock. *Shock, 38*, 474-479.

Kashio, M., & Tominaga, M. (2022). TRP channels in thermosensation. *Curr Opin Neurobiol, 75*, 102591.

Kaya, E., Dervisoglu, A., & Polat, C. (2007). Evaluation of diagnostic findings and scoring systems in outcome prediction in acute pancreatitis. *World J Gastroenterol, 13*, 3090-3094.

Keringer, P., Furedi, N., Gaszner, B., Miko, A., Pakai, E., Fekete, K., Olah, E., Kelava, L., Romanovsky, A. A., Rumbus, Z., & Garami, A. (2022). The hyperthermic effect of central cholecystokinin is mediated by the cyclooxygenase-2 pathway. *Am J Physiol Endocrinol Metab, 322*, E10-E23.

Keskinen, P., Leppaniemi, A., Pettila, V., Piilonen, A., Kemppainen, E., & Hynninen, M. (2007). Intra-abdominal pressure in severe acute pancreatitis. *World J Emerg Surg, 2*, 2.

Kirov, M. Y., Evgenov, O. V., Evgenov, N. V., Egorina, E. M., Sovershaev, M. A., Sveinbjornsson, B., Nedashkovsky, E. V., & Bjertnaes, L. J. (2001). Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. *Crit Care Med, 29*, 1860-1867.

Kleger, G. R., Turgay, M., Imoberdorf, R., McNurlan, M. A., Garlick, P. J., & Ballmer, P. E. (2001). Acute metabolic acidosis decreases muscle protein synthesis but not albumin synthesis in humans. *Am J Kidney Dis, 38*, 1199-1207.

Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1985). APACHE II: a severity of disease classification system. *Crit Care Med, 13*, 818-829.

Kobayashi, K., Fukuoka, T., Obata, K., Yamanaka, H., Dai, Y., Tokunaga, A., & Noguchi, K. (2005). Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat

primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. *J Comp Neurol, 493*, 596-606.

Kushimoto, S., Gando, S., Saitoh, D., Mayumi, T., Ogura, H., Fujishima, S., Araki, T., Ikeda, H., Kotani, J., Miki, Y., Shiraishi, S., Suzuki, K., Suzuki, Y., Takeyama, N., Takuma, K., Tsuruta, R., Yamaguchi, Y., Yamashita, N., Aikawa, N., & Group, J. S. R. S. (2013). The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. *Crit Care, 17*, R271.

Kushimoto, S., Yamanouchi, S., Endo, T., Sato, T., Nomura, R., Fujita, M., Kudo, D., Omura, T., Miyagawa, N., & Sato, T. (2014). Body temperature abnormalities in non-neurological critically ill patients: a review of the literature. *J Intensive Care, 2*, 14.

Lane, R., & Adams, L. (1993). Metabolic acidosis and breathlessness during exercise and hypercapnia in man. *J Physiol, 461*, 47-61.

Le Gall, J. R., Lemeshow, S., & Saulnier, F. (1993). A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA, 270*, 2957-2963.

Lee, Inui, D., Suh, G. Y., Kim, J. Y., Kwon, J. Y., Park, J., Tada, K., Tanaka, K., Ietsugu, K., Uehara, K., Dote, K., Tajimi, K., Morita, K., Matsuo, K., Hoshino, K., Hosokawa, K., Lee, K. H., Lee, K. M., Takatori, M., Nishimura, M., Sanui, M., Ito, M., Egi, M., Honda, N., Okayama, N., Shime, N., Tsuruta, R., Nogami, S., Yoon, S. H., Fujitani, S., Koh, S. O., Takeda, S., Saito, S., Hong, S. J., Yamamoto, T., Yokoyama, T., Yamaguchi, T., Nishiyama, T., Igarashi, T., Kakihana, Y., Koh, Y., Fever, & Antipyretic in Critically ill patients Evaluation Study, G. (2012). Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. *Crit Care, 16*, R33.

Lee, & Papachristou, G. I. (2019). New insights into acute pancreatitis. *Nat Rev Gastroenterol Hepatol, 16*, 479-496.

Lee, Y., Hong, S., Cui, M., Sharma, P. K., Lee, J., & Choi, S. (2015). Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014). *Expert Opin Ther Pat, 25*, 291-318.

Lehto, S. G., Tamir, R., Deng, H., Klionsky, L., Kuang, R., Le, A., Lee, D., Louis, J. C., Magal, E., Manning, B. H., Rubino, J., Surapaneni, S., Tamayo, N., Wang, T., Wang, J., Wang, J., Wang, W., Youngblood, B., Zhang, M., Zhu, D., Norman, M. H., & Gavva, N. R. (2008). Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. *J Pharmacol Exp Ther, 326*, 218-229.

Lei, H., Minghao, W., Xiaonan, Y., Ping, X., Ziqi, L., & Qing, X. (2013). Acute lung injury in patients with severe acute pancreatitis. *Turk J Gastroenterol, 24*, 502-507.

Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J. L., Ramsay, G., & Sccm/Esicm/Accp/Ats/Sis. (2003). 2001

SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med, 31*, 1250-1256.

Liu, E., Lewis, K., Al-Saffar, H., Krall, C. M., Singh, A., Kulchitsky, V. A., Corrigan, J. J., Simons, C. T., Petersen, S. R., Musteata, F. M., Bakshi, C. S., Romanovsky, A. A., Sellati, T. J., & Steiner, A. A. (2012). Naturally occurring hypothermia is more advantageous than fever in severe forms of lipopolysaccharide- and Escherichia coli-induced systemic inflammation. *Am J Physiol Regul Integr Comp Physiol, 302*, R1372-1383.

Mackowiak, P. A., Browne, R. H., Southern, P. M., Jr., & Smith, J. W. (1980). Polymicrobial sepsis: an analysis of 184 cases using log linear models. *Am J Med Sci, 280*, 73-80.

MacRury, S., Neilson, R., & Goodwin, K. (1987). Benylin dependence, metabolic acidosis and hyperglycaemia. *Postgrad Med J, 63*, 587-588.

Manthous, C. A., Hall, J. B., Olson, D., Singh, M., Chatila, W., Pohlman, A., Kushner, R., Schmidt, G. A., & Wood, L. D. (1995). Effect of cooling on oxygen consumption in febrile critically ill patients. *Am J Respir Crit Care Med, 151*, 10-14.

Marfin, A. A., Sporrer, J., Moore, P. S., & Siefkin, A. D. (1995). Risk factors for adverse outcome in persons with pneumococcal pneumonia. *Chest, 107*, 457-462.

Martin, W. J., & Matzke, G. R. (1982). Treating severe metabolic alkalosis. *Clin Pharm, 1*, 42-48.

Matsumoto, S., Haberle, J., Kido, J., Mitsubuchi, H., Endo, F., & Nakamura, K. (2019). Urea cycle disorders-update. *J Hum Genet, 64*, 833-847.

McGaraughty, S., Chu, K. L., Perner, R. J., Didomenico, S., Kort, M. E., & Kym, P. R. (2010). TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats. *Mol Pain, 6*, 14.

McIntyre, P., McLatchie, L. M., Chambers, A., Phillips, E., Clarke, M., Savidge, J., Toms, C., Peacock, M., Shah, K., Winter, J., Weerasakera, N., Webb, M., Rang, H. P., Bevan, S., & James, I. F. (2001). Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). *Br J Pharmacol, 132*, 1084-1094.

Megged, O., Yinnon, A. M., Raveh, D., Rudensky, B., & Schlesinger, Y. (2006). Group A streptococcus bacteraemia: comparison of adults and children in a single medical centre. *Clin Microbiol Infect, 12*, 156-162.

Memis, D., Karamanlioglu, B., Turan, A., Koyuncu, O., & Pamukcu, Z. (2004). Effects of lornoxicam on the physiology of severe sepsis. *Crit Care, 8*, R474-482.

Miller, M. S., Jones, A. B., Chauhan, D. P., & Anderson, L. M. (1990). Role of the maternal environment in determining susceptibility to transplacentally induced chemical carcinogenesis in mouse fetuses. *Carcinogenesis, 11*, 1979-1984.

Mills, C., McMackin, M., Jaffe, R., Yu, J., Zininberg, E., Slee, D., Gogas, K., & Bradbury, M. (2008). Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat. *Neuroscience, 156*, 165-174.

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med, 6*, e1000097.

Mohr, N., Skrupky, L., Fuller, B., Moy, H., Alunday, R., Wallendorf, M., Micek, S., & Fagley, R. (2012). Early antipyretic exposure does not increase mortality in patients

with gram-negative severe sepsis: a retrospective cohort study. *Intern Emerg Med, 7*, 463-470.

Molina, J., Penuela, I., Lepe, J. A., Gutierrez-Pizarraya, A., Gomez, M. J., Garcia-Cabrera, E., Cordero, E., Aznar, J., & Pachon, J. (2013). Mortality and hospital stay related to coagulase-negative Staphylococci bacteremia in non-critical patients. *J Infect, 66*, 155-162.

Nair, S., Yadav, D., & Pitchumoni, C. S. (2000). Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. *Am J Gastroenterol, 95*, 2795-2800.

Neuberger, A., Yahav, D., Daitch, V., Akayzen, Y., Farbman, L., Avni, T., Leibovici, L., & Paul, M. (2015). The significance of persistent fever in the treatment of suspected bacterial infections among inpatients: a prospective cohort study. *Eur J Clin Microbiol Infect Dis, 34*, 805-810.

Noble, M. D., Romac, J., Vigna, S. R., & Liddle, R. A. (2008). A pH-sensitive, neurogenic pathway mediates disease severity in a model of post-ERCP pancreatitis. *Gut, 57*, 1566-1571.

Nowik, M., Kampik, N. B., Mihailova, M., Eladari, D., & Wagner, C. A. (2010). Induction of metabolic acidosis with ammonium chloride (NH4Cl) in mice and rats--species differences and technical considerations. *Cell Physiol Biochem, 26*, 1059-1072.

Olah, E., Poto, L., Hegyi, P., Szabo, I., Hartmann, P., Solymar, M., Petervari, E., Balasko, M., Habon, T., Rumbus, Z., Tenk, J., Rostas, I., Weinberg, J., Romanovsky, A. A., & Garami, A. (2018). Therapeutic whole-body hypothermia reduces death in severe traumatic brain injury if the cooling index is sufficiently high: meta-analyses of the effect of single cooling parameters and their integrated measure. *J Neurotrauma, 35*, 2407-2417.

Olah, E., Rumbus, Z., Kormos, V., Tekus, V., Pakai, E., Wilson, H. V., Fekete, K., Solymar, M., Kelava, L., Keringer, P., Gaszner, B., Whiteman, M., Keeble, J., Pinter, E., & Garami, A. (2021). The hypothermic effect of hydrogen sulfide is mediated by the transient receptor potential ankyrin-1 channel in mice. *Pharmaceuticals (Basel), 14*.

Opal, S. M. (2005). Concept of PIRO as a new conceptual framework to understand sepsis. *Pediatr Crit Care Med, 6*, S55-60.

Pakai, E., Garami, A., Nucci, T. B., Ivanov, A. I., & Romanovsky, A. A. (2015). Hyperbilirubinemia exaggerates endotoxin-induced hypothermia. *Cell Cycle, 14*, 1260-1267.

Pakai, E., Tekus, V., Zsiboras, C., Rumbus, Z., Olah, E., Keringer, P., Khidhir, N., Matics, R., Deres, L., Ordog, K., Szentes, N., Pohoczky, K., Kemeny, A., Hegyi, P., Pinter, E., & Garami, A. (2018). The neurokinin-1 receptor contributes to the early phase of lipopolysaccharide-induced fever via stimulation of peripheral cyclooxygenase-2 protein expression in mice. *Front Immunol, 9*, 166.

Pallagi, P., Hegyi, P., & Rakonczay, Z., Jr. (2015). The physiology and pathophysiology of pancreatic ductal secretion: the background for clinicians. *Pancreas, 44*, 1211-1233.

Pallagi, P., Venglovecz, V., Rakonczay, Z., Jr., Borka, K., Korompay, A., Ozsvari, B., Judak, L., Sahin-Toth, M., Geisz, A., Schnur, A., Maleth, J., Takacs, T., Gray, M. A., Argent, B. E., Mayerle, J., Lerch, M. M., Wittmann, T., & Hegyi, P. (2011). Trypsin

reduces pancreatic ductal bicarbonate secretion by inhibiting CFTR Cl(-) channels and luminal anion exchangers. *Gastroenterology, 141*, 2228-2239 e2226.

Parniczky, A., Kui, B., Szentesi, A., Balazs, A., Szucs, A., Mosztbacher, D., Czimmer, J., Sarlos, P., Bajor, J., Godi, S., Vincze, A., Illes, A., Szabo, I., Par, G., Takacs, T., Czako, L., Szepes, Z., Rakonczay, Z., Izbeki, F., Gervain, J., Halasz, A., Novak, J., Crai, S., Hritz, I., Gog, C., Sumegi, J., Golovics, P., Varga, M., Bod, B., Hamvas, J., Varga-Muller, M., Papp, Z., Sahin-Toth, M., Hegyi, P., & Hungarian Pancreatic Study, G. (2016). Prospective, multicentre, nationwide clinical data from 600 cases of acute pancreatitis. *PLoS One, 11*, e0165309.

Patil, M. J., Jeske, N. A., & Akopian, A. N. (2010). Transient receptor potential V1 regulates activation and modulation of transient receptor potential A1 by Ca2+. *Neuroscience, 171*, 1109-1119.

Pestana, D., Casanova, E., Villagran, M. J., Tormo, C., Perez-Chrzanowska, H., Redondo, J., Caldera, M. V., & Royo, C. (2007). Continuous hemofiltration in hyperthermic septic shock patients. *J Trauma, 63*, 751-756.

Pittet, D., Thievent, B., Wenzel, R. P., Li, N., Auckenthaler, R., & Suter, P. M. (1996). Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. *Am J Respir Crit Care Med, 153*, 684-693.

Proud, G. O. (1953). Indications for tonsillectomy and adenoidectomy in children. *Laryngoscope, 63*, 262-266.

Pupelis, G., Plaudis, H., Grigane, A., Zeiza, K., & Purmalis, G. (2007). Continuous veno-venous haemofiltration in the treatment of severe acute pancreatitis: 6-year experience. *HPB (Oxford), 9*, 295-301.

Ranson, J. H., Rifkind, K. M., & Turner, J. W. (1976). Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. *Surg Gynecol Obstet, 143*, 209-219.

Rapoport, S. I., & Thompson, H. K. (1974). Effect of intravenous NH4Cl and NaHCO3 on the pH of the brain surface, as related to respiration and the blood-brain barrier. *Exp Neurol, 42*, 320-333.

Reaich, D., Channon, S. M., Scrimgeour, C. M., & Goodship, T. H. (1992). Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. *Am J Physiol, 263*, E735-739.

Reed, A. M., Husain, S. Z., Thrower, E., Alexandre, M., Shah, A., Gorelick, F. S., & Nathanson, M. H. (2011). Low extracellular pH induces damage in the pancreatic acinar cell by enhancing calcium signaling. *J Biol Chem, 286*, 1919-1926.

Relman, A. S., Shelburne, P. F., & Talman, A. (1961). Profound acidosis resulting from excessive ammonium chloride in previously healthy subjects. A study of two cases. *N Engl J Med, 264*, 848-852.

Rhodes, A., Lamb, F. J., Malagon, I., Newman, P. J., Grounds, R. M., & Bennett, E. D. (1999). A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis, or septic shock. *Crit Care Med, 27*, 2361-2366.

Rice, M., Ismail, B., & Pillow, M. T. (2014). Approach to metabolic acidosis in the emergency department. *Emerg Med Clin North Am, 32*, 403-420.

Romanovsky, A. A., Almeida, M. C., Aronoff, D. M., Ivanov, A. I., Konsman, J. P., Steiner, A. A., & Turek, V. F. (2005). Fever and hypothermia in systemic inflammation: recent discoveries and revisions. *Front Biosci, 10*, 2193-2216.

Romanovsky, A. A., Almeida, M. C., Garami, A., Steiner, A. A., Norman, M. H., Morrison, S. F., Nakamura, K., Burmeister, J. J., & Nucci, T. B. (2009). The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. *Pharmacol Rev, 61*, 228-261.

Romanovsky, A. A., Ivanov, A. I., & Shimansky, Y. P. (2002). Selected contribution: ambient temperature for experiments in rats: a new method for determining the zone of thermal neutrality. *J Appl Physiol (1985), 92*, 2667-2679.

Romanovsky, A. A., & Szekely, M. (1998). Fever and hypothermia: two adaptive thermoregulatory responses to systemic inflammation. *Med Hypotheses, 50*, 219-226.

Roos, A., & Boron, W. F. (1981). Intracellular pH. *Physiol Rev, 61*, 296-434.

Rothe, K. F., & Schimek, F. (1984). New aspects of acid-base balance influences of NH4Cl on intra- and extracellular acid-base equilibrium studies in the rat. *J Med, 15*, 135-148.

Rudaya, A. Y., Steiner, A. A., Robbins, J. R., Dragic, A. S., & Romanovsky, A. A. (2005). Thermoregulatory responses to lipopolysaccharide in the mouse: dependence on the dose and ambient temperature. *Am J Physiol Regul Integr Comp Physiol, 289*, R1244-1252.

Rumbus, Z., Fekete, K., Kelava, L., Gardos, B., Klonfar, K., Keringer, P., Pinter, E., Pakai, E., & Garami, A. (2024). Ammonium chloride-induced hypothermia is attenuated by transient receptor potential channel vanilloid-1, but augmented by ankyrin-1 in rodents. *Life Sci, 346*, 122633.

Rumbus, Z., & Garami, A. (2019). Fever, hypothermia, and mortality in sepsis: Comment on: Rumbus Z, Matics R, Hegyi P, Zsiboras C, Szabo I, Illes A, Petervari E, Balasko M, Marta K, Miko A, Parniczky A, Tenk J, Rostas I, Solymar M, Garami A. Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials. PLoS One. 2017;12(1):e0170152. DOI: 10.1371/journal.pone.0170152. *Temperature (Austin), 6*, 101-103.

Rumbus, Z., Matics, R., Hegyi, P., Zsiboras, C., Szabo, I., Illes, A., Petervari, E., Balasko, M., Marta, K., Miko, A., Parniczky, A., Tenk, J., Rostas, I., Solymar, M., & Garami, A. (2017). Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials. *PLoS One, 12*, e0170152.

Rumbus, Z., Toth, E., Poto, L., Vincze, A., Veres, G., Czako, L., Olah, E., Marta, K., Miko, A., Rakonczay, Z., Jr., Balla, Z., Kaszaki, J., Foldesi, I., Maleth, J., Hegyi, P., & Garami, A. (2018). Bidirectional relationship between reduced blood pH and acute pancreatitis: a translational study of their noxious combination. *Front Physiol, 9*, 1360.

Saper, C. B., Romanovsky, A. A., & Scammell, T. E. (2012). Neural circuitry engaged by prostaglandins during the sickness syndrome. *Nat Neurosci, 15*, 1088-1095.

Sarmin, M., Ahmed, T., Bardhan, P. K., & Chisti, M. J. (2014). Specialist hospital study shows that septic shock and drowsiness predict mortality in children under five with diarrhoea. *Acta Paediatr, 103*, e306-311.

Sawyer, R. G., Claridge, J. A., Nathens, A. B., Rotstein, O. D., Duane, T. M., Evans, H. L., Cook, C. H., O'Neill, P. J., Mazuski, J. E., Askari, R., Wilson, M. A., Napolitano, L. M., Namias, N., Miller, P. R., Dellinger, E. P., Watson, C. M., Coimbra, R., Dent, D. L., Lowry, S. F., Cocanour, C. S., West, M. A., Banton, K. L., Cheadle, W. G., Lipsett, P. A., Guidry, C. A., Popovsky, K., & Investigators, S.-I. T. (2015). Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med, 372*, 1996-2005.

Schicho, R., Florian, W., Liebmann, I., Holzer, P., & Lippe, I. T. (2004). Increased expression of TRPV1 receptor in dorsal root ganglia by acid insult of the rat gastric mucosa. *Eur J Neurosci, 19*, 1811-1818.

Schortgen, F., Clabault, K., Katsahian, S., Devaquet, J., Mercat, A., Deye, N., Dellamonica, J., Bouadma, L., Cook, F., Beji, O., Brun-Buisson, C., Lemaire, F., & Brochard, L. (2012). Fever control using external cooling in septic shock: a randomized controlled trial. *Am J Respir Crit Care Med, 185*, 1088-1095.

Schulman, N. N., Doherty J, Manning RJ, Li P, Elhaddad A, et al. (2005). The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study. *Surg Infect (Larchmt). 6(4)*, 369–375.

Seguin, P., Roquilly, A., Mimoz, O., Le Maguet, P., Asehnoune, K., Biederman, S., Carise, E., Malledant, Y., & AtlanRea, G. (2012). Risk factors and outcomes for prolonged versus brief fever: a prospective cohort study. *Crit Care, 16*, R150.

Sellers, A. L., & Kast, E. C. (1945). The treatment of alkalosis with intravenous ammonium chloride solution. *Perm Found Med Bull, 3*, 171-174.

Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & Group, P.-P. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ, 350*, g7647.

Sharma, V., Shanti Devi, T., Sharma, R., Chhabra, P., Gupta, R., Rana, S. S., & Bhasin, D. K. (2014). Arterial pH, bicarbonate levels and base deficit at presentation as markers of predicting mortality in acute pancreatitis: a single-centre prospective study. *Gastroenterol Rep (Oxf), 2*, 226-231.

Shen, X., Ke, L., Yang, D., Sun, J., Tong, Z., Li, B., Li, G., Li, W., Li, J., & Bellomo, R. (2016). The prognostic value of the strong ion gap in acute pancreatitis. *J Crit Care, 36*, 140-145.

Shinzeki, M., Ueda, T., Takeyama, Y., Yasuda, T., Matsumura, N., Sawa, H., Nakajima, T., Matsumoto, I., Fujita, T., Ajiki, T., Fujino, Y., & Kuroda, Y. (2008). Prediction of early death in severe acute pancreatitis. *J Gastroenterol, 43*, 152-158.

Siami, Z., Aghajanian, S., Mansouri, S., Mokhames, Z., Pakzad, R., Kabir, K., Norouzi, M., Soleimani, A., Hedayat Yaghoobi, M., Shadabi, S., Tajbakhsh, R., Kargar Kheirabad, A., & Mozhgani, S. H. (2021). Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial. *Int J Infect Dis, 108*, 306-308.

Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J. D., Coopersmith, C. M., Hotchkiss, R. S., Levy, M. M., Marshall, J. C., Martin, G. S., Opal, S. M., Rubenfeld, G. D., van der Poll, T., Vincent, J. L., & Angus, D. C. (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA, 315*, 801-810.

Sleisenger, M. H., & Freedberg, A. S. (1951). Ammonium chloride acidosis; a report of six cases. *Circulation, 3*, 837-845.

Song, Y. H., Shin, T. G., Kang, M. J., Sim, M. S., Jo, I. J., Song, K. J., & Jeong, Y. K. (2012). Predicting factors associated with clinical deterioration of sepsis patients with intermediate levels of serum lactate. *Shock, 38*, 249-254.

Starowicz, K., Cristino, L., & Di Marzo, V. (2008). TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. *Curr Pharm Des, 14*, 42-54.

Staruschenko, A., Jeske, N. A., & Akopian, A. N. (2010). Contribution of TRPV1-TRPA1 interaction to the single channel properties of the TRPA1 channel. *J Biol Chem, 285*, 15167-15177.

Stauber, A., Radanovic, T., Stange, G., Murer, H., Wagner, C. A., & Biber, J. (2005). Regulation of intestinal phosphate transport. II. Metabolic acidosis stimulates Na(+)-dependent phosphate absorption and expression of the Na(+)-P(i) cotransporter NaPi-IIb in small intestine. *Am J Physiol Gastrointest Liver Physiol, 288*, G501-506.

Steiner, A. A., Turek, V. F., Almeida, M. C., Burmeister, J. J., Oliveira, D. L., Roberts, J. L., Bannon, A. W., Norman, M. H., Louis, J. C., Treanor, J. J., Gavva, N. R., & Romanovsky, A. A. (2007). Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. *J Neurosci, 27*, 7459-7468.

Su, L., Han, B., Liu, C., Liang, L., Jiang, Z., Deng, J., Yan, P., Jia, Y., Feng, D., & Xie, L. (2012). Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. *BMC Infect Dis, 12*, 157.

Swenson, B. R., Hedrick, T. L., Popovsky, K., Pruett, T. L., & Sawyer, R. G. (2007). Is fever protective in surgical patients with bloodstream infection? *J Am Coll Surg, 204*, 815-821; discussion 822-813.

Szallasi, A., Nilsson, S., Farkas-Szallasi, T., Blumberg, P. M., Hokfelt, T., & Lundberg, J. M. (1995). Vanilloid (capsaicin) receptors in the rat: distribution in the brain, regional differences in the spinal cord, axonal transport to the periphery, and depletion by systemic vanilloid treatment. *Brain Res, 703*, 175-183.

Takacs, T., Rosztoczy, A., Maleth, J., Rakonczay, Z., Jr., & Hegyi, P. (2013). Intraductal acidosis in acute biliary pancreatitis. *Pancreatology, 13*, 333-335.

Taylor, T. E., Wills, B. A., Courval, J. M., & Molyneux, M. E. (1998). Intramuscular artemether vs intravenous quinine: an open, randomized trial in Malawian children with cerebral malaria. *Trop Med Int Health, 3*, 3-8.

Tizianello, A., De Ferrari, G., Gurreri, G., & Acquarone, N. (1977). Effects of metabolic alkalosis, metabolic acidosis and uraemia on whole-body intracellular pH in man. *Clin Sci Mol Med, 52*, 125-135.

Tominaga, M., Caterina, M. J., Malmberg, A. B., Rosen, T. A., Gilbert, H., Skinner, K., Raumann, B. E., Basbaum, A. I., & Julius, D. (1998). The cloned capsaicin receptor integrates multiple pain-producing stimuli. *Neuron, 21*, 531-543.

Villar, J., & Slutsky, A. S. (1993). Effects of induced hypothermia in patients with septic adult respiratory distress syndrome. *Resuscitation, 26*, 183-192.

Vincent, J. L., Marshall, J. C., Namendys-Silva, S. A., Francois, B., Martin-Loeches, I., Lipman, J., Reinhart, K., Antonelli, M., Pickkers, P., Njimi, H., Jimenez, E., Sakr, Y., & investigators, I. (2014). Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. *Lancet Respir Med, 2*, 380-386.

Vincent, J. L., & Moreno, R. (2010). Clinical review: scoring systems in the critically ill. *Crit Care, 14*, 207.

Walkey, A. J., Lagu, T., & Lindenauer, P. K. (2015). Trends in sepsis and infection sources in the United States. A population-based study. *Ann Am Thorac Soc, 12*, 216-220.

Wang, Chang, R. B., Allgood, S. D., Silver, W. L., & Liman, E. R. (2011). A TRPA1-dependent mechanism for the pungent sensation of weak acids. *J Gen Physiol, 137*, 493-505.

Wang, Chang, R. B., & Liman, E. R. (2010). TRPA1 is a component of the nociceptive response to CO2. *J Neurosci, 30*, 12958-12963.

Wang, H., & Siemens, J. (2015). TRP ion channels in thermosensation, thermoregulation and metabolism. *Temperature (Austin), 2*, 178-187.

Wanner, S. P., Garami, A., Pakai, E., Oliveira, D. L., Gavva, N. R., Coimbra, C. C., & Romanovsky, A. A. (2012). Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory. *Cell Cycle, 11*, 343-349.

Ward, S. T., Gilbert, S., Mulchandani, M., & Garrett, W. V. (2008). Unnecessary investigations in patients with acute pancreatitis: arterial blood sampling and serum biochemistry. *Surgeon, 6*, 282-287.

Watabiki, T., Kiso, T., Kuramochi, T., Yonezawa, K., Tsuji, N., Kohara, A., Kakimoto, S., Aoki, T., & Matsuoka, N. (2011). Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect. *J Pharmacol Exp Ther, 336*, 743-750.

Weinstein, M. P., Murphy, J. R., Reller, L. B., & Lichtenstein, K. A. (1983). The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. *Rev Infect Dis, 5*, 54-70.

White, H. D., Vazquez-Sandoval, A., Quiroga, P. F., Song, J., Jones, S. F., & Arroliga, A. C. (2018). Utility of venous blood gases in severe sepsis and septic shock. *Proc (Bayl Univ Med Cent), 31*, 269-275.

Wong, K. M., Chak, W. L., Cheung, C. Y., Chan, Y. H., Choi, K. S., Chau, K. F., & Li, C. S. (2001). Hypokalemic metabolic acidosis attributed to cough mixture abuse. *Am J Kidney Dis, 38*, 390-394.

Wood, F. J. (1955). Ammonium chloride acidosis. *Clin Sci, 14*, 81-89.

Young, P., Saxena, M., Bellomo, R., Freebairn, R., Hammond, N., van Haren, F., Holliday, M., Henderson, S., Mackle, D., McArthur, C., McGuinness, S., Myburgh, J.,

Weatherall, M., Webb, S., Beasley, R., Investigators, H., Australian, & New Zealand Intensive Care Society Clinical Trials, G. (2015). Acetaminophen for fever in critically ill patients with suspected infection. *N Engl J Med, 373*, 2215-2224.

Zhan, X. B., Guo, X. R., Yang, J., Li, J., & Li, Z. S. (2015). Prevalence and risk factors for clinically significant upper gastrointestinal bleeding in patients with severe acute pancreatitis. *J Dig Dis, 16*, 37-42.

Zhu, A. J., Shi, J. S., & Sun, X. J. (2003). Risk factors influencing mortality of patients with severe acute pancreatitis within 24 hours after admission. *Hepatobiliary Pancreat Dis Int, 2*, 453-457.

# Fever Is Associated with Reduced, Hypothermia with Increased Mortality in Septic Patients: A Meta-Analysis of Clinical Trials

**Zoltan Rumbus[1], Robert Matics[1], Peter Hegyi[1,2,3], Csaba Zsiboras[1], Imre Szabo[4], Anita Illes[4], Erika Petervari[1], Marta Balasko[1], Katalin Marta[1,2], Alexandra Miko[1], Andrea Parniczky[1,4], Judit Tenk[1], Ildiko Rostas[1], Margit Solymar[1], Andras Garami[1]** *

1 Institute for Translational Medicine, Medical School, University of Pecs, Pecs, Hungary, 2 Department of Translational Medicine, First Department of Medicine, University of Pecs, Pecs, Hungary, 3 Momentum Gastroenterology Multidisciplinary Research Group, Hungarian Academy of Sciences - University of Szeged, Szeged, Hungary, 4 Department of Gastroenterology, First Department of Medicine, University of Pecs, Pecs, Hungary

* andras.garami@aok.pte.hu

## Abstract

### Background

Sepsis is usually accompanied by changes of body temperature ($T_b$), but whether fever and hypothermia predict mortality equally or differently is not fully clarified. We aimed to find an association between $T_b$ and mortality in septic patients with meta-analysis of clinical trials.

### Methods

We searched the PubMed, EMBASE, and Cochrane Controlled Trials Registry databases (from inception to February 2016). Human studies reporting $T_b$ and mortality of patients with sepsis were included in the analyses. Average $T_b$ with SEM and mortality rate of septic patient groups were extracted by two authors independently.

### Results

Forty-two studies reported $T_b$ and mortality ratios in septic patients ($n = 10,834$). Pearson correlation analysis revealed weak negative linear correlation ($R^2 = 0.2794$) between $T_b$ and mortality. With forest plot analysis, we found a 22.2% (CI, 19.2–25.5) mortality rate in septic patients with fever ($T_b > 38.0°C$), which was higher, 31.2% (CI, 25.7–37.3), in normothermic patients, and it was the highest, 47.3% (CI, 38.9–55.7), in hypothermic patients ($T_b < 36.0°C$). Meta-regression analysis showed strong negative linear correlation between $T_b$ and mortality rate (regression coefficient: -0.4318; $P < 0.001$). Mean $T_b$ of the patients was higher in the lowest mortality quartile than in the highest: 38.1°C (CI, 37.9–38.4) vs 37.1°C (CI, 36.7–37.4).

## Conclusions

Deep $T_b$ shows negative correlation with the clinical outcome in sepsis. Fever predicts lower, while hypothermia higher mortality rates compared with normal $T_b$. Septic patients with the lowest (< 25%) chance of mortality have higher $T_b$ than those with the highest chance (> 75%).

## Introduction

Sepsis constitutes a global burden for medical care with an estimated 31 million cases per year worldwide [1]. The incidence of sepsis has remained considerable [2–4] and it is associated with high mortality rates even nowadays [3]. It also underlies the importance and actuality of the topic for clinical praxis that the definitions of sepsis and associated illnesses have been updated recently [5].

As a systemic inflammation response, sepsis is often associated with changes of deep body temperature ($T_b$), which can be manifested as fever or hypothermia in experimental animals [6–8], as well as in human patients [8–10]. Not surprisingly, deep $T_b$ is regularly measured as one of the vital signs in the clinical praxis. In fact, many scoring systems (e.g., APACHE II, PIRO, SAPS II, SIRS), which help in the diagnosis or in the assessment of the progress of sepsis, include an abnormal deviation of $T_b$ from the normal range [5, 11–14]. Usually $T_b$s below 36.0°C or above 38.0°C are considered equally pathological [15], which values are in accordance with the criteria of the systemic inflammatory response syndrome [5, 11]. Based mainly on experimental data from animal studies Romanovksy and colleagues [6, 8] proposed that fever and hypothermia can both develop as two distinct adaptive mechanisms in sickness syndrome. The former characteristically occurs at the onset of an infection, representing an active fight against the pathogen, while the latter is usually associated with progressed stage or severity of the disease and it aims to secure the vital systems of the host [6, 8]. The two adaptive strategies can develop sequentially (e.g., early phase fever followed by late phase hypothermia) as the severity of the disease progresses [8], but hypothermia can be also one of the earliest developing events in animal models of endotoxin shock [16], moreover, septic patients admitted to ICU develop hypothermia more frequently in the early than in the late stages of their stay [17]. Despite the different pathological background of fever and hypothermia in systemic inflammation, both the increase and the decrease of $T_b$ are evaluated commonly as equally severe signs in the clinical praxis [15]. This can be, at least in part, due to the standpoint that fever and hypothermia both represent an adaptive (though different) biological response to infection [8]. Accordingly, beneficial effects have been shown for elevated $T_b$ on the clinical outcome of sepsis in clinical trials [18, 19], although no association between fever and disease severity was also reported [20]. Therapeutic (i.e., induced) hypothermia has been also shown to improve the outcome of sepsis in human studies [21, 22], but in case of spontaneously occurring hypothermia usually a positive association with mortality rate was found [20, 23, 24]. The definite association of $T_b$ and mortality rate in a large study population has remained unknown.

We hypothesized that the deviation of $T_b$ from the normal range predicts the clinical outcome in sepsis differently, and consequently septic patients with fever have lower chances for mortality than those who develop hypothermia. We performed an extensive literature search for human studies in septic patients and collected data on their $T_b$ and mortality rate. The data were then analyzed with multiple statistical approaches, including Pearson regression, forest

plot, and meta-regression analyses. Based on a high number of patients, we show a strong association between $T_b$ and mortality ratio in sepsis across a wide temperature range.

## Materials and Methods

Our meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols [25] (S1 Table). The analysis was based on the Participants, Intervention (prognostic factor), Comparison, Outcome (PICO) model: in septic population, we aimed to assess the predictive role of $T_b$ deviations on the mortality ratio. No review protocol has been registered for the current meta-analysis.

### Search strategy

A search of the PubMed, EMBASE, and Cochrane Controlled Trials Registry databases was performed with using the following Medical Subject Headings and search terms (from inception to February 2016): sepsis OR bacteremia OR "septic syndrome" AND ("body temperature" OR fever OR hypothermia OR normothermia OR hyperthermia) AND (mortality OR survival). We restricted our search to original human studies published in English without time period limitations. Publications reporting immunosuppressive conditions (e.g., cancer, transplantation, HIV infection) were not included in the analysis. As a specific example, in the EMBASE database, which identified the highest number of articles, the term "sepsis OR bacteremia OR "septic syndrome" AND ("body temperature" OR fever OR hypothermia OR normothermia OR hyperthermia) AND (mortality OR survival) NOT (cancer OR immunosuppressive OR aids OR hiv OR transplantation)" was entered, and then the following filters were selected: humans, English, article, article in press, conference abstract, conference paper, major clinical study, case control study, clinical trial, cohort analysis, comparative study, controlled clinical trial, controlled study, cross-sectional study, double blind procedure, medical record review, multicenter study, observational study, outcomes research, phase 3 clinical trial, prospective study, randomized controlled trial, retrospective study. The search was conducted separately by two authors (ZR, AG), who also assessed study eligibility and extracted data from the selected studies independently. Disagreements were resolved by consensus with the help of a third party (MR).

### Study selection and data extraction

The titles and abstracts of the publications from the literature search were screened and the full text of potentially eligible articles was obtained. We included studies in which both the $T_b$ values and the mortality ratios were reported for the same group(s) of patients with systemic inflammation accompanied by suspected or confirmed blood infection. From all included articles we extracted the sample size, the reported mean $T_b$ value of the patients with its standard error (SEM), and the mortality ratio within the group during 28–30 days in most cases. To analyze the influence of fever, normothermia, and hypothermia on the mortality ratio in sepsis we separated the collected data into three study groups based on the mean $T_b$ of the patients.

### Statistical analysis

We have used event rates (mortality rates) as effect size data. Studies were grouped by $T_b$ as low (up to 36.0°C; $n = 890$), medium (36.1 to 38.0°C; $n = 3,904$) and high (above 38.0°C; $n = 6,040$) and forest plots in the three groups were used to describe mortality. Selection of the $T_b$ groups was based on the SIRS criteria [5, 11]. Another grouping was conducted by mortalities, these were split into quartiles and the means of $T_b$s were compared by investigating the

presence or absence of overlaps in the 95% confidence intervals (CI), just like in case of the grouping by $T_b$.

Between-study heterogeneity was tested with $Q$ homogeneity test ($P$ values of less than 0.05 were considered as indicators of significant heterogeneity) and with $I^2$ statistical test, where $I^2$ is the proportion of total variation attributable to between-study variability (an $I^2$ value of more than 50 was considered as indicating considerable heterogeneity). These two values were used to model selection purposes as well (fixed vs random). The tests revealed considerable heterogeneity in the overall study population ($Q = 809.509$; $I^2 = 89.25$) and also in all three $T_b$ groups, in particular $Q = 270.447$; $I^2 = 85.58$ in the high, $Q = 373.357$; $I^2 = 90.63$ in the medium, and $Q = 36.843$; $I^2 = 70.14$ in the low $T_b$ group. Consequently, we applied the random effect model in our forest plot and meta-regression analyses.

Publication bias was tested by inspecting the funnel plot. Meta-regression was performed to assess the overall effect of $T_b$ to mortality. Except for the Pearson correlation analysis for which Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) was used, all analyses were performed with the Comprehensive Meta-Analysis software (Biostat, Inc., Engelwood, MJ, USA).

## Results

### Study selection

The flow chart of the study selection is presented in Fig 1. Until February 29, 2016 the electronic literature search identified altogether 6,083 studies from the PubMed, EMBASE, and Cochrane databases. After enabling filters for human studies and English language, 762 articles remained, which were screened on title and abstract for inclusion criteria. In 720 studies $T_b$ or mortality rate was not suitably reported in the septic patients, these were also excluded, as a result 42 full-text publications were found eligible for statistical analysis which included data from a total of 10,834 septic patients.

### Incidence of mortality in septic patients with fever, normothermia, and hypothermia

As a rude approach, first we performed a common (Pearson) correlation analysis between $T_b$ and mortality rate of all septic patients. A weak negative linear correlation was found ($y = -0.0909x + 3.6902$; $R^2 = 0.2794$), which suggests an association between $T_b$ and mortality in sepsis. This method, however, did not allow us to weight the collected data according to the size of the studied populations, thus a detailed meta-analysis was needed.

First, we investigated the incidence of mortality in fever associated with sepsis. We found 29 studies [18–20, 23, 26–50], in which the authors reported fever (defined as $T_b > 38.0°C$) in sepsis. From these studies, 40 groups of septic patients could be separated and included in the analysis with the random effect model. The meta-analysis of the mortality rates in the septic patients with fever revealed an average event rate of 22.2% (95% CI, 19.2–25.5%; Z = -13.4331) (Fig 2). This percentage was significantly ($P = 0.000$) lower than the 50% chance of mortality, which could be regarded as a random outcome.

Next, we analyzed the mortality ratios of patients who developed neither fever nor hypothermia in association with sepsis, therefore this population could be regarded as normothermic ($T_b = 36.0–38.0°C$). From the 25 studies, in which normal $T_b$ was reported in the septic patients [20, 22, 24, 28, 31, 35–37, 39–41, 43, 44, 47, 50–60], 36 subgroups of patients were separated, which were then analyzed with the random effect model. We found that the average mortality ratio was 31.2% (95% CI, 25.7–37.3%; Z = -5.7089) (Fig 3), which was higher than in

**Fig 1. Flowchart of study selection and inclusion.**

doi:10.1371/journal.pone.0170152.g001

the fever group. The mortality rate was significantly ($P < 0.001$) lower than 50% in this study population.

Then, we examined the incidence of mortality in hypothermic ($T_b < 36.0°C$) septic patients. We identified 11 studies [20, 22–24, 27, 29, 30, 35, 50, 54, 61], which included data on both $T_b$ and mortality in septic patients. From these, the patients could be divided in 12 sub-groups, which served as the basis of the meta-analysis. The random effect model revealed that the average mortality rate was the highest, 47.3% (95% CI, 38.9–55.7; Z = 0.520491) in the hypothermic patients (Fig 4), which did not significantly differ from the 50% random chance ($P = 0.603$).

As a further statistical approach, we also performed a meta-regression analysis on the collected data. We found a significant ($P < 0.001$) negative linear correlation between $T_b$ and mortality rate (regression coefficient: -0.4318; 95% CI, -0.6699 - -0.1938) based on 51 studies included in the analysis (Fig 5).

Last, we divided the patients into quartiles (Q1-Q4) of mortality ratios (Q1: 0–25, Q2: 26–50, Q3: 51–75, and Q4: 76–100%) and calculated the average $T_b$ for each mortality quartile.

| Study name and subgroup | Mortality rate | Lower limit | Upper limit | Deaths / cases | Mortality rate and 95% CI | Relative weight |
|---|---|---|---|---|---|---|
| Green 2014 grp 2 | 0.085 | 0.045 | 0.154 | 9 / 110 | | 2.36 |
| Kushimoto 2013 grp 3 | 0.162 | 0.117 | 0.220 | 32 / 197 | | 3.01 |
| Kang 2012 grp 1 | 0.128 | 0.086 | 0.187 | 22 / 172 | | 2.87 |
| Seguin 2012 grp 1 | 0.190 | 0.148 | 0.240 | 53 / 278 | | 3.16 |
| Seguin 2012 grp 2 | 0.150 | 0.089 | 0.241 | 13 / 87 | | 2.55 |
| Lee 2012 grp 1 | 0.258 | 0.209 | 0.314 | 69 / 267 | | 3.21 |
| Schortgen 2012 grp 2 | 0.343 | 0.256 | 0.442 | 34 / 99 | | 2.94 |
| Aceng 2005 grp 1 | 0.192 | 0.106 | 0.321 | 10 / 52 | | 2.32 |
| Aceng 2005 grp 2 | 0.118 | 0.054 | 0.239 | 6 / 51 | | 1.98 |
| Kirov 2001 grp 1 | 0.500 | 0.225 | 0.775 | 5 / 10 | | 1.34 |
| Rhodes 1999 grp 2 | 0.071 | 0.010 | 0.370 | 1 / 14 | | 0.65 |
| Arons 1999 grp 1 | 0.350 | 0.305 | 0.398 | 143 / 409 | | 3.32 |
| Taylor 1998 grp 1 | 0.110 | 0.059 | 0.197 | 9 / 83 | | 2.32 |
| Taylor 1998 grp 2 | 0.160 | 0.095 | 0.257 | 13 / 81 | | 2.53 |
| Clemmer 1992 grp 2 | 0.260 | 0.217 | 0.309 | 90 / 348 | | 3.26 |
| Asiimwe 2015 grp 1 | 0.300 | 0.232 | 0.378 | 45 / 150 | | 3.07 |
| Gozel 2012 grp 1 | 0.370 | 0.310 | 0.434 | 85 / 230 | | 3.22 |
| Hoeboer 2012 grp 1 | 0.300 | 0.184 | 0.450 | 13 / 44 | | 2.42 |
| Hoeboer 2012 grp 2 | 0.200 | 0.107 | 0.342 | 9 / 45 | | 2.23 |
| Hoeboer 2012 grp 3 | 0.330 | 0.129 | 0.621 | 4 / 12 | | 1.39 |
| Molina 2013 grp 1 | 0.286 | 0.170 | 0.439 | 12 / 42 | | 2.37 |
| Neuberger 2015 grp 1 | 0.235 | 0.163 | 0.326 | 24 / 103 | | 2.85 |
| Song 2012 grp 1 | 0.060 | 0.040 | 0.089 | 22 / 366 | | 2.90 |
| Song 2012 grp 2 | 0.240 | 0.169 | 0.329 | 26 / 108 | | 2.88 |
| Su 2012 grp 2 | 0.431 | 0.276 | 0.601 | 14 / 33 | | 2.32 |
| Diekema 2003 grp 2 | 0.200 | 0.176 | 0.227 | 186 / 929 | | 3.37 |
| Heffner 2010 grp 1 | 0.250 | 0.173 | 0.347 | 24 / 95 | | 2.83 |
| Heffner 2010 grp 2 | 0.140 | 0.088 | 0.216 | 16 / 116 | | 2.69 |
| Hung 2005 grp 1 | 0.150 | 0.064 | 0.315 | 5 / 33 | | 1.78 |
| Marfin 1995 grp 2 | 0.008 | 0.001 | 0.118 | 0 / 60 | | 0.38 |
| Megged 2006 grp 1 | 0.183 | 0.104 | 0.301 | 11 / 60 | | 2.40 |
| Megged 2006 grp 2 | 0.026 | 0.004 | 0.164 | 1 / 38 | | 0.68 |
| Swenson 2007 grp 1 | 0.129 | 0.103 | 0.160 | 70 / 541 | | 3.25 |
| Bryant 1971 grp 1 | 0.310 | 0.213 | 0.427 | 22 / 70 | | 2.73 |
| Bryant 1971 grp 2 | 0.270 | 0.199 | 0.355 | 33 / 124 | | 2.97 |
| Hodgin 1965 grp 1 | 0.440 | 0.256 | 0.642 | 10 / 23 | | 2.04 |
| Hodgin 1965 grp 2 | 0.480 | 0.338 | 0.625 | 21 / 44 | | 2.54 |
| Weinstein 1983 grp 3 | 0.287 | 0.241 | 0.338 | 96 / 334 | | 3.27 |
| Weinstein 1983 grp 4 | 0.225 | 0.143 | 0.336 | 16 / 71 | | 2.62 |
| Pittet 1996 grp 1 | 0.350 | 0.267 | 0.443 | 39 / 111 | | 2.99 |
| **Overall** | 0.222 | 0.192 | 0.255 | | | |

0.00    0.50    1.00

**Fig 2. Forest plot analysis of mortality rate using random-effects model in septic patients with fever (body temperature above 38.0˚C; *n* = 6,040).**

doi:10.1371/journal.pone.0170152.g002

| Study name and subgroup | Mortality rate | Lower limit | Upper limit | Deaths / cases | Mortality rate and 95% CI | Relative weight |
|---|---|---|---|---|---|---|
| Sawyer 2015 grp 1 | 0.218 | 0.172 | 0.273 | 56 / 257 | | 3.42 |
| Sawyer 2015 grp 2 | 0.223 | 0.176 | 0.278 | 58 / 260 | | 3.42 |
| Green 2014 grp 1 | 0.211 | 0.109 | 0.368 | 8 / 38 | | 2.76 |
| Kushimoto 2013 grp 2 | 0.205 | 0.140 | 0.290 | 23 / 112 | | 3.24 |
| Drewry 2013 grp 1 | 0.281 | 0.153 | 0.458 | 9 / 32 | | 2.77 |
| Drewry 2013 grp 2 | 0.069 | 0.017 | 0.238 | 2 / 29 | | 1.79 |
| Yang 2013 grp 1 | 0.618 | 0.448 | 0.764 | 21 / 34 | | 2.90 |
| Yang 2013 grp 2 | 0.258 | 0.135 | 0.437 | 8 / 31 | | 2.72 |
| Kang 2012 grp 2 | 0.228 | 0.167 | 0.303 | 33 / 145 | | 3.32 |
| Schortgen 2012 grp 1 | 0.188 | 0.123 | 0.276 | 19 / 101 | | 3.18 |
| Pestana 2007 grp 1 | 0.316 | 0.149 | 0.549 | 6 / 19 | | 2.46 |
| Kirov 2001 grp 1 | 0.700 | 0.376 | 0.900 | 7 / 10 | | 1.89 |
| Rhodes 1999 grp 1 | 0.909 | 0.700 | 0.977 | 20 / 22 | | 1.77 |
| Memis 2004 grp 1 | 0.350 | 0.177 | 0.574 | 7 / 20 | | 2.53 |
| Memis 2004 grp 2 | 0.400 | 0.214 | 0.620 | 8 / 20 | | 2.57 |
| Bernard 1997 grp 1 | 0.370 | 0.309 | 0.435 | 83 / 224 | | 3.44 |
| Bernard 1997 grp 2 | 0.400 | 0.339 | 0.465 | 92 / 231 | | 3.45 |
| Villar 1993 grp 1 | 0.955 | 0.552 | 0.997 | 10 / 10 | | 0.73 |
| Villar 1993 grp 3 | 0.950 | 0.525 | 0.997 | 9 / 9 | | 0.73 |
| Asiimwe 2015 grp 2 | 0.230 | 0.172 | 0.300 | 38 / 167 | | 3.35 |
| Drewry 2015 grp 2 | 0.249 | 0.208 | 0.295 | 95 / 381 | | 3.47 |
| Molina 2013 grp 2 | 0.048 | 0.016 | 0.138 | 3 / 63 | | 2.17 |
| Neuberger 2015 grp 2 | 0.168 | 0.132 | 0.212 | 56 / 336 | | 3.43 |
| Sarmin 2014 grp 1 | 0.670 | 0.566 | 0.760 | 59 / 88 | | 3.25 |
| Sarmin 2014 grp 2 | 0.140 | 0.088 | 0.216 | 16 / 116 | | 3.15 |
| Su 2012 grp 1 | 0.333 | 0.218 | 0.472 | 17 / 51 | | 3.06 |
| Su 2012 grp 3 | 0.067 | 0.025 | 0.165 | 4 / 60 | | 2.39 |
| Young 2015 grp 1 | 0.139 | 0.106 | 0.180 | 48 / 346 | | 3.41 |
| Young 2015 grp 2 | 0.137 | 0.105 | 0.178 | 47 / 344 | | 3.41 |
| Carl 2010 grp 1 | 0.523 | 0.417 | 0.627 | 44 / 85 | | 3.28 |
| Carl 2010 grp 2 | 0.683 | 0.558 | 0.786 | 42 / 62 | | 3.13 |
| Hung 2005 grp 2 | 0.420 | 0.226 | 0.643 | 8 / 19 | | 2.55 |
| Hung 2005 grp 4 | 0.260 | 0.155 | 0.403 | 12 / 47 | | 2.96 |
| Marfin 1995 grp 1 | 0.595 | 0.442 | 0.731 | 25 / 42 | | 3.01 |
| DuPont 1969 grp 1 | 0.220 | 0.055 | 0.577 | 2 / 9 | | 1.62 |
| Weinstein 1983 grp 2 | 0.417 | 0.317 | 0.525 | 35 / 84 | | 3.27 |
| **Overall** | 0.312 | 0.257 | 0.373 | | | |



**Fig 3. Forest plot analysis of mortality rate using random-effects model in septic patients with normothermia (body temperature between 36.1 and 38.0˚C; $n = 3,904$).**

The weighted average $T_b$s were 38.1 (95% CI, 37.9–38.4˚C), 37.8 (95% CI, 37.5–38.2˚C), 37.6 (95% CI, 36.5–38.7˚C), and 37.1˚C (95% CI, 36.7–37.4˚C) in the Q1, Q2, Q3, and Q4 groups, respectively. These results also indicate that in sepsis a higher $T_b$ is associated with better outcome, while a lower $T_b$ is related with higher risk of mortality. Of note, the $T_b$s in Q1 and Q4

| Study name and subgroup | Mortality rate | Lower limit | Upper limit | Deaths / cases | Mortality rate and 95% CI | Relative weight |
|---|---|---|---|---|---|---|
| Bro-Jeppesen 2015 grp 1 | 0.360 | 0.266 | 0.466 | 31 / 86 | | 13.06 |
| Bro-Jeppesen 2015 grp 2 | 0.300 | 0.211 | 0.407 | 25 / 83 | | 12.68 |
| Kushimoto 2013 grp 1 | 0.404 | 0.312 | 0.503 | 40 / 99 | | 13.56 |
| Arons 1999 grp 2 | 0.700 | 0.550 | 0.816 | 31 / 44 | | 10.45 |
| Clemmer 1992 grp 1 | 0.620 | 0.449 | 0.765 | 21 / 34 | | 9.88 |
| Villar 1993 grp 2 | 0.670 | 0.336 | 0.891 | 6 / 9 | | 4.42 |
| Drewry 2015 grp 1 | 0.500 | 0.380 | 0.620 | 32 / 64 | | 12.41 |
| Gozel 2012 grp 2 | 0.875 | 0.266 | 0.993 | 3 / 3 | | 1.23 |
| Diekema 2003 grp 1 | 0.400 | 0.356 | 0.446 | 180 / 449 | | 15.89 |
| Hung 2005 grp 3 | 0.200 | 0.027 | 0.691 | 1 / 5 | | 2.11 |
| DuPont 1969 grp 2 | 0.400 | 0.100 | 0.800 | 2 / 5 | | 2.98 |
| Weinstein 1983 grp 1 | 0.950 | 0.525 | 0.997 | 9 / 9 | | 1.32 |
| **Overall** | 0.473 | 0.389 | 0.557 | | | |



**Fig 4. Forest plot analysis of mortality rate using random-effects model in septic patients with hypothermia (body temperature up to 36.0°C; $n = 890$).**

doi:10.1371/journal.pone.0170152.g004

(i.e., in the groups with lowest and highest mortality, respectively) are clearly distinct from each other, as the 95% CIs do not overlap.

## Discussion

In the current analysis we revealed a clear association between $T_b$ and mortality in septic patients by using a detailed statistical approach which was based on an extensive literature search of previous human studies. We found that the presence of fever reduces, while that of hypothermia promotes mortality in septic patients as compared to normothermic subjects.

From previous studies of septic patients only limited information is available to show an association between $T_b$ and mortality in a wide temperature range. While a worse outcome was consistently found to be related to hypothermia [20, 23, 24, 27], those studies compared hypothermia with fever [23, 27] or with nonhypothermic (i.e., by merging febrile and normo-thermic) patients [20, 24]. In one study, no association was found between hypothermia and the clinical outcome of sepsis [19]. Regarding the role of fever, different clinical trials came to controversial results in sepsis. Several authors showed that a higher $T_b$ was beneficial [18, 19, 50, 62], others that it was disadvantageous [44, 63], and a few found no association between fever and mortality [20, 60]. The discrepancy among the studies may result from the limited sample size used in the trials. Another explanation for not detecting significant association could be the insensitivity of the used statistical method. Indeed, when we first performed a commonly used regression analysis, the Pearson correlation, which did not allow us to weight the collected data for example for sample size, we found only a very weak negative correlation ($P = 0.047$) between $T_b$ and mortality ratio in sepsis. Thus, we applied more precise statistical tools (forest plot and meta-regression analyses).

In our analyses, we used a sizeable, heterogeneous population of septic patients ($n = 10,834$) with a wide range of $T_b$ (33.0–39.9°C). We showed that in sepsis mortality rates are lower if fever is present and higher in cases of hypothermia as compared to the normothermic group. In addition, we demonstrated a strong negative correlation ($P = 0.0004$) between $T_b$ and

**Fig 5. Meta-regression analysis of the association between body temperature and mortality ratio in septic patients (*n* = 10, 834).**

mortality ratio with the help of meta-regression analysis. In our statistical approach, we also included a substantial number of septic patient groups with average $T_b$s within the normal range (*n* = 3,904). Furthermore, when we calculated the mean $T_b$s of septic patients in the mortality quartiles, we found that it gradually decreased from the lowest to the highest quartile and it was significantly higher in the lowest (0–25%) than in the highest quartile (75–100%) of mortality (38.1 ± 0.1 vs 37.1 ± 0.2°C for mean ± SEM, respectively). Taken together the results from all of our statistical approaches, our data strongly suggest a predictive role of $T_b$ for the outcome of sepsis.

Sepsis continues to constitute a major challenge in critical care medicine [1–4]. As a systemic inflammation process, sepsis is frequently accompanied by abnormalities of $T_b$, like fever and hypothermia. In animal experiments, lower doses of endotoxin usually cause fever, whilst higher doses lead to the development of hypothermia [64, 65], indicating that the severity of the disease determines the change in $T_b$ and not the way around. Based on our statistical analyses of human studies fever seems beneficial, but hypothermia rather disadvantageous for the organism regarding the outcome. However, it has to be noted that the current analysis does not allow us to conclude that the change of $T_b$ per se is responsible for the lower and higher mortality rates in fever and hypothermia, respectively. Instead of a cause-effect relationship, the abnormal $T_b$ should be rather regarded as a prognostic vital parameter of the severity and progress of the inflammation, and as such, as a warning sign, which can help doctors to asses the outcome of to the infection.

With regard to the adaptive biological value of $T_b$ alterations in mammals, the development of fever in systemic inflammation is considered to indicate the activation of defense mechanisms of the body to fight the intruding agent [6–8]. By enhancing immune functions and accelerating the elimination of the microorganism from the body, at the onset of the inflammation fever is an adaptive, beneficial thermoregulatory response, although it involves a higher energy cost [6–8]. Therefore, fever itself is assumed to have a direct, advantageous effect on the mortality ratio in systemic inflammation (e.g., sepsis), when it is affordable for the host. However, $T_b$ regulation should be considered in the framework of complex energy balance [66], therefore, the beneficial value of fever as an energetically expensive defense response is doubtable when there is a risk of energy deficiency, which often develops as the severity of the disease further progresses. In support of that, the administration of antipyretics resulted in an increase of mortality rate of critically ill patients in prospective clinical trials [38, 67]. However, in severe sepsis or septic shock, the use of pharmacological antipyretics did not influence mortality [51, 68], while fever control with external cooling decreased early mortality in human studies [44].

Spontaneous hypothermia represents a distinct, adaptive mechanism to systemic inflammation in experimental animals [69] and in septic patients [17]. It characteristically develops in severe cases of already progressed diseases, when—instead of actively coping with the microorganism—the organism attempts to increase survival by saving its energy resources [6, 8]. A recent study by Fonseca et al. [17] revealed that spontaneous hypothermia is a transient, self-limiting, and nonterminal event in human sepsis, which underlies its biological value as an adaptive mechanism in the critically ill patients.

Although the results of our analysis showed that hypothermia is associated with higher mortality, it should be noted that we can not be sure how mortality ratio of the patients would have changed if hypothermia had not developed or if the patients were rewarmed. As of today, to our knowledge, the effect of rewarming vs non-rewarming on the mortality of septic patients with spontaneous hypothermia has not been compared in randomized controlled trials. Therefore, hypothermia in itself should not be regarded harmful for the body as the associated higher mortality rate of the septic patients is presumably due to their more severe clinical condition. We suggest that the difference between the mortality rates of febrile and hypothermic patients with sepsis is due to the different severity and progression of the inflammation and not due to $T_b$ itself. As a consequence, $T_b$ itself serves not as a detrimental factor, but instead, as an indicative predictor for the severity of the disease and as such for mortality in sepsis.

From a clinical perspective, our results highlight the importance of precise and regular measurements of deep $T_b$, since its abnormalities can help physicians—especially in critical care medicine—not only in the diagnosis, but also in the follow up of the progression, and in the prognosis of sepsis. Based on our findings, it would be worth to consider that hypothermia should be weighted differently than fever and not equally as currently used in many scoring systems (e.g., SIRS, APACHE, PIRO), since hypothermia indicates a more severe stage of sepsis, and, therefore it is associated with worse clinical outcome. Regarding therapeutic interventions, the $T_b$ management of septic patients should be always carefully evaluated and perhaps guidelines could be established (e.g., for the initiation of antipyretic treatment) to improve the clinical outcome in sepsis.

## Conclusions

The abnormalities of deep $T_b$ are strongly associated with the clinical outcome in sepsis. The mortality ratio of febrile patients is lower, while in patients with hypothermia it is markedly

higher than that of patients with normal $T_b$. In cases of sepsis, there is a strong negative correlation between the mortality ratio and deep $T_b$ in a wide temperature range. Septic patients with the lowest ($< 25\%$) chance of mortality have significantly higher deep $T_b$ than those who belong to the highest mortality quartile ($> 75\%$).

## Strengths and Limitations

Our meta-analysis included data from a total of 10,834 septic patients with overall 2,724 mortality events. We believe that our search strategy was adequately broad and included the three main databases of human studies. As result, 42 full-text articles could be indentified and used in our analyses. Although the sample size and the overall event rate can be considered large enough to draw solid conclusions about the association of $T_b$ and mortality rate in sepsis, our study has certain limitations.

First, due to the nature of the meta-analysis method, we have studied the reported mean $T_b$s in populations of patients, rather than the association between $T_b$ and the outcome of sepsis in individual patients. The latter approach would certainly allow one to draw firmer conclusions about the association between $T_b$ and mortality, but it would also necessitate access to the original data of the analyzed articles, which is not feasible. Alternatively, a well-designed clinical trial with a big sample size could also provide high-quality individual data and based on our results it can be warranted to conduct such trials.

Second, the studied population of patients is quite diverse, which diversity could also have its own impact on the results. For example, $T_b$ measurements were performed in different ways and not at the same time points in the analyzed studies. Despite such differences, we believe that the size of the analyzed sample was big enough to mitigate the methodological differences among the studies and to allow for drawing conclusions about the association of $T_b$ and mortality in the septic patients.

## Supporting Information

**S1 Table. PRISMA 2009 checklist.**
(DOC)

## Author Contributions

**Conceptualization:** ZR AG.

**Data curation:** RM.

**Formal analysis:** ZR RM AG.

**Funding acquisition:** PH AG.

**Investigation:** ZR RM CZ EP MB KM AM JT IR MS.

**Methodology:** ZR RM AG.

**Project administration:** ZR PH AG.

**Resources:** PH AG.

**Software:** RM PH.

**Supervision:** PH EP MB AG.

**Visualization:** ZR RM CZ KM AM AP JT IR AG.

**Writing – original draft:** ZR AG.

**Writing – review & editing:** ZR RM PH CZ IS AI EP MB KM AM AP JT IR MS AG.

## References

1. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med. 2016; 193(3):259–72. Epub 2015/09/29. doi: 10.1164/rccm.201504-0781OC PMID: 26414292

2. Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med. 2007; 35(5):1284–9. Epub 2007/04/07. doi: 10.1097/01.CCM.0000260960.94300.DE PMID: 17414725

3. Vincent JL, Marshall JC, Namendys-Silva SA, Francois B, Martin-Loeches I, Lipman J, et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir Med. 2014; 2(5):380–6. Epub 2014/04/18. doi: 10.1016/S2213-2600(14)70061-X PMID: 24740011

4. Walkey AJ, Lagu T, Lindenauer PK. Trends in sepsis and infection sources in the United States. A population-based study. Ann Am Thorac Soc. 2015; 12(2):216–20. Epub 2015/01/09. doi: 10.1513/AnnalsATS.201411-498BC PMID: 25569845

5. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801–10. Epub 2016/02/24. doi: 10.1001/jama.2016.0287 PMID: 26903338

6. Romanovsky AA, Almeida MC, Aronoff DM, Ivanov AI, Konsman JP, Steiner AA, et al. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front Biosci. 2005; 10:2193–216. Epub 2005/06/23. PMID: 15970487

7. Saper CB, Romanovsky AA, Scammell TE. Neural circuitry engaged by prostaglandins during the sickness syndrome. Nat Neurosci. 2012; 15(8):1088–95. Epub 2012/07/28. doi: 10.1038/nn.3159 PMID: 22837039

8. Romanovsky AA, Szekely M. Fever and hypothermia: two adaptive thermoregulatory responses to systemic inflammation. Med Hypotheses. 1998; 50(3):219–26. Epub 1998/05/13. PMID: 9578327

9. Cunha BA. With sepsis: If fever is good, then hypothermia is bad! Crit Care Med. 2012; 40(10):2926. Epub 2012/09/19. doi: 10.1097/CCM.0b013e31825f78aa PMID: 22986674

10. Kushimoto S, Yamanouchi S, Endo T, Sato T, Nomura R, Fujita M, et al. Body temperature abnormalities in non-neurological critically ill patients: a review of the literature. J Intensive Care. 2014; 2(1):14. Epub 2014/12/19. doi: 10.1186/2052-0492-2-14 PMID: 25520830

11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101(6):1644–55. Epub 1992/06/01. PMID: 1303622

12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10):818–29. Epub 1985/10/01. PMID: 3928249

13. Opal SM. Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med. 2005; 6(3 Suppl):S55–60. Epub 2005/04/29. doi: 10.1097/01.PCC.0000161580.79526.4C PMID: 15857560

14. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993; 270(24):2957–63. Epub 1993/12/22. PMID: 8254858

15. Beverly A, Walter E, Carraretto M. Management of hyperthermia and hypothermia in sepsis: A recent survey of current practice across UK intensive care units. J Intensive Care Soc. 2016; 17(1):88–9.

16. Corrigan JJ, Fonseca MT, Flatow EA, Lewis K, Steiner AA. Hypometabolism and hypothermia in the rat model of endotoxic shock: independence of circulatory hypoxia. J Physiol. 2014; 592(17):3901–16. Epub 2014/06/22. doi: 10.1113/jphysiol.2014.277277 PMID: 24951620

17. Fonseca MT, Rodrigues AC, Cezar LC, Fujita A, Soriano FG, Steiner AA. Spontaneous hypothermia in human sepsis is a transient, self-limiting, and nonterminal response. J Appl Physiol (1985). 2016; 120 (12):1394–401. Epub 2016/03/19.

18. Bryant RE, Hood AF, Hood CE, Koenig MG. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971; 127(1):120–8. Epub 1971/01/01. PMID: 4923385

19. Megged O, Yinnon AM, Raveh D, Rudensky B, Schlesinger Y. Group A streptococcus bacteraemia: comparison of adults and children in a single medical centre. Clin Microbiol Infect. 2006; 12(2):156–62. Epub 2006/01/31. doi: 10.1111/j.1469-0691.2005.01311.x PMID: 16441454

20. Kushimoto S, Gando S, Saitoh D, Mayumi T, Ogura H, Fujishima S, et al. The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. Crit Care. 2013; 17(6):R271. Epub 2013/11/14. doi: 10.1186/cc13106 PMID: 24220071

21. Blair E, Henning G, Hornick R, Cowley RA. Hypothermia in Bacteremic Shock. Arch Surg. 1964; 89:619–29. Epub 1964/10/01. PMID: 14186792

22. Villar J, Slutsky AS. Effects of induced hypothermia in patients with septic adult respiratory distress syndrome. Resuscitation. 1993; 26(2):183–92. Epub 1993/10/01. PMID: 8290813

23. Clemmer TP, Fisher CJ Jr., Bone RC, Slotman GJ, Metz CA, Thomas FO. Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1992; 20(10):1395–401. Epub 1992/10/11. PMID: 1395659

24. Drewry AM, Fuller BM, Skrupky LP, Hotchkiss RS. The presence of hypothermia within 24 hours of sepsis diagnosis predicts persistent lymphopenia. Crit Care Med. 2015; 43(6):1165–9. Epub 2015/03/21. doi: 10.1097/CCM.0000000000000940 PMID: 25793436

25. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 349:g7647. Epub 2015/01/04. doi: 10.1136/bmj.g7647 PMID: 25555855

26. Aceng JR, Byarugaba JS, Tumwine JK. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. BMJ. 2005; 330(7487):334. Epub 2005/02/12. doi: 10.1136/bmj.330.7487.334 PMID: 15705690

27. Arons MM, Wheeler AP, Bernard GR, Christman BW, Russell JA, Schein R, et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med. 1999; 27(4):699–707. Epub 1999/05/13. PMID: 10321658

28. Asiimwe SB, Abdallah A, Ssekitoleko R. A simple prognostic index based on admission vital signs data among patients with sepsis in a resource-limited setting. Crit Care. 2015; 19:86. Epub 2015/04/19. doi: 10.1186/s13054-015-0826-8 PMID: 25888322

29. Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol. 2003; 41(8):3655–60. Epub 2003/08/09. doi: 10.1128/JCM.41.8.3655-3660.2003 PMID: 12904371

30. Gozel MG, Erbay A, Bodur H, Eren SS. Risk factors for mortality in patients with nosocomial gram-negative bacteremia. Turkiye Klinikleri J Med Sci. 2012; 32(6):1641–7.

31. Green JE, Ariathianto Y, Wong SM, Aboltins C, Lim K. Clinical and inflammatory response to bloodstream infections in octogenarians. BMC Geriatr. 2014; 14:55. Epub 2014/04/24. doi: 10.1186/1471-2318-14-55 PMID: 24754903

32. Heffner AC, Horton JM, Marchick MR, Jones AE. Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department. Clin Infect Dis. 2010; 50(6):814–20. Epub 2010/02/11. doi: 10.1086/650580 PMID: 20144044

33. Hodgin UG, Sanford JP. Gram-negative rod bacteremia. An analysis of 100 patients. Am J Med. 1965; 39(6):952–60. Epub 1965/12/01. PMID: 5853047

34. Hoeboer SH, Alberts E, van den Hul I, Tacx AN, Debets-Ossenkopp YJ, Groeneveld AB. Old and new biomarkers for predicting high and low risk microbial infection in critically ill patients with new onset fever: a case for procalcitonin. J Infect. 2012; 64(5):484–93. Epub 2012/01/18. doi: 10.1016/j.jinf.2012.01.002 PMID: 22248983

35. Hung MN, Chen SY, Wang JL, Chang SC, Hsueh PR, Liao CH, et al. Community-acquired anaerobic bacteremia in adults: one-year experience in a medical center. J Microbiol Immunol Infect. 2005; 38 (6):436–43. Epub 2005/12/13. PMID: 16341345

36. Kang MJ, Shin TG, Jo IJ, Jeon K, Suh GY, Sim MS, et al. Factors influencing compliance with early resuscitation bundle in the management of severe sepsis and septic shock. Shock. 2012; 38(5):474–9. Epub 2012/10/09. doi: 10.1097/SHK.0b013e31826eea2b PMID: 23042195

37. Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001; 29 (10):1860–7. Epub 2001/10/06. PMID: 11588440

38. Lee BH, Inui D, Suh GY, Kim JY, Kwon JY, Park J, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care. 2012; 16(1):R33. Epub 2012/03/01. doi: 10.1186/cc11211 PMID: 22373120

39. Marfin AA, Sporrer J, Moore PS, Siefkin AD. Risk factors for adverse outcome in persons with pneumococcal pneumonia. Chest. 1995; 107(2):457–62. Epub 1995/02/01. PMID: 7842778

40. Molina J, Penuela I, Lepe JA, Gutierrez-Pizarraya A, Gomez MJ, Garcia-Cabrera E, et al. Mortality and hospital stay related to coagulase-negative Staphylococci bacteremia in non-critical patients. J Infect. 2013; 66(2):155–62. Epub 2012/10/30. doi: 10.1016/j.jinf.2012.10.021 PMID: 23103291

41. Neuberger A, Yahav D, Daitch V, Akayzen Y, Farbman L, Avni T, et al. The significance of persistent fever in the treatment of suspected bacterial infections among inpatients: a prospective cohort study. Eur J Clin Microbiol Infect Dis. 2015; 34(4):805–10. Epub 2014/12/17. doi: 10.1007/s10096-014-2288-3 PMID: 25502509

42. Pittet D, Thievent B, Wenzel RP, Li N, Auckenthaler R, Suter PM. Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med. 1996; 153(2):684–93. Epub 1996/02/01. doi: 10.1164/ajrccm.153.2.8564118 PMID: 8564118

43. Rhodes A, Lamb FJ, Malagon I, Newman PJ, Grounds RM, Bennett ED. A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis, or septic shock. Crit Care Med. 1999; 27(11):2361–6. Epub 1999/12/01. PMID: 10579249

44. Schortgen F, Clabault K, Katsahian S, Devaquet J, Mercat A, Deye N, et al. Fever control using external cooling in septic shock: a randomized controlled trial. Am J Respir Crit Care Med. 2012; 185(10):1088–95. Epub 2012/03/01. doi: 10.1164/rccm.201110-1820OC PMID: 22366046

45. Seguin P, Roquilly A, Mimoz O, Le Maguet P, Asehnoune K, Biederman S, et al. Risk factors and outcomes for prolonged versus brief fever: a prospective cohort study. Crit Care. 2012; 16(4):R150. Epub 2012/08/15. doi: 10.1186/cc11465 PMID: 22889136

46. Song YH, Shin TG, Kang MJ, Sim MS, Jo IJ, Song KJ, et al. Predicting factors associated with clinical deterioration of sepsis patients with intermediate levels of serum lactate. Shock. 2012; 38(3):249–54. Epub 2012/06/12. doi: 10.1097/SHK.0b013e3182613e33 PMID: 22683735

47. Su L, Han B, Liu C, Liang L, Jiang Z, Deng J, et al. Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis. 2012; 12:157. Epub 2012/07/20. doi: 10.1186/1471-2334-12-157 PMID: 22809118

48. Swenson BR, Hedrick TL, Popovsky K, Pruett TL, Sawyer RG. Is fever protective in surgical patients with bloodstream infection? J Am Coll Surg. 2007; 204(5):815–21; discussion 22–3. Epub 2007/05/08. doi: 10.1016/j.jamcollsurg.2007.01.033 PMID: 17481490

49. Taylor TE, Wills BA, Courval JM, Molyneux ME. Intramuscular artemether vs intravenous quinine: an open, randomized trial in Malawian children with cerebral malaria. Trop Med Int Health. 1998; 3(1):3–8. Epub 1998/03/04. PMID: 9484961

50. Weinstein MP, Murphy JR, Reller LB, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis. 1983; 5(1):54–70. Epub 1983/01/01. PMID: 6828812

51. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997; 336(13):912–8. Epub 1997/03/27. doi: 10.1056/NEJM199703273361303 PMID: 9070471

52. Carl DE, Grossman C, Behnke M, Sessler CN, Gehr TW. Effect of timing of dialysis on mortality in critically ill, septic patients with acute renal failure. Hemodial Int. 2010; 14(1):11–7. Epub 2010/04/10. doi: 10.1111/j.1542-4758.2009.00407.x PMID: 20377649

53. Drewry AM, Fuller BM, Bailey TC, Hotchkiss RS. Body temperature patterns as a predictor of hospital-acquired sepsis in afebrile adult intensive care unit patients: a case-control study. Crit Care. 2013; 17 (5):R200. Epub 2013/09/14. doi: 10.1186/cc12894 PMID: 24028682

54. DuPont HL, Spink WW. Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958–1966. Medicine (Baltimore). 1969; 48 (4):307–32. Epub 1969/07/01.

55. Memis D, Karamanlioglu B, Turan A, Koyuncu O, Pamukcu Z. Effects of lornoxicam on the physiology of severe sepsis. Crit Care. 2004; 8(6):R474–82. Epub 2004/11/30. doi: 10.1186/cc2969 PMID: 15566594

56. Pestana D, Casanova E, Villagran MJ, Tormo C, Perez-Chrzanowska H, Redondo J, et al. Continuous hemofiltration in hyperthermic septic shock patients. J Trauma. 2007; 63(4):751–6. Epub 2007/12/20. doi: 10.1097/TA.0b013e31802b9575 PMID: 18090001

57. Sarmin M, Ahmed T, Bardhan PK, Chisti MJ. Specialist hospital study shows that septic shock and drowsiness predict mortality in children under five with diarrhoea. Acta Paediatr. 2014; 103(7):e306–11. Epub 2014/03/26. doi: 10.1111/apa.12640 PMID: 24661049

58.   Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015; 372(21):1996–2005. Epub 2015/05/21. doi: 10.1056/NEJMoa1411162 PMID: 25992746

59.   Yang YL, Liu DW, Wang XT, Long Y, Zhou X, Chai WZ. Body temperature control in patients with refractory septic shock: too much may be harmful. Chin Med J (Engl). 2013; 126(10):1809–13. Epub 2013/05/16.

60.   Young P, Saxena M, Bellomo R, Freebairn R, Hammond N, van Haren F, et al. Acetaminophen for Fever in Critically Ill Patients with Suspected Infection. N Engl J Med. 2015; 373(23):2215–24. Epub 2015/10/06. doi: 10.1056/NEJMoa1508375 PMID: 26436473

61.   Bro-Jeppesen J, Kjaergaard J, Wanscher M, Nielsen N, Friberg H, Bjerre M, et al. Systemic Inflammatory Response and Potential Prognostic Implications After Out-of-Hospital Cardiac Arrest: A Substudy of the Target Temperature Management Trial. Crit Care Med. 2015; 43(6):1223–32. Epub 2015/03/11. doi: 10.1097/CCM.0000000000000937 PMID: 25756419

62.   Mackowiak PA, Browne RH, Southern PM Jr., Smith JW. Polymicrobial sepsis: an analysis of 184 cases using log linear models. Am J Med Sci. 1980; 280(2):73–80. Epub 1980/09/01. PMID: 7435520

63.   Manthous CA, Hall JB, Olson D, Singh M, Chatila W, Pohlman A, et al. Effect of cooling on oxygen consumption in febrile critically ill patients. Am J Respir Crit Care Med. 1995; 151(1):10–4. Epub 1995/01/01. doi: 10.1164/ajrccm.151.1.7812538 PMID: 7812538

64.   Pakai E, Garami A, Nucci TB, Ivanov AI, Romanovsky AA. Hyperbilirubinemia exaggerates endotoxin-induced hypothermia. Cell Cycle. 2015; 14(8):1260–7. Epub 2015/03/17. doi: 10.1080/15384101.2015.1014150 PMID: 25774749

65.   Rudaya AY, Steiner AA, Robbins JR, Dragic AS, Romanovsky AA. Thermoregulatory responses to lipopolysaccharide in the mouse: dependence on the dose and ambient temperature. Am J Physiol Regul Integr Comp Physiol. 2005; 289(5):R1244–52. Epub 2005/08/06. doi: 10.1152/ajpregu.00370.2005 PMID: 16081879

66.   Garami A, Szekely M. Body temperature: Its regulation in framework of energy balance. Temperature (Austin). 2014; 1(1):28–9. Epub 2014/04/01. [pii].

67.   Schulman CI, Namias N, Doherty J, Manning RJ, Li P, Elhaddad A, et al. The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study. Surg Infect (Larchmt). 2005; 6(4):369–75. Epub 2006/01/26.

68.   Mohr N, Skrupky L, Fuller B, Moy H, Alunday R, Wallendorf M, et al. Early antipyretic exposure does not increase mortality in patients with gram-negative severe sepsis: a retrospective cohort study. Intern Emerg Med. 2012; 7(5):463–70. Epub 2012/08/29. doi: 10.1007/s11739-012-0848-z PMID: 22926744

69.   Liu E, Lewis K, Al-Saffar H, Krall CM, Singh A, Kulchitsky VA, et al. Naturally occurring hypothermia is more advantageous than fever in severe forms of lipopolysaccharide- and Escherichia coli-induced systemic inflammation. Am J Physiol Regul Integr Comp Physiol. 2012; 302(12):R1372–83. Epub 2012/04/20. doi: 10.1152/ajpregu.00023.2012 PMID: 22513748

# PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| **TITLE** | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| **ABSTRACT** | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| **INTRODUCTION** | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3-4 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4 |
| **METHODS** | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 4 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4-5 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 4 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 5 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 6 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 5 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$) for each meta-analysis. | 5-6 |

# PRISMA 2009 Checklist

| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 6 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 6 |
| **RESULTS** | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 6; Fig. 1 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Figs. 2-4 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 6 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 6-8; Figs. 2-4 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 6-8; Figs. 2-4 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 6 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 7-9; Fig. 5 |
| **DISCUSSION** | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 9-12 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 12-13 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 12 |
| **FUNDING** | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | submitted to journal |

*From:* Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: **www.prisma-statement.org**.

# Bidirectional Relationship Between Reduced Blood pH and Acute Pancreatitis: A Translational Study of Their Noxious Combination

Zoltan Rumbus [1†], Emese Toth [2,3†], Laszlo Poto [4], Aron Vincze [5], Gabor Veres [6], Laszlo Czako [3], Emoke Olah [1], Katalin Marta [1,7], Alexandra Miko [1,7], Zoltan Rakonczay Jr. [8], Zsolt Balla [8], Jozsef Kaszaki [9], Imre Foldesi [10], Jozsef Maleth [3,11], Peter Hegyi [1,2,7*] and Andras Garami [1*]

[1] Institute for Translational Medicine, Medical School, University of Pecs, Pecs, Hungary, [2] Momentum Gastroenterology Multidisciplinary Research Group, Hungarian Academy of Sciences–University of Szeged, Szeged, Hungary, [3] First Department of Medicine, University of Szeged, Szeged, Hungary, [4] Institute of Bioanalysis, Medical School, University of Pecs, Pecs, Hungary, [5] Department of Gastroenterology, First Department of Medicine, University of Pecs, Pecs, Hungary, [6] First Department of Pediatrics, Semmelweis University, Budapest, Hungary, [7] Department of Translational Medicine, First Department of Medicine, University of Pecs, Pecs, Hungary, [8] Department of Pathophysiology, University of Szeged, Szeged, Hungary, [9] Institute of Surgical Research, University of Szeged, Szeged, Hungary, [10] Department of Laboratory Medicine, University of Szeged, Szeged, Hungary, [11] Momentum Epithel Cell Signaling and Secretion Research Group, Hungarian Academy of Sciences–University of Szeged, Szeged, Hungary

Acute pancreatitis (AP) is often accompanied by alterations in the acid-base balance, but how blood pH influences the outcome of AP is largely unknown. We studied the association between blood pH and the outcome of AP with meta-analysis of clinical trials, and aimed to discover the causative relationship between blood pH and AP in animal models. PubMed, EMBASE, and Cochrane Controlled Trials Registry databases were searched from inception to January 2017. Human studies reporting systemic pH status and outcomes (mortality rate, severity scores, and length of hospital stay) of patient groups with AP were included in the analyses. We developed a new mouse model of chronic metabolic acidosis (MA) and induced mild or severe AP in the mice. Besides laboratory blood testing, the extent of pancreatic edema, necrosis, and leukocyte infiltration were assessed in tissue sections of the mice. Thirteen studies reported sufficient data in patient groups with AP ($n = 2,311$). Meta-analysis revealed markedly higher mortality, elevated severity scores, and longer hospital stay in AP patients with lower blood pH or base excess ($P < 0.001$ for all studied outcomes). Meta-regression analysis showed significant negative correlation between blood pH and mortality in severe AP. In our mouse model, pre-existing MA deteriorated the pancreatic damage in mild and severe AP and, vice versa, severe AP further decreased the blood pH of mice with MA. In conclusion, MA worsens the outcome of AP, while severe AP augments the decrease of blood pH. The discovery of this vicious metabolic cycle opens up new therapeutic possibilities in AP.

Keywords: experimental pancreatitis, acidosis, acid-base balance, meta-analysis, mortality

# INTRODUCTION

Acute pancreatitis (AP) is one of the most frequent gastrointestinal causes of hospitalization with significant morbidity and mortality in the US (Yadav and Lowenfels, 2013; Parniczky et al., 2016). Although the mortality rate in mild and moderate AP is low, this value is still unacceptably high (30%) in its severe form (Parniczky et al., 2016). Since no specific therapy is available, only prompt and accurate interventions, such as aggressive fluid therapy can be beneficial (Vinish et al., 2017).

An important function of the pancreas is bicarbonate production, which is required to maintain its constant "milieu intérieur," thereby to prevent premature activation of pancreatic proteases (Pallagi et al., 2011, 2015; Hegyi and Petersen, 2013). When pancreatic bicarbonate production is challenged by local or systemic acid load (i.e., metabolic acidosis, MA), the resulting lower pH can facilitate pancreatic enzyme activation and deteriorate cell damage (Reed et al., 2011). Furthermore, injection of acidic contrast solution either into the pancreatic duct or into the vein significantly increased the severity of AP in rats (Noble et al., 2008; Bhoomagoud et al., 2009). Beside an external acid load, the pancreatic pH balance can also be compromised by tissue injury such as AP, which can lead to acidification of local tissues, thus deteriorate cell damage (Behrendorff et al., 2010). The luminal pH of the main pancreatic duct was also lower in human patients with AP compared to controls (Takacs et al., 2013), suggesting that the development of AP is accompanied by a reduction of local pH. Multiple mechanisms have been implicated in AP which can lead to MA, including direct mechanisms such as the loss of bicarbonate-rich pancreatic juice via pancreatic fistula or drainage (Rice et al., 2014), as well as indirect ones through lactic acidosis which can sequentially occur in AP due to shock, sepsis, cardiovascular failure, or upper gastrointestinal bleeding (Zhan et al., 2015). However, the interaction between AP and systemic pH is still not fully clarified.

Acidosis is often considered as a marker of disease severity, viz., a by-product of systemic dysregulation, and as such it is a proven prognostic factor in the assessment of critically ill patients (Vincent and Moreno, 2010). Despite the fact that scoring systems, which are used to help the diagnosis and the assessment of the progression of AP, include the changes in systemic pH balance of the patients (e.g., Acute Physiology and Chronic Health Evaluation, APACHE II and Ranson scores), clinical trials aiming to reveal a correlation between the acid-base status and the outcome of AP are scarce. To our knowledge, the sole published human study, which aimed to directly answer this question showed that changes in the parameters of systemic acid-base status can predict mortality in AP (Sharma et al., 2014). On the contrary, the necessity of arterial blood gas sampling was questioned in patients with AP in another human study (Ward

**Abbreviations:** AP, acute pancreatitis; APACHE, acute physiology and chronic health evaluation; CI, confidence interval; CRP, C-reactive protein; ES, estimated logit mortality rate; IL, interleukin; i.p., intraperitoneal(ly); LOS, length of hospital stay; MA, metabolic acidosis; MAP and SAP, mild and severe acute pancreatitis, respectively; SEM, standard error of mean; SMD, standardized mean difference; TNF, tumor necrosis factor.

et al., 2008). With regards to the results obtained in experimental animals, a detailed analysis of the correlation between systemic pH and the outcome of AP would be of utmost importance, because it could establish blood pH as a predictor of the severity and the outcome of the disease and, arguably, identify acidosis as a therapeutic target in AP.

In the present study, by using a dual, translational approach, we have discovered a vicious, bidirectional interaction between blood pH and the outcome of AP. Based on our discovery, the possibility of new therapeutic approaches in AP can be suggested.

# MATERIALS AND METHODS

## Study Design 1: Meta-Analysis of Clinical Trials

### Search Strategy

Our meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (Moher et al., 2009) (**Supplementary Table 1**), similarly as in our recent study (Olah et al., 2018). The analysis was based on the Patients, Intervention (or indicator), Comparison, Outcome (PICO) model: in patients with AP, we aimed to assess the predictive role of the change in pH status (as assessed by blood pH, bicarbonate concentration, base excess, or base deficit) on disease severity (indicated by clinical scores), length of hospital stay (LOS), and mortality ratio. This meta-analysis has been registered with PROSPERO (CRD42017055396).

A search in the PubMed, EMBASE, and Cochrane Controlled Trials Registry databases was performed from inception to January 2017 using the following terms: "pancreatitis AND (mortality OR survival OR severity) AND ("arterial pH" OR "blood pH" OR "systemic pH" OR "base deficit" OR "base excess" OR bicarbonate OR HCO3- OR "anion gap" OR acidosis OR alkalosis OR acid-base)." We restricted our search to original human studies published in English without time period limitations. A manual search of the reference lists of relevant full-text articles was conducted to identify further potentially eligible articles. The search was conducted separately by two authors (ZRu, AG), who also assessed study eligibility and extracted data from the selected studies independently. Disagreements were resolved by consensus with the help of a third party (PH).

### Study Selection and Data Extraction

The titles and abstracts of the publications from the literature search were screened and the full text of potentially eligible articles was obtained. We included studies in which blood pH or a related parameter (e.g., base excess, base deficit, or bicarbonate) and severity scores or LOS or mortality ratios were reported for the same group(s) of patients with AP. From all included articles we extracted the sample size, the reported mean pH or its related parameter for the studied patient groups with the corresponding standard error (SEM) or deviation, as well as the severity score, LOS, and mortality ratio within the group. To analyze the influence of the change in acid-base status on the severity and the outcome of AP, in each study we assigned the patient groups as a lower pH group and as a higher pH group,

irrespective from the original basis for grouping used by the authors of the study.

## Outcomes of Interest

We used mortality ratio of the AP patients groups as the primary outcome. Regarding secondary outcomes, we used two commonly applied severity indices (i.e., APACHE II and Ranson scores) and the LOS.

## Quality Assessment

We assessed the quality of each study included in the meta-analysis by using the Newcastle-Ottawa Scale (Wells et al., 2000; **Supplementary Table 2**).

## Statistical Analysis

We used logit transformation of event rates for mortality ratios and standardized mean difference (SMD) for LOS and severity scores as the effect size data. The secondary outcomes were compared between the lower and higher pH groups (see above) within each study, and then the estimated pooled mean values were calculated. The relevant studies were compared with standard meta-analysis tools (e.g., forest plot) in case of each outcome.

Between-study heterogeneity was assessed by $I^2$ statistical test, where $I^2$ is the proportion of total variation attributable to between-study variability (an $I^2$ value of more than 50 was considered as indication of considerable statistical heterogeneity). The selection of patients, study design, and the used methods showed variability among the studies included in our analyses, which also resulted in statistical heterogeneity. Since the lack of statistical significant results on these heterogeneity tests could be also due to the lack of power because of the small number of studies eligible for the analyses, we used the random effect model in case of each forest plot, similarly to our earlier meta-analysis (Rumbus et al., 2017). Publication bias was assessed by funnel-plot analysis, Egger's test and Duval and Tweedie trim and fill method (**Supplementary Figures 1–5**). Publication bias plots were used to assess whether studies with small sizes could have been missed in our analyses, however, due to the design of these tests they do not allow to firmly rule out the possibility that some papers missed the inclusion criteria of our search.

As a different statistical approach to reveal a correlation between systemic pH and mortality in moderate and severe forms of AP, we performed meta-regression analysis of those studies in which both blood pH and mortality rate were reported within the same patient group. The meta-analyses were performed with Comprehensive Meta-Analysis (version 3.3; Biostat, Inc., Engelwood, MJ, USA) and Stata (version 11.1; StataCorp, College Station, TX, USA) software.

## Study Design 2: Experimental Procedures
### Animals

The experiments were performed in 40 female FVB/N mice (Charles Rivers Laboratories, Wilmington, MA, USA). This commercially available, multipurpose mouse strain is characterized by excellent reproductive performance and it

was repeatedly used by our group to study the mechanisms of AP (Kui et al., 2015; Maleth et al., 2015). The mice were housed in standard plastic cages kept in a room with an ambient temperature of $24°C$ on a 12-h light-dark cycle in the animal facility of the First Department of Medicine at the University of Szeged. The mice were allowed free access to water and standard laboratory chow for rodents (Biofarm, Zagyvaszanto, Hungary).

## Ethics

All experiments were approved by the Institutional Animal Care and Use Committee of the University of Szeged and also by an independent committee assembled by national authorities (XII/3773/2012.). All experiments were conducted in compliance with the European Union Directive (2010/63/EU) and the Hungarian government decree (40/2013, II.14.).

## Experimental Modeling of Chronic MA in Mice

To develop a mouse model of chronic MA, the mice were randomly divided into the following 4 groups for a 12-day treatment: (i) ammonium chloride ($NH_4Cl$) administration with drinking water ($8.2 \pm 0.5$ ml/day/mouse) as reported in earlier studies (Galicek et al., 1981; Nowik et al., 2010); (ii) intraperitoneal (i.p.) injections of $NH_4Cl$ (0.5 ml, 0.28 M) on days 1 and 6; (iii) administration of $NH_4Cl$ with drinking water (as in group 1) and i.p. injections (as in group 2); and (iv) controls, receiving $NH_4Cl$-free tap water and 2 i.p. injections of saline on days 1 and 6.

## Experimental Modeling of AP

Two different types of AP were used in this study. Mild acute pancreatitis (MAP) was induced by alcohol and fatty acid as described earlier (Huang et al., 2014; Maleth et al., 2015). Severe acute pancreatitis (SAP) was induced by the injections of cerulein (50 μg/kg, i.p.) at start time, and then at every hour for 9 h (Mareninova et al., 2006). In the chronic MA model, MAP and SAP were induced on day 12 of the acidifying treatment.

## Laboratory Measurements

Animals were euthanized by i.p. injection of sodium pentobarbital (50 mg/kg). Blood samples were collected by cardiac puncture. Serum amylase activity was measured by using a colorimetric kinetic method (Diagnosticum, Budapest, Hungary). Serum concentrations of creatinine and glucose as well as urea concentration in urine were measured with commercially available laboratory kits (Institute of Laboratory Medicine, University of Szeged). Arterial blood samples were collected in sealed plastic capillaries (170 μl), which were previously treated with lithium and heparin. Analysis of the arterial blood samples was performed by a blood gas analyzer (Cobas b221 system; Roche Ltd., Basel, Switzerland) within 1 min after blood collection at room temperature ($22°C$).

## Histology

Histological evaluations were performed as described earlier (Kui et al., 2015). In brief, the extent of pancreatic edema (0: none; 1: patchy interlobular; 2: diffuse interlobular; 3: diffuse interlobular and intraacinar), necrosis (%), and leukocyte infiltration (0: none; 1: rare patchy interlobular; 2: patchy interlobular; 3: diffuse

interlobular; 4: diffuse interlobular and intraacinar) were assessed in pancreatic tissue sections stained with haematoxylin and eosin under a light microscope (Zeiss Axio scope A1 microscope) at 40x magnification by an investigator who was expert in pancreas histology, however blinded to the animal's treatment group. The percentage of acinar cell necrosis was evaluated by ImageJ software (NIH, Bethesda, MD, USA).

## Statistical Analysis

Data were compared by one-way ANOVA followed by Holm-Sidak test, two-way ANOVA followed by Fischer Least Significant Difference test, or two-tailed Student's $t$ test, as appropriate. SPSS 23.0 (IBM, Armonk, NY, USA) and Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) software was used for statistical analysis. The effects were considered significant when $P < 0.05$. In the experimental part of the study, data are reported in the Mean ± SEM format.

# RESULTS

## Meta-Analysis

### Study Selection

The flow chart of the study selection is presented in **Figure 1**. Until January 2017 the electronic literature search identified altogether 1,076 studies from the PubMed, EMBASE, and Cochrane databases. After enabling filters for human studies and English language and removal of duplicates, 793 articles remained, which were screened on title and abstract for inclusion criteria. Full texts of the remaining 122 articles were reviewed in detail. In 109 studies pH parameters or outcomes were not suitably reported in the patients with AP, therefore these were also excluded. As a result, 13 full-text publications were found eligible for statistical analysis which included data from a total of 2,311 patients (Ranson et al., 1976; Nair et al., 2000; Eachempati et al., 2002; Zhu et al., 2003; Kaya et al., 2007; Keskinen et al., 2007; Pupelis et al., 2007; De Campos et al., 2008; Shinzeki et al., 2008; Lei et al., 2013; Sharma et al., 2014; Zhan et al., 2015; Shen et al., 2016). The characteristics of these studies are summarized in **Supplementary Table 3**.

### Reduction of Blood pH Is Associated With Higher Mortality Rate in AP

First, we investigated the association between systemic (blood) pH status and our strongest endpoint, viz., the mortality. Our meta-analysis revealed a logit event rate of −0.09 (95% CI, −0.79, 0.61), corresponding to an average mortality rate of 51.0% (95% CI, 31.5, 70.1) in the more acidotic patient groups, while in the patient groups with higher pH or bicarbonate level the logit event rate was −3.68 (95% CI, −4.81, −2.55), which corresponds to an average mortality rate of 3.0% (95% CI, 1.2, 7.1) (**Figure 2**). The mortality ratios were significantly different between the two groups ($P < 0.001$).

### Lower pH or Bicarbonate Concentration Worsens the Severity of AP

We wanted to know whether the change in acid-base status can also predict the severity of AP as assessed by clinical scores. Thus,

we studied the association between blood pH and clinical severity scores. We found two scores, the Ranson and the APACHE II scores, which were reported in sufficient number of studies for statistical analysis (Ranson et al., 1976; Nair et al., 2000; Eachempati et al., 2002; Zhu et al., 2003; Kaya et al., 2007; Keskinen et al., 2007; Pupelis et al., 2007; De Campos et al., 2008; Shinzeki et al., 2008; Lei et al., 2013; Sharma et al., 2014; Zhan et al., 2015; Shen et al., 2016). Meta-analysis revealed that the pooled SMDs of the Ranson score (0.92, 95% CI, 0.58, 1.26) and the APACHE II score (1.38, 95% CI, 0.95, 1.81) were significantly positive between the patient groups with lower pH or bicarbonate levels and the less acidotic groups of patients ($P < 0.001$) (**Figures 3A,B**). These standardized values correspond to 1.60 (95% CI, 0.77, 2.42) higher Ranson score and 7.40 (95% CI, 5.05, 9.75) higher APACHE II score in the more acidotic patients with AP. The correlation found between lower blood pH and higher clinical scores could be expected as these scores also include blood pH in their calculation (Vincent and Moreno, 2010), nevertheless, these results confirm the feasibility of our meta-analysis approach to reveal an interaction between systemic pH and the outcome of AP.

### Acidosis Is Associated With Longer Hospitalization in AP

Next, we analyzed the LOS in patients with AP by using the same grouping of acid-base status as used for mortality and severity scores. For the meta-analysis, LOS was expressed as SMD between the patient groups. We found that the pooled difference was significantly positive between the more acidotic patient groups and the groups with higher pH or bicarbonate concentrations (0.89, 95% CI, 0.73, 1.04; $P < 0.001$) (**Figure 4**), which difference corresponds to 15.05 days (95% CI, 10.84, 19.19) longer LOS in the more acidotic AP patient group.

### Meta-Regression Analysis

As a further statistical approach to determine a correlation between blood pH and mortality in the more progressed forms of AP, we also performed a meta-regression analysis on the collected data. For that, we used those study groups, in which pH and mortality rate was reported in moderately severe or severe manifestations of AP for the same patient groups (Zhu et al., 2003; Lei et al., 2013; Shen et al., 2016). We found a significant correlation between pH and mortality rate with a regression slope of −55.4 (95% CI, −97.9, −12.9; $P = 0.011$) (**Figure 5**). The potential reason for statistical heterogeneity, as revealed in the forest plots, could not be evaluated in the meta-regression analysis because of the small number of eligible studies.

## Experimental Animal Model

### Acidosis Is Augmented in Severe Form of AP

Analyses of data from 2,311 patients showed strong association between acidosis and the outcome of AP. Therefore, we moved from the "bedside to the bench" to clarify their causative relationship. First, we developed a new experimental model to mimic chronic MA by comparing different types (oral or i.p. or both) of acidifying treatments in mice. We

**FIGURE 1 |** Flow chart of study selection and inclusion.

found that MA can be induced in mice by the combined administration of oral and i.p. $NH_4Cl$, which decreased blood pH to $6.80 \pm 0.04$, but it did not cause any pancreatic damage (**Supplementary Figure 6**), nor did it change serum glucose and urine urea levels (**Supplementary Figure 7**). Similarly to pH, arterial blood bicarbonate level decreased most significantly ($P < 0.001$) in the combination (oral and i.p.) treatment group as compared to controls ($16.5 \pm 0.9$ vs. $26.4 \pm 0.8$ mmol/l) (**Supplementary Figure 7**). We detected no significant differences in the serum concentrations of creatinine, sodium, and potassium among the different treatment groups (data not shown). We used this MA model to study the interaction between acidosis and AP. For that, mice with or without pre-existing MA were assigned to MAP, SAP, and control (no AP) groups and their arterial blood pH were compared. As expected, pre-existing MA induced by dual (oral and i.p.) acidifying treatment resulted in significantly decreased blood pH in the mice without AP, as well as in mice with either MAP or SAP (**Figure 6**). In the mice with pre-existing MA, the extent of the pH reduction was similar in the sham AP and MAP groups ($7.08 \pm 0.04$ and $7.11 \pm 0.03$, respectively), while in the mice with SAP the arterial pH decreased to $6.97 \pm 0.05$, which was significantly lower than in the sham AP and MAP groups ($P < 0.05$ compared to both), suggesting

that SAP further deteriorates MA (**Figure 6**). As expected, MA also resulted in decreased arterial blood bicarbonate levels, which reached the level of significance in the MAP group ($16.7 \pm 1.4$ mmol/l; $P < 0.01$) (**Supplementary Figure 8**). The levels of urea in the urine were markedly decreased in mice with SAP ($3.6 \pm 0.2$ mmol/l) regardless of their pH status as compared to the urine urea levels in the sham AP groups without and with pre-existing MA ($7.4 \pm 0.2$ and $7.5 \pm 0.1$ mmol/l, respectively; $P < 0.001$ for both). Importantly, MA significantly lowered urine urea levels in mice with MAP compared to mice with MAP without pre-existing MA ($5.9 \pm 0.7$ vs. $8.9 \pm 1.0$ mmol/l; $P < 0.05$) (**Supplementary Figure 8**). We did not detect significant difference in the serum concentrations of glucose (**Supplementary Figure 8**), and in the levels of creatinine, sodium, and potassium among the different treatment groups (data not shown).

## Pre-existing Acidosis Deteriorates Both Mild and Severe Forms of AP in Mice

To determine whether the presence of pre-existing MA has any effects on the pancreatic damage during AP, pancreatic edema, necrosis, and leukocyte infiltration scores were assessed in pancreatic sections of mice without AP, or with MAP or SAP in the presence and the absence of pre-existing MA. The

**FIGURE 2 |** Forest plot of mortality rate using random-effects model in different systemic pH groups of patients with acute pancreatitis (AP). For each patient group, black circles and horizontal lines represent the estimated logit mortality rate (ES) and the corresponding confidence interval (CI), respectively. Lower ES corresponds with lower mortality rate and vice versa. Gray squares indicate the relative statistical weight of a given patient group. Open diamonds show the average ES and CI of patient groups with higher systemic pH (top), lower systemic pH (middle), and all patient groups (bottom).

acidifying treatment caused no pancreatic damage in the control (no AP) mice (**Figure 7**), which is line with our previous results (**Supplementary Figure 6**). On the contrary, in mice with pre-existing MA, MAP resulted in significantly larger edema ($2.0 \pm 0.3$ vs. $1.4 \pm 0.2$; $P < 0.05$), increased necrosis ($21.0 \pm 2.4$ vs. $10.0 \pm 2.2\%$; $P < 0.05$), and elevated leukocyte infiltration ($2.5 \pm 0.4$ vs. $1.6 \pm 0.2$; $P < 0.05$) compared to MAP in mice with normal blood pH (**Figure 7**). Pancreatic damage was also markedly more pronounced in SAP in mice with pre-existing MA compared to SAP in mice with normal blood pH as indicated by increased edema ($3.6 \pm 0.2$ vs. $2.4 \pm 0.2$; $P < 0.05$), necrosis ($38.6 \pm 5.0$ vs. $25 \pm 2.2\%$; $P < 0.01$), leukocyte infiltration ($3.6 \pm 0.4$ vs. $2.6 \pm 0.2$; $P < 0.05$), and serum amylase activity ($12{,}730 \pm 384$ vs. $11{,}362 \pm 106$ Unit/l; $P < 0.05$) (**Figure 7**). These results suggest that MA further deteriorates pancreatic damage in both MAP and SAP.

## DISCUSSION

In the present study, we revealed a strong association between blood pH and the outcome of AP with meta-analysis of human studies. Our analyses showed that lower blood pH predicts higher mortality rate, longer LOS, and worsens the severity of AP. A significant negative correlation between blood pH and mortality rate in severe forms of AP was found with meta-regression analysis of the human studies. To better clarify how MA can interact with AP, we developed a mouse model of chronic MA and showed that SAP worsens the MA in the mice. In the same model we also demonstrated that pre-existing MA further deteriorates the tissue damage in both mild and severe forms of AP.

Although previous human studies indicated a link between MA and AP (Nair et al., 2000; Zhu et al., 2003; Shinzeki et al., 2008; Sharma et al., 2014; Shen et al., 2016), we found only one,

FIGURE 3 | Forest plot of (A) Ranson scores and (B) Acute Physiology and Chronic Health Evaluation (APACHE II) scores using random-effects model in different systemic pH groups of patients with acute pancreatitis. Here and in Figure 4, in each study the standardized mean difference (SMD) of the outcome was calculated between the patient group with lower and higher pH. Black circles represent the SMD for each study, while the left and right horizontal arms of the circles indicate the corresponding 95% confidence intervals (CI) for the SMD for each study. The size of the gray box is proportional to the sample size of the study; bigger box represents larger sample size, thus bigger relative weight of the study, and vice versa. Circles close to zero represent smaller SMD between the lower and higher pH groups in the given study. A positive SMD means higher score (Figure 3) or longer hospital stay (Figure 4) in the patient group with lower pH compared to the patient group with higher pH. The diamond on the bottom represents the averaged SMD calculated from the SMDs of all the individual studies. The vertical dashed line is determined by the two vertical points of the diamond and indicates the value of the averaged SMD of all studies. The horizontal points of the diamond represent the 95% CI of the averaged SMD.

single-center prospective study which directly aimed to explore this correlation (Sharma et al., 2014). Because of the scarcity of data available from targeted clinical trials, we aimed to clarify

the association between MA and AP by systematic review of the current literature and by meta-analysis of the available data. By identifying 13 eligible studies for the analysis (Ranson et al.,

**FIGURE 4** | Forest plot analysis of the length of hospital stay using random-effects model in different systemic pH groups of patients with acute pancreatitis. For explanation, see the legend of **Figure 3**. SMD, standardized mean difference; CI, confidence interval.



**FIGURE 5** | Meta-regression analysis of the association between blood pH and mortality rate in patients with moderately severe and severe forms of acute pancreatitis. The circles indicate estimated logit mortality rate calculated for each patient group. A lower calculated value corresponds with lower mortality rate and vice versa. The circle size is proportional to the precision of the estimated logit mortality rate. The solid black line represents the weighted regression line based on variance-weighted least squares.

1976; Nair et al., 2000; Eachempati et al., 2002; Zhu et al., 2003; Kaya et al., 2007; Keskinen et al., 2007; Pupelis et al., 2007; De Campos et al., 2008; Shinzeki et al., 2008; Lei et al., 2013; Sharma et al., 2014; Zhan et al., 2015; Shen et al., 2016), we included 2,311 patients with AP in the analyses. In all of these studies, blood sample analysis was performed at admission or within 24 h thereafter, hence the blood pH parameters were determined with practically the same latency compared to the time when AP was

diagnosed. Unavoidably however, the disease could progress to different stages in the different patients before the diagnosis has been reached. There were huge differences between the protocols of the individual studies, but it is remarkable that no matter how the patients were grouped by the authors originally, the patient group with lower pH had always (with no exceptions) worse outcomes (mortality rate, LOS, severity scores) than the group with higher pH in AP, which suggests that in the early stages (viz., until the time of diagnosis) of AP acidosis is an important influencing factor of the outcome regardless from the actual progression of the disease. Unfortunately, the design of the studies did not allow to analyze the causative relationship between MA and AP. In most of the studies, the systemic pH status of the patients prior to or repeatedly after the diagnosis of AP was not reported, thus the dynamics in the changes of pH during the time course of AP could not be assessed in the current analysis, but it is notable that the average base deficit was markedly (4-8 fold) higher in populations of patients, who did not survive SAP (Kaya et al., 2007; Keskinen et al., 2007). In the prospective trial by Sharma et al. (2014), in those SAP patients, who had a blood pH of less than 7.35, the mortality rate was nearly 10 times higher than in those patients whose pH was above this level (54 vs. 6.5%).

As limitations of our study, it should be mentioned that even though our meta-analysis showed a clear association between blood pH and the outcome of AP, since originally the patients were not divided into subgroups based on their blood pH by the authors, the independent effect of lower blood pH on the outcome and the cause-effect relationship between MA and AP could not be assessed. Because of the same reason and also to reduce the inter-study heterogeneity, in each of the analyzed

**FIGURE 6 |** Arterial pH of mice with metabolic acidosis (MA) induced by combination of oral and i.p. $NH_4Cl$ administration and without acidifying treatment (control). On day 12 of the acidifying treatment, mild acute pancreatitis (MAP) or severe acute pancreatitis (SAP) was induced by alcohol and fatty acid or cerulein, respectively. Mice in the sham pancreatitis group (no AP) were injected i.p. with saline. Statistically significant differences are marked with *between MA and control (non-acidotic) groups, with #between no AP and MAP groups in MA, and with $between no AP and SAP groups in MA, as follows: *$P < 0.05$ and **$P < 0.01$ for MA vs. control in no AP, MAP, and SAP; #$P < 0.05$ for no AP in MA vs. SAP in MA; $$P < 0.05$ for MAP in MA vs. SAP in MA.



**FIGURE 7 |** Assessment of the severity of acute pancreatitis (AP) in mice with and without metabolic acidosis (MA and control, respectively). **(A)** Representative microphotographs of pancreatic sections, **(B)** histological evaluation of edema scores, necrosis, and leukocyte infiltration scores, and **(C)** serum amylase levels of MA and control mice with mild acute pancreatitis (MAP), severe acute pancreatitis (SAP) or without acute pancreatitis (no AP). Scale bar represents $20\,\mu$m. Statistically significant differences are marked with *between MA and control (non-acidotic) groups and with #between no AP and either MAP or SAP groups, as follows: *$P < 0.05$; **$P < 0.01$ for MA vs. control in MAP and SAP; #$P < 0.05$, ##$P < 0.01$, and ###$P < 0.001$ for no AP vs. MAP and SAP.

studies we assigned one patient group as the lower pH group and the other one as the higher pH group. Since the reported pH values differed substantially among the analyzed studies, the cut-off value between the lower and the higher pH groups was individually determined for each study. Consequently, in the present analysis we could not determine a specific cut-off pH value which would be detrimental for the outcome of AP. The most convincing method to obtain direct evidence for the role of acidosis as an independent risk factor in AP, determine a detrimental cut-off pH value, and gain insight into the cause-effect relationship in humans would be to conduct targeted clinical trials in which patients with AP are grouped based on their blood pH at admission and their acid-base status as well as the severity and the outcome of AP is continuously monitored. By collecting data of individual patients in such clinical trials, it would be possible to statistically analyze the direct (independent) effect of acid-base disturbances on AP. Until such or similar trials are conducted, we are restricted to use different (not so direct) approaches such as meta-analyses and animal experiments.

To discover whether a pre-existing MA worsens the outcome of AP or MA is rather the result of the progression of AP, we moved from the "bedside to the bench." Gorelick's workgroup has discovered that low extracellular pH induces pathophysiological changes in acinar cells (Bhoomagoud et al., 2009; Reed et al., 2011). They described that reduced pH sensitizes the acinar cell to secretagogue-induced pancreatitis responses in rats, and enhances connexin32 degradation and ryanodine receptor-mediated calcium signaling in the basolateral region of the acinar cell which mechanisms are responsible for the injurious effects of low extracellular pH on the exocrine pancreas (Bhoomagoud et al., 2009; Reed et al., 2011, 2014). However, the authors have not investigated the causative relationship between low pH and pancreatitis. Since no mouse model of chronic MA was available in the literature, first we designed a set of experiments to develop the most suitable MA model. Dual administration (oral and i.p.) of acidic fluid induced a marked pH drop in the blood without damaging the pancreas. By supplementing the oral treatment with i.p. acidification, our model also accounted for such conditions, when primarily the pH of the peritoneal fluid is reduced such as bacterial peritonitis (Glinska-Suchocka et al., 2016), carbon dioxide insufflation during laparoscopy (Duerr et al., 2008), or peritoneal dialysis (Farhat et al., 2008). Notably, in our model, MA developed gradually and persisted for several days in the mice which is very similar to the development of MA in human patients. Indeed, there is evidence that in human patients AP can develop in pre-existing MA, for instance in diabetic ketoacidosis either via hyperlipidemia (Nair and Pitchumoni, 1997; Nair et al., 2000) or through distinct mechanisms (Gianfrate and Ferraris, 1998). It should be noted however that in clinical settings MA typically occurs as a consequence of AP and in many cases it does not pre-exist. The shown reverse relationship between MA and AP, namely that the presence of a pre-existing acidosis can influence the severity of AP, warrants for careful pH management in such clinical situations.

Sodium bicarbonate therapy is widely accepted for the treatment of MA in conditions associated with the loss of bicarbonate (e.g., renal tubular acidosis, diarrhea), however its use to increase pH in diseases associated with acidosis not due to bicarbonate loss is questionable because of its adverse effects, for example, intracellular acidosis, hypokalemia, and decreased serum ionized calcium concentration (for reviews, see Adeva-Andany et al., 2014; Hopper, 2017). In AP, bicarbonate production becomes impaired due to the damage of the pancreatic tissue, hence when systemic pH decreases bicarbonate administration can be beneficial to maintain normal pH, thereby to improve the outcome based on our results. It has to be noted that, to our knowledge, currently there is no evidence for the benefits of bicarbonate administration in AP. In contrast with sodium bicarbonate therapy, a growing body of evidence supports the beneficial effects of lactated Ringer's solution in the treatment of AP. Since lactate is metabolized to bicarbonate in the liver, lactated Ringer's solution was successfully used to lessen the metabolic acidosis by elevating blood bicarbonate levels and to attenuate the systemic inflammation response as assessed by lower C-reactive protein (CRP) levels in patients with AP (Wu et al., 2011; de-Madaria et al., 2018). Administration of lactated Ringer's solution resulted in lower mortality rate in critically ill patients with AP (Aboelsoud et al., 2016) and it lead to transiently reduced systemic inflammation in patients with MAP (Choosakul et al., 2018), although it had no therapeutic benefits in AP in a retrospective study (Lipinski et al., 2015). For the initial management of AP, the American College of Gastroenterology guideline recommends lactated Ringer's solution as the preferred isotonic crystalloid fluid replacement with moderate quality of evidence (Tenner et al., 2013). Future clinical trials are warranted to confirm the beneficial effects of tightly controlled pH management and to identify the optimal type of fluid resuscitation in patients with AP and pre-existing MA.

Our experiments clearly showed a strong bilateral link between pH and AP. We showed that pre-existing MA worsens the outcome of AP, whereas AP reduces pH in the blood which vicious cycle could be one of the main reasons for the high mortality rate in AP. The exact mechanism of how MA can deteriorate AP remains subject for future studies, but it can be assumed that complex regulatory mechanisms, such as the pancreatic damage and zymogen activation, neurogenic inflammation, and activation of inflammatory cells and mediators, are involved; for a comprehensive review, see Gorelick and Thrower (2009). Similarly, the question of whether the augmented acidosis is a direct or an indirect consequence (e.g., through impaired kidney and/or lung functions) or a combination of these in AP remains to be answered. Indeed, several complications of AP such as renal, pulmonary, and cardiovascular failure can cause disturbances in the acid-base balance. The development of acute renal dysfunction was reported in several of the analyzed studies (Keskinen et al., 2007; Pupelis et al., 2007; Lei et al., 2013; Sharma et al., 2014; Shen et al., 2016), and the impaired kidney function (determined by increased serum creatinine and blood urea nitrogen levels) was associated with significantly worse outcome, including higher mortality rates in AP (Talamini et al., 1999; Eachempati et al., 2002). Moreover, the frequency of renal failure increased by 5-10 times if acidosis (i.e., blood pH < 7.35, base deficit > 4 mEq/l, or bicarbonate < 22 mEq/l) occurred in AP (Sharma et al., 2014). Since we found only one clinical trial which directly

investigated the relationship between renal failure and acidosis in AP (Sharma et al., 2014), the available data in humans were not sufficient for meta-analysis. In our experimental model, acute renal dysfunction occurred in mice with SAP regardless of their pH status, moreover the presence of pre-existing MA significantly impaired the kidney functions in mice with MAP, which is in harmony with the observations in humans and provides direct experimental support to the association between acidosis and renal failure in AP.

Cytokines are important mediators in the whole process of AP. A number of proinflammatory mediators, such as interleukin (IL)-1, 6, 8, and tumor necrosis factor (TNF)-α, were shown to play a role in AP in experimental animals (Norman et al., 1997; Liu et al., 2003; Meng et al., 2005) and in human patients (de Beaux et al., 1996; McKay et al., 1996; Brivet et al., 1999; Mayer et al., 2000). Cytokine production occurs in the pancreas first, and then with the progression of the disease in distant organs like the lungs, liver, and spleen (Norman et al., 1997). The levels of IL-6, 8, and TNF-α are even more increased in SAP than in MAP (McKay et al., 1996; Pooran et al., 2003). Active digestive enzymes which are released from injured pancreatic cells can potently stimulate proinflammatory cytokine production in macrophages (Desser et al., 1994; Lundberg et al., 2000), moreover the pancreatic acinar cells can also produce proinflammatory cytokines (Gukovskaya et al., 1997; Brady et al., 2002). For example, amylase can induce the production of IL-1, 6, and TNF-α in human peripheral blood mononuclear cells and in dermal fibroblasts (Desser et al., 1994; Malpass et al., 2013). Lipase markedly induced TNF-α production in rat macrophages (Jaffray et al., 2000), while CRP was shown to strongly correlate with IL-6 levels in patients with AP (Viedma et al., 1992). In our mouse model, we found that amylase level was elevated in SAP, and it was further increased in the presence of a pre-existing acidosis, therefore it can be expected that circulating cytokine levels are also higher in the co-existence of SAP and MA than in SAP without acidosis. In patients with SAP, the serum lipase and CRP levels were higher when their blood pH was lower (Pupelis et al., 2007), thus suggesting higher levels of circulating cytokines.

The production of pro- and anti-inflammatory cytokines was repeatedly shown to depend from the extracellular pH (for reviews, see Kellum et al., 2004b; Okajima, 2013; Casimir et al., 2018). Although the different forms and severities of acidosis can differently influence cytokine production (Kellum et al., 2004b), a proinflammatory effect, including enhanced TNF-α synthesis and augmented nuclear factor-κB activation, of hyperchloremic acidification was shown in activated macrophages by independent groups (Bellocq et al., 1998; Heming et al., 2001; Kellum et al., 2004a). Also, decreasing extracellular pH caused increasing IL-8 expression and nuclear factor-κB activation in human pancreatic tumor cells (Shi et al., 2000). In addition to the recruitment of immune cells by the low pH-induced cytokine release, extracellular acidosis *per se* promotes the activation of neutrophils (Martinez et al., 2006), which is in line with the increased leukocyte infiltration in MAP and SAP with pre-existing acidosis compared to MAP

and SAP with initially normal blood pH, as observed in the present study (**Figure 7B**). Here, we revealed a bidirectional relationship constituting a vicious circle between AP and acidosis and developed a mouse model for studying the underlying mechanisms of the progression of AP in pre-existing MA. However, the experimental conformation of the dynamics of tissue and circulating cytokine concentrations and other potential processes (e.g., calcium signaling) in this model remains subject for future studies.

In summary, by the meta-analysis of literature data available from human studies we found a significant correlation between low systemic pH and the outcome of AP, indicating that lower pH level is associated with higher mortality rates, longer LOS, and more severe AP. With regards to the mechanism, in experimental animals we showed the existence of a bidirectional interaction between MA and AP, in which pre-existing MA deteriorates AP and, vice versa, AP further increases the severity of MA. Our findings suggest that systemic pH level should be closely monitored in patients with AP and that interventions to normalize the low pH of patients with AP should be considered in clinical settings. Well-designed, targeted clinical trials are warranted to evaluate the effects of the therapeutic interventions of acidosis in patients with AP.

## AUTHOR CONTRIBUTIONS

ZRu and AG conducted the literature search of meta-analysis and the quality assessment of included studies, and extracted data from the articles. ET, JM, ZB, and PH performed the experiments. PH and AG conceived and supervised the meta-analysis and the experimental procedures and obtained funding. ZRu, ET, LP, JM, AG, and PH analyzed and interpreted the data. ZRu, ET, LP, PH, and AG wrote the paper. LP, EO, AV, GV, LC, KM, AM, ZRa, ZB, JK, IF, and JM reviewed and contributed to the manuscript. All authors approved the final manuscript.

## FUNDING

## ACKNOWLEDGMENTS

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2018.01360/full#supplementary-material

# REFERENCES

Aboelsoud, M. M., Siddique, O., Morales, A., Seol, Y., and Al-Qadi, M. O. (2016). Fluid choice matters in critically-ill patients with acute pancreatitis: lactated Ringer's vs. isotonic saline. *R. I. Med. J.* (2013) 99, 39–42. Available online at: http://www.rimed.org/rimedicaljournal/2016/10/2016-10-39-cont-aboelsoud.pdf

Adeva-Andany, M. M., Fernandez-Fernandez, C., Mourino-Bayolo, D., Castro-Quintela, E., and Dominguez-Montero, A. (2014). Sodium bicarbonate therapy in patients with metabolic acidosis. *Sci. World J.* 2014:627673. doi: 10.1155/2014/627673

Behrendorff, N., Floetenmeyer, M., Schwiening, C., and Thorn, P. (2010). Protons released during pancreatic acinar cell secretion acidify the lumen and contribute to pancreatitis in mice. *Gastroenterology* 139, 1711–1720. doi: 10.1053/j.gastro.2010.07.051

Bellocq, A., Suberville, S., Philippe, C., Bertrand, F., Perez, J., Fouqueray, B., et al. (1998). Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages. Evidence for involvement of nuclear factor-kappaB activation. *J. Biol. Chem.* 273, 5086–5092. doi: 10.1074/jbc.273.9.5086

Bhoomagoud, M., Jung, T., Atladottir, J., Kolodecik, T. R., Shugrue, C., Chaudhuri, A., et al. (2009). Reducing extracellular pH sensitizes the acinar cell to secretagogue-induced pancreatitis responses in rats. *Gastroenterology* 137, 1083–1092. doi: 10.1053/j.gastro.2009.05.041

Brady, M., Bhatia, M., Christmas, S., Boyd, M. T., Neoptolemos, J. P., and Slavin, J. (2002). Expression of the chemokines MCP-1/JE and cytokine-induced neutrophil chemoattractant in early acute pancreatitis. *Pancreas* 25, 260–269. doi: 10.1097/00006676-200210000-00008

Brivet, F. G., Emilie, D., and Galanaud, P. (1999). Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian study group on acute pancreatitis. *Crit. Care Med.* 27, 749–755. doi: 10.1097/00003246-199904000-00029

Casimir, G. J., Lefevre, N., Corazza, F., Duchateau, J., and Chamekh, M. (2018). The acid-base balance and gender in inflammation: a mini-review. *Front. Immunol.* 9:475. doi: 10.3389/fimmu.2018.00475

Choosakul, S., Harinwan, K., Chirapongsathorn, S., Opuchar, K., Sanpajit, T., Piyanirun, W., et al. (2018). Comparison of normal saline versus lactated Ringer's solution for fluid resuscitation in patients with mild acute pancreatitis, a randomized controlled trial. *Pancreatology* 18, 464–614. doi: 10.1016/j.pan.2018.04.016

de Beaux, A. C., Goldie, A. S., Ross, J. A., Carter, D. C., and Fearon, K. C. (1996). Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. *Br. J. Surg.* 83, 349–353. doi: 10.1002/bjs.1800830317

De Campos, T., Braga, C. F., Kuryura, L., Hebara, D., Assef, J. C., and Rasslan, S. (2008). Changes in the management of patients with severe acute pancreatitis. *Arq. Gastroenterol.* 45, 181–185. doi: 10.1590/S0004-28032008000300002

de-Madaria, E., Herrera-Marante, I., Gonzalez-Camacho, V., Bonjoch, L., Quesada-Vazquez, N., Almenta-Saavedra, I., et al. (2018). Fluid resuscitation with lactated Ringer's solution vs normal saline in acute pancreatitis: a triple-blind, randomized, controlled trial. *United Eur. Gastroenterol. J.* 6, 63–72. doi: 10.1177/2050640617707864

Desser, L., Rehberger, A., and Paukovits, W. (1994). Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells *in vitro*. *Cancer Biother.* 9, 253–263. doi: 10.1089/cbr.1994.9.253

Duerr, F. M., Twedt, D. C., and Monnet, E. (2008). Changes in pH of peritoneal fluid associated with carbon dioxide insufflation during laparoscopic surgery in dogs. *Am. J. Vet. Res.* 69, 298–301. doi: 10.2460/ajvr.69.2.298

Eachempati, S. R., Hydo, L. J., and Barie, P. S. (2002). Severity scoring for prognostication in patients with severe acute pancreatitis: comparative analysis of the Ranson score and the APACHE III score. *Arch. Surg.* 137, 730–736. doi: 10.1001/archsurg.137.6.730

Farhat, K., van Ittersum, F. J., Ter Wee, P. M., and Douma, C. E. (2008). Conventional versus biocompatible peritoneal dialysis fluids: more questions than answers? *NDT Plus* 1(Suppl. 4), iv46–iv50. doi: 10.1093/ndtplus/sfn124

Galicek, J., Seow, F., and Lingard, J. M. (1981). The effect of chronic acid/base disturbances on renal amino acid clearances in the rat. *Aust. J. Exp. Biol. Med. Sci.* 59, 383–391. doi: 10.1038/icb.1981.32

Gianfrate, L., and Ferraris, L. (1998). Acute pancreatitis, hyperlipidemia, and diabetic ketoacidosis: who comes first? *Am. J. Gastroenterol.* 93, 1393–1394. doi: 10.1111/j.1572-0241.1998.1393a.x

Glinska-Suchocka, K., Slawuta, P., Jankowski, M., Kubiak, K., Spuzak, J., and Borusewicz, P. (2016). An analysis of pH, pO2 and pCO2 in the peritoneal fluid of dogs with ascites of various etiologies. *Pol. J. Vet. Sci.* 19, 141–145. doi: 10.1515/pjvs-2016-0018

Gorelick, F. S., and Thrower, E. (2009). The acinar cell and early pancreatitis responses. *Clin. Gastroenterol. Hepatol.* 7, S10–S14. doi: 10.1016/j.cgh.2009.07.036

Gukovskaya, A. S., Gukovsky, I., Zaninovic, V., Song, M., Sandoval, D., Gukovsky, S., et al. (1997). Pancreatic acinar cells produce, release, and respond to tumor necrosis factor-alpha. Role in regulating cell death and pancreatitis. *J. Clin. Invest.* 100, 1853–1862. doi: 10.1172/JCI119714

Hegyi, P., and Petersen, O. H. (2013). The exocrine pancreas: the acinar-ductal tango in physiology and pathophysiology. *Rev. Physiol. Biochem. Pharmacol.* 165, 1–30. doi: 10.1007/112_2013_14

Heming, T. A., Dave, S. K., Tuazon, D. M., Chopra, A. K., Peterson, J. W., and Bidani, A. (2001). Effects of extracellular pH on tumour necrosis factor-alpha production by resident alveolar macrophages. *Clin. Sci.* 101, 267–274. doi: 10.1042/cs1010267

Hopper, K. (2017). Is bicarbonate therapy useful? *Vet. Clin. North Am. Small Anim. Pract.* 47, 343–349. doi: 10.1016/j.cvsm.2016.09.005

Huang, W., Booth, D. M., Cane, M. C., Chvanov, M., Javed, M. A., Elliott, V. L., et al. (2014). Fatty acid ethyl ester synthase inhibition ameliorates ethanol-induced $Ca^{2+}$-dependent mitochondrial dysfunction and acute pancreatitis. *Gut* 63, 1313–1324. doi: 10.1136/gutjnl-2012-304058

Jaffray, C., Mendez, C., Denham, W., Carter, G., and Norman, J. (2000). Specific pancreatic enzymes activate macrophages to produce tumor necrosis factor-alpha: role of nuclear factor kappa B and inhibitory kappa B proteins. *J. Gastrointest. Surg.* 4, 370–377. doi: 10.1016/S1091-255X(00)80015-3

Kaya, E., Dervisoglu, A., and Polat, C. (2007). Evaluation of diagnostic findings and scoring systems in outcome prediction in acute pancreatitis. *World J. Gastroenterol.* 13, 3090–3094. doi: 10.3748/wjg.v13.i22.3090

Kellum, J. A., Song, M., and Li, J. (2004a). Lactic and hydrochloric acids induce different patterns of inflammatory response in LPS-stimulated RAW 264.7 cells. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 286, R686–R692. doi: 10.1152/ajpregu.00564.2003

Kellum, J. A., Song, M., and Li, J. (2004b). Science review: extracellular acidosis and the immune response: clinical and physiologic implications. *Crit. Care* 8, 331–336. doi: 10.1186/cc2900

Keskinen, P., Leppaniemi, A., Pettila, V., Piilonen, A., Kemppainen, E., and Hynninen, M. (2007). Intra-abdominal pressure in severe acute pancreatitis. *World J. Emerg. Surg.* 2:2. doi: 10.1186/1749-7922-2-2

Kui, B., Balla, Z., Vasas, B., Vegh, E. T., Pallagi, P., Kormanyos, E. S., et al. (2015). New insights into the methodology of L-arginine-induced acute pancreatitis. *PLoS ONE* 10:e0117588. doi: 10.1371/journal.pone.0117588

Lei, M., Minghao, W., Xiaonan, Y., Ping, X., Ziqi, L., and Qing, X. (2013). Acute lung injury in patients with severe acute pancreatitis. *Turk. J. Gastroenterol.* 24, 502–507. doi: 10.4318/tjg.2013.0544

Lipinski, M., Rydzewska-Rosolowska, A., Rydzewski, A., and Rydzewska, G. (2015). Fluid resuscitation in acute pancreatitis: normal saline or lactated Ringer's solution? *World J. Gastroenterol.* 21, 9367–9372. doi: 10.3748/wjg.v21.i31.9367

Liu, H. S., Pan, C. E., Liu, Q. G., Yang, W., and Liu, X. M. (2003). Effect of NF-kappaB and p38 MAPK in activated monocytes/macrophages on pro-inflammatory cytokines of rats with acute pancreatitis. *World J. Gastroenterol.* 9, 2513–2518. doi: 10.3748/wjg.v9.i11.2513

Lundberg, A. H., Eubanks, J. W. III, Henry, J., Sabek, O., Kotb, M., Gaber, L., et al. (2000). Trypsin stimulates production of cytokines from peritoneal macrophages *in vitro* and *in vivo*. *Pancreas* 21, 41–51. doi: 10.1097/00006676-200007000-00050

Maleth, J., Balazs, A., Pallagi, P., Balla, Z., Kui, B., Katona, M., et al. (2015). Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis. *Gastroenterology* 148, 427–439. doi: 10.1053/j.gastro.2014.11.002

Malpass, G. E., Arimilli, S., Prasad, G. L., and Howlett, A. C. (2013). Complete artificial saliva alters expression of proinflammatory cytokines in human dermal fibroblasts. *Toxicol. Sci.* 134, 18–25. doi: 10.1093/toxsci/kft103

Mareninova, O. A., Sung, K. F., Hong, P., Lugea, A., Pandol, S. J., Gukovsky, I., et al. (2006). Cell death in pancreatitis: caspases protect from necrotizing pancreatitis. *J. Biol. Chem.* 281, 3370–3381. doi: 10.1074/jbc.M511276200

Martinez, D., Vermeulen, M., Trevani, A., Ceballos, A., Sabatte, J., Gamberale, R., et al. (2006). Extracellular acidosis induces neutrophil activation by a mechanism dependent on activation of phosphatidylinositol 3-kinase/Akt and ERK pathways. *J. Immunol.* 176, 1163–1171. doi: 10.4049/jimmunol.176.2.1163

Mayer, J., Rau, B., Gansauge, F., and Beger, H. G. (2000). Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. *Gut* 47, 546–552. doi: 10.1136/gut.47.4.546

McKay, C. J., Gallagher, G., Brooks, B., Imrie, C. W., and Baxter, J. N. (1996). Increased monocyte cytokine production in association with systemic complications in acute pancreatitis. *Br. J. Surg.* 83, 919–923. doi: 10.1002/bjs.1800830712

Meng, Y., Ma, Q. Y., Kou, X. P., and Xu, J. (2005). Effect of resveratrol on activation of nuclear factor kappa-B and inflammatory factors in rat model of acute pancreatitis. *World J. Gastroenterol.* 11, 525–528. doi: 10.3748/wjg.v11.i4.525

Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 6:e1000097. doi: 10.1371/journal.pmed.1000097

Nair, S., and Pitchumoni, C. S. (1997). Diabetic ketoacidosis, hyperlipidemia, and acute pancreatitis: the enigmatic triangle. *Am. J. Gastroenterol.* 92, 1560–1561.

Nair, S., Yadav, D., and Pitchumoni, C. S. (2000). Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. *Am. J. Gastroenterol.* 95, 2795–2800. doi: 10.1111/j.1572-0241.2000.03188.x

Noble, M. D., Romac, J., Vigna, S. R., and Liddle, R. A. (2008). A pH-sensitive, neurogenic pathway mediates disease severity in a model of post-ERCP pancreatitis. *Gut* 57, 1566–1571. doi: 10.1136/gut.2008.148551

Norman, J. G., Fink, G. W., Denham, W., Yang, J., Carter, G., Sexton, C., et al. (1997). Tissue-specific cytokine production during experimental acute pancreatitis. A probable mechanism for distant organ dysfunction. *Dig. Dis. Sci.* 42, 1783–1788. doi: 10.1023/A:1018886120711

Nowik, M., Kampik, N. B., Mihailova, M., Eladari, D., and Wagner, C. A. (2010). Induction of metabolic acidosis with ammonium chloride (NH4Cl) in mice and rats–species differences and technical considerations. *Cell Physiol. Biochem.* 26, 1059–1072. doi: 10.1159/000323984

Okajima, F. (2013). Regulation of inflammation by extracellular acidification and proton-sensing GPCRs. *Cell Signal.* 25, 2263–2271. doi: 10.1016/j.cellsig.2013.07.022

Olah, E., Poto, L., Hegyi, P., Szabo, I., Hartmann, P., Solymar, M., et al. (2018). Therapeutic whole-body hypothermia reduces death in severe traumatic brain injury if the cooling index is sufficiently high: meta-analyses of the effect of single cooling parameters and their integrated measure. *J. Neurotrauma* doi: 10.1089/neu.2018.5649. [Epub ahead of print].

Pallagi, P., Hegyi, P., and Rakonczay, Z. Jr. (2015). The physiology and pathophysiology of pancreatic ductal secretion: the background for clinicians. *Pancreas* 44, 1211–1233. doi: 10.1097/MPA.0000000000000421

Pallagi, P., Venglovecz, V., Rakonczay, Z. Jr., Borka, K., Korompay, A., Ozsvari, B., et al. (2011). Trypsin reduces pancreatic ductal bicarbonate secretion by inhibiting CFTR $Cl^-$ channels and luminal anion exchangers. *Gastroenterology* 141, 2228–2239. doi: 10.1053/j.gastro.2011.08.039

Parniczky, A., Kui, B., Szentesi, A., Balazs, A., Szucs, A., Mosztbacher, D., et al. (2016). Prospective, multicentre, nationwide clinical data from 600 cases of acute pancreatitis. *PLoS ONE* 11:e0165309. doi: 10.1371/journal.pone.0165309

Pooran, N., Indaram, A., Singh, P., and Bank, S. (2003). Cytokines (IL-6, IL-8, TNF): early and reliable predictors of severe acute pancreatitis.

*J. Clin. Gastroenterol.* 37, 263–266. doi: 10.1097/00004836-200309000-00013

Pupelis, G., Plaudis, H., Grigane, A., Zeiza, K., and Purmalis, G. (2007). Continuous veno-venous haemofiltration in the treatment of severe acute pancreatitis: 6-year experience. *HPB* 9, 295–301. doi: 10.1080/13651820701329225

Ranson, J. H., Rifkind, K. M., and Turner, J. W. (1976). Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. *Surg. Gynecol. Obstet.* 143, 209–219.

Reed, A. M., Husain, S. Z., Thrower, E., Alexandre, M., Shah, A., Gorelick, F.S., et al. (2011). Low extracellular pH induces damage in the pancreatic acinar cell by enhancing calcium signaling. *J. Biol. Chem.* 286, 1919–1926. doi: 10.1074/jbc.M110.158329

Reed, A. M., Kolodecik, T., Husain, S. Z., and Gorelick, F. S. (2014). Low pH enhances connexin32 degradation in the pancreatic acinar cell. *Am. J. Physiol. Gastrointest. Liver Physiol.* 307, G24–G32. doi: 10.1152/ajpgi.00010.2014

Rice, M., Ismail, B., and Pillow, M. T. (2014). Approach to metabolic acidosis in the emergency department. *Emerg. Med. Clin. North Am.* 32, 403–420. doi: 10.1016/j.emc.2014.01.002

Rumbus, Z., Matics, R., Hegyi, P., Zsiboras, C., Szabo, I., Illes, A., et al. (2017). Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials. *PLoS ONE* 12:e0170152. doi: 10.1371/journal.pone.0170152

Sharma, V., Shanti Devi, T., Sharma, R., Chhabra, P., Gupta, R., Rana, S. S., et al. (2014). Arterial pH, bicarbonate levels and base deficit at presentation as markers of predicting mortality in acute pancreatitis: a single-centre prospective study. *Gastroenterol. Rep. (Oxf).* 2, 226–231. doi: 10.1093/gastro/gou037

Shen, X., Ke, L., Yang, D., Sun, J., Tong, Z., Li, B., et al. (2016). The prognostic value of the strong ion gap in acute pancreatitis. *J. Crit. Care* 36, 140–145. doi: 10.1016/j.jcrc.2016.06.035

Shi, Q., Le, X., Wang, B., Xiong, Q., Abbruzzese, J. L., and Xie, K. (2000). Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. *J. Interferon Cytokine Res.* 20, 1023–1028. doi: 10.1089/10799900050198471

Shinzeki, M., Ueda, T., Takeyama, Y., Yasuda, T., Matsumura, N., Sawa, H., et al. (2008). Prediction of early death in severe acute pancreatitis. *J. Gastroenterol.* 43, 152–158. doi: 10.1007/s00535-007-2131-z

Takacs, T., Rosztoczy, A., Maleth, J., Rakonczay, Z. Jr., and Hegyi, P. (2013). Intraductal acidosis in acute biliary pancreatitis. *Pancreatology* 13, 333–335. doi: 10.1016/j.pan.2013.05.011

Talamini, G., Uomo, G., Pezzilli, R., Rabitti, P. G., Billi, P., Bassi, C., et al. (1999). Serum creatinine and chest radiographs in the early assessment of acute pancreatitis. *Am. J. Surg.* 177, 7–14. doi: 10.1016/S0002-9610(98)00296-7

Tenner, S., Baillie, J., DeWitt, J., Vege, S. S., and American College of, G. (2013). American College of Gastroenterology guideline: management of acute pancreatitis. *Am. J. Gastroenterol.* 108, 1400–1415. doi: 10.1038/ajg.2013.218

Viedma, J. A., Perez-Mateo, M., Dominguez, J. E., and Carballo, F. (1992). Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. *Gut* 33, 1264–1267. doi: 10.1136/gut.33.9.1264

Vincent, J. L., and Moreno, R. (2010). Clinical review: scoring systems in the critically ill. *Crit. Care* 14:207. doi: 10.1186/cc8204

Vinish, D. B., Abishek, V., Sujatha, K., Arulprakash, S., Solomon, R., and Ganesh, P. (2017). Role of bedside pancreatic scores and C-reactive protein in predicting pancreatic fluid collections and necrosis. *Indian J. Gastroenterol.* 36, 43–49. doi: 10.1007/s12664-017-0728-6

Ward, S. T., Gilbert, S., Mulchandani, M., and Garrett, W. V. (2008). Unnecessary investigations in patients with acute pancreatitis: arterial blood sampling and serum biochemistry. *Surgeon* 6, 282–287. doi: 10.1016/S1479-666X(08)80052-2

Wells, G. A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., et al. (2000). *The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses.* Available online at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed November, 2017).

Wu, B. U., Hwang, J. Q., Gardner, T. H., Repas, K., Delee, R., Yu, S., et al. (2011). Lactated Ringer's solution reduces systemic inflammation compared with saline

in patients with acute pancreatitis. *Clin. Gastroenterol. Hepatol.* 9, 710–717. doi: 10.1016/j.cgh.2011.04.026

Yadav, D., and Lowenfels, A. B. (2013). The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 144, 1252–1261. doi: 10.1053/j.gastro.2013.01.068

Zhan, X. B., Guo, X. R., Yang, J., Li, J., and Li, Z. S. (2015). Prevalence and risk factors for clinically significant upper gastrointestinal bleeding in patients with severe acute pancreatitis. *J. Dig. Dis.* 16, 37–42. doi: 10.1111/1751-2980.12206

Zhu, A. J., Shi, J. S., and Sun, X. J. (2003). Risk factors influencing mortality of patients with severe acute pancreatitis within 24 hours after admission. *Hepatobiliary Pancreat. Dis. Int.* 2, 453–457. Available online at: http://www.hbpdint.com/EN/Y2003/V2/I3/453

# Supplementary material

**Supplementary Table 1.** PRISMA checklist.

| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| **TITLE** | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | not applicable |
| **ABSTRACT** | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1 |
| **INTRODUCTION** | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 2 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 2 |
| **METHODS** | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 2 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 2 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 2 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 2 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 2 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 2 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 2-3 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 3 |

| | | | |
|---|---|---|---|
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 3 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$) for each meta-analysis. | 3 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 3 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 3 |
| **RESULTS** | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 4; Figure 1 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 4; Figure 1; Supplementary table 3 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 3; Supplementary table 2 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 4; Figures 2-4 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 4 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 4; Supplementary figures 1-5 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 4; Figure 5 |
| **DISCUSSION** | | | |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 6 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 8-10 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 11 |
| **FUNDING** | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 11 |

**Supplementary Table 2.** Quality assessment of the studies included in the meta-analysis with the Newcastle-Ottawa Scale. A score of 7 to 9 indicates high methodological quality, a score of 4 to 6 indicates moderate quality and score of 0 to 3 indicates low quality.

| First author | Year | Selection | Comparability | Outcome/Exposure | Total score |
|---|---|---|---|---|---|
| De Campos | 2008 | *** | ** | *** | 8 |
| Eachempati | 2002 | *** | ** | *** | 8 |
| Kaya | 2007 | *** | ** | *** | 8 |
| Keskinen | 2007 | ** | ** | * | 5 |
| Lei | 2013 | **** | ** | *** | 9 |
| Nair | 2000 | *** | ** | *** | 8 |
| Pupelis | 2007 | *** | ** | *** | 8 |
| Ranson | 1976 | *** | ** | *** | 8 |
| Sharma | 2014 | *** | * | ** | 6 |
| Shen | 2016 | *** | ** | *** | 8 |
| Shinzeki | 2008 | ** | ** | ** | 6 |
| Zahn | 2015 | *** | ** | *** | 8 |
| Zhu | 2003 | ** | ** | * | 5 |

**Supplementary Table 3.** Summary of study characteristics for publications included in the meta-analyses.

| First author | Year | Design | Country | Study period | Sample size (lower pH/ higher pH) | Newcastle-Ottawa score |
|---|---|---|---|---|---|---|
| Ranson | 1976 | Retro- and prospective | USA | 01/1971-02/1975 | 300 (56/244) | 8 |
| Nair | 2000 | Prospective observational | USA | 01/1998-02/1999 | 90 (11/-) | 8 |
| Eachempati | 2002 | Prospective | USA | 01/1993-05/2001 | 76 (16/60) | 8 |
| Zhu | 2003 | Retrospective | China | 01/1993-12/2002 | 74 (12/62) | 5 |
| Kaya | 2007 | Prospective | Turkey | 1998-2002 | 199 (27/172) | 8 |
| Keskinen | 2007 | Retrospective | Finland | 2001-2003 | 59 (9/28) | 5 |
| Pupelis | 2007 | Prospective | Latvia | 2000-2005 | 111 (72/39) | 8 |
| De Campos | 2008 | Retro- and prospective | Brazil | 01/1999-11/2005 | 71 (47/24) | 8 |
| Shinzeki | 2008 | Prospective | Japan | 07/1995-06/2006 | 93 (5/88) | 6 |
| Lei | 2012 | Retrospective | China | 04/2007-07/2010 | 184 (51/133) | 9 |
| Sharma | 2014 | Prospective single center | India | 01/2012-11/2013 | 205 (35/170) | 6 |
| Zhan | 2015 | Retrospective | China | 07/2006-06/2010 | 101 (18/83) | 8 |
| Shen | 2016 | Retrospective cohort | China | 11/2010-06/2014 | 186 (85/101) | 8 |

**Funnel Plot of Standard Error by Logit event rate**



**Supplementary Figure 1.** Funnel plot of the studies that were included in the forest plot of mortality rate and reported higher systemic pH in patient groups with acute pancreatitis (AP). Here and in Supplementary Figures 2-5, open symbols represent results from studies included in the forest plot, while closed symbols indicate studies that appeared to be missing according to the trim and fill method of Duval and Tweedie. Open and closed diamonds represent the average estimated effect size without (open diamond) and with trim and fill correction (closed diamond). Duval and Tweedie corrected value: -2.85 (95% CI, -3.85, -1.84); $P = 0.029$ with Egger's test.

## Funnel Plot of Standard Error by Logit event rate



**Supplementary Figure 2.** Funnel plot of the studies that were included in the forest plot of mortality rate and reported lower systemic pH in patient groups with AP. Duval and Tweedie trim and fill corrected value: -0.615 (95% CI, -1.36, 0.134); *P* = 0.154 with Egger's test.

**Funnel Plot of Standard Error by Std diff in means**

**Supplementary Figure 3.** Funnel plot of the studies that were included in the forest plot of the Ranson score in different systemic pH groups of patients with AP. Duval and Tweedie trim and fill corrected value: 0.675 (95% CI, 0.30, 2.06); $P = 0.234$ with Egger's test.

**Funnel Plot of Standard Error by Std diff in means**

**Supplementary Figure 4.** Funnel plot of the studies that were included in the forest plot of the Acute Physiology and Chronic Health Evaluation (APACHE II) score in different systemic pH groups of patients with AP. Duval and Tweedie trim and fill corrected value: 0.99 (95% CI, 0.52, 1.46); $P = 0.138$ with Egger's test.

**Funnel Plot of Standard Error by Std diff in means**

**Supplementary Figure 5.** Funnel plot of the studies that were included in the forest plot of the length of hospital stay (LOS) in different systemic pH groups of patients with AP. Duval and Tweedie trim and fill corrected value: 0.917 (95% CI, 0.771, 1.064); *P* = 0.231 with Egger's test.

**A** Histology

Control

Oral

i.p.

Oral and i.p.

Legend:
- Control
- Oral
- i.p.
- Oral and i.p.

**Edema (score)**
(3) (4) (4) (4)

**Necrosis (%)**
(4) (4) (4)

**Leukocyte infiltration (score)**
(3) (4) (4) (4)

**B** Arterial blood pH

Control (3), Oral (4), i.p. (4), Oral and i.p. (4)
$ # ** markers on Oral and i.p.

**Supplementary Figure 6.** Induction of metabolic acidosis with different types (oral, i.p. or both) of $NH_4Cl$ administration in mice. (**A**) None of the treatments caused pancreatic edema or necrosis, and only minimal (not significant) increase of leukocyte infiltration was observed in all three $NH_4Cl$ treatment groups compared to the controls. (**B**) Arterial blood pH decreased minimally in the oral or i.p. treatment groups, while the combined (oral and i.p.) treatment significantly decreased arterial pH. **, $P < 0.01$ for the control group versus the oral and i.p. group; #, $P < 0.05$ for the oral group versus the oral and i.p. group; and $, $P < 0.05$ for the i.p. group versus the oral and i.p. group. Scale bar represents 20 µm. Here and in Supplementary Figures 7 and 8, numbers in parentheses indicate the number of animals in the corresponding groups.

**Supplementary Figure 7.** Arterial blood bicarbonate, urine urea, and serum glucose levels after different types (oral, i.p. or both) of $NH_4Cl$ administration in mice. Arterial blood bicarbonate level decreased minimally in the i.p. treatment group, while the oral and the combined (oral and i.p.) treatment significantly decreased arterial bicarbonate level. Serum glucose and urine urea levels were not changed significantly in the treatment groups. *, $P < 0.05$ for the control group versus the oral group; ##, $P < 0.001$ for the control group versus the oral and i.p. group; and $, $P < 0.05$ for the oral group versus the oral and i.p. group.

**Supplementary Figure 8.** Arterial blood bicarbonate, urine urea, and serum glucose levels of mice with and without metabolic acidosis (MA) in sham acute pancreatitis (No AP) and after induction of mild acute pancreatitis (MAP) or severe acute pancreatitis (SAP). Arterial blood bicarbonate and urine urea levels decreased significantly in the MAP and MA group compared to controls. Urine urea levels also decreased in SAP regardless of the pH status. Serum glucose level was not changed significantly. *, $P < 0.05$ for the No AP and control group versus the MAP and MA group; [##], $P < 0.001$ for the No AP and control group versus the SAP and control group; [$$], $P < 0.001$ for the No AP and MA group versus the SAP and MA group; [§§], $P < 0.001$ for the MAP and control group versus the SAP and control group, and [†], $P < 0.05$ for the MAP and control group versus the MAP and MA group.

# Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis

Andras Garami [a,*], Yury P. Shimansky [b], Zoltan Rumbus [a], Robson C.L. Vizin [c], Nelli Farkas [d], Judit Hegyi [d], Zsolt Szakacs [d], Margit Solymar [a], Alexandra Csenkey [a], Dan A. Chiche [e], Ram Kapil [f], Donald J. Kyle [f], Wade D. Van Horn [g], Peter Hegyi [d,h], Andrej A. Romanovsky [c,g,i,**]

[a] Department of Thermophysiology, Institute for Translational Medicine, Medical School, University of Pecs, Pecs, Hungary
[b] Department of Neurobiology, Barrow Neurological Institute, Dignity Health, Phoenix, AZ, USA
[c] Thermoregulation and Systemic Inflammation Laboratory (FeverLab), Trauma Research, St. Joseph's Hospital and Medical Center, Dignity Health, Phoenix, AZ, USA
[d] Institute for Translational Medicine, Medical School and Szentagothai Research Centre, University of Pecs, Pecs, Hungary
[e] NEOMED Institute, Montreal, Quebec, Canada
[f] Purdue Pharma LP, Cranbury, NJ, USA
[g] School of Molecular Sciences, Arizona State University, Tempe, AZ, USA
[h] Department of Translational Medicine, First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary
[i] Zharko Pharma Inc., Olympia, WA, USA

## ARTICLE INFO

## ABSTRACT

Antagonists of the transient receptor potential vanilloid-1 (TRPV1) channel alter body temperature ($T_b$) in laboratory animals and humans: most cause hyperthermia; some produce hypothermia; and yet others have no effect. TRPV1 can be activated by capsaicin (CAP), protons (low pH), and heat. First-generation (polymodal) TRPV1 antagonists potently block all three TRPV1 activation modes. Second-generation (mode-selective) TRPV1 antagonists potently block channel activation by CAP, but exert different effects (e.g., potentiation, no effect, or low-potency inhibition) in the proton mode, heat mode, or both. Based on our earlier studies in rats, only one mode of TRPV1 activation – by protons – is involved in thermoregulatory responses to TRPV1 antagonists. In rats, compounds that potently block, potentiate, or have no effect on proton activation cause hyperthermia, hypothermia, or no effect on $T_b$, respectively. A $T_b$ response occurs when a TRPV1 antagonist blocks (in case of hyperthermia) or potentiates (hypothermia) the tonic TRPV1 activation by protons somewhere in the trunk, perhaps in muscles, and – via the acido-antithermogenic and acido-antivasoconstrictor reflexes – modulates thermogenesis and skin vasoconstriction. In this work, we used a mathematical model to analyze $T_b$ data from human clinical trials of TRPV1 antagonists. The analysis suggests that, in humans, the hyperthermic effect depends on the antagonist's potency to block TRPV1 activation not only by protons, but also by heat, while the CAP activation mode is uninvolved. Whereas in rats TRPV1 drives thermoeffectors by mediating pH signals from the trunk, but not $T_b$ signals, our analysis suggests that TRPV1 mediates both pH and thermal signals driving thermoregulation in humans. Hence, in humans (but not in rats), TRPV1 is likely to serve as a thermosensor of the thermoregulation system. We also conducted a meta-analysis of $T_b$ data from human trials and found that polymodal TRPV1 antagonists (ABT-102, AZD1386, and V116517) increase $T_b$, whereas the mode-selective blocker NEO6860 does not. Several strategies of harnessing the thermoregulatory effects of TRPV1 antagonists in humans are discussed.

© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

## 1. Introduction

Since it was first cloned by Caterina et al. (1997), the transient receptor potential (TRP) vanilloid-1 (V1) channel, formerly known as either the capsaicin receptor or VR1, has remained in the focus of pain research and drug development (Kaneko & Szallasi, 2014). Interestingly, the effects of pharmacological inactivation of this channel were studied since the 1950s (Jancso & Santha, 2015; Szolcsanyi, 2015). At that time, high doses of capsaicin (CAP), a pungent constituent of chili peppers (genus *Capsicum*), were shown to desensitize a subset of sensory nerves with consequent effects on many physiological functions. CAP is a TRPV1 agonist, and the term desensitization refers to the state of a decreased neuronal sensitivity to stimuli that normally activate TRPV1-expressing neurons, *e.g.*, noxious heat (for review, see Holzer, 1991; Szallasi & Blumberg, 1999). Studies of the desensitizing effects of CAP and other vanilloids, *e.g.*, resiniferatoxin [(RTX), an ultrapotent TRPV1 agonist naturally found in plants of the genus *Euphorbia* (Szallasi & Blumberg, 1989)], paved the way for using TRPV1 agonists to treat pain (Craft & Porreca, 1992; Szallasi & Blumberg, 1999). For example, epidermal Qutenza (CAP-containing patch) was developed for treating neuropathic pain, while intrathecal RTX has been proposed for treating pain in some forms of cancer (Chung & Campbell, 2016; Moran & Szallasi, 2018). In the late 1990s, while continuing to work on analgesic treatments based on the desensitizing property of TRPV1 agonists, multiple pharmaceutical companies had started developing TRPV1 antagonists (Holzer, 2008; Kyle & Tafesse, 2006; Lee et al., 2015). (Throughout this review, we use the terms "antagonist" and "blocker" interchangeably.) Highly potent and selective TRPV1 antagonists were, and perhaps still are, hoped to usher in a new generation of non-opioid analgesics. However, during the *in-vivo* testing of TRPV1 antagonists, adverse effects on body temperature ($T_b$), primarily hyperthermia, were repeatedly observed in animal studies and human clinical trials alike (*vide infra*). This review examines the thermal effects of TRPV1 antagonists and reports the results of a mathematical-modeling analysis and meta-analysis of $T_b$ data from human trials.

In addition to vanilloids, many other stimuli are known to activate (open) the TRPV1 channel (Jordt, Tominaga, & Julius, 2000). Traditionally, when studying the TRPV1-antagonizing property of compounds, pharmaceutical companies use the following stimuli to activate this channel: CAP, low extracellular pH ($< 6$), and sometimes heat ($> 42°C$) (Fig. 1). Hence, in this review, we discuss three modes of TRPV1 activation: CAP, proton, and heat, respectively. It is now known that TRPV1 antagonists can affect these three modes differentially (for review, see Blumberg, Pearce, & Lee, 2011; Romanovsky et al., 2009). For example, a compound can potently block TRPV1 activation by CAP, but potentiate TRPV1 activation by protons (Garami, Pakai, et al., 2018; Lehto et al., 2008). In the present work, we attempted to determine the activation-mode profiles of TRPV1 antagonists that induce hyperthermia, have no effect on $T_b$, or even cause hypothermia in humans. Based on the results of our analyses, presented herein, we examine the strategies of minimizing the thermoregulatory effects of TRPV1 antagonists, but also of using these effects for therapeutic purposes, in humans.

## 2. The hyperthermic effect of TRPV1 antagonists in laboratory animals

### 2.1. Phenomenology

Upon systemic administration, whether intravenous (i.v.), intraperitoneal (i.p.), or peroral (p.o.), many TRPV1 antagonists cause hyperthermia in a variety of laboratory animal species, including the mouse, rat, guinea pig, dog, and cynomolgus monkey (*Macaca fascicularis*) (Fig. 2). This hyperthermia appears to be independent of chemical structure. It has been shown to develop in response to small-molecule TRPV1 antagonists belonging to different chemotypes, *viz.*, cinnamides (AMG0347 and AMG9810), pyrimidines (AMG 517), ureas (JYL 1421 and A-425619), and piperazines (BCTC), thus suggesting an on-target action (for review, see Romanovsky et al., 2009). Indeed, the on-target nature of the hyperthermic effect of TRPV1 antagonists was determined definitively, when Steiner et al. (2007) and Garami et al. (2011, 2010) showed that TRPV1 knockout mice did not increase $T_b$ in response to either AMG0347 or AMG 517, whereas wild-type mice responded to either compound with hyperthermia.

However, not all TRPV1 antagonists are made equal as far as their ability to cause hyperthermia. While most TRPV1 antagonists produce the hyperthermic response at systemic doses in the mg/kg range (Gavva, Bannon, Surapaneni, et al., 2007; Swanson et al., 2005), others (*e.g.*, AMG0347) are effective already at 10 µg/kg (Gavva et al., 2008; Steiner et al., 2007), and yet others (*e.g.*, AS1928370) do not seem to affect $T_b$ at all (Watabiki, Kiso, Kuramochi, et al., 2011). Some TRPV1 antagonists have been shown to be hyperthermic in several mammalian species, whereas others cause hyperthermia only in particular species. For example, AMG0347 and AMG 517 increase $T_b$ in both rats and mice (Garami et al., 2010; Steiner et al., 2007), whereas capsazepine (CPZ) increases $T_b$ in guinea pigs but has no thermal effect in rats (Garami et al., 2010). Intriguingly, some TRPV1 antagonists (*e.g.*, A-1165901, A-425619, AMG7905, and AMG8562) cause hypothermia instead of hyperthermia (Garami, Pakai, et al., 2018; Lehto et al., 2008; Mills et al., 2008). And yet other compounds appear to affect $T_b$ regulation in a species-specific fashion, *e.g.*, JYL1421 was shown to cause hyperthermia in dogs and cynomolgus monkeys [Fig. 2D and E; also see Gavva, Bannon, Surapaneni et al. (2007)] but hypothermia in rats [Fig. 3D; also see Garami et al. (2010)]. Similar to the hyperthermic effect, the hypothermic effect of TRPV1 antagonists is also independent of the chemotype, as hypothermia occurs in response to small molecules with diverse chemical structures, *e.g.*, A-1165901, AMG7905, JYL1421 (Fig. 3), or AbbVie's Compound 3 (Gomtsyan et al., 2015). Two polypeptide TRPV1 antagonists, APHC1 and APHC3, have also been reported to cause hypothermia in rats (Andreev et al., 2013). In agreement with this, the hypothermic effect of TRPV1 antagonists is absent in TRPV1 knockout mice (Garami, Pakai, et al., 2018). Hence, both the hyper- and hypothermic effects of TRPV1 antagonists occur by acting on the same receptor, TRPV1, which is a highly unusual scenario. When a compound causes two opposite responses, these responses are typically mediated by different receptors (Garami, Pakai, et al., 2018). This paradox of a dual thermoregulatory action mediated by

**Fig. 1.** TRPV1 activation: a schematic. Upon stimulation by CAP, protons, or heat, the TRPV1 channel opens, and Na$^+$ and Ca$^{2+}$ cations from the extracellular space enter the cell.

the same receptor is just the tip of the iceberg – the thermoregulatory effects of TRPV1 antagonists have several other surprising physiological features.

### 2.2. Physiological mechanisms

Those TRPV1 antagonists that induce hyperthermia do so (at least in rats) by recruiting autonomic cold-defense effectors, *i.e.*, triggering tail-skin vasoconstriction and activating nonshivering thermogenesis in brown adipose tissue (Garami et al., 2010; Steiner et al., 2007). The same thermoeffectors – but working in reverse – bring about the hypo-thermic response to TRPV1 antagonists, when it occurs. In the latter case, tail-skin vasoconstriction is replaced by vasodilation, while ther-mogenesis is suppressed (Garami, Pakai, et al., 2018). Because the TRPV1 channel is highly sensitive to temperature (for review, see Zheng & Wen, 2019), it is often assumed that temperature signals trans-mitted by TRPV1 drive effector responses of the thermoregulation sys-tem, or, in other words, that the TRPV1 channel serves as a

thermosensor for the thermoregulation system. Accordingly, it is fur-ther assumed that the thermoregulatory effects of TRPV1 antagonists are due to the blockade of the channel's thermosensory function (McGaraughty et al., 2009; Seebacher et al., 2010; Szolcsanyi, 2015; Vriens, Nilius, & Voets, 2014). This, however, appeared not to be the case (Romanovsky et al., 2009).

If the activity of thermoeffectors (and, consequently, the deep $T_b$) were to depend on TRPV1-mediated thermal signals, the magnitude of the hyperthermic effect of TRPV1 antagonists would depend on tissue temperatures in different areas of the body – deep (if the sensors are lo-cated inside the body), superficial (if the sensors are in the skin), or both. High $T_b$s represent strong warmth signals (that inhibit cold de-fenses, activate heat defenses, and – through a negative feedback loop – suppress $T_b$); under such conditions, TRPV1 antagonists would re-move this $T_b$ suppression and be expected to bring about a strong hy-perthermic effect. Low $T_b$s are equivalent to the lack of warmth signals affecting thermoregulation; under such conditions, the removal of the nonexistent warmth signals by TRPV1 antagonists would be expected



**Fig. 2.** Hyperthermic responses to TRPV1 antagonists in laboratory mammals. A) Effect of AMG0347 (500 μg/kg, i.p.) or its vehicle on abdominal temperature in mice at a neutral ambient temperature ($T_a$) of 31°C. B) Effect of AMG 517 (100 μg/kg, i.v.) or its vehicle on colonic temperature in rats at a neutral $T_a$ of 26°C. C) Effect of capsazepine (CPZ; 25 mg/kg, i.v.) or its vehicle on abdominal temperature of guinea pigs at a neutral $T_a$ of 27°C. D) Effect of JYL1421 (30 mg/kg, p.o.) or its vehicle on $T_b$ (location not specified) in dogs at room temperature. E) Effect of JYL1421 (30 mg/kg, p.o.) or its vehicle on $T_b$ (location not specified) in cynomolgus monkeys at room temperature. Modified from Steiner et al. (2007) (A); modified with permission from Gavva et al. (2008) (B); modified from Garami et al. (2010) (C) and Gavva, Bannon, Surapaneni, et al. (2007) (D, E).

**Fig. 3.** Hypothermic responses to different TRPV1 antagonists in rats and mice. A) Effect of A-1165901 (10 mg/kg, i.p.) or its vehicle on abdominal temperature in mice at a subneutral $T_a$ of 20°C. B) Effect of AMG7905 (10 mg/kg, i.p.) or its vehicle on abdominal temperature in mice at a subneutral $T_a$ of 20°C. C) Effect of A-1165901 (3 mg/kg, i.p.) or its vehicle on colonic temperature in rats at a $T_a$ of 26°C (the low end of the thermoneutral zone). D) Effect of JYL1421 (111 mg/kg, i.p.) or its vehicle on colonic temperature in rats at a $T_a$ of 26°C (the low end of the thermoneutral zone). Graphs are reprinted from Garami, Pakai, et al. (2018) (A, B, C) or plotted for this work using data from Garami et al. (2010) (D).

not to affect $T_b$ at all. *Mutatis mutandis*, these assumptions were shown to be true for the cold-sensitive TRP channel melastatin-8 (TRPM8). TRPM8 antagonists cause hypothermia in rats (Almeida et al., 2012; de Oliveira et al., 2014), and the magnitude of the hypothermic response increases with a decrease in the ambient temperature ($T_a$) and $T_b$s, including skin temperatures – when the thermal (*i.e.*, cold) activation of TRPM8 is stronger, the blockade of this activation with an antagonist causes a stronger $T_b$ response (Almeida et al., 2012). Hence, TRPM8 is a physiologically important temperature sensor that drives thermoeffector responses in the rat.

For the TRPV1 channel, the assumptions described above turned out to be incorrect, at least in the case of young male rats. Steiner et al. (2007) have analyzed whether the extent of hyperthermia depends on the initial (preinjection) temperatures (deep $T_b$, tail-skin temperature, and $T_a$) in response to an i.v. injection of the potent TRPV1 antagonist AMG0347. The authors found no positive correlation between the magnitude of the hyperthermia and any of the initial temperatures measured (Fig. 4). The lack of a positive correlation indicates that the tonic activation of TRPV1 channels, which maintains the tonic suppression of $T_b$, is nonthermal in nature. *A priori*, such nonthermal factors may include a low pH, inorganic cations, or endovanilloids. The fact that TRPV1 activation by heat plays no role in the thermoregulatory effects of TRPV1 antagonists (or in thermoregulation in general), at least in male rats, was confirmed in later studies [for more detail, see section 2.4 and Garami et al. (2010), Garami, Pakai, et al. (2018), Lehto et al. (2008)].

The highest levels of TRPV1 expression are found in the primary sensory neurons of dorsal-root and trigeminal ganglia, both in rodents



**Fig. 4.** In rats, the magnitude of the hyperthermic response to a TRPV1 antagonist is independent of both the initial (at the time of drug administration) colonic temperature or initial tail-skin temperature in a wide range of temperatures. A) AMG0347 (50 µg/kg, i.v.) was injected in rats at a $T_a$ of 17, 24, or 28°C. At all $T_a$ values tested, the drug induced hyperthermic responses of similar magnitude. No positive correlation was found when the response magnitude (the maximal increase in colonic temperature) for each rat was plotted either against the initial colonic temperature (B) or against the initial tail-skin temperature (C). Reprinted with permission from Romanovsky et al. (2009); the figure uses data from Steiner et al. (2007).

(Jang et al., 2012; Sanchez, Krause, & Cortright, 2001) and in humans (Cortright et al., 2001). However, TRPV1 channels are widely distributed throughout the body and expressed abundantly on neural elements both within and outside of the central nervous system; they are also found in non-neural tissues (reviewed by Romanovsky et al., 2009). Where are the TRPV1 channels that mediate the $T_b$ effects of nonthermal tonic stimuli (and, consequently, the thermoregulatory effects of TRPV1 antagonists) located? To answer this question, Steiner

**Table 1**
Sites of TRPV1 desensitization in RTX- or vehicle-pretreated rats

| Pre-treatment | Compartment | | | | | Desensitization pattern | Desensitization extent |
|---|---|---|---|---|---|---|---|
| | Abdominal cavity | Eyes | Skin | Thoracic cavity | Brain | | |
| Vehicle | 0 | 0 | 0 | 0 | 0 | | None |
| RTX 0.2 mg/kg i.p. | X | X | X | X | X | | Systemic |
| RTX 0.02 mg/kg i.p. | X | 0 | 0 | 0 | 0 | | Localized intra-abdominal |

The state of TRPV1 channels in different bodily compartments is marked as follows: X, desensitized; 0, non-desensitized. In schematics of the desensitization pattern, the desensitized compartments are shown in grey; the non-desensitized compartments are shown in white. Reprinted with permission from Romanovsky et al. (2009); the table was built based on the data reported by Steiner et al. (2007).

et al. (2007) compared the thermoregulatory effects of AMG0347 administered directly into the central nervous system (*viz.*, intracerebroventricularly or intrathecally) and systematically (i.v.). If a central administration were to cause hyperthermia at much lower (10-100 times) doses than a peripheral administration, this would indicate a central action. This, however, was not the case. The authors found that the threshold hyperthermic dose of AMG0347, when administered i.v., was ~6 μg/kg (a significant effect was observed at 10 μg/kg), but that the drug did not cause any changes in $T_b$ when the dose of 6 μg/kg was administered centrally (either intracerebroventricularly or intrathecally). These findings allowed the authors to exclude a central origin of the hyperthermic response to AMG0347.

To obtain a more precise location of the channels responsible for the hyperthermic effect of TRPV1 antagonists, Steiner et al. (2007) administered AMG0347 i.v. in rats that had TRPV1 channels desensitized in different compartments of the body. As explained above (Introduction), desensitization means a decreased neuronal sensitivity to exogenous or endogenous vanilloids or other stimuli that normally activate TRPV1-expressing neurons, *e.g.*, noxious heat (Craft & Porreca, 1992; Szallasi & Blumberg, 1999). Steiner et al. (2007) administered repeated, escalating i.p. doses of RTX to rats to achieve different desensitization patterns (Table 1). At higher doses (~200 μg/kg), RTX impairs the function of TRPV1 channels throughout the entire body (systemic desensitization). When lower doses are used (~20 μg/kg), the desensitizing effect is limited to the abdominal cavity (localized, intra-abdominal desensitization). In the latter case, TRPV1-mediated reflexes triggered from the abdominal cavity (*e.g.*, RTX-induced writhing) are suppressed, while TRPV1 sensitivity in all other body compartments remains intact (Table 1). It was found that the hyperthermic response to either AMG0347 [Fig. 5; also see Steiner et al. (2007)] or another TRPV1 antagonist, A-889425 (McGaraughty et al., 2009), was absent in rats with localized, intra-abdominal desensitization. More recently, we have shown that the hypothermic effect of the TRPV1 antagonist A-1165901 is also abolished following the intra-abdominal TRPV1 desensitization in rats (Garami, Pakai, et al., 2018). The results in RTX-desensitized rats show that both the hyper- and hypothermic responses to TRPV1 antagonists are triggered from the abdomen, perhaps the intra-abdominal viscera or abdominal-wall muscles (for further discussion, see Garami, Pakai, et al., 2018).

To summarize this section, the following picture has emerged. TRPV1 antagonists produce their thermoregulatory effects by acting on TRPV1 channels located somewhere in the abdomen: in the abdominal viscera or abdominal-wall muscles. The abdominal TRPV1 channels are tonically activated by some nonthermal stimuli. The most common thermoregulatory effect of TRPV1 antagonists – hyperthermia – results from the blockade of this nonthermal TRPV1 activation and, consequently, from disinhibition of cold defenses. What stimuli tonically activate the abdominal TRPV1 channels under normal conditions? Why would thermoregulatory responses be triggered by nonthermal, TRPV1-mediated stimuli from the trunk? Before we answer these

questions, we will take a more careful look at different ways to activate the TRPV1 channel.

### 2.3. Mode selectivity of TRPV1 activation and differential TRPV1 pharmacology

Rat (r) TRPV1 is the most studied TRPV1 ortholog, for which six cryo-electron microscopy structures with a resolution varying from 3.0 to 4.2 Å have been obtained, thus providing direct insight into the polymodal regulation of this channel (Cao, Liao, Cheng, & Julius, 2013; Gao, Cao, Julius, & Cheng, 2016; Liao, Cao, Julius, & Cheng, 2013). Derived from the structural biology studies, the molecular architecture of TRPV1 shows that the channel is a tetramer with six transmembrane helices (S1-S6). The transmembrane domain is further divided into two structural (sub-)domains: the voltage-sensing-like (sub-)domain (helices S1-S4) and the pore (sub-)domain (S5-S6), as illustrated in Fig. 6. The pore domain houses the upper and lower gates that open and close in response to diverse stimuli, including CAP, protons, and heat (Yang et al., 2018).

The combined data from a variety of methods paint the clearest picture of the molecular mechanisms associated with rTRPV1 activation by CAP and related vanilloid compounds (Yang & Zheng, 2017). Early comparative studies of TRPV1 orthologs with different CAP sensitivity identified the vanilloid-binding pocket, of which there are four per a



**Fig. 5.** The hyperthermic response to TRPV1 antagonists does not occur in rats with localized intra-abdominal TRPV1 desensitization. Shown is the abolished hyperthermic effect of AMG0347 (50 μg/kg, i.v.) in rats pretreated with RTX (20 μg/kg, i.p.). Reprinted with permission from Romanovsky et al. (2009); the figure uses data from Steiner et al. (2007).

Fig. 6. Molecular architecture of TRPV1. A) A color-coded schematic of a TRPV1 monomer shows the voltage-sensing-like subdomain (S1-S4; red) and the pore subdomain (S5-S6; purple) of the transmembrane domain, as well as the S4-S5 helix linker (cyan) and the TRP helix (orange). The intracellular N- and C-termini include a series of six ankyrin-repeat domains and a C-terminal domain, respectively. The so-called selectivity filter of TRPV1 is formed from the loop that links the pore helix with the S6-helix. B) The tetrameric structure of TRPV1 (pdb ID: 3J5P) is shown with the same color-coding. The pore subdomain (purple), in its tetrameric form, includes the upper and lower gates that regulate channel activation. C) An extracellular view of the TRPV1 structure shows how the tetrameric pore subdomain forms an ion-conductive pathway (pore), which is regulated by CAP, protons, and heat.



Fig. 7. Activation of TRPV1 by distinct stimuli. TRPV1 is activated by a variety of diverse stimuli, including protons, CAP, and heat, *via* spatially distinct mechanisms. A) The canonical vanilloid agonist CAP binds to the voltage-sensing-like membrane subdomain in the intracellular leaflet. B) The proton-sensing mechanism is localized primarily on the extracellular loops of the TRPV1 pore subdomain. C) The heat-activation mechanism is not well-understood. The current data suggest that the core heat-sensing architecture is harbored by the transmembrane region.

functional TRPV1 channel (Gavva et al., 2004; Jordt & Julius, 2002). The vanilloid-binding pocket (Fig. 7A) was further validated by functional, computational, and structural studies (Cao, Liao, et al., 2013; Yang et al., 2015). Activation of TRPV1 by CAP is initiated at the intracellular side of the membrane, where CAP binds to the voltage-sensing-like domain within the pocket. The vanilloid-binding pocket is energetically coupled with the pore domain, and CAP binding causes the lower gate at the S6 helix bundle crossing to open, followed by further conformational rearrangements and coupling that are propagated to the selectivity filter on the extracellular side of the membrane (*i.e.*, the upper gate), resulting in channel activation (Yang et al., 2018). While TRPV1 is the only TRPV family member that is inherently activated by vanilloids, the mechanistic understanding of TRPV1 proved to be sufficient for engineering vanilloid sensitivity into the TRPV2 and TRPV3 channels (Yang, Vu, Yarov-Yarovoy, & Zheng, 2016; Zhang et al., 2016), hence further validating the proposed model of CAP sensitivity.

Proton activation of rTRPV1 is also relatively well-studied (Boukalova, Teisinger, & Vlachova, 2013; Jordt et al., 2000). The key regions that impart proton sensitivity are located in the extracellular loops of the pore domain, across the membrane from the vanilloid-binding pocket (Fig. 7B). Canonically, two glutamate residues (E600 and E648) function as putative proton sensors, where the magnitude and range of TRPV1 pH sensitivity depend on the chemical nature of these side chains. Proton activation is initiated in the extracellular pore domain loops and then propagated to the pore helix and the upper gate (Ryu, Liu, Yao, Fu, & Qin, 2007). From there, the activation is spread to the lower gate, thus resulting in proton-dependent channel opening, *i.e.*, gating. Given the distinct spatial origins of CAP (vanilloid) and proton activation, it is interesting to note that other modes of TRPV1 regulation and activation are thought to occur extracellularly, with overlapping mechanisms to proton activation (Bohlen et al., 2010; Cao, Liao, et al., 2013; Jara-Oseguera, Bae, & Swartz, 2016). Specifically, a sodium-binding site is known to stabilize the rTRPV1 closed state in this region

(Jara-Oseguera et al., 2016), whereas a spider toxin (i.e., the tarantula double-knot toxin) activates TRPV1 in the pore domain extracellular loops (Bohlen et al., 2010).

The mechanism of heat activation of rTRPV1 is still debated, as is the exact location of where heat is sensed within the channel, or even if a discreet "heat-sensor" location exists at all (Voets et al., 2004; Zheng & Wen, 2019). Indeed, virtually all areas of TRPV1 have, at one point or another, been ascribed some participation in heat activation (Hilton, Rath, Helsell, Beckstein, & Van Horn, 2015; Voets, 2014). Nonetheless, it is clear that thermosensitivity is an inherent feature of TRPV1 (Cao, Cordero-Morales, Liu, Qin, & Julius, 2013). Based on the current literature, the transmembrane region is emerging as central to thermosensitivity (Hilton, Kim, & Van Horn, 2019; also see Fig. 7C). Recent studies have shown that the pore domain of rTRPV1 is sufficient to endow a non-thermosensitive channel with heat activation, indicating that this domain is crucial for thermosensitivity (Zhang et al., 2018). There is also recent evidence that the human (h) TRPV1 voltage-sensing-like domain contributes to thermosensitivity (Kim et al., 2019). This domain undergoes a temperature-dependent conformational change that has been implicated in channel activation through the S4 helix to the pore domain, with some similarities to the mechanism of vanilloid activation. While there is strong evidence for species-specific phenotypes in TRPV1 and other TRP channels (Garcia-Avila & Islas, 2019; Hilton et al., 2015), the available data suggest that the transmembrane domain is central to heat activation, with extramembrane domains potentially modulating thermal responses. For the TRP ankyrin-1 (TRPA1) channel, a distinct thermosensitive channel, which shares the transmembrane architecture and ankyrin-repeat-based intracellular domain structures with TRPV1 (Saito & Tominaga, 2017), the temperature-sensitive region has been narrowed down to the transmembrane and C-terminal regions (Moparthi et al., 2014). More recently, temperature sensing in the TRPV3 channel has also been localized to the transmembrane domain (Singh, McGoldrick, & Sobolevsky, 2018).

Species differences, especially between rTRPV1 and hTRPV1, deserve a separate discussion. Given that the two orthologs originate from a common evolutionary ancestor and share ~85% sequence identity, as well as most general structural features, including the conserved transmembrane domain, they are expected to function similarly (Hilton et al., 2019). Indeed, the concentration of CAP that produces a half-maximal response in vitro is similar for the two channels (McIntyre et al., 2001), and they also have similar heat activation thresholds (McIntyre et al., 2001) and thermosensitivities (Kim et al., 2019). However, the sensitivity to protons differs between the two channels. In vitro, the half-maximal response occurs at the pH of ~5.8 in rTRPV1 but at the pH of ~5.5 in hTRPV1 (McIntyre et al., 2001), with the difference between the two pH values (~0.3) being very large from the physiological point of view. Hence, rTRPV1 is substantially more sensitive to protons than hTRPV1.

To summarize, it is clear that TRPV1 activation by diverse mechanisms can be spatially distinct, as evidenced by activation by CAP and protons. It is important that the spatial separation of different activation modes of TRPV1 can be exploited pharmacologically. Some TRPV1 antagonists block activation of TRPV1 in all modes (i.e., by CAP, heat, and protons) with similarly high potency; these antagonists are called polymodal, mode-nonspecific (or mode-nonselective) and represent the first generation of TRPV1 antagonists. Examples of the first-generation blockers include AMG1629, AMG3731, AMG 517, AMG0347, and ABT-102 (Table 2). Yet other compounds affect TRPV1 activation in different modes differentially; they are called mode-specific (or mode-selective) and represent the second generation of TRPV1 antagonists. Second-generation compounds potently block the CAP and heat activation modes (e.g., AMG2820 and AMG7988) or just solely the CAP mode (e.g., SB-366791), while not affecting the remaining modes, blocking them with lower potency, or even potentiating TRPV1 activation in these modes. Examples of compounds that potentiate TRPV1 activation by protons include A-1165901, AMG8562, and JYL1421, while the TRPV1 antagonist AMG7905 potentiates TRPV1 activation by both heat and protons (Table 2). It should be noted, however, that different scientists may assign the same compound to a different generation, because the potencies of a TRPV1 antagonist in all three main activation modes are never identical, and a big difference for one author may look insignificant to another. It is also important to note that, to the best of our knowledge, all TRPV1 antagonists block TRPV1 activation by CAP with reasonable potency. This is due to the fact that pharmaceutical companies, while working on TRPV1 antagonists (at least at the early stages of their TRPV1 programs), often "discarded" any molecules that did not block TRPV1 activation by CAP – such compounds would not be considered TRPV1 antagonists. Of interest, according to R. Kapil and D. J. Kyle (personal communication), the TRPV1 program at Purdue Pharma, one of the pioneers in the field of TRPV1 antagonists, never found a molecule that blocked TRPV1 activation by protons without also blocking CAP activation.

## 2.4. Modeling: which modes of TRPV1 activation contribute to the hyperthermic response in rats?

We now know (Table 2) that TRPV1 antagonists can affect $T_b$ in several ways, even in the same species (e.g., the rat): many of them readily produce hyperthermia (sometimes, they are called "hyperthermic" compounds); some have no thermal effect at comparable doses ("thermally neutral" compounds); and yet others can cause hypothermia ("hypothermic" compounds). Can the ability of TRPV1 antagonists to cause different thermoregulatory responses be ascribed to their different effects on different modes of TRPV1 activation? This question was asked by scientists at Amgen (and later, among others, by scientists at AbbVie, formerly Abbott Laboratories), who synthesized a variety of compounds with differential effects on TRPV1 activation in different modes. Lehto et al. (2008) observed that, in rats, TRPV1 antagonists that potently blocked channel activation by protons (many examples are given in Section 2.3 above; also see Table 2) typically caused hyperthermia, whereas compounds that potentiated proton activation (e.g., AMG8562 and AMG7905) caused hypothermia instead of hyperthermia (Table 2). However, without an advanced quantitative analysis, it is difficult to identify with certainty the relationship between the potency of a compound to block TRPV1 activation in any given mode in vitro and the effect of this compound on $T_b$ in vivo. This uncertainty is due to, among other factors, the fact that both the thermoregulatory effect and the effect on channel activation are dose-dependent. For example, if a compound does not affect $T_b$, it can be inherently incapable of affecting it or, alternatively, it might have been used at a subthreshold dose for the hyperthermic effect. Furthermore, if a compound is a moderately potent blocker of TRPV1 activation in a certain mode, e.g., by heat, and causes hyperthermia at moderate doses, it can be interpreted that blockers of TRPV1 activation by heat cause hyperthermia, even though the administration of a relatively low dose of this, relatively weak, blocker of TRPV1 activation by heat, could have resulted in the in-vivo concentrations that were insufficient to block heat activation. Not surprisingly, therefore, some studies based on comparing thermoregulatory effects of a small number of compounds administered at a couple of doses resulted in unfounded conclusions. For example, at one point, a conclusion was made that hyperthermic TRPV1 antagonists are those that block TRPV1 activation by both CAP and heat, regardless of their effect on proton activation (Gavva, Bannon, Surapaneni, et al., 2007). This conclusion was then adopted in many reviews and original-research articles (see, for example, Alawi & Keeble, 2010; Rawls & Benamar, 2011; Wong & Gavva, 2009). Yet, the subsequent research showed that this conclusion had to be modified (Garami, Pakai, et al., 2018). Clearly, a comprehensive quantitative analysis was needed.

A quantitative analysis of the contribution of the blockade of different activation modes of the TRPV1 channel to the hyperthermic response to TRPV1 antagonists was performed by our group (Garami

**Table 2**
TRPV1 antagonists: Their effects on deep $T_b$ upon systemic administration in rats and their potencies at different activation modes of rat TRPV1 in vitro

| Compound | Effect(s) on deep $T_b$ | | *In vitro*: IC$_{50}$ (nM) for different activation modes | | | |
| | Effect(s) | Reference(s) | CAP (10 nM-3 μM) | pH (5.0-6.2) | Heat (45-53°C) | Reference(s) |
|---|---|---|---|---|---|---|
| 1 | ↑ | Gomtsyan et al., 2015 | | | Not studied | Gomtsyan et al., 2015 |
| 74 | ↑ | Norman et al., 2007 | | | Not studied | Norman et al., 2007 |
| A-1098807 | ↑ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1098808 | ↑ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1106625 | ↑ | Reilly et al., 2012 | | | Not studied | Reilly et al., 2012 |
| A-1153818 | ↑ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1241407 | ↑ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-889425[†] | ↑ | McGaraughty et al., 2009; Reilly et al., 2012 | | Not studied | Not studied | McGaraughty et al., 2009; Reilly et al., 2012 |
| A-993610 | ↑ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| ABT-102 | | | | | | Surowy et al., 2008 |
| | ↑ | Honore et al., 2009; Voight et al., 2014 | | | | |
| AMG1629 | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | | | Gavva, Bannon, Surapaneni, et al., 2007 |
| AMG2820 | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | X | | Gavva, Bannon, Surapaneni, et al., 2007 |
| AMG3731 | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | | | Gavva, Bannon, Surapaneni, et al., 2007 |
| AMG7988 | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | X | | Gavva, Bannon, Surapaneni, et al., 2007 |
| AMG8563 | ↑ | Lehto et al., 2008 | | X | | Lehto et al., 2008 |
| C | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | | | Gavva, Bannon, Surapaneni, et al., 2007 |
| D | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | | | Gavva, Bannon, Surapaneni, et al., 2007 |
| E | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | | | Gavva, Bannon, Surapaneni, et al., 2007 |

| Compound | Effect(s) on deep $T_b$ | | *In vitro*: IC$_{50}$ (nM) for different activation modes | | | |
| | Effect(s) | Reference(s) | CAP (10 nM-3 μM) | pH (5.0-6.2) | Heat (45-53°C) | Reference(s) |
| --- | --- | --- | --- | --- | --- | --- |
| G | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | | | Gavva, Bannon, Surapaneni, et al., 2007 |
| H | ↑ | Gavva, Bannon, Surapaneni, et al., 2007 | | | | Gavva, Bannon, Surapaneni, et al., 2007 |
| JNJ-39729209 | ↑ | Maher et al., 2011 | | | Not studied | Maher et al., 2011 |
| V116517 | ↑ | Tafesse et al., 2014 | | | Not studied | Tafesse et al., 2014 |
| A-425619 | ↔, ↑ | Garami et al., 2010; Gavva, Bannon, Surapaneni, et al., 2007; Mills et al., 2008 | | | | El Kouhen et al., 2005; Gavva, Bannon, Surapaneni, et al., 2007; McDonald et al., 2008; Neelands, Jarvis, Han, Faltynek, & Surowy, 2005 |
| AMG 517 | ↔, ↑ | Garami et al., 2017; 2010; Gavva, Bannon, Hovland Jr., et al., 2007; 2008; Nash et al., 2012; Tamayo et al., 2008 | | | | Gavva, Bannon, Hovland Jr., et al., 2007; Tamayo et al., 2008; Wang, Katon, et al., 2007; Wang, Chakrabarti, et al., 2007 |
| AMG0347 | ↔, ↑ | Garami et al., 2010; Steiner et al., 2007 | | | | Steiner et al., 2007 |
| AMG8163 | ↔, ↑ | Garami et al., 2010; Gavva, Bannon, Hovland Jr., et al., 2007; Gavva, Bannon, Surapaneni, et al., 2007; Lehto et al., 2008 | | | | Gavva, Bannon, Surapaneni, et al., 2007; Lehto et al., 2008 |
| BCTC | ↔, ↑ | Gavva, Bannon, Surapaneni, et al., 2007; Watabiki, Kiso, Kuramochi, et al., 2011 | | | | Correll, Phelps, Anthes, Umland, & Greenfeder, 2004; Gavva, Bannon, Surapaneni, et al., 2007; 2005; Kanai, Nakazato, Fujiuchi, Hara, & Imai, 2005; Papakosta et al., 2011; Valenzano et al., 2003; Watabiki, Kiso, Kuramochi, et al., 2011 |
| BCTP | ↔, ↑ | Nash et al., 2012 | | | | Nash et al., 2012 |
| JNJ-17203212 | ↔, ↑ | Kelly et al., 2015; Swanson et al., 2005 | | | Not studied | Swanson et al., 2005 |

| Compound | Effect(s) on deep $T_b$ | | *In vitro*: IC$_{50}$ (nM) for different activation modes | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | Effect(s) | Reference(s) | CAP (10 nM-3 μM) | pH (5.0-6.2) | Heat (45-53°C) | Reference(s) |
| JNJ-39439335 | ↔, ↑ | Parsons et al., 2015 | | Not studied | Not studied | Parsons et al., 2015 |
| JTS-653 | ↔, ↑ | Kitagawa et al., 2012 | | | | Kitagawa et al., 2012 |
| 2 | ↔ | Gomtsyan et al., 2015 | | Not studied | Not studied | Gomtsyan et al., 2015 |
| A-1105512 | ↔ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1165442 | ↔ | Reilly et al., 2012; Voight et al., 2014 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1165746 | ↔ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1208747 | ↔ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1233371 | ↔ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1233372 | ↔ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| A-1241797 | ↔ | Reilly et al., 2012 | | Not studied | Not studied | Reilly et al., 2012 |
| CPZ[†] | ↔ | Garami et al., 2010; Steiner, et al., 2011 | X | X | X | Appendino et al., 2003; Bevan et al., 1992; Correll et al., 2004; Dickenson & Dray, 1991; Gavva et al., 2005; Jakab et al., 2005; Kanai, Hara, & Imai, 2006; Kirschstein, Greffrath, Busselberg, & Treede, 1999; Maione et al., 2007; McDonald et al., 2008; McIntyre et al., 2001; Park et al., 2003; Phillips, Reeve, Bevan, & McIntyre, 2004; Price, Patwardhan, Akopian, Hargreaves, & Flores, 2004; Rigoni et al., 2003; Savidge et al., 2002; Seabrook et al., 2002; Swanson et al., 2005; Valenzano et al., 2003 |
| SB-366791 | ↔ | Garami et al., 2010 | | X | X | Gavva et al., 2005; Varga et al., 2005 |
| 3[*] | ↓ | Gomtsyan et al., 2015 | | Not studied | Not studied | Gomtsyan, et al., 2015 |
| A-1165901 | ↓ | Garami, Pakai, et al., 2018 | | Potentiation | Not studied | Garami, Pakai, et al., 2018 |
| AMG7905 | | Lehto et al., 2008 | | Potentiation | Potentiation | |

| Compound | Effect(s) on deep $T_b$ | | *In vitro*: IC$_{50}$ (nM) for different activation modes | | | |
| | Effect(s) | Reference(s) | CAP (10 nM-3 μM) | pH (5.0-6.2) | Heat (45-53°C) | Reference(s) |
| --- | --- | --- | --- | --- | --- | --- |
| | ↓ | | | | | Garami, Pakai, et al., 2018; Lehto et al., 2008 |
| AMG8562 | ↓ | Lehto et al., 2008 | ▮ (orange) | Potentiation | X | Lehto et al., 2008 |
| I-RTX* | ↓ | Dogan et al., 2004 | ▮ (orange) | ▮ (blue) | Not studied | Appendino et al., 2003; Correll et al., 2004; Johnson et al., 2006; Kanai et al., 2006; Price et al., 2004; Rigoni et al., 2003; Seabrook et al., 2002; Shimizu et al., 2005 |
| AS1928370 | ↔, ↓ | Watabiki, Kiso, Kuramochi, et al., 2011 | ▮ (light orange) | X | Not studied | Watabiki, Kiso, Kuramochi, et al., 2011 |
| JYL 1421 | ↔, ↓ | Garami et al., 2010; Gavva, Bannon, Surapaneni, et al., 2007; Suh et al., 2003 | ▮ (orange) | Potentiation | X | Gavva, Bannon, Surapaneni, et al., 2007; Jakab et al., 2005; Papakosta et al., 2011; Suh et al., 2003 |
| AMG9810 | ↔, ↑, ↓ | Barrett, Roy, Rivard, Wilson, & Scantlebury, 2018; Garami et al., 2010; Gavva, Bannon, Surapaneni, et al., 2007; Patrone et al., 2019 | ▮ (light orange) | ▮ (light blue) | ▮ (red/pink) | Gavva, Bannon, Surapaneni, et al., 2007; Gavva et al., 2005; Norman et al., 2007 |

The effects on deep $T_b$ are marked as follows: ↑, an increase; ↓, a decrease; ↔, none.

The range of IC$_{50}$ values in the three activation modes is color-coded as follows: 1-9 nM: ▮ (CAP), ▮ (proton), ▮ (heat); 10-99 nM: ▮ (CAP), ▮ (proton), ▮ (heat); 100-999 nM: ▮ (CAP), ▮ (proton), ▮ (heat); >1,000 nM: X (any activation mode). These ranges roughly correspond to the following inhibition potencies: strong, moderate, weak, and none, respectively. When different potencies are reported for the same compound, they are shown (as different colors) within the same cell. When potentiation occurs instead of inhibition, the effect is marked as such.

Other notes: *Compound 3 and I-RTX are partial agonists (Gomtsyan et al., 2015; Shimizu et al., 2005); †CAP concentration used in the study of A-889425 by McGaraughty et al. (2009) and in the study of CPZ by Phillips, Reeve, Bevan, and McIntyre (2004) was not specified.

et al., 2010). We developed a mathematical model and used it to analyze a set of data obtained from 49 groups of rats, where each group was treated with either a distinct dose of a TRPV1 antagonist (eight antagonists were used) or vehicle. Of the antagonists studied, seven caused dose-dependent hyperthermia, whereas one (JYL1421) caused dose-dependent hypothermia. The analysis revealed that the hyperthermic response to a TRPV1 antagonist is highly sensitive to changes in the compound's *in-vitro* potency to block TRPV1 activation by protons, but is completely insensitive to the potency to block either heat or CAP activation of the channel (Fig. 8). In other words, only potent antagonists of proton activation of rTRPV1 cause hyperthermia in young male rats, and this effect does not depend on the antagonist's potency to block other modes of rTRPV1 activation. We later confirmed that those antagonists that potentiate the proton activation of TRPV1 cause hypothermia (Garami, Pakai, et al., 2018).

As explained elsewhere (Garami, Pakai, et al., 2018), the results with the CAP activation mode were initially not as clear as described in the paragraph above. In fact, the Garami et al. (2010) model produced two different outcomes, depending on whether the hypothermic antagonist JYL1421 was included in the analysis or not. The results described above and shown in Fig. 8 were obtained with a complete data set, *i.e.*, with JYL1421. If JYL1421 was excluded from the analysis, the hyperthermic response to a TRPV1 antagonist became somewhat sensitive to changes in the antagonist's potency to block CAP activation of TRPV1 – in addition to being highly sensitive to changes in the proton mode and insensitive to changes in the heat mode. At the time when the rat study (Garami et al., 2010) was conducted, we did not know whether the hyper- and hypothermic responses to TRPV1 antagonists had two distinct mechanisms (*e.g.*, one represented an off-target action) or, alternatively, whether they were brought about by the same mechanism,

**Fig. 8.** Schematic presentation of the mathematical modeling results to show the contribution of different modes of TRPV1 activation to the development of TRPV1 antagonist-induced hyperthermia in rats. Signals activating TRPV1 in the heat mode (red line), proton mode (blue line), and CAP mode (orange line) are differentially blocked by TRPV1 antagonists (black lines) to cause the hyperthermic response $H$ (see Supplementary Methods). The $k_1$, $k_2$, and $k_3$ values are relative sensitivities of $H$ to the extent of TRPV1 blockade in the heat, proton, and CAP modes, respectively. Reprinted from Garami et al. (2010).

just working in reverse. In the former case, the results with JYL1421 should have been excluded from the analysis; in the latter case, they should have been included. In a more recent work (Garami, Pakai, et al., 2018), we studied the hypothermia-inducing TRPV1 antagonists A-1165901 and AMG7905 and found that the hyper- and hypothermic responses are similar from the mechanismic point of view. Both represent an on-target action (do not occur in TRPV1 knockout animals); both recruit the exact same thermoeffectors (but working in reverse); and both are characterized by the same dependence of thermoeffectors on $T_a$; and both depend on the proton mode of TRPV1 activation (potently block vs. potentiate it). Hence, we concluded that TRPV1 antagonists cause hypothermia by engaging the same mechanisms as the hyperthermic TRPV1 antagonists but in reverse (Garami, Pakai, et al., 2018). Therefore, our earlier mathematical modeling study (Garami et al., 2010) should have been interpreted using a complete data set (with JYL1421), and the results obtained on the complete data set are described herein (Fig. 8).

### 2.5. Putting it all together: "illogical" acidification-induced antihyperthermic reflexes

A concept has emerged (Garami, Pakai, et al., 2018; Romanovsky et al., 2009) proposing that, at least in young male rats, TRPV1 does not serve as a thermosensor that drives thermoeffector responses – even though the thermosensing function of the channel is involved in pain in this species (Jhaveri, Elmes, Kendall, & Chapman, 2005; McGaraughty, Chu, Faltynek, & Jarvis, 2006; Vandewauw et al., 2018). Instead, TRPV1 participates in thermoregulation by sensing protons (or other stimuli that activate the channel through the same mechanism as protons). The TRPV1 channels that are tonically activated by protons and drive thermoeffectors are located somewhere in the abdominal viscera or muscles. TRPV1 antagonists affect thermoregulation, at least in young male rats, by affecting the activation of these TRPV1 channels. This picture has been drawn based on the robust experimental support (reviewed herein and elsewhere). Furthermore, as evident from the consensus paper (Garami, Pakai, et al., 2018), this view is now accepted not only by some academic scientists, but also by colleagues from Amgen and AbbVie – two companies that carried out a great amount of pioneering work with TRPV1 antagonists. And yet, this picture is rarely mentioned in the literature, while the alternative view (i.e., that TRPV1 plays a thermosensory role in mammalian thermoregulation, and that TRPV1 antagonists affect $T_b$ by blocking thermal activation of TRPV1) is widely spread. To the best of our knowledge, the thermal nature of the effector-driving TRPV1 signals – the cornerstone of this alternative view – has not been demonstrated so far, not even in a single study. Perhaps the main reason for the slow acceptance of the new reflexes, which can be called acido-antithermogenic and acido-

antivasoconstrictor, is related to fact that they do not "make sense" at the first glance. Indeed, what is the biological significance of bringing the $T_b$ down when the environment in the trunk is acidified?

Those reflexes that seem to make no sense are called "illogical" (Partridge, 1982; Romanovsky et al., 2009). The autonomic regulation, including thermoregulation, is executed by multiple, independent effector loops using both humoral and neural signals; the latter are called reflexes (Romanovsky, 2018). These reflexes are quite diverse, and only a small subset of them is active under any given set of external and internal conditions; when conditions change, a different subset of loops is recruited. We readily understand those reflexes that are vital, often engaged in everyday life of the organism, and well-studied, e.g., various baroreflexes used in the cardiovascular control. Such reflexes seem "logical". Yet, there are many other reflexes that we do not understand, and some thermoregulatory reflexes that are triggered by nonthermal stimuli belong to this group. For example, skin vasoconstriction is affected by colorectal distension (Laird, Carrive, & Waite, 2006), while nonshivering thermogenesis is modulated by gastric stretching (Petervari, Garami, Pakai, & Szekely, 2005), the level of intraportal glucose (Sakaguchi & Yamazaki, 1988), and the osmolarity of the content in different parts of the gastrointestinal tract (Boschmann et al., 2007; Osaka, Kobayashi, & Inoue, 2002). All of the abovementioned reflexes seem illogical – but only until we study them, find the conditions under which they are expressed, or just start thinking about them. For example, the concentration of glucose in the portal blood, as well as gastric stretching, can be viewed as indices of energy intake, whereas nonshivering thermogenesis is a major mechanism of energy expenditure in rodents; it should not be a surprise that the latter is modulated by the former.

What could be the biological significance of the unusual TRPV1-mediated reflexes that link pH and $T_b$? Because polymodal TRPV1 antagonists induce robust hyperthermia in different species (Fig. 2), it is probably related to some basic physiological interactions. Initially (Steiner et al., 2007), we thought that interactions between the feeding status, gastrointestinal pH, and $T_b$ were involved. However, in view of our recent results showing that the hyperthermic response to TRPV1 antagonists is affected neither by vagotomy (A. Garami, A. A. Steiner, and A. A. Romanovsky, unpublished observations) nor by the transection of the greater splanchnic nerves (A. Garami and A. A. Romanovsky, unpublished observations), we dismissed the visceral location of the TRPV1 channels of interest and the entire "gastrointestinal" scenario (Garami, Pakai, et al., 2018).

Instead, we propose that interactions between the acid-base homeostasis, $T_b$, and physical activity can be relevant. Strenuous physical activity is well-known to cause metabolic acidosis, including marked acidemia (Robergs, Ghiasvand, & Parker, 2004), and it increases deep $T_b$ and often peripheral temperatures. Based on the tight co-expression of TRPV1 with acid-sensing ion channel-3 on

metaboreceptive afferents in muscle arterioles, it has been proposed that TRPV1 channels at this location may function as sensors for reflexes triggered by the acidic environment and elevated temperature of working muscles (Molliver et al., 2005). In those situations, when physical activity is especially strenuous (*e.g.*, when an animal is running for life from a predator), $T_b$s can reach extremely high values. In a study by Taylor and Lyman (1972), an abdominal temperature of > 47°C was recorded in a running gazelle. By the same token, high $T_b$s (whether shell or core) inhibit physical performance (Cheung & Sleivert, 2004; Nybo, Rasmussen, & Sawka, 2014; Schlader, Simmons, Stannard, & Mundel, 2011). Hence, a negative-feedback cycle is formed: an animal has to run as fast as it can to survive ➔ $T_b$s increase ➔ the capability to run decreases. Would it not be highly beneficial to counteract the development of hyperthermia by inhibiting cold-defense responses (thermoregulatory heat conservation and heat production), thus cancelling the performance-inhibiting feedback? We think it would, and the TRPV1-mediated acido-antithermogenic and acido-antivasoconstrictor reflexes discussed herein may do just that. When an animal runs, its internal environment acidifies, and the low pH, *via* TRPV1 channels (perhaps in the massive trunk muscles that are rich with slow-twitch, type-1 muscle fibers and are involved in breathing), inhibits cold defenses, thus preventing a further rise in $T_b$ or bringing it down. This speculative line of thought has already found support in the studies showing that acute administration of CAP causes sympathetic activation and increases exercise endurance in rats and mice (Kim, Kawada, Ishihara, Inoue, & Fushiki, 1997; Oh, Oh, & Ohta, 2003). Furthermore, Luo et al. (2012) have shown that TRPV1 activation by chronic dietary CAP or transgenic TRPV1 overexpression also increases exercise endurance in mice, and that this effect of CAP does not occur in TRPV1-deficient mice. The concept presented here can be tested further by blocking TRPV1-mediated reflexes in exercising animals.

At the first glance, the proposed scenario is difficult to reconcile with the fact that lactic acid is a potent inhibitor (not activator) of TRPV1 (de la Roche et al., 2016), whereas acidosis during physical activity is accompanied by massive production of lactate (Bangsbo, Madsen, Kiens, & Richter, 1996) and, for a long time, was known as "lactic acidosis." It was believed that the increased production of lactic acid causes the release of protons and the formation of the acid salt sodium lactate, eventually exceeding the cellular buffering capacity and resulting in proton accumulation and a pH decrease. As explained by Robergs et al. (2004), the lactic acidosis concept has been disproved. While lactate production coincides with metabolic acidosis in strenuous exercise, it retards – not causes – it. In intense physical work, nonmitochondrial ATP from glycolysis is used heavily to fuel muscle contraction, thus releasing protons and causing acidosis. While extracellular lactate inhibits TRPV1, at least *in vitro* (de la Roche et al., 2016), the channel is gated open by extracellular protons (pH < 6), and milder acidosis (pH between 6 and 7) sensitizes it (reviewed by Holzer, 2009). The critical importance of TRPV1 in acid-sensing has been also demonstrated *in vivo* – using mice genetically deficient in TRPV1 (Caterina et al., 2000; Leffler, Monter, & Koltzenburg, 2006).

## 3. The hyperthermic effect of TRPV1 antagonists in human clinical trials

### 3.1. Phenomenology: effects of TRPV1 antagonists on $T_b$ in humans

As of today, a relatively large number of TRPV1 antagonists has already been tested in humans (Table 3). Besides healthy adult volunteers, patients with a variety of conditions and symptoms were studied, often involving pain and inflammation (*e.g.*, dental or neuropathic pain, arthritis, or dermatitis), but also itching, coughing, and chronic pulmonary obstruction. As part of safety assessment, deep $T_b$ was measured in several trials, and it is now well-known that many TRPV1 antagonists had adverse effects on $T_b$ in humans (Gavva et al.,

2008; Krarup et al., 2011; Lee et al., 2017; Manitpisitkul et al., 2015; Rowbotham et al., 2011).

As in laboratory animals (see 2.1), the thermoregulatory effects of TRPV1 antagonists in humans are diverse (Fig. 9). In one of the first human trials, AMG 517 caused marked hyperthermia with deep $T_b$ exceeding 40°C (Gavva et al., 2008), which led to a premature termination of the trial. A dose-dependent (and, at higher doses, pronounced: 0.8-1.4°C) $T_b$ rise was also observed in human trials with ABT-102 and V116517 (Fig. 9A and 9B, respectively), as well as with XEN-D0501 (Round, Priestley, & Robinson, 2011), while AZD1386 caused a milder (0.4°C) elevation in $T_b$ (Fig. 9C). Another TRPV1 antagonist, SB-705498, had no thermal effect in humans, even at doses as high as 600 mg p.o. (Fig. 9D), whereas the mode-selective antagonist NEO6860 seemed to cause a small (0.2°C) decrease in deep $T_b$ (Fig. 9E). As in laboratory animals, the thermal effects of TRPV1 antagonists in humans show no obvious association with the antagonist's chemical structure, thus suggesting an on-target action.

Because TRPV1 remains a promising therapeutic target in many human diseases and conditions (Brito, Sheth, Mukherjea, Rybak, & Ramkumar, 2014; Feketa & Marrelli, 2015; Gram, Holst, & Szallasi, 2017; Nilius & Appendino, 2013), it is important to understand what determines the thermoregulatory effects of TRPV1 antagonists in our own species. We already know that some TRPV1 antagonists, *e.g.*, CPZ and JYL1421, affect thermoregulation in a species-specific manner (see Section 2.1 above). We also know that at least some TRPV1 antagonists affect the TRPV1 channel in a species-specific manner as well and, hence, have different activation-mode pharmacological profiles against the TRPV1 channel in different species. A famous example is the TRPV1 antagonist AMG8562, which was the first one reported to cause analgesia without hyperthermia in rats (Lehto et al., 2008). It is thought to cause no hyperthermia in this species, because it does not inhibit proton activation of rTRPV1. However, if this assumption is true, the success of AMG8562 in causing hyperthermia-free analgesia in rats cannot be reproduced in humans – this antagonist is a potent inhibitor of all modes of activation of hTRPV1, including the proton mode (Lehto et al., 2008). Furthermore, the regulation of thermoregulatory responses in rats and humans is not likely to be identical; at the very least, rats do not sweat, whereas humans do not use tail-skin vasodilation or thermoregulatory salivation, and neither do humans rely on nonshivering thermogenesis in brown fat to the same extent as rats do (Romanovsky, 2018). Being several hundred times heavier than rats, humans take advantage of substantial thermal inertia and, accordingly, do not face the problem of readily losing the constancy of $T_b$ (homeothermia) in view of environmental perturbations, at least not to the same extent as small rodents do. Consequently, peripheral thermal signals (including those mediated by TRPV1) are expected to play a smaller role in humans than in rodents (Romanovsky, 2014, 2018).

Last but not least, TRPV1 has different sensitivity to both temperature and chemical ligands in different species. For example, a TRPV1 isoform found in vampire bats is activated by temperatures as low as 30°C, which presumably makes TRPV1 a radiant-heat sensor for the detection of warm-blooded prey (Gracheva et al., 2011). On the other extreme, Bactrian camels express a TRPV1 ortholog that is not activated by temperature as high as 46°C (Laursen, Schneider, Merriman, Bagriantsev, & Gracheva, 2016), which, we think, is a genetic adaptation to high surface temperatures in camels' habitat during summer. Another dramatic example refers to TRPV1 sensitivity to CAP. Avian TRPV1 is not sensitive to CAP (Nagy & Rang, 2000), which allows birds to feed on spicy, pungent, CAP-rich fruits such as hot chili peppers. In contrast, most mammals, including mice (Garami et al., 2011), do not consume hot chili. In fact, CAP-containing repellants are used to protect crops from browsing by many species of mammalian pests (Romanovsky, 2015). In each of these examples, a pharmacological blockade of TRPV1 would have a distinct effect.

Based on the above, it is quite possible that TRPV1 antagonists cause their thermoregulatory effect somewhat differently in humans than in

**Table 3**
Characteristics of clinical studies of TRPV1 antagonists

| Compound (company) | Patient or volunteer population | Thermometry site | Thermal effect | ClinicalTrials.gov identifier | Reference(s) |
|---|---|---|---|---|---|
| ABT-102 (Abbott) | Healthy male and female volunteers, 18-55 years | Oral | Increase in $T_b$ | NCT00854659 | Rowbotham et al., 2011 |
| ABT-102 (Abbott) | Healthy volunteers | Oral or abdominal | Increase in $T_b$ | Not reported | Othman et al., 2013 |
| ABT-102 (Abbott) | Healthy male volunteers, 18-60 years | Aural | Dose-dependent increase in $T_b$ | Not reported | Schaffler et al., 2013 |
| AMG 517 (Amgen) | Patients with pain due to molar extraction | Oral and tympanic | Plasma concentration-dependent increase in $T_b$ | Not reported | Gavva et al., 2008 |
| AZD1386 (AstraZeneca) | Patients with pain due to lower "wisdom tooth" extraction | $T_b$ not measured | $T_b$ not measured | NCT00672646 | ClinicalTrials.gov |
| AZD1386 (AstraZeneca) | Healthy volunteers | $T_b$ not measured | $T_b$ not measured | NCT00692146 | ClinicalTrials.gov |
| AZD1386 (AstraZeneca) | Patients with post-traumatic or postherpetic neuralgia | $T_b$ not measured | $T_b$ not measured | NCT00976534 | ClinicalTrials.gov |
| AZD1386 (AstraZeneca) | Patients with pain due to third molar extraction | Oral | Increase in $T_b$ | Not reported | Quiding et al., 2013 |
| AZD1386 (AstraZeneca) | Patients with knee osteoarthritis | $T_b$ not measured | $T_b$ not measured | NCT00878501 | Miller, Bjornsson, Svensson, & Karlsten, 2014 |
| AZD1386 (AstraZeneca) | Healthy male volunteers | Not reported | Dose-dependent increase in $T_b$ | NCT00711048 | Krarup et al., 2011 |
| AZD1386 (AstraZeneca) | Patients with reflux disease responsive to proton-pump inhibitors | Not reported | Increase in maximum $T_b$ | NCT01019928 | Krarup et al., 2013 |
| DWP05195 (Daewoong) | Patients with postherpetic neuralgia | $T_b$ not measured | $T_b$ not measured | NCT01557010 | ClinicalTrials.gov |
| DWP05195 (Daewoong) | Healthy male volunteers | Not reported | Dose-dependent increase in $T_b$ (tendency) | NCT00969787 (single dose) NCT01094834 (multiple doses) | Lee et al., 2017 |
| GRC-6211 (Glenmark, Eli Lilly) | Patients with osteoarthritic pain, incontinence, or neuropathic pain | $T_b$ not measured | $T_b$ not measured | Not reported | Myers, 2008 |
| JNJ-38893777 (Johnson & Johnson) | Healthy male volunteers | Oral | Small increase in $T_b$ | Not reported | Manitpisitkul et al., 2015 |
| JNJ-39439335 (Johnson & Johnson) | Healthy male volunteers | $T_b$ not measured | $T_b$ not measured | NCT01006304 | ClinicalTrials.gov |
| JNJ-39439335 (Johnson & Johnson) | Healthy male volunteers | Oral | Small increase in $T_b$ | Not reported | Manitpisitkul et al., 2016 |
| JNJ-39439335 (Johnson & Johnson) | Healthy male volunteers | Oral | No clinically meaningful increase in $T_b$ | Not reported | Manitpisitkul, Shalayda, Russel, Sanga, Solanki, et al., 2018 |
| JNJ-39439335 (Johnson & Johnson) | Healthy male volunteers (Part 1); male and female patients with knee osteoarthritis (Part 2) | Oral | Plasma concentration-independent increase in $T_b$ | Not reported | Manitpisitkul, Flores, et al., 2018 |
| JNJ-39439335 (Johnson & Johnson) | Healthy male volunteers | Oral | Small increase in $T_b$ | Not reported | Manitpisitkul, Shalayda, Russel, Sanga, Williams, et al., 2018 |
| JNJ-39439335 (Johnson & Johnson) | Patients with knee osteoarthritis | Not reported | $T_b$ increased in one patient (of 33 patients) | Not reported | Mayorga et al., 2017 |
| MK-2295, or NGD-8243 (Merck) | Patients with postoperative dental pain | $T_b$ not measured | $T_b$ not measured | NCT00387140 | ClinicalTrials.gov |
| MR-1817 (Mochida) | Healthy adult volunteers | $T_b$ not measured | $T_b$ not measured | NCT00960180 | ClinicalTrials.gov |
| NEO6860 (NEOMED, Convance) | Healthy male volunteers | Gastrointestinal (ingestible transmitter) | No clinically significant change in $T_b$ | NCT02337543 | Brown et al., 2017 |
| NEO6860 (NEOMED) | Adult patients with pain due to knee osteoarthritis | Oral | No increase of more than 1°C in $T_b$ | NCT02712957 | Arsenault et al., 2018 |
| PAC-14028, or asivatrep (Amorepacific) | Patients with dermal pruritus | $T_b$ not measured | $T_b$ not measured | NCT02052531 | ClinicalTrials.gov |
| PAC-14028, or asivatrep (Amorepacific) | Patients with dermal pruritus | $T_b$ not measured | $T_b$ not measured | NCT02565134 | ClinicalTrials.gov |
| PAC-14028, or asivatrep (Amorepacific) | Patients with erythema-telangiectatic or papulopustular rosacea | $T_b$ not measured | $T_b$ not measured | NCT02052999 | ClinicalTrials.gov |
| PAC-14028, or asivatrep (Amorepacific) | Patients with mild-to-moderate atopic dermatitis | $T_b$ not measured | $T_b$ not measured | NCT02757729 NCT02583022 NCT02965118 | ClinicalTrials.gov |
| PAC-14028, or asivatrep (Amorepacific) | Patients with mild-to-moderate seborrheic dermatitis of the face | $T_b$ not measured | $T_b$ not measured | NCT02749383 | ClinicalTrials.gov |
| PAC-14028, or asivatrep (Amorepacific, Seoul National University Hospital) | Healthy male volunteers | $T_b$ not measured | $T_b$ not measured | NCT02309008 | ClinicalTrials.gov |
| PAC-14028, or asivatrep (Amorepacific) | Healthy male volunteers | $T_b$ not measured | $T_b$ not measured | NCT01264224 | ClinicalTrials.gov |

**Table 3** (*continued*)

| Compound (company) | Patient or volunteer population | Thermometry site | Thermal effect | ClinicalTrials.gov identifier | Reference(s) |
|---|---|---|---|---|---|
| PAC-14028, or asivatrep (Amorepacific) | Healthy adult volunteers | $T_b$ not measured | $T_b$ not measured | NCT01638117 | ClinicalTrials.gov |
| PAC-14028, or asivatrep (Amorepacific) | Patients with rosacea | $T_b$ not measured | $T_b$ not measured | NCT02583009 | ClinicalTrials.gov |
| PAC-14028, or asivatrep (Amorepacific) | Pediatric patients with atopic dermatitis | $T_b$ not measured | $T_b$ not measured | NCT02748993 | ClinicalTrials.gov |
| PHE-377 (PharmEste) | Patients with neuropathic pain | $T_b$ not measured | $T_b$ not measured | Not reported | Evans, 2011 |
| SB-705498 (GlaxoSmith-Kline) | Patients with migraine | $T_b$ not measured | $T_b$ not measured | NCT00269022 | ClinicalTrials.gov |
| SB-705498 (GlaxoSmith-Kline) | Patients with third molar extraction | Tympanic | Maximal change in $T_b$ from baseline was $0.8 \pm 0.5°C$ at 1,000 mg (baseline not reported) | NCT00281684 | ClinicalTrials.gov |
| SB-705498 (GlaxoSmith-Kline) | Healthy adult volunteers | Tympanic | Not reported | NCT01476098 (oral) | ClinicalTrials.gov |
| SB-705498 (GlaxoSmith-Kline) | Healthy adult volunteers | $T_b$ not measured | $T_b$ not measured | NCT01673529 (topical) | ClinicalTrials.gov |
| SB-705498 (GlaxoSmith-Kline) | Patients with rectal pain | $T_b$ not measured | $T_b$ not measured | NCT00461682 | ClinicalTrials.gov |
| SB-705498 (GlaxoSmith-Kline) | Healthy adult volunteers | $T_b$ not measured | $T_b$ not measured | Not reported | Chizh et al., 2007 |
| SB-705498 (GlaxoSmith-Kline) | Patients with refractory chronic cough | Tympanic | No change in $T_b$ | Not reported | Khalid et al., 2014 |
| SB-705498 (GlaxoSmith-Kline) | Patients with seasonal allergic rhinitis | Oral | No change in $T_b$ | NCT01424397 | Bareille et al., 2013 |
| SYL-1001 (Sylentis) | Patients with ocular pain due to dry-eye syndrome | $T_b$ not measured | $T_b$ not measured | NCT01776658 NCT01438281 NCT02455999 | Benitez-Del-Castillo et al., 2016 |
| V116517 (Purdue) | Subjects with moderate-to-severe pain due to knee osteoarthritis | $T_b$ not measured | $T_b$ not measured | NCT01688934 | ClinicalTrials.gov |
| V116517 (Purdue) | Patients with moderate-to-severe postherpetic neuralgia | $T_b$ not measured | $T_b$ not measured | NCT01688947 | ClinicalTrials.gov |
| V116517 (Purdue) | Healthy male volunteers | Oral | No change in $T_b$ | NCT02695745 | Arendt-Nielsen et al., 2016 |
| XEN-D0501 (Xention, Ario) | Patients with chronic idiopathic cough | $T_b$ not measured | $T_b$ not measured | NCT02233699 | ClinicalTrials.gov |
| XEN-D0501 (Xention, Ario) | Patients with refractory chronic cough | Not reported | Not reported | Not reported | Belvisi et al., 2017 |
| XEN-D0501 (Xention) | Healthy male (Part 1) or male and female (Part 2) volunteers | Aural | Dose-dependent increase in $T_b$ | Not reported | Round et al., 2011 |
| XEN-D0501 (Xention, Ario) | Patients with chronic obstructive pulmonary disease | $T_b$ not measured | $T_b$ not measured | NCT02233686 | Smith et al., 2017 |

rats. Nothing is known about the contributions of different modes of hTRPV1 activation to the thermoregulatory effect of TRPV1 antagonists in humans. By conducting the mathematical analyses presented below, we intended to fill this void.

### 3.2. Mathematical modeling: which modes of hTRPV1 activation contribute to the hyperthermic response in humans?

For the present work, we identified 87 published reports on human clinical trials of TRPV1 antagonists, of which 18 trials involved recording some measure of deep (core) $T_b$ (Fig. S1). Using the sets of inclusion and exclusion criteria (Tables S1 and S2), we were able to select five studies for a mathematical-modeling analysis, and also for meta-analysis (see Section 3.3. below). The full set of data used for modeling analysis is shown in Table S3. The model, which is based on the one we developed earlier (Garami et al., 2010), is described in detail in Supplementary Methods.

The modeling analysis has found that the hyperthermic effect of TRPV1 antagonists in humans is the most sensitive to the extent of hTRPV1 blockade in the proton activation mode. The sensitivity coefficient of the hyperthermic response to potency changes in the proton mode (mean $\pm$ SE) is $1.37 \pm 0.00$ ($P = 2.48 \times 10^{-39}$). In this respect, the hyperthermic response to TRPV1 antagonists in humans is similar to that in rats: in both species, potent blockers of proton activation cause an increase in $T_b$ (Fig. 10). While preparing our recent study (Garami, Pakai, et al., 2018), we already had the information about the

importance of the proton activation mode, based on preliminary results of our modeling analysis presented here, and we used these results to explain the phenomenon that was not well understood. It was reported that the TRPV1 antagonist V116517 potently blocked rTRPV1 activation by protons and caused hyperthermia in rats (Tafesse et al., 2014), but yet it did not cause hyperthermia in a human clinical trial, while potently blocking hTRPV1 activation by protons (Arendt-Nielsen et al., 2016). We proposed (Garami, Pakai, et al., 2018) that this discrepancy could be explained by the use of subthreshold (for causing hyperthermia) doses of V116517 in that particular trial, and that V116517 is an intrinsically hyperthermic (not neutral) compound. The data presented in the present work (Fig. 9B) show that our hypothesis is correct.

The present analysis has also found that, differently from the hyperthermic response in rats (which is insensitive to potency changes in the heat activation mode), the response in humans is highly sensitive to the antagonist's potency in the heat mode. For the human response, the sensitivity coefficient to potency changes in the heat mode is $1.09 \pm 0.00$ ($P = 1.92 \times 10^{-39}$). As for the CAP mode of activation, blocking it is not important for the hyperthermic response in either rats or humans. In humans, the response sensitivity to potency changes in the CAP mode is negative and six times lower in magnitude than the sensitivity in the proton activation mode. The sensitivity coefficient of the human response to potency changes in the CAP mode is $-0.23 \pm 0.00$ ($P = 4.71 \times 10^{-38}$).

In addition to the set of mean sensitivity coefficients listed above and illustrated in Fig. 10, we have also found the best-fitted set of sensitivity

**Fig. 9.** Deep $T_b$ responses of humans to TRPV1 antagonists vary from high hyperthermia to low hyperthermia, no effect, or hypothermia. A) Effect of ABT-102 (2, 6, and 30 mg/kg, p.o.) or placebo on oral temperature. B) Effect of V116517 (30, 100, and 1,000 mg/kg, p.o.) or placebo on oral temperature. C) Effect of AZD1386 (95 mg/kg, p.o.) or placebo on oral temperature. D) Effect of SB-705498 (600 mg/kg, p.o.) or placebo on oral temperature. E) Effect of NEO6860 (500 mg/kg, p.o.) or placebo on oral temperature. Plotted for this work based on data from Othman et al. (2013) (A), Arendt-Nielsen et al. (2016) (see also Table S6) (B), Quiding et al. (2013) (C), Khalid et al. (2014) (D), and Arsenault et al. (2018) (E).

coefficients (by using a Monte Carlo technique to run the model with randomly generated parameters; see Mathematical model description, Supplementary Information). The best-fitted set includes the following sensitivity coefficient values: -0.21 (CAP mode), 1.25 (proton mode), and 1.00 (heat mode). With this set, the model accounts for a maximal share of the hyperthermic response variation: 83% ($r^2 = 0.83$). The best-fitted set complements the mean values in characterizing how the potency in each activation mode affects the hyperthermic response to TRPV1 antagonists in humans.

In addition to the high value of $r^2$, the high quality of data fitting in our model is demonstrated by the low values of the so-called "mismatch errors", *i.e.*, the differences between the hyperthermic response values measured in clinical trials for the 16 antagonist doses used in this analysis (Table S3) and the corresponding response values predicted by our model. In our current analysis, the mismatch error varies from -0.3 to 0.4°C; the quadratic mean is 0.2°C.

The more complex nature of the hyperthermic response to TRPV1 antagonists in humans, as compared to that in rats (dependence on two activation modes *vs.* one), is also evident from how varying the antagonist potency in different activation modes contributes to the statistical variance of the human hyperthermic response (Fig. 10). In rats, > 81% of the statistical variance of the hyperthermic response is determined by the proton mode; the contributions of both the heat mode and the CAP mode are negligible (~1% each); and the contribution of factors unaccounted for by our model is 16%. In humans, these contributions are: 35% for the proton mode, 37% for the heat mode, 10% for the CAP mode, and 17% for unaccounted factors.

The main finding of our analysis is that the hyperthermic response to TRPV1 antagonists depends on the activation-mode TRPV1 pharmacology differently (and in a more complex fashion) in the human than in the rat. In rats, of the three modes studied (CAP, proton, and heat), only the proton mode matters: the hyperthermic response is highly sensitive to potency changes in this mode and is totally insensitive to potency changes in the CAP or heat mode. Accordingly, only potent blockers of rTRPV1 activation by protons cause hyperthermia in rats. In humans, the hyperthermic response is highly sensitive to potency changes in the proton mode of hTRPV1 activation as well. But it is also sensitive, almost to the same extent, to potency changes in the heat mode. Hence, perhaps the most interesting and somewhat unexpected conclusion from our analysis is that TRPV1 plays different roles in thermoregulation in humans, as compared to rats. In rats, it mediates the tonic suppression of thermogenesis and skin vasoconstriction by protons (or proton-like stimuli) in the abdomen, perhaps in trunk muscles; it does not serve as a thermosensor to the thermoregulation system in this species, or at least not in young male adults. In humans, TRPV1 also seems to mediate the effect of acidity on thermoregulation, but, in addition to this, it is likely to play a role of a true thermal sensor for the thermoregulation system – detecting $T_b$s to drive thermoeffector responses. Our analysis suggests that, in order to be thermally neutral in humans, a TRPV1 antagonist should have low potency in both temperature and proton activation modes of hTRPV1.

Our model also predicts that the strongest hyperthermic response in humans is induced by TRPV1 antagonists that are highly potent inhibitors of hTRPV1 activation by both protons and heat. This prediction is

**Fig. 10.** Contribution of different modes of TRPV1 activation to the development of TRPV1 antagonist-induced hyperthermia in rats (A, B) and humans (C, D). TRPV1 antagonists differentially affect TRPV1 activation by CAP, protons, and heat; some TRPV1 antagonists cause the hyperthermic response. The sensitivity of the hyperthermic response to the antagonist potency in each of the three activation modes is presented as bars (mean ± standard error) for rats (A) and humans (C). While the hyperthermic response to TRPV1 antagonists in rats depends solely on the antagonist's potency to block TRPV1 activation by protons, the hyperthermic response in humans depends on the antagonist's potencies in both proton and heat modes. The pie charts depict the relative contributions of each mode (as well as of the factors unaccounted for by the model) to the statistical variance of the hyperthermic response in rats (B) and humans (D). Graphs are plotted from data reported by Garami et al. (2010) (A, B) or derived from the present mathematical analysis (C, D).

supported by the clinical trial of AMG 517 reported by Gavva et al. (2008). We could not use the Gavva et al. (2008) data in our analysis (Table S2), because the published report contained only the maximal values of $T_b$ over a period of time (instead of the exact values at different time points). However, from the maximal $T_b$ data presented, it is clear that AMG 517 causes marked hyperthermia in humans already at the very low dose of 2 mg (~5 μmol). AMG 517 is a highly potent blocker of hTRPV1 activation by both protons and heat; the corresponding $IC_{50}$ values are 0.6 and 1.3 nM, respectively [Table S2; also see Gavva, Bannon, Surapaneni, et al. (2007)].

Furthermore, $T_b$ data reported for most of the TRPV1 antagonists with a known pharmacological profile against hTRPV1 seem to be compatible with our model results (Arsenault et al., 2018; Gavva et al., 2008; Othman, Nothaft, Awni, & Dutta, 2013; Quiding et al., 2013; Rowbotham et al., 2011). SB-705498 may be an exception, as this compound blocks all three activation modes of hTRPV1 with high (3-6 nM) potency (Gunthorpe et al., 2007), and yet, in the trial reported by Khalid et al. (2014), a high dose of this compound (600 mg, p.o.) failed to increase deep $T_b$ (Fig. 9D). However, the TRPV1 channel occupancy in that trial (based on the peak plasma SB-705498 concentration) was only 45%, thus suggesting that the dose used might have been insufficient for triggering on-target effects, including hyperthermia.

While the modeling analysis presented here enables us to make unique conclusions about the relationship between the activation-mode pharmacological profiles of TRPV1 antagonists and their thermal

effects in humans, some caution should be exercised when these conclusions are interpreted or applied.

First, the model processed pharmacological profiles obtained against hTRPV1 *in vitro* and thermal responses recorded in humans *in vivo*, with measurements performed by different groups and by different methodologies. We do not know whether the channel behaves similarly *in vitro* and *in vivo*. We also ignore any pharmacokinetics-related differences between different compounds.

A less obvious, but perhaps very important, reason for caution is that the model assumes that there are only three modes of TRPV1 activation, and that they are independent of each other. In reality, however, the TRPV1 channel can be activated not only by CAP (and other vanilloids and some endocannabinoids), protons (acidic pH), and heat, but also by the myriad of other endogenous and exogenous ligands, including – just to give some examples – divalent (*e.g.*, $Ni^{2+}$) and trivalent (*e.g.*, $Gd^{3+}$) cations, polyamines, basic pH, eicosanoids, phospholipids, and terpenoids (for review, see Calixto, Kassuya, Andre, & Ferreira, 2005; Nilius & Szallasi, 2014). In fact, TRPV1 is known as the polymodal receptor *par excellence* (Holzer, 2009). Furthermore, there is certainly a crosstalk between different modes of TRPV1 activation (Blumberg et al., 2011), *e.g.*, mild acidosis sensitizes TRPV1 to both CAP and heat (reviewed by Holzer, 2009). The interdependence of different modes of TRPV1 activation clouds any interpretations of our modeling results.

Last but not least, the inordinate promiscuity of the TRPV1 channel makes it utterly sensitive to its environment. Accordingly, the channel is likely to play different physiological roles with changes in conditions, even in the same species. Consequently, effects of TRPV1 antagonists can also be expected to differ under different conditions. In the study by Gram et al. (2019) in Zucker obese rats, the TRPV1 antagonist BCTC improved insulin secretion at a young age of 6 months, but did not have this effect at a more mature age of 9 months. In our study (Wanner et al., 2012), the hyperthermic effect of AMG 517 in aged (44 weeks) mice was very similar to that in young (12 weeks) mice, but the effect of the antagonist on systemic inflammation changed with aging from anti-inflammatory to proinflammatory. Furthermore, the effect of AMG 517 on mortality of systemic inflammation in aged mice depended on whether the inflammation was septic (induced by colonic ligation and puncture) or aseptic (induced by a high dose of bacterial lipopolysaccharide).

A sex-dependent effect of the TRPV1 antagonist ABT-116 on locomotor activity was found in dogs; this compound produced a stronger effect in males than in females (Malek et al., 2012). Sex-dependent differences in the effects of CPZ on audiogenic seizures in rats (Cho, Vaca, Miranda, & N'Gouemo, 2018) and on the urethral response to noxious stimulation in mice (Yoshiyama, Araki, Kobayashi, Zakoji, & Takeda, 2010) have also been reported. These differences may be due to the demonstrated effects of ovariectomy, pregnancy, and sex hormones (*viz.*, progesterone, estradiol, and prolactin) on the expression and activity of TRPV1 in mice and rats (Diogenes et al., 2006; Ortiz-Renteria et al., 2018; Payrits et al., 2017; Wu et al., 2010). Estradiol has also been shown to upregulate TRPV1 at the mRNA level in human sensory neurons derived from embryonic stem cells (Greaves, Grieve, Horne, & Saunders, 2014).

Some thermoregulatory effects of TRPV1 antagonists may also be sex-dependent. Based on our experiments with AMG0347 in male rats (Steiner et al., 2007), we concluded that TRPV1 antagonists readily recruit autonomic thermoeffectors in the hyperthermic response, but do not use behavioral regulation (we are now revisiting the latter conclusion in a new study). Based on our experiments with multiple TRPV1 antagonists in male rats (Garami et al., 2010; Steiner et al., 2007), we concluded that blocking thermal signals does not affect thermoregulation. To our surprise, our recent experiments have shown that several TRPV1 antagonists affect behavioral thermoregulation in female rats, possibly by blocking thermal signals (Romanovsky, 2019). Clearly, more studies are needed, and any results obtained with TRPV1 antagonists should be generalized with great care. Without having a model of a

biological phenomenon in one's head, it is impossible to further study this phenomenon in a systematic way, but one should always be ready to change the model as new experimental data arrive.

### 3.3. Human clinical trials: meta-analysis

In addition to mathematical modeling, we also conducted a meta-analysis of the data reported in the identified articles, using standard meta-analysis tools (see Supplementary Methods), in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews (Table S4) and Meta-Analysis Protocols (Moher, Liberati, Tetzlaff, & Altman, 2009). This analysis was registered with PROSPERO (CRD 42018095220).

We included the studies that reported deep $T_b$ values in both TRPV1 antagonist-treated and placebo groups at least at two time points: (i) at or shortly before the drug (or placebo) administration and (ii) at 3 h after the time of administration (Table S1). Studies for which all the necessary information could not be obtained were excluded from the analysis (Table S2). In certain cases, we had to make limited assumptions or simplifications, as explained in Table S5. The demographic profiles of the studies are outlined in Table S6. For each included study, we calculated the change in deep $T_b$ as a difference between the $T_b$ values at 3 h after the drug (placebo) administration vs. at the time of administration (0 h); this is the $T_b$ change that was used in the modeling analysis as the value $H$ of the hyperthermic response. We then calculated the difference between the $T_b$ changes induced by a drug and those induced by placebo (difference in means); we considered the latter difference to represent the thermal effect of the drug in our meta-analysis. For all doses, the differences in means were standardized (based on variances) to obtain standardized differences in means (SDMs). The SDMs with 95% confidence intervals (CIs) were used as primary measures of effect size and are presented as a "forest plot" (Fig. 11). We considered each TRPV1 antagonist to be either mode-nonselective (ABT-102, AZD1386, and V116517) or mode-selective (NEO6860). To characterize the non-selective group, SDMs for the corresponding antagonists were weighted based on sample size and inversed variance.

All three antagonists in the mode-nonselective group caused hyperthermia, which was dose-dependent for those compounds that were administered at multiple doses, viz., ABT-102 and V116517 (Fig. 11).

The highest hyperthermic effect (SDM: 2.5; CI: 1.4-3.5) occurred in the group treated with the 86 μmol dose of ABT-102. The mean thermal effect of all doses of all mode-nonselective TRPV1 antagonists in the analyzed clinical trials was an SDM of 1.2 (CI: 0.9-1.6; $P < 0.001$). These results of meta-analysis agree with our mathematical-modeling results in that the blockade of the proton and heat activation modes of the hTRPV1 channel, as typically observed for polymodal TRPV1 antagonists, results in hyperthermia.

NEO6860, the only mode-selective TRPV1 antagonist that we were able to include in our analysis, did not cause hyperthermia at the dose used (1.2 mmol) but, instead, decreased the deep $T_b$ (SDM: -0.7; CI: -0.3 to -1.1; $P < 0.001$). The lack of hyperthermia in response to NEO6860 agrees with our mathematical model, since this compound blocks neither proton nor heat activation of hTRPV1. The hypothermic effect of NEO6860 could be explained by the reported partial agonistic activity of this compound against hTRPV1 (Arsenault et al., 2018). TRPV1 agonists are well-known to cause hypothermia (Romanovsky et al., 2009; Szolcsanyi, 2015). TRPV1 antagonists with partial TRPV1 agonistic properties, such as 5'-iodo-RTX (Blumberg et al., 2011; Dogan et al., 2004; Shimizu, Iida, Horiuchi, & Caterina, 2005) or AbbVie's Compound 3 (Gomtsyan et al., 2015), also cause hypothermia. As a limitation of our meta-analysis, it should be mentioned that we analyzed only one dose of a single mode-selective drug; this analysis should be repeated as more data become available.

## 4. Tackling the thermal effects of TRPV1 antagonists: approaches to drug development

### 4.1. Designing thermally neutral antagonists based on mode-selective TRPV1 pharmacology

Perhaps the best solution would be to design a TRPV1 antagonist that possesses sufficient efficacy as an analgesic (or in respect to any other desired effects) but does not cause any of the on-target adverse effects on $T_b$, i.e., hypo- or especially hyperthermia. Based on the current work, the thermal effects are likely to be minimal in humans for the compounds that do not block hTRPV1 activation by protons and temperature, even if they are still potent blockers of the channel activation by CAP. If the proton- and heat-blocking potencies are low enough,



| Group | TRPV1 antagonist | Dose (μmol) | SDM | CI limits Lower | CI limits Upper | P value | SDM and CI | Relative weight |
|---|---|---|---|---|---|---|---|---|
| Non-mode-selective | ABT-102 | 2.9 | 0.0 | -0.8 | 0.8 | 1.000 | | 0.08 |
| | | 5.7 | 1.0 | 0.4 | 1.5 | 0.001 | | 0.10 |
| | | 11 | 0.9 | 0.3 | 1.6 | 0.005 | | 0.09 |
| | | 17 | 1.9 | 1.0 | 2.9 | 0.000 | | 0.07 |
| | | 23 | 1.0 | 0.7 | 1.8 | 0.035 | | 0.08 |
| | | 52 | 2.4 | 1.4 | 3.4 | 0.000 | | 0.07 |
| | | 86 | 2.5 | 1.4 | 3.5 | 0.000 | | 0.07 |
| | | 115 | 1.9 | 1.0 | 2.9 | 0.000 | | 0.07 |
| | AZD1386 | 225 | 0.8 | 0.4 | 1.3 | 0.000 | | 0.11 |
| | V116517 | 68 | 0.5 | -0.7 | 1.7 | 0.411 | | 0.06 |
| | | 226 | 0.9 | -0.3 | 2.1 | 0.137 | | 0.05 |
| | | 678 | 0.9 | -0.28 | 2.1 | 0.130 | | 0.05 |
| | | 1,357 | 1.5 | 0.2 | 2.8 | 0.022 | | 0.05 |
| | | 2,261 | 1.7 | 0.4 | 3.1 | 0.010 | | 0.05 |
| | All drugs | All doses | 1.2 | 0.9 | 1.6 | 0.000 | | 1.00 |
| Mode-selective | NEO6860 | 1,149 | -0.7 | -1.1 | -0.3 | 0.000 | | 1.00 |

**Fig. 11.** Forest plot of the thermal effects of TRPV1 antagonists. For each antagonist dose, an SDM (a measure of the $T_b$ response) and CI were calculated as described in the text (section 3.3) and are shown in the figure with a square and a horizontal bar, respectively. The area of the square is proportional to the sample size and inversed variance. The rhombus refers to the weighted mean SDM for the mode-nonselective group; the vertical diagonal of the rhombus points at the SDM value, whereas the horizontal diagonal represents the CI. Red symbols refer to mode-nonselective TRPV1 antagonists; the green square and bar refer to the selective antagonist NEO6860.

while the CAP-blocking potency is high enough, such a compound or biological has a chance of possessing sufficient efficacy (by potently blocking hTRPV1 activation by vanilloids) without affecting $T_b$. Rational design of therapeutics with this activation-mode profile clearly pushes the current boundaries of molecular pharmacology. Nonetheless, there are hints from TRPV1 mutational data that this may be possible. Early studies of TRPV1 orthologs showed that residues in the vanilloid-binding pocket could be mutated (Tyr511Ala and Ser512Tyr), which would selectively disrupt the CAP sensitivity, while retaining high sensitivity in the heat and proton activation modes (Jordt & Julius, 2002). Similarly, mutations in the pore turret of murine TRPV1 can selectively abrogate heat activation without impacting CAP activation (Cui et al., 2012), while distinct but proximal mutations have been shown to selectively disrupt proton activation (Jordt et al., 2000). More recently, random scanning mutagenesis of rTRPV1 has identified hundreds of specific mutations across the TRPV1 protein that retain either CAP- or heat-selective activation – although it is unclear how these mutations impact proton activation (Sosa-Pagan, Iversen, & Grandl, 2017). Taken together, these data prove that TRPV1 activation involves at least some stimuli-specific mechanismic differences. Leveraging these differences in gating-coupling modes of TRPV1 activation can potentially be instrumental for developing therapeutics. Indeed, multiple TRPV1 antagonists with various degrees of mode-selectivity (second-generation antagonists) have been synthesized, and some even tested in humans (vide supra).

There are two main obstacles for this approach. First, limited by the extent of the current knowledge, rational engineering of mode-selective TRPV1 compounds remains at an early stage. Second, there may be an intrinsic limit on how much the overall activation of TRPV1 can be blocked (for therapeutic purposes) without blocking channel activation by protons and temperature (to prevent thermoregulatory side effects). Reflecting this inherent limitation, the reasons for failure of TRPV1 antagonist clinical trials are now different than they were a decade ago. The early trials were conducted with first-generation (mode-nonselective) antagonists, and they typically failed due to the adverse hyperthermic effect; the trial with AMG 517 being a well-known example (Gavva et al., 2008). In contrast, several more recent trials were conducted with second-generation (mode-selective) TRPV1 antagonists, and some of these trials did not demonstrate the anticipated level of analgesia; trials of NEO6860 (Arsenault et al., 2018) being an example.

While rational engineering of TRPV1 antagonists with a desired profile is maturing, less efficient tools can also be used to achieve the same results, e.g., "random" synthesis and in-vitro pharmacological screening. Based on publications, several thermally neutral, mode-selective TRPV1 antagonists have been (or were) considered by pharmaceutical companies for further development, including A-1165442 and A-1115760 by Abbott Laboratories and AbbVie (Reilly et al., 2012; Voight et al., 2014), AS1928370 (ASP8370) by Astellas Pharma (Oka et al., 2018; Watabiki, Kiso, Kuramochi, et al., 2011; Watabiki, Kiso, Tsukamoto, Aoki, & Matsuoka, 2011), and NEO6860 by NEOMED Institute (Arsenault et al., 2018; Brown et al., 2017).

### 4.2. Using therapeutic doses that are subthreshold for the hyperthermic response

In the section above, we discussed development of TRPV1 antagonists that are thermally neutral, meaning that they do not cause a thermal response in the entire dose range that can be reasonably expected to be used. However, the developers will always face conflicting demands: a thermally neutral antagonist, at least according to our model, should not block heat and proton activation of hTRPV1, whereas in order to be an efficacious analgesic (or whatever the desired therapeutic effect might be), it should potently block TRPV1 activation, sometimes in all modes. As a result, "compromise" antagonists are likely to emerge that exhibit some antagonism in non-CAP modes of activation at the price of causing hyperthermia at higher doses. Finding such a

compromise, i.e., using potentially hyperthermic antagonists at doses that are subthreshold for causing hyperthermia, can be viewed as a separate approach for dealing with the thermoregulatory side effects. This approach exploits differential sensitivity of the therapeutic vs. side effects to changes in exposure; it is also known as the therapeutic index-based approach. As evident from the literature, this approach might have been explored by Purdue Pharma in connection with the development of V116517, as discussed in section 3.2 (also see Fig. 9B). Since in an earlier trial in humans the TRPV1 antagonist XEN-D0501 caused dose-dependent hyperthermia (Round et al., 2011), one could speculate that the same approach may be used by the young pharmaceutical company Pila Pharma, which is developing XEN-D0501 for treating obesity and diabetes (Gram et al., 2017). Pila Pharma is also likely to be taking advantage of the approach described in the next section.

### 4.3. Taking advantage of the tachyphylaxis phenomenon

Another strategy to minimize the hyperthermia is by taking advantage of the fact that the hyperthermic effect of some TRPV1 antagonists fades away with repeated administration, whereas the desired effect (e.g., analgesic) may not undergo such an attenuation (Gavva, Bannon, Hovland Jr., et al., 2007). The fading of the effect with repeated administration is called desensitization, or tachyphylaxis; we will use the latter term – to avoid confusion with CAP- or RTX-induced desensitization discussed in previous sections. In different animal models it has been shown that repeated dosing of AMG 517, AMG8163 (Gavva, Bannon, Hovland Jr., et al., 2007) or ABT-102 (Honore et al., 2009) can favorably shift the ratio of the desired effect (analgesia) to the adverse effect (hyperthermia). It is speculated that the selective modulation of some (but not other) effects of TRPV1 antagonists with repeated dosing can be due to the antagonist-sensitive regulation of the subcellular distribution of TRPV1, which can lead to relative strengthening or weakening of TRPV1-mediated responses generated from different locations within a cell (Johansen, Reilly, & Yost, 2006). While the exact molecular mechanisms of the effect-specific tachyphylaxis seen at the whole-body level are unknown, it is interesting that rTRPV1 desensitization in vitro (revealed as reduced ion conductance) has different mechanisms when caused by different stimuli. Whereas CAP-induced desensitization is $Ca^{2+}$- and calmodulin-dependent (Rosenbaum, Gordon-Shaag, Munari, & Gordon, 2004) and at least partially reversible (Numazaki et al., 2003), heat-induced desensitization is independent of either $Ca^{2+}$ or calmodulin and, on the experimental time scale, is irreversible (Sanchez-Moreno et al., 2018).

Repeated administration of TRPV1 antagonists was also tested in human clinical trials. In the trial by Amgen (Gavva et al., 2008), the hyperthermic response to the highest dose (10 mg) of AMG 517 (but not to a lower dose of 2 or 5 mg) was attenuated with repeated antagonist administration (Fig. 12A). In the trials conducted by Abbott Laboratories, the hyperthermic response to any dose of ABT-102 used (1, 2, or 4 mg, twice a day) attenuated gradually with repeated dosing and faded by day 7 [Fig. 12B; also see Rowbotham et al. (2011)]. In the trial reported by Round et al. (2011), XEN-D0501 caused a dose-dependent core $T_b$ increase, which was greatest on the first day of dosing but rapidly attenuated thereafter for all doses tested (1, 2.5, and 5 mg, twice a day) and, by day 14, was 0.3°C or less (as compared to the placebo group) for all doses studied.

A priori, any pharmaceutical company that deals with a chronic condition, thus requiring repeated drug administration, and works on TRPV1 antagonists with an inherent hyperthermic activity may try to use a tachyphylaxis protocol, whether by desire or as an added benefit of repeated dosing. Purdue Pharma conducted clinical trials of their TRPV1 antagonist V116517 (NCT01688934, 2012; NCT01688947, 2012). According to R. Kapil and D. J. Kyle (unpublished observations), the company saw a rapid abatement of hyperthermia with repeated dosing of V116517 in laboratory animals and humans alike, thus

**Fig. 12.** The magnitude of the hyperthermic response to TRPV1 antagonists decreases with subsequent administration in humans. A) The effect of AMG 517 (2, 5, and 10 mg/kg, p.o., twice a day) or placebo on maximum tympanic temperature is shown for the first 7 days of treatment (days 0-6). B) The effect of ABT-102 (1, 2, and 4 mg/kg, p.o., twice a day) or placebo on abdominal temperature is shown for the first 7 days of treatment. Plotted for this work based on data from Gavva et al. (2008) (A) and Rowbotham et al. (2011) (B).

reducing the possible safety concerns for the drug. In addition to Purdue Pharma, several other companies, including Amgen, Daewoong Pharmaceutical, Pila Pharma, and Abbott Laboratories exercised (or at least considered) this approach, as is evident from the published reports (Gavva et al., 2008; Lee et al., 2017; Round et al., 2011; Rowbotham et al., 2011).

### 4.4. Combining a TRPV1 antagonist with an antihyperthermic drug

The low-hanging fruit was picked first. Several TRP programs at pharmaceutical companies considered combining a hyperthermic TRPV1 antagonist with some of the most obvious choices for drugs decreasing $T_b$ – conventional antipyretics. Amgen published some research on this topic. Amgen's first report (Gavva, Bannon, Hovland Jr., et al., 2007) described an attempt of combining the TRPV1 antagonist AMG8163 with acetaminophen, an active constituent of Tylenol (and of more than 500 other over-the-counter and prescription medicines used to treat fever and pain). It appeared that acetaminophen did

attenuate the hyperthermia induced by AMG8163 but only at a super high, hypothermia-inducing dose of 300 mg/kg, which is analogous to a 21-g bolus dose for a 70-kg human. Lower doses of acetaminophen that are normally used to treat fever (and that do not affect $T_b$ in afebrile – without fever – conditions) do not diminish the hyperthermic response to AMG8163 in rats (Gavva, Bannon, Hovland Jr., et al., 2007). Nor do they affect the hyperthermic response to AMG 517 in human patients undergoing molar extraction (Gavva et al., 2008).

These negative results should not come as a surprise, because acetaminophen is thought to block fever by inhibiting cyclooxygenase (Engstrom Ruud et al., 2013), the key enzyme in the synthesizing cascade of prostaglandin $E_2$ (Ivanov & Romanovsky, 2004). While prostaglandin $E_2$ is the principal mediator of fever (Garami, Steiner, & Romanovsky, 2018), there are no data on prostaglandin involvement in the genesis of the hyperthermic response to TRPV1 antagonists. The noninvolvement of prostaglandin $E_2$ would explain the resistance of AMG8163- or AMG 517-induced hyperthermia to acetaminophen. On the other hand, the attenuation of AMG8163-induced hyperthermia in rats by the super high dose of acetaminophen (Gavva, Bannon, Hovland Jr., et al., 2007) is likely to be independent of TRPV1 and has been proposed to involve TRPA1 (Mirrasekhian et al., 2018), even though TRPA1 does not seem to play a role in $T_b$ regulation in rats (de Oliveira et al., 2014). Alternatively, the hypothermic action of very high doses of acetaminophen can be, at least partially, due to the accumulation of acetaminophen metabolites, some of which exert a TRPV1-agonistic action (Eberhardt et al., 2017; Ohashi et al., 2017; Stueber et al., 2018).

A more fruitful approach can be combining a hyperthermic TRPV1 antagonist with a drug that blocks the sympathetic activation. Indeed, TRPV1 antagonists increase $T_b$ by mounting the autonomic cold-defense responses: thermogenesis and skin vasoconstriction (Gavva et al., 2008; Steiner et al., 2007). These responses are sympathetically-driven not only when they are triggered by cold exposure or pyrogens (Morrison, 2011), but also when they are induced by TRPV1 antagonists, e.g., AMG9810 (Alawi et al., 2015). The sympathetic mediation of TRPV1 antagonist-induced hyperthermia paves a way for combining a TRPV1 antagonist with a sympatholytic (sympathoplegic) drug, i.e., a drug that opposes the downstream propagation of the neural signal in the sympathetic nervous system. The broad class of sympatholytics exploits a plethora of mechanisms and includes postsynaptic α- and β-adrenoreceptor antagonists, presynaptic $α_2$-adrenoreceptor agonists, catecholamine synthesis inhibitors, vesicular monoamine transporter inhibitors, and drugs with some other mechanisms of action (Stowe & Ebert, 2013). Based on the public information (Gomtsian, 2019), the pharmaceutical startup Synventa may be using the strategy described in this section. Synventa proposes that the $α_2$-adrenoreceptor agonist lofexidine can prevent the hyperthermic effect of a TRPV1 antagonist and that using the two together will result in a thermally neutral analgesic combination.

### 4.5. Turning the adverse hyperthermia into a desired effect

Yet another approach to dealing with the adverse effect of TRPV1 antagonists on $T_b$ would be to exploit their hyperthermic potential for a therapeutic purpose, e.g., for counteracting hypothermia associated with general anesthesia in surgery (Schmidt, 2017) and possibly other types of hypothermia, especially when accompanied by pain or hyperalgesia. Anesthesia-associated hypothermia can be dramatic in magnitude (several degrees Celsius) and carries a significant risk of serious adverse effects, including coagulopathy and blood loss, as well as an increased propensity for wound infection (Ruetzler & Kurz, 2018). In animal models (Fig. 13), TRPV1 antagonists readily prevent or reverse anesthesia-associated hypothermia, while reducing the need for opioids for coping with postsurgical pain (Garami et al., 2017). As evident from the literature (Schmidt, 2017) and a published patent application

**Fig. 13.** AMG 517 causes hyperthermia in conscious rats but prevents hypothermia during anesthesia – without causing hyperthermia. A) The effect of AMG 517 (1 mg/kg, i.v.) or its vehicle on colonic temperature of rats pretreated with saline (i.p.) at a subneutral $T_a$ of 23°C. B) The effect of AMG 517 (1 mg/kg, i.v.) or its vehicle on colonic temperature of rats pretreated with ketamine (100 mg/kg, i.p.) at a subneutral $T_a$ of 23°C. Modified with permission from Garami et al. (2017).

(Patwardhan, Porreca, & Romanovsky, 2017), the strategy described in this section is used by the pharmaceutical startup Catalina Pharma.

## 5. Summary and conclusions

1. In rats and other laboratory animals, TRPV1 antagonists alter the level of $T_b$: most cause hyperthermia, whereas some produce hypothermia, and yet others exert no effect on thermoregulation. In general, the thermoregulatory effects of TRPV1 antagonists are dose-dependent. For some compounds, the effects are species-specific. The most common effect – hyperthermia – often fades with repeated dosing. Despite their diversity, all these thermoregulatory responses are likely to reflect an on-target (TRPV1-mediated) action of TRPV1 antagonists.

2. The TRPV1 protein is a species-specific channel that can be activated by a variety of stimuli, including (but not limited to) CAP and other vanilloids, protons (low pH), and heat. Activation of TRPV1 by different stimuli involves at least some mechanismic differences related to distinct portions on the channel structure and different loci of the molecule. These activation-mode-specific differences pave the way for developing mode-selective (mode-specific) TRPV1 antagonists. TRPV1 antagonists that potently block all activation modes are called mode-nonselective (or mode-nonspecific); they represent the first generation of TRPV1 antagonists. Second-generation (mode-selective) TRPV1 antagonists potently block the channel activation by CAP, but exert different effects (e.g., potentiation, no effect, or low-potency inhibition) in either the proton mode or the heat mode, or both.

3. In young male rats, TRPV1 channels are not used as thermosensors for the thermoregulation system: thermal ($T_b$) signals that are mediated by TRPV1 do not normally drive thermoeffector responses in this species. Hence, blocking thermal activation by TRPV1 antagonists has no thermoregulatory effect in rats. Contrary to the widespread assumption, the mechanism of thermoregulatory effects of TRPV1 antagonists in this species does not involve blocking TRPV1-mediated thermosensation. Instead, TRPV1 antagonists affect thermoregulation by blocking the tonic TRPV1 activation by protons (or other ligands that share the proton activation mechanism) on sensory afferents somewhere in the trunk (abdomen), perhaps in the muscles. The hyper- and hypothermic responses share the same mechanism, which utilizes the acido-antithermogenic and acido-antivasoconstrictor reflexes. When the tonic activation of truncal TRPV1 channels is blocked (by hyperthermic antagonists) or potentiated (by hypothermic antagonists), the autonomic cold defenses (thermogenesis and cutaneous vasoconstriction) become either disinhibited or further inhibited, respectively, and either hyper- or hypothermia occurs. This mechanism may play a vital role during strenuous exercise by attenuating the inhibitory effect of $T_b$ on physical performance.

4. If one were to design an "ideal" TRPV1 antagonist to treat pain in rats, such a compound would belong to the second generation and be a potent blocker of rTRPV1 activation by CAP and heat (to be an efficacious analgesic) but would not affect rTRPV1 activation by protons (to be free of the adverse effects on $T_b$).

5. Similar to their effects in laboratory rodents, TRPV1 antagonists alter the level of $T_b$ in humans: most cause dose-dependent hyperthermia, whereas some may produce hypothermia. The hyperthermic effect often fades with repeated dosing.

6. The mathematical modeling used in the present work shows that the hyperthermic effect of a TRPV1 antagonist in humans depends on the compound's potency to block channel activation not only by protons, but also by heat. The connection between the hyperthermic response to TRPV1 antagonists and the heat mode of TRPV1 activation is present only in humans, not in rats. Similar to the hyperthermia in rats, the thermoregulatory response to a TRPV1 antagonist in humans does not depend on the compound's potency to block TRPV1 activation by CAP.

7. Based on the model analysis, we speculate that the role of TRPV1 in thermoregulation differs drastically between rats and humans. Whereas in rats TRPV1 channels modulate $T_b$ via, most likely, pH signals from the trunk but are not used as thermosensors by the thermoregulation system, TRPV1 channels in humans may play both roles. The location of TRPV1 channels that sense $T_b$s (whether shell or core) to drive thermoeffector responses in humans is unknown and can be different from the location of the channels that are tonically activated by protons. Knowing that the skin plays a prominent thermosensory role in all species, at least some TRPV1 channels that mediate thermal signals to drive thermoeffectors in humans can be speculated to be located in the skin.

8. An "ideal" TRPV1 antagonist to treat pain in humans would belong to the second generation and be a potent blocker of hTRPV1 activation by CAP (to be an efficacious analgesic) but would not affect hTRPV1 activation by protons or heat (to be free of the adverse effects on $T_b$). The main concern about such an antagonist would be potentially a reduction in the level of efficacy. Such a drug would be most suited for treating pain caused exclusively through the CAP mode of TRPV1 activation – without any involvement of the heat and proton activation modes of activation; it is unclear whether such pain exists under natural conditions.

9. Our meta-analysis of the human-trial data has confirmed that the first-generation TRPV1 antagonists cause hyperthermia in humans, whereas the second-generation compounds may lack this effect.

10. The strategies of harnessing the thermoregulatory effects of TRPV1 antagonists in humans include: (i) creating inherently thermally neutral compounds based on mode-selective TRPV1 pharmacology, either by rational design or by more traditional approaches; (ii) creating potentially hyperthermic TRPV1 antagonists but with such profiles that would allow balancing the therapeutic effect with the adverse hyperthermic effect by using therapeutic doses that are subthreshold for the hyperthermia; (iii) taking advantage of the tachyphylaxis phenomenon (fading of the hyperthermic effect with repeated dosing) – in those cases when the desired therapeutic effect does not fade; (iv) combining a hyperthermic TRPV1 antagonist with an antihyperthermic drug (*e.g.*, a sympatholytic); and (v) turning the adverse hyperthermia into a desired effect, *e.g.*, by using TRPV1 antagonists to prevent anesthesia-associated hypothermia.

## Declaration of Competing Interest

## Acknowledgements

## Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.pharmthera.2020.107474.

## References

Alawi, K., & Keeble, J. (2010). The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. *Pharmacology & Therapeutics 125*, 181–195.

Alawi, K. M., Aubdool, A. A., Liang, L., Wilde, E., Vepa, A., Psefteli, M. P., et al. (2015). The sympathetic nervous system is controlled by transient receptor potential vanilloid 1 in the regulation of body temperature. *The FASEB Journal 29*, 4285–4298.

Almeida, M. C., Hew-Butler, T., Soriano, R. N., Rao, S., Wang, W., Wang, J., et al. (2012). Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature. *The Journal of Neuroscience 32*, 2086–2099.

Andreev, Y. A., Kozlov, S. A., Korolkova, Y. V., Dyachenko, I. A., Bondarenko, D. A., Skobtsov, D. I., et al. (2013). Polypeptide modulators of TRPV1 produce analgesia without hyperthermia. *Marine Drugs 11*, 5100–5115.

Arendt-Nielsen, L., Harris, S., Whiteside, G. T., Hummel, M., Knappenberger, T., O'Keefe, S., et al. (2016). A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile. *Pain 157*, 2057–2067.

Arsenault, P., Chiche, D., Brown, W., Miller, J., Treister, R., Leff, R., et al. (2018). NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain. *Pain Reports 3*, e696.

Bangsbo, J., Madsen, K., Kiens, B., & Richter, E. A. (1996). Effect of muscle acidity on muscle metabolism and fatigue during intense exercise in man. *The Journal of Physiology 495*, 587–596.

Bareille, P., Murdoch, R. D., Denyer, J., Bentley, J., Smart, K., Yarnall, K., et al. (2013). The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. *International Journal of Clinical Pharmacology and Therapeutics 51*, 576–584.

Belvisi, M. G., Birrell, M. A., Wortley, M. A., Maher, S. A., Satia, I., Badri, H., et al. (2017). XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. *American Journal of Respiratory and Critical Care Medicine 196*, 1255–1263.

Benitez-Del-Castillo, J. M., Moreno-Montanes, J., Jimenez-Alfaro, I., Munoz-Negrete, F. J., Turman, K., Palumaa, K., et al. (2016). Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. *Investigative Ophthalmology & Visual Science 57*, 6447–6454.

Blumberg, P. M., Pearce, L. V., & Lee, J. (2011). TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation. *Current Topics in Medicinal Chemistry 11*, 2151–2158.

Bohlen, C. J., Priel, A., Zhou, S., King, D., Siemens, J., & Julius, D. (2010). A bivalent tarantula toxin activates the capsaicin receptor, TRPV1, by targeting the outer pore domain. *Cell 141*, 834–845.

Boschmann, M., Steiniger, J., Franke, G., Birkenfeld, A. L., Luft, F. C., & Jordan, J. (2007). Water drinking induces thermogenesis through osmosensitive mechanisms. *The Journal of Clinical Endocrinology and Metabolism 92*, 3334–3337.

Boukalova, S., Teisinger, J., & Vlachova, V. (2013). Protons stabilize the closed conformation of gain-of-function mutants of the TRPV1 channel. *Biochimica et Biophysica Acta 1833*, 520–528.

Brito, R., Sheth, S., Mukherjea, D., Rybak, L. P., & Ramkumar, V. (2014). TRPV1: A potential drug target for treating various diseases. *Cells 3*, 517–545.

Brown, W., Leff, R. L., Griffin, A., Hossack, S., Aubray, R., Walker, P., et al. (2017). Safety, pharmacokinetics, and pharmacodynamics study in healthy subjects of oral NEO6860, a modality selective transient receptor potential vanilloid subtype 1 antagonist. *The Journal of Pain 18*, 726–738.

Calixto, J. B., Kassuya, C. A., Andre, E., & Ferreira, J. (2005). Contribution of natural products to the discovery of the transient receptor potential (TRP) channels family and their functions. *Pharmacology & Therapeutics 106*, 179–208.

Cao, E., Cordero-Morales, J. F., Liu, B., Qin, F., & Julius, D. (2013). TRPV1 channels are intrinsically heat sensitive and negatively regulated by phosphoinositide lipids. *Neuron 77*, 667–679.

Cao, E., Liao, M., Cheng, Y., & Julius, D. (2013). TRPV1 structures in distinct conformations reveal activation mechanisms. *Nature 504*, 113–118.

Caterina, M. J., Leffler, A., Malmberg, A. B., Martin, W. J., Trafton, J., Petersen-Zeitz, K. R., et al. (2000). Impaired nociception and pain sensation in mice lacking the capsaicin receptor. *Science 288*, 306–313.

Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature 389*, 816–824.

Cheung, S. S., & Sleivert, G. G. (2004). Multiple triggers for hyperthermic fatigue and exhaustion. *Exercise and Sport Sciences Reviews 32*, 100–106.

Chizh, B. A., O'Donnell, M. B., Napolitano, A., Wang, J., Brooke, A. C., Aylott, M. C., et al. (2007). The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. *Pain 132*, 132–141.

Cho, S. J., Vaca, M. A., Miranda, C. J., & N'Gouemo, P. (2018). Inhibition of transient potential receptor vanilloid type 1 suppresses seizure susceptibility in the genetically epilepsy-prone rat. *CNS Neuroscience & Therapeutics 24*, 18–28.

Chung, M. K., & Campbell, J. N. (2016). Use of capsaicin to treat pain: mechanistic and therapeutic considerations. *Pharmaceuticals (Basel) 9*, 66.

Cortright, D. N., Crandall, M., Sanchez, J. F., Zou, T., Krause, J. E., & White, G. (2001). The tissue distribution and functional characterization of human VR1. *Biochemical and Biophysical Research Communications 281*, 1183–1189.

Craft, R. M., & Porreca, F. (1992). Treatment parameters of desensitization to capsaicin. *Life Sciences 51*, 1767–1775.

Cui, Y., Yang, F., Cao, X., Yarov-Yarovoy, V., Wang, K., & Zheng, J. (2012). Selective disruption of high sensitivity heat activation but not capsaicin activation of TRPV1 channels by pore turret mutations. *The Journal of General Physiology 139*, 273–283.

Diogenes, A., Patwardhan, A. M., Jeske, N. A., Ruparel, N. B., Goffin, V., Akopian, A. N., et al. (2006). Prolactin modulates TRPV1 in female rat trigeminal sensory neurons. *The Journal of Neuroscience 26*, 8126–8136.

Dogan, M. D., Patel, S., Rudaya, A. Y., Steiner, A. A., Szekely, M., & Romanovsky, A. A. (2004). Lipopolysaccharide fever is initiated via a capsaicin-sensitive mechanism

independent of the subtype-1 vanilloid receptor. *British Journal of Pharmacology 143*, 1023–1032.

Eberhardt, M. J., Schillers, F., Eberhardt, E. M., Risser, L., de la Roche, J., Herzog, C., et al. (2017). Reactive metabolites of acetaminophen activate and sensitize the capsaicin receptor TRPV1. *Scientific Reports 7*, 12775.

Engstrom Ruud, L., Wilhelms, D. B., Eskilsson, A., Vasilache, A. M., Elander, L., Engblom, D., et al. (2013). Acetaminophen reduces lipopolysaccharide-induced fever by inhibiting cyclooxygenase-2. *Neuropharmacology 71*, 124–129.

Evans, S. (2011). A safety, tolerability, PK and PD study of PHE377 in healthy males. https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-safety-tolerability-pk-and-pd-study-of-phe377-in-healthy-males/ (Accessed October 26, 2019).

Feketa, V. V., & Marrelli, S. P. (2015). Induction of therapeutic hypothermia by pharmacological modulation of temperature-sensitive TRP channels: Theoretical framework and practical considerations. *Temperature (Austin) 2*, 244–257.

Gao, Y., Cao, E., Julius, D., & Cheng, Y. (2016). TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. *Nature 534*, 347–351.

Garami, A., Ibrahim, M., Gilbraith, K., Khanna, R., Pakai, E., Miko, A., et al. (2017). Transient receptor potential vanilloid 1 antagonists prevent anesthesia-induced hypothermia and decrease postincisional opioid dose requirements in rodents. *Anesthesiology 127*, 813–823.

Garami, A., Pakai, E., McDonald, H. A., Reilly, R. M., Gomtsyan, A., Corrigan, J. J., et al. (2018). TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development. *Acta Physiologica (Oxford) 223*, e13038.

Garami, A., Pakai, E., Oliveira, D. L., Steiner, A. A., Wanner, S. P., Almeida, M. C., et al. (2011). Thermoregulatory phenotype of the Trpv1 knockout mouse: Thermoeffector dysbalance with hyperkinesis. *The Journal of Neuroscience 31*, 1721–1733.

Garami, A., Shimansky, Y. P., Pakai, E., Oliveira, D. L., Gavva, N. R., & Romanovsky, A. A. (2010). Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. *The Journal of Neuroscience 30*, 1435–1440.

Garami, A., Steiner, A. A., & Romanovsky, A. A. (2018). Fever and hypothermia in systemic inflammation. *Handbook of Clinical Neurology 157*, 565–597.

Garcia-Avila, M., & Islas, L. D. (2019). What is new about mild temperature sensing? A review of recent findings. *Temperature (Austin) 6*, 132–141.

Gavva, N. R., Bannon, A. W., Hovland, D. N., Jr., Lehto, S. G., Klionsky, L., Surapaneni, S., et al. (2007). Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. *The Journal of Pharmacology and Experimental Therapeutics 323*, 128–137.

Gavva, N. R., Bannon, A. W., Surapaneni, S., Hovland, D. N., Jr., Lehto, S. G., Gore, A., et al. (2007). The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. *The Journal of Neuroscience 27*, 3366–3374.

Gavva, N. R., Klionsky, L., Qu, Y., Shi, L., Tamir, R., Edenson, S., et al. (2004). Molecular determinants of vanilloid sensitivity in TRPV1. *The Journal of Biological Chemistry 279*, 20283–20295.

Gavva, N. R., Treanor, J. J., Garami, A., Fang, L., Surapaneni, S., Akrami, A., et al. (2008). Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. *Pain 136*, 202–210.

Gomtsian, A. (2019). Fixed dose analgesic combination with non-opioid mechanism to prevent opioid misuse. https://projectreporter.nih.gov/project_info_details.cfm?aid=9912257&icde=0 (Accessed October 26, 2019).

Gomtsyan, A., McDonald, H. A., Schmidt, R. G., Daanen, J. F., Voight, E. A., Segreti, J. A., et al. (2015). TRPV1 ligands with hyperthermic, hypothermic and no temperature effects in rats. *Temperature (Austin) 2*, 297–301.

Gracheva, E. O., Cordero-Morales, J. F., Gonzalez-Carcacia, J. A., Ingolia, N. T., Manno, C., Aranguren, C. I., et al. (2011). Ganglion-specific splicing of TRPV1 underlies infrared sensation in vampire bats. *Nature 476*, 88–91.

Gram, D. X., Fribo, J., Nagy, I., Gotfredsen, C., Charrua, A., Hansen, J. B., et al. (2019). TRPV1 antagonists as novel anti-diabetic agents: regulation of oral glucose tolerance and insulin secretion through reduction of low-grade inflammation? *Medical Sciences (Basel) 7*, 82.

Gram, D. X., Holst, J. J., & Szallasi, A. (2017). TRPV1: a potential therapeutic target in type 2 diabetes and comorbidities? *Trends in Molecular Medicine 23*, 1002–1013.

Greaves, E., Grieve, K., Horne, A. W., & Saunders, P. T. (2014). Elevated peritoneal expression and estrogen regulation of nociceptive ion channels in endometriosis. *The Journal of Clinical Endocrinology and Metabolism 99*, E1738–E1743.

Gunthorpe, M. J., Hannan, S. L., Smart, D., Jerman, J. C., Arpino, S., Smith, G. D., et al. (2007). Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. *The Journal of Pharmacology and Experimental Therapeutics 321*, 1183–1192.

Hilton, J. K., Kim, M., & Van Horn, W. D. (2019). Structural and evolutionary insights point to allosteric regulation of TRP ion channels. *Accounts of Chemical Research 52*, 1643–1652.

Hilton, J. K., Rath, P., Helsell, C. V., Beckstein, O., & Van Horn, W. D. (2015). Understanding thermosensitive transient receptor potential channels as versatile polymodal cellular sensors. *Biochemistry 54*, 2401–2413.

Holzer, P. (1991). Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. *Pharmacological Reviews 43*, 143–201.

Holzer, P. (2008). The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. *British Journal of Pharmacology 155*, 1145–1162.

Holzer, P. (2009). Acid-sensitive ion channels and receptors. *Handbook of Experimental Pharmacology*, 283–332.

Honore, P., Chandran, P., Hernandez, G., Gauvin, D. M., Mikusa, J. P., Zhong, C., et al. (2009). Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. *Pain 142*, 27–35.

Ivanov, A. I., & Romanovsky, A. A. (2004). Prostaglandin E2 as a mediator of fever: synthesis and catabolism. *Frontiers in Bioscience 9*, 1977–1993.

Jancso, G., & Santha, P. (2015). The foundation of sensory pharmacology: Nicholas (Miklos) Jancso and the Szeged contribution. *Temperature (Austin) 2*, 152–157.

Jang, Y., Lee, Y., Kim, S. M., Yang, Y. D., Jung, J., & Oh, U. (2012). Quantitative analysis of TRP channel genes in mouse organs. *Archives of Pharmacal Research 35*, 1823–1830.

Jara-Oseguera, A., Bae, C., & Swartz, K. J. (2016). An external sodium ion binding site controls allosteric gating in TRPV1 channels. *eLife 5*, e13356.

Jhaveri, M. D., Elmes, S. J., Kendall, D. A., & Chapman, V. (2005). Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naive, carrageenan-inflamed and neuropathic rats. *European Journal of Neuroscience 22*, 361–370.

Johansen, M. E., Reilly, C. A., & Yost, G. S. (2006). TRPV1 antagonists elevate cell surface populations of receptor protein and exacerbate TRPV1-mediated toxicities in human lung epithelial cells. *Toxicological Sciences 89*, 278–286.

Jordt, S. E., & Julius, D. (2002). Molecular basis for species-specific sensitivity to "hot" chili peppers. *Cell 108*, 421–430.

Jordt, S. E., Tominaga, M., & Julius, D. (2000). Acid potentiation of the capsaicin receptor determined by a key extracellular site. *Proceedings of the National Academy of Sciences of the United States of America 97*, 8134–8139.

Kaneko, Y., & Szallasi, A. (2014). Transient receptor potential (TRP) channels: a clinical perspective. *British Journal of Pharmacology 171*, 2474–2507.

Khalid, S., Murdoch, R., Newlands, A., Smart, K., Kelsall, A., Holt, K., et al. (2014). Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. *The Journal of Allergy and Clinical Immunology 134*, 56–62.

Kim, K. M., Kawada, T., Ishihara, K., Inoue, K., & Fushiki, T. (1997). Increase in swimming endurance capacity of mice by capsaicin-induced adrenal catecholamine secretion. *Bioscience, Biotechnology, and Biochemistry 61*, 1718–1723.

Kim, M., Sisco, N. J., Hilton, J. K., Montano, C. M., Castro, M. A., Cherry, B. R., et al. (2019). Evidence that the TRPV1 S1-S4 membrane domain contributes to thermosensing. *bioRxiv*, 711499.

Krarup, A. L., Ny, L., Astrand, M., Bajor, A., Hvid-Jensen, F., Hansen, M. B., et al. (2011). Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. *Alimentary Pharmacology & Therapeutics 33*, 1113–1122.

Krarup, A. L., Ny, L., Gunnarsson, J., Hvid-Jensen, F., Zetterstrand, S., Simren, M., et al. (2013). Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. *Scandinavian Journal of Gastroenterology 48*, 274–284.

Kyle, D. J., & Tafesse, L. (2006). TRPV1 antagonists: a survey of the patent literature. *Expert Opinion on Therapeutic Patents 16*, 977–996.

Laird, A. S., Carrive, P., & Waite, P. M. (2006). Cardiovascular and temperature changes in spinal cord injured rats at rest and during autonomic dysreflexia. *The Journal of Physiology 577*, 539–548.

Laursen, W. J., Schneider, E. R., Merriman, D. K., Bagriantsev, S. N., & Gracheva, E. O. (2016). Low-cost functional plasticity of TRPV1 supports heat tolerance in squirrels and camels. *Proceedings of the National Academy of Sciences of the United States of America 113*, 11342–11347.

Lee, J., Kim, B. H., Yu, K. S., Kim, H. S., Kim, J. D., Cho, J. Y., et al. (2017). A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers. *Drug Design, Development and Therapy 11*, 1301–1313.

Lee, Y., Hong, S., Cui, M., Sharma, P. K., Lee, J., & Choi, S. (2015). Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014). *Expert Opinion on Therapeutic Patents 25*, 291–318.

Leffler, A., Monter, B., & Koltzenburg, M. (2006). The role of the capsaicin receptor TRPV1 and acid-sensing ion channels (ASICS) in proton sensitivity of subpopulations of primary nociceptive neurons in rats and mice. *Neuroscience 139*, 699–709.

Lehto, S. G., Tamir, R., Deng, H., Klionsky, L., Kuang, R., Le, A., et al. (2008). Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluorom ethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. *The Journal of Pharmacology and Experimental Therapeutics 326*, 218–229.

Liao, M., Cao, E., Julius, D., & Cheng, Y. (2013). Structure of the TRPV1 ion channel determined by electron cryo-microscopy. *Nature 504*, 107–112.

Luo, Z., Ma, L., Zhao, Z., He, H., Yang, D., Feng, X., et al. (2012). TRPV1 activation improves exercise endurance and energy metabolism through PGC-1alpha upregulation in mice. *Cell Research 22*, 551–564.

Malek, S., Sample, S. J., Schwartz, Z., Nemke, B., Jacobson, P. B., Cozzi, E. M., et al. (2012). Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis. *BMC Veterinary Research 8*, 185.

Manitpisitkul, P., Brandt, M., Flores, C. M., Kenigs, V., Moyer, J. A., Romano, G., et al. (2016). TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study. *Pain Reports 1*, e576.

Manitpisitkul, P., Flores, C. M., Moyer, J. A., Romano, G., Shalayda, K., Tatikola, K., et al. (2018). A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep). *Scandinavian Journal of Pain 18*, 151–164.

Manitpisitkul, P., Mayorga, A., Shalayda, K., De Meulder, M., Romano, G., Jun, C., et al. (2015). Safety, tolerability and pharmacokinetic and pharmacodynamic learnings from a double-blind, randomized, placebo-controlled, sequential group

first-in-human study of the TRPV1 antagonist, JNJ-38893777, in healthy men. *Clinical Drug Investigation 35*, 353–363.

Manitpisitkul, P., Shalayda, K., Russell, L., Sanga, P., Solanki, B., Caruso, J., et al. (2018). Pharmacokinetics and safety of mavatrep (JNJ-39439335), a TRPV1 antagonist in healthy Japanese and Caucasian men: a double-blind, randomized, placebo-controlled, sequential-group phase 1 study. *Clinical Pharmacology in Drug Development 7*, 712–726.

Manitpisitkul, P., Shalayda, K., Russell, L., Sanga, P., Williams, Y., Solanki, B., et al. (2018). Bioavailability and pharmacokinetics of TRPV1 antagonist mavatrep (JNJ-39439335) tablet and capsule formulations in healthy men: two open-label, crossover, single-dose phase 1 studies. *Clinical Pharmacology in Drug Development 7*, 699–711.

Mayorga, A. J., Flores, C. M., Trudeau, J. J., Moyer, J. A., Shalayda, K., Dale, M., et al. (2017). A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis. *Scandinavian Journal of Pain 17*, 134–143.

McGaraughty, S., Chu, K. L., Faltynek, C. R., & Jarvis, M. F. (2006). Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats. *Journal of Neurophysiology 95*, 18–25.

McGaraughty, S., Segreti, J. A., Fryer, R. M., Brown, B. S., Faltynek, C. R., & Kym, P. R. (2009). Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats. *Brain Research 1268*, 58–67.

McIntyre, P., McLatchie, L. M., Chambers, A., Phillips, E., Clarke, M., Savidge, J., et al. (2001). Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). *British Journal of Pharmacology 132*, 1084–1094.

Miller, F., Bjornsson, M., Svensson, O., & Karlsten, R. (2014). Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis. *Contemporary Clinical Trials 37*, 189–199.

Mills, C., McMackin, M., Jaffe, R., Yu, J., Zininberg, E., Slee, D., et al. (2008). Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat. *Neuroscience 156*, 165–174.

Mirrasekhian, E., Nilsson, J. L. A., Shionoya, K., Blomgren, A., Zygmunt, P. M., Engblom, D., et al. (2018). The antipyretic effect of paracetamol occurs independent of transient receptor potential ankyrin 1-mediated hypothermia and is associated with prostaglandin inhibition in the brain. *The FASEB Journal 32*, 5751–5759.

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G.The PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine 6*, e1000097.

Molliver, D. C., Immke, D. C., Fierro, L., Pare, M., Rice, F. L., & McCleskey, E. W. (2005). ASIC3, an acid-sensing ion channel, is expressed in metaboreceptive sensory neurons. *Molecular Pain 1*, 35.

Moparthi, L., Survery, S., Kreir, M., Simonsen, C., Kjellbom, P., Hogestatt, E. D., et al. (2014). Human TRPA1 is intrinsically cold- and chemosensitive with and without its N-terminal ankyrin repeat domain. *Proceedings of the National Academy of Sciences of the United States of America 111*, 16901–16906.

Moran, M. M., & Szallasi, A. (2018). Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. *British Journal of Pharmacology 175*, 2185–2203.

Morrison, S. F. (2011). 2010 Carl Ludwig distinguished lectureship of the APS neural control and autonomic regulation section: central neural pathways for thermoregulatory cold defense. *Journal of Applied Physiology 110*, 1137–1149 1985.

Myers, C. (2008). Further clinical trials in osteoarthritis pain suspended for GRC 6211. https://www.fiercebiotech.com/biotech/further-clinical-trials-osteoarthritis-pain-suspended-for-grc-6211 (Accessed October 26, 2019).

Nagy, I., & Rang, H. (2000). Comparison of currents activated by noxious heat in rat and chicken primary sensory neurons. *Regulatory Peptides 96*, 3–6.

NCT01688934 ClinicalTrials.gov (2012). A phase 2, randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter study evaluating the analgesic efficacy and safety of V116517 in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. https://clinicaltrials.gov/ct2/show/NCT01688934 (Accessed October 26, 2019).

NCT01688947 ClinicalTrials.gov (2012). A phase 2, randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter study evaluating the analgesic efficacy and safety of V116517 in subjects with moderate to severe chronic pain due to postherpetic neuralgia (PHN). https://clinicaltrials.gov/ct2/show/record/NCT01688947 (Accessed October 26, 2019).

Nilius, B., & Appendino, G. (2013). Spices: the savory and beneficial science of pungency. *Reviews of Physiology, Biochemistry and Pharmacology 164*, 1–76.

Nilius, B., & Szallasi, A. (2014). Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. *Pharmacological Reviews 66*, 676–814.

Numazaki, M., Tominaga, T., Takeuchi, K., Murayama, N., Toyooka, H., & Tominaga, M. (2003). Structural determinant of TRPV1 desensitization interacts with calmodulin. *Proceedings of the National Academy of Sciences of the United States of America 100*, 8002–8006.

Nybo, L., Rasmussen, P., & Sawka, M. N. (2014). Performance in the heat-physiological factors of importance for hyperthermia-induced fatigue. *Comprehensive Physiology 4*, 657–689.

Oh, T. W., Oh, T. W., & Ohta, F. (2003). Dose-dependent effect of capsaicin on endurance capacity in rats. *British Journal of Nutrition 90*, 515–520.

Ohashi, N., Uta, D., Sasaki, M., Ohashi, M., Kamiya, Y., & Kohno, T. (2017). Acetaminophen metabolite N-acylphenolamine induces analgesia via transient receptor potential vanilloid 1 receptors expressed on the primary afferent terminals of C-fibers in the spinal dorsal horn. *Anesthesiology 127*, 355–371.

Oka, H., Yonezawa, K., Kamikawa, A., Ikegai, K., Asai, N., Shirakami, S., et al. (2018). Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists. *Bioorganic & Medicinal Chemistry 26*, 3716–3726.

de Oliveira, C., Garami, A., Lehto, S. G., Pakai, E., Tekus, V., Pohoczky, K., et al. (2014). Transient receptor potential channel ankyrin-1 is not a cold sensor for autonomic thermoregulation in rodents. *The Journal of Neuroscience 34*, 4445–4452.

Ortiz-Renteria, M., Juarez-Contreras, R., Gonzalez-Ramirez, R., Islas, L. D., Sierra-Ramirez, F., Llorente, I., et al. (2018). TRPV1 channels and the progesterone receptor Sig-1R interact to regulate pain. *Proceedings of the National Academy of Sciences of the United States of America 115*, E1657–E1666.

Osaka, T., Kobayashi, A., & Inoue, S. (2002). Vago-sympathoadrenal reflex in thermogenesis induced by osmotic stimulation of the intestines in the rat. *The Journal of Physiology 540*, 665–671.

Othman, A. A., Nothaft, W., Awni, W. M., & Dutta, S. (2013). Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials. *British Journal of Clinical Pharmacology 75*, 1029–1040.

Partridge, L. D. (1982). The good enough calculi of evolving control systems: evolution is not engineering. *American Journal of Physiology 242*, R173–R177.

Patwardhan, A., Porreca, F., & Romanovsky, A. A. (2017). Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia (Publ. No. WO2017112693A1). https://patents.google.com/patent/WO2017112693A1/e.

Payrits, M., Saghy, E., Cseko, K., Pohoczky, K., Bolcskei, K., Ernszt, D., et al. (2017). Estradiol sensitizes the transient receptor potential vanilloid 1 receptor in pain responses. *Endocrinology 158*, 3249–3258.

Petervari, E., Garami, A., Pakai, E., & Szekely, M. (2005). Effects of perineural capsaicin treatment of the abdominal vagus on endotoxin fever and on a non-febrile thermoregulatory event. *Journal of Endotoxin Research 11*, 260–266.

Phillips, E., Reeve, A., Bevan, S., & McIntyre, P. (2004). Identification of species-specific determinants of the action of the antagonist capsazepine and the agonist PPAHV on TRPV1. *The Journal of Biological Chemistry 279*, 17165–17172.

Quiding, H., Jonzon, B., Svensson, O., Webster, L., Reimfelt, A., Karin, A., et al. (2013). TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction. *Pain 154*, 808–812.

Rawls, S. M., & Benamar, K. (2011). Effects of opioids, cannabinoids, and vanilloids on body temperature. *Frontiers in Bioscience 3*, 822–845.

Reilly, R. M., McDonald, H. A., Puttfarcken, P. S., Joshi, S. K., Lewis, L., Pai, M., et al. (2012). Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature. *The Journal of Pharmacology and Experimental Therapeutics 342*, 416–428.

Robergs, R. A., Ghiasvand, F., & Parker, D. (2004). Biochemistry of exercise-induced metabolic acidosis. *American Journal of Physiology – Regulatory, Integrative and Comparative Physiology 287*, R502–R516.

de la Roche, J., Walther, I., Leonow, W., Hage, A., Eberhardt, M., Fischer, M., et al. (2016). Lactate is a potent inhibitor of the capsaicin receptor TRPV1. *Scientific Reports 6*, 36740.

Romanovsky, A. A. (2014). Skin temperature: its role in thermoregulation. *Acta Physiologica (Oxford) 210*, 498–507.

Romanovsky, A. A. (2015). Protecting western redcedar from deer browsing-with a passing reference to TRP channels. *Temperature (Austin) 2*, 142–149.

Romanovsky, A. A. (2018). The thermoregulation system and how it works. *Handbook of Clinical Neurology 156*, 3–43.

Romanovsky, A. A. (2019). Novel treatment for hot flushes (Publ. No. WO2017112693A1). https://patents.google.com/patent/WO2019010293A1/en.

Romanovsky, A. A., Almeida, M. C., Garami, A., Steiner, A. A., Norman, M. H., Morrison, S. F., et al. (2009). The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. *Pharmacological Reviews 61*, 228–261.

Rosenbaum, T., Gordon-Shaag, A., Munari, M., & Gordon, S. E. (2004). Ca2+/calmodulin modulates TRPV1 activation by capsaicin. *The Journal of General Physiology 123*, 53–62.

Round, P., Priestley, A., & Robinson, J. (2011). An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. *British Journal of Clinical Pharmacology 72*, 921–931.

Rowbotham, M. C., Nothaft, W., Duan, W. R., Wang, Y., Faltynek, C., McGaraughty, S., et al. (2011). Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. *Pain 152*, 1192–1200.

Ruetzler, K., & Kurz, A. (2018). Consequences of perioperative hypothermia. *Handbook of Clinical Neurology 157*, 687–697.

Ryu, S., Liu, B., Yao, J., Fu, Q., & Qin, F. (2007). Uncoupling proton activation of vanilloid receptor TRPV1. *The Journal of Neuroscience 27*, 12797–12807.

Saito, S., & Tominaga, M. (2017). Evolutionary tuning of TRPA1 and TRPV1 thermal and chemical sensitivity in vertebrates. *Temperature (Austin) 4*, 141–152.

Sakaguchi, T., & Yamazaki, M. (1988). Hepatic portal injection of glucose elevates efferent sympathetic discharges of interscapular brown adipose tissue. *Experimental Neurology 101*, 464–466.

Sanchez, J. F., Krause, J. E., & Cortright, D. N. (2001). The distribution and regulation of vanilloid receptor VR1 and VR1 5' splice variant RNA expression in rat. *Neuroscience 107*, 373–381.

Sanchez-Moreno, A., Guevara-Hernandez, E., Contreras-Cervera, R., Rangel-Yescas, G., Ladron-de-Guevara, E., Rosenbaum, T., et al. (2018). Irreversible temperature gating in trpv1 sheds light on channel activation. *eLife 7*, e36372.

Schaffler, K., Reeh, P., Duan, W. R., Best, A. E., Othman, A. A., Faltynek, C. R., et al. (2013). An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin. *British Journal of Clinical Pharmacology 75*, 404–414.

Schlader, Z. J., Simmons, S. E., Stannard, S. R., & Mundel, T. (2011). Skin temperature as a thermal controller of exercise intensity. *European Journal of Applied Physiology 111*, 1631–1639.

Schmidt, W. K. (2017). Turning up the heat on surgical cold. *Temperature (Austin) 4*, 97–100.

Seebacher, F., Brand, M. D., Else, P. L., Guderley, H., Hulbert, A. J., & Moyes, C. D. (2010). Plasticity of oxidative metabolism in variable climates: molecular mechanisms. *Physiological and Biochemical Zoology 83*, 721–732.

Shimizu, I., Iida, T., Horiuchi, N., & Caterina, M. J. (2005). 5-Iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. *The Journal of Pharmacology and Experimental Therapeutics 314*, 1378–1385.

Singh, A. K., McGoldrick, L. L., & Sobolevsky, A. I. (2018). Structure and gating mechanism of the transient receptor potential channel TRPV3. *Nature Structural & Molecular Biology 25*, 805–813.

Smith, J. A., Birrell, M. A., Wortley, M. A., Maher, S. A., Dockry, R., Turner, P., et al. (2017). TRPV1 antagonism with XEN-D0501 in chronic obstructive pulmonary disease: Translation from pre-clinical model to clinical trial. *American Journal of Respiratory and Critical Care Medicine 195*, A6339.

Sosa-Pagan, J. O., Iversen, E. S., & Grandl, J. (2017). TRPV1 temperature activation is specifically sensitive to strong decreases in amino acid hydrophobicity. *Scientific Reports 7*, 549.

Steiner, A. A., Turek, V. F., Almeida, M. C., Burmeister, J. J., Oliveira, D. L., Roberts, J. L., et al. (2007). Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. *The Journal of Neuroscience 27*, 7459–7468.

Stowe, D. F., & Ebert, T. J. (2013). Sympathomimetic and sympatholytic drugs. In A. S. Evers, E. D. Kharasch, & M. Maze (Eds.), *Anesthetic Pharmacology: Basic Principles and Clinical Practice* (pp. 648–665) (2 ed.). Cambridge: Cambridge University Press.

Stueber, T., Meyer, S., Jangra, A., Hage, A., Eberhardt, M., & Leffler, A. (2018). Activation of the capsaicin-receptor TRPV1 by the acetaminophen metabolite N-arachidonoylaminophenol results in cytotoxicity. *Life Sciences 194*, 67–74.

Swanson, D. M., Dubin, A. E., Shah, C., Nasser, N., Chang, L., Dax, S. L., et al. (2005). Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. *Journal of Medicinal Chemistry 48*, 1857–1872.

Szallasi, A., & Blumberg, P. M. (1989). Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. *Neuroscience 30*, 515–520.

Szallasi, A., & Blumberg, P. M. (1999). Vanilloid (capsaicin) receptors and mechanisms. *Pharmacological Reviews 51*, 159–212.

Szolcsanyi, J. (2015). Effect of capsaicin on thermoregulation: an update with new aspects. *Temperature (Austin) 2*, 277–296.

Tafesse, L., Kanemasa, T., Kurose, N., Yu, J., Asaki, T., Wu, G., et al. (2014). Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain management. *Journal of Medicinal Chemistry 57*, 6781–6794.

Taylor, C. R., & Lyman, C. P. (1972). Heat storage in running antelopes: Independence of brain and body temperatures. *American Journal of Physiology 222*, 114–117.

Vandewauw, I., De Clercq, K., Mulier, M., Held, K., Pinto, S., Van Ranst, N., et al. (2018). A TRP channel trio mediates acute noxious heat sensing. *Nature 555*, 662–666.

Voets, T. (2014). TRP channels and thermosensation. *Handbook of Experimental Pharmacology 223*, 729–741.

Voets, T., Droogmans, G., Wissenbach, U., Janssens, A., Flockerzi, V., & Nilius, B. (2004). The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. *Nature 430*, 748–754.

Voight, E. A., Gomtsyan, A. R., Daanen, J. F., Perner, R. J., Schmidt, R. G., Bayburt, E. K., et al. (2014). Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy. *Journal of Medicinal Chemistry 57*, 7412–7424.

Vriens, J., Nilius, B., & Voets, T. (2014). Peripheral thermosensation in mammals. *Nature Reviews Neuroscience 15*, 573–589.

Wanner, S. P., Garami, A., Pakai, E., Oliveira, D. L., Gavva, N. R., Coimbra, C. C., et al. (2012). Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory. *Cell Cycle 11*, 343–349.

Watabiki, T., Kiso, T., Kuramochi, T., Yonezawa, K., Tsuji, N., Kohara, A., et al. (2011). Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect. *The Journal of Pharmacology and Experimental Therapeutics 336*, 743–750.

Watabiki, T., Kiso, T., Tsukamoto, M., Aoki, T., & Matsuoka, N. (2011). Intrathecal administration of AS1928370, a transient receptor potential vanilloid 1 antagonist, attenuates mechanical allodynia in a mouse model of neuropathic pain. *Biological and Pharmaceutical Bulletin 34*, 1105–1108.

Wong, G. Y., & Gavva, N. R. (2009). Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. *Brain Research Reviews 60*, 267–277.

Wu, Y. W., Bi, Y. P., Kou, X. X., Xu, W., Ma, L. Q., Wang, K. W., et al. (2010). 17-Beta-estradiol enhanced allodynia of inflammatory temporomandibular joint through upregulation of hippocampal TRPV1 in ovariectomized rats. *The Journal of Neuroscience 30*, 8710–8719.

Yang, F., Vu, S., Yarov-Yarovoy, V., & Zheng, J. (2016). Rational design and validation of a vanilloid-sensitive TRPV2 ion channel. *Proceedings of the National Academy of Sciences of the United States of America 113*, E3657–E3666.

Yang, F., Xiao, X., Cheng, W., Yang, W., Yu, P., Song, Z., et al. (2015). Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. *Nature Chemical Biology 11*, 518–524.

Yang, F., Xiao, X., Lee, B. H., Vu, S., Yang, W., Yarov-Yarovoy, V., et al. (2018). The conformational wave in capsaicin activation of transient receptor potential vanilloid 1 ion channel. *Nature Communications 9*, 2879.

Yang, F., & Zheng, J. (2017). Understand spiciness: mechanism of TRPV1 channel activation by capsaicin. *Protein & Cell 8*, 169–177.

Yoshiyama, M., Araki, I., Kobayashi, H., Zakoji, H., & Takeda, M. (2010). Functional roles of TRPV1 channels in lower urinary tract irritated by acetic acid: in vivo evaluations of the sex difference in decerebrate unanesthetized mice. *American Journal of Physiology – Renal Physiology 298*, F1351–F1359.

Zhang, F., Hanson, S. M., Jara-Oseguera, A., Krepkiy, D., Bae, C., Pearce, L. V., et al. (2016). Engineering vanilloid-sensitivity into the rat TRPV2 channel. *eLife 5*, e16409.

Zhang, F., Jara-Oseguera, A., Chang, T. H., Bae, C., Hanson, S. M., & Swartz, K. J. (2018). Heat activation is intrinsic to the pore domain of TRPV1. *Proceedings of the National Academy of Sciences of the United States of America 115*, E317–E324.

Zheng, W., & Wen, H. (2019). Heat activation mechanism of TRPV1: new insights from molecular dynamics simulation. *Temperature (Austin) 6*, 120–131.

## Additional References for Table 2

Appendino, G., Harrison, S., De Petrocellis, L., Daddario, N., Bianchi, F., Schiano Moriello, A., et al. (2003). Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. *British Journal of Pharmacology 139*, 1417–1424.

Barrett, K. T., Roy, A., Rivard, K. B., Wilson, R. J. A., & Scantlebury, M. H. (2018). Vagal TRPV1 activation exacerbates thermal hyperpnea and increases susceptibility to experimental febrile seizures in immature rats. *Neurobiology of Disease 119*, 172–189.

Bevan, S., Hothi, S., Hughes, G., James, I. F., Rang, H. P., Shah, K., et al. (1992). Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. *British Journal of Pharmacology 107*, 544–552.

Correll, C. C., Phelps, P. T., Anthes, J. C., Umland, S., & Greenfeder, S. (2004). Cloning and pharmacological characterization of mouse TRPV1. *Neuroscience Letters 370*, 55–60.

Dickenson, A. H., & Dray, A. (1991). Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception. *British Journal of Pharmacology 104*, 1045–1049.

El Kouhen, R., Surowy, C. S., Bianchi, B. R., Neelands, T. R., McDonald, H. A., Niforatos, W., et al. (2005). A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. *The Journal of Pharmacology and Experimental Therapeutics 314*, 400–409.

Gavva, N. R., Tamir, R., Qu, Y., Klionsky, L., Zhang, T. J., Immke, D., et al. (2005). AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. *The Journal of Pharmacology and Experimental Therapeutics 313*, 474–484.

Jakab, B., Helyes, Z., Varga, A., Bolcskei, K., Szabo, A., Sandor, K., et al. (2005). Pharmacological characterization of the TRPV1 receptor antagonist JYL1421 (SC0030) in vitro and in vivo in the rat. *European Journal of Pharmacology 517*, 35–44.

Johnson, D. M., Garrett, E. M., Rutter, R., Bonnert, T. P., Gao, Y. D., Middleton, R. E., et al. (2006). Functional mapping of the transient receptor potential vanilloid 1 intracellular binding site. *Molecular Pharmacology 70*, 1005–1012.

Kanai, Y., Hara, T., & Imai, A. (2006). Participation of the spinal TRPV1 receptors in formalin-evoked pain transduction: a study using a selective TRPV1 antagonist, iodo-resiniferatoxin. *The Journal of Pharmacy and Pharmacology 58*, 489–493.

Kanai, Y., Nakazato, E., Fujiuchi, A., Hara, T., & Imai, A. (2005). Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. *Neuropharmacology 49*, 977–984.

Kelly, S., Chapman, R. J., Woodhams, S., Sagar, D. R., Turner, J., Burston, J. J., et al. (2015). Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain. *Annals of the Rheumatic Diseases 74*, 252–259.

Kirschstein, T., Greffrath, W., Busselberg, D., & Treede, R. D. (1999). Inhibition of rapid heat responses in nociceptive primary sensory neurons of rats by vanilloid receptor antagonists. *Journal of Neurophysiology 82*, 2853–2860.

Kitagawa, Y., Miyai, A., Usui, K., Hamada, Y., Deai, K., Wada, M., et al. (2012). Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyrid in-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist. *The Journal of Pharmacology and Experimental Therapeutics 342*, 520–528.

Maher, M. P., Bhattacharya, A., Ao, H., Swanson, N., Wu, N. T., Freedman, J., et al. (2011). Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl-(4-trifluoromethyl-phenyl) -amine (JNJ-39729209) as a novel TRPV1 antagonist. *European Journal of Pharmacology 663*, 40–50.

Maione, S., De Petrocellis, L., de Novellis, V., Moriello, A. S., Petrosino, S., Palazzo, E., et al. (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. *British Journal of Pharmacology 150*, 766–781.

McDonald, H. A., Neelands, T. R., Kort, M., Han, P., Vos, M. H., Faltynek, C. R., et al. (2008). Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia. *European Journal of Pharmacology 596*, 62–69.

Nash, M. S., McIntyre, P., Groarke, A., Lilley, E., Culshaw, A., Hallett, A., et al. (2012). 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4 -one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity. *The Journal of Pharmacology and Experimental Therapeutics 342*, 389–398.

Neelands, T. R., Jarvis, M. F., Han, P., Faltynek, C. R., & Surowy, C. S. (2005). Acidification of rat TRPV1 alters the kinetics of capsaicin responses. *Molecular Pain 1*, 28.

Norman, M. H., Zhu, J., Fotsch, C., Bo, Y., Chen, N., Chakrabarti, P., et al. (2007). Novel vanilloid receptor-1 antagonists: 1. conformationally restricted analogues of trans-cinnamides. *Journal of Medicinal Chemistry 50*, 3497–3514.

Papakosta, M., Dalle, C., Haythornthwaite, A., Cao, L., Stevens, E. B., Burgess, G., et al. (2011). The chimeric approach reveals that differences in the TRPV1 pore domain determine species-specific sensitivity to block of heat activation. *The Journal of Biological Chemistry 286*, 39663–39672.

Park, H., Park, M., Choi, J., Choi, S., Lee, J., Suh, Y., et al. (2003). Synthesis of 2-substituted-pyrrolidinethiourea derivatives and their antagonist effect on vanilloid receptor. *Bioorganic & Medicinal Chemistry Letters 13*, 197–200.

Parsons, W. H., Calvo, R. R., Cheung, W., Lee, Y. K., Patel, S., Liu, J., et al. (2015). Benzo[d] imidazole transient receptor potential vanilloid 1 antagonists for the treatment of pain: discovery of trans-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol (mavatrep). *Journal of Medicinal Chemistry 58*, 3859–3874.

Patrone, L. G. A., Duarte, J. B., Bicego, K. C., Steiner, A. A., Romanovsky, A. A., & Gargaglioni, L. H. (2019). TRPV1 inhibits the ventilatory response to hypoxia in adult rats, but not the CO(2)-drive to breathe. *Pharmaceuticals (Basel) 12*, 19.

Price, T. J., Patwardhan, A., Akopian, A. N., Hargreaves, K. M., & Flores, C. M. (2004). Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. *British Journal of Pharmacology 141*, 1118–1130.

Rigoni, M., Trevisani, M., Gazzieri, D., Nadaletto, R., Tognetto, M., Creminon, C., et al. (2003). Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin. *British Journal of Pharmacology 138*, 977–985.

Savidge, J., Davis, C., Shah, K., Colley, S., Phillips, E., Ranasinghe, S., et al. (2002). Cloning and functional characterization of the guinea pig vanilloid receptor 1. *Neuropharmacology 43*, 450–456.

Seabrook, G. R., Sutton, K. G., Jarolimek, W., Hollingworth, G. J., Teague, S., Webb, J., et al. (2002). Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxin. *The Journal of Pharmacology and Experimental Therapeutics 303*, 1052–1060.

Steiner, A. A., Molchanova, A. Y., Dogan, M. D., Patel, S., Petervari, E., Balasko, M., et al. (2011). The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. *The Journal of Physiology 589*, 2415–2431.

Suh, Y. G., Lee, Y. S., Min, K. H., Park, O. H., Seung, H. S., Kim, H. D., et al. (2003). Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects. *Bioorganic & Medicinal Chemistry Letters 13*, 4389–4393.

Surowy, C. S., Neelands, T. R., Bianchi, B. R., McGaraughty, S., El Kouhen, R., Han, P., et al. (2008). (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. *The Journal of Pharmacology and Experimental Therapeutics 326*, 879–888.

Tamayo, N., Liao, H., Stec, M. M., Wang, X., Chakrabarti, P., Retz, D., et al. (2008). Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists. *Journal of Medicinal Chemistry 51*, 2744–2757.

Valenzano, K. J., Grant, E. R., Wu, G., Hachicha, M., Schmid, L., Tafesse, L., et al. (2003). N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. *The Journal of Pharmacology and Experimental Therapeutics 306*, 377–386.

Varga, A., Nemeth, J., Szabo, A., McDougall, J. J., Zhang, C., Elekes, K., et al. (2005). Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. *Neuroscience Letters 385*, 137–142.

Wang, H. L., Katon, J., Balan, C., Bannon, A. W., Bernard, C., Doherty, E. M., et al. (2007). Novel vanilloid receptor-1 antagonists: 3. the identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. *Journal of Medicinal Chemistry 50*, 3528–3539.

Wang, X., Chakrabarti, P. P., Ognyanov, V. I., Pettus, L. H., Tamir, R., Tan, H., et al. (2007). Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility. *Bioorganic & Medicinal Chemistry Letters 17*, 6539–6545.

## SUPPLEMENTARY INFORMATION

## Supplementary Methods

## Mathematical model description

The hyperthermic effect $H$ of a transient receptor potential vanilloid-1 (TRPV1) channel antagonist was defined as a body temperature ($T_b$) difference at 3 h *vs.* 0 h post-administration (Table S3). We assumed that the hyperthermic effect occurs due to a blockade of three independent modes of TRPV1 activation: by heat ($M_1$), protons ($M_2$), and capsaicin (CAP) ($M_3$). Thus,

$$H = H(\Delta M_1, \Delta M_2, \Delta M_3),$$

where $\Delta M_i$ is the extent to which a TRPV1 antagonist blocks the $i$-th mode of activation ($i$ is either 1, 2, or 3). For the $j$-th antagonist ($j$ is an integer between 1 and 4), the extent of blockade in each activation mode was considered to be a function of antagonist dose $D$:

$$\Delta M_i = \Delta M_i(D).$$

Hence, the effect $H$ was also a function of a dose:

$$H = H(D) = H(\Delta M_1(D), \Delta M_2(D), \Delta M_3(D)).$$

The $H(D)$ function was tabulated for each antagonist based on the data reported in Table S3. It was required to determine how sensitive $H$ is to the extent of blockade of each mode of TRPV1 activation, *i.e.*, to find the sensitivity coefficients $k_i$. A high value of $k_i$ would indicate that

the potency of an antagonist in the $i$-th activation mode strongly and positively affects the hyperthermic response; a 0 value would indicate the absence of such an effect; a negative value would mean that the potency in the $i$-th mode has a negative effect on $H$. To find $k_i$, we approximated the tabular $H(D)$ data for each antagonist with a sigmoid function commonly used for pharmacological dose-effect relationships (see, *e.g.*, Di Veroli et al., 2015; Meddings, Scott, & Fick, 1989):

$$H(D) = v_0 + \frac{v_1}{e^{-(w_0 + w_1 D)} + 1}.$$

In the above formula, $v_0$, $v_1$, and $w_0$ are constants, and the coefficient $w_1$ is defined as follows:

$$w_1 = \frac{k_1}{d_1} + \frac{k_2}{d_2} + \frac{k_3}{d_3},$$

where $d_i$ is the 50% inhibitory concentration of an antagonist ($IC_{50}$) for the $i$-th mode of TRPV1 activation (Table S3).

Hence, $H(D)$ was a function that contained six unknown parameters: the sensitivities $k_1$, $k_2$, and $k_3$ and the constants $v_0$, $v_1$, and $w_0$, all of which were identified through best-fitting the mathematical model described above to the tabulated data. Each row of that table corresponded to an equation, thus resulting in 15 equations.

To minimize a systematic approximation error in this nonlinear model, and also to estimate the statistical significance of the results of model fitting, we accounted for the statistical variance of $H$. Using a Monte Carlo simulation technique (Metropolis & Ulam, 1949), 10 datasets (replicates) were generated randomly, according to the Gaussian probability distribution, with the mean and standard deviation (SD) values taken from Table S3. The datasets generated were used to find the unknown parameters $k_1$, $k_2$, $k_3$, $v_0$, $v_1$, and $w_0$ by applying the standard least squares technique (Wolberg, 2006). The set of parameter values that corresponded to the minimal fitting

error was taken as an initial approximation. This step was needed to maximize the consistency of model fitting. Next, the initial approximation was used for model fitting into each of additional 20 replicates. Thus, 20 sets of the six unknown parameters were obtained, from which the mean value and the variance estimates were calculated for each sensitivity. We assumed that the $T_b$ measurements at 0 h *vs.* 3 h were uncorrelated. Then, the statistical variance $H$ (the difference between these two values) should be equal to the sum of the respective variances, which were calculated as squares of the respective SD values (Table S3).

## Meta-analysis description

*Search strategy*

Our meta-analysis was conducted in accordance with the guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) protocols (Moher, Liberati, Tetzlaff, Altman, & Group, 2009) (Table S4). The analysis was based on the so-called PICO [Patients, Intervention (or Indicator), Comparison, Outcome] model: in adult human subjects, we aimed at assessing the effect of TRPV1 antagonists (as compared to placebo) on deep $T_b$. This meta-analysis has been registered with PROSPERO (CRD42018095220).

A search in the PubMed, EMBASE, and Cochrane Controlled Trials Registry databases was performed for the period from database inception to February 2019 using the following terms: "(TRPV1 OR TRPV-1 OR VR1 OR VR-1 OR vanilloid OR capsaicin) AND (antagonist OR blocker OR inhibitor) AND (temperature OR hyperthermia OR fever OR hypothermia)". We restricted our search to original human studies published in English. A manual search through the

reference lists of relevant full-text articles was also conducted to identify additional articles. The search was conducted independently by two authors (AG, ZR), who also selected studies for analysis and extracted data from the selected studies (see below). Any disagreements were resolved by consensus, with the help of a third author (AAR).

*Study selection, data extraction, and risk of bias assessment*

The titles and abstracts of the publications identified by the literature search were screened, and the full text of potentially eligible articles was obtained. We included studies in which deep $T_b$ was reported in both TRPV1 antagonist-treated and placebo groups at (at least) two time points: (i) at or before and (ii) 3 h after the drug (or placebo) administration. Furthermore, an *in-vitro* activation-mode pharmacological profile of the TRPV1 antagonist used had to be available (Table S1). From all included articles, we extracted the mean deep $T_b$ with the corresponding SD and the sample size (or other statistical information, which allowed us to calculate or estimate these parameters).

Two authors (AG and ZR) evaluated the quality of the trials according to the Cochrane risk-of-bias tool (Higgins et al., 2011), *i.e.*, by assessing independently the methodology of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data, and selective outcome reporting (Table S7).

*Statistical analysis*

We used a standardized difference in means (SDM) as a measure of the effect on $T_b$ response (see main text, section 3.3). For standardization, the means were divided by their corresponding SD values, which was required because the different $T_b$-measuring methods and

dose ranges could result in different variances among the study groups and influence the results. SDM values were calculated by using the random effect model by DerSimonian and Laird (1986), and then compared using standard meta-analysis tools, such as "forest plot" (Fig. 11). The presence of publication bias was determined by visual inspection of a "funnel plot" for the lack of asymmetry and evaluated quantitatively by Egger's test ($P < 0.1$ indicating publication bias). Both the visual inspection (Fig. S2) and the results of Egger's test revealed no asymmetry ($P = 0.128$). The meta-analyses were performed with Comprehensive Meta-Analysis (version 3.3; Biostat, Engelwood, MJ, USA) software.

## Recording thermal effects of V116517 in trial NCT02695745

Thirty-six healthy male volunteers (age: 18-45 years; body mass: 50-100 kg) were randomized in a double-blind, controlled clinical trial. Participants received 30, 100, 300, 600, or 1,000 mg of V116517 in suspension or placebo *per os*. Oral temperature was recorded at different time points in each treatment group from 24 h before to 72 h after drug or placebo administration. The results (for 0-24 h) are shown in Table S8.

## TABLE S1

*Human studies that used a TRPV1 antagonist and measured $T_b$: included in analyses*

| TRPV1 antagonist | ABT-102 | AZD1386 | NEO6860 | V116517 |
|---|---|---|---|---|
| For trial details, refer to the following lines in Table 3 | 1, 2 | 8 | 25 | 48 |
| Molecular mass (g/mol), as reported in the literature | 349 | 423 | Not reported* | 442 |
| $IC_{50}$ against CAP (nM) | 7.0 | 7.9 | 32 | 35 |
| $IC_{50}$ against protons (nM) | 6.0 | 79 | > 10,000 | 40 |
| $IC_{50}$ against heat (nM) | Unknown | 100 | > 10,000 | Unknown |
| Dose range used (mg) [dose range used (µmol)] | 1.0-40 [2.9-115] | 95 [225] | 500 [1,150] | 30-1,000 [68-2,261] |
| Did the study have a placebo group? | Yes | Yes | Yes | Yes |
| Was a patient-level or group mean $T_b$ before or at the time of drug (placebo) administration reported? | Yes | Yes | Yes | No* |
| Was a patient-level or group mean $T_b$ at 3 h after drug (placebo) administration reported? | Yes | Yes | Yes | No* |

*For explanation on how the missing information was obtained, see Table S5.

**TABLE S2**

*Human studies that used a TRPV1 antagonist and measured $T_b$: excluded from analyses*

| TRPV1 antagonist | ABT-102 | AMG 517 | AZD 1386 | DWP 05195 | JNJ-38893777 | JNJ-39439335 | JNJ-39439335 | NEO 6860 | SB-705498 | SB-705498 | XEN-D0501 | XEN-D0501 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| For trial details, refer to the following lines in Table 3 | 3 | 4 | 10, 11 | 13 | 15 | 17-19, 21 | 20 | 24 | 43 | 44 | 50 | 51 |
| Molecular mass (g/mol), as reported in the literature | 348 | 430 | 423 | Not reported | 537 | 423 | 423 | 435 | 429 | 429 | Not reported | Not reported |
| $IC_{50}$ against CAP (nM) | 7.0 | 0.8 | 7.9 | Not reported | 8.3 | 4.6-23 | 4.6-23 | 32 | 3.0 | 3.0 | Not reported | Not reported |
| $IC_{50}$ against protons (nM) | 6.0 | 0.6 | 79 | Not reported | 7.4 | 6.8 | 6.8 | > 10,000 | 5.3 | 5.3 | Not reported | Not reported |
| $IC_{50}$ against heat (nM) | Not reported | 1.3 | 100 | Not reported | Not reported | Not reported | Not reported | > 10,000 | 6.0 | 6.0 | Not reported | Not reported |
| Did the study have a placebo group? | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Was a patient-level or group mean $T_b$ before or at the time of drug (placebo) administration reported? | No | No* | No | Yes | No | No | No | No | Yes | No | No | Yes |
| Was a patient-level or group mean $T_b$ at 3 h after drug (placebo) administration reported? | No | No* | No | No | No | No | No | No | No | No | No | Yes |
| Additional reasons for exclusion | | | | | | | | | Low target occupancy | Intranasal administration | | |

Reasons for exclusion are highlighted in pink. *Only maximal $T_b$ values for different periods of time were reported.

**TABLE S3**

*Data on $T_b$ and $IC_{50}$ values of TRPV1 antagonists: used in the modeling analysis*

| TRPV1 antagonist | Dose (µmol) | $T_b$ at 0 h (°C) Mean | SD | $T_b$ at 3 h (°C) Mean | SD | 3 h − 0 h $T_b$ difference (°C)* Mean | SD | Number of subjects | Reference(s) | IC50 values against human TRPV1 in different activation modes (nM) Heat | pH (5.0-5.5) | CAP (50-100 nM) | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT-102 | 2.9 | 37.0 | 0.3 | 37.3 | 0.2 | 0.3 | 0.4 | 8 | Othman, Nothaft, Awni, & Dutta, 2013; Rowbotham, et al., 2011 | | 6.0 | 7.0 | Surowy, et al., 2008 |
| | 5.7 | 36.5 | 0.3 | 37.2 | 0.3 | 0.7 | 0.4 | 20 | | | | | |
| | 11 | 36.7 | 0.3 | 37.4 | 0.3 | 0.7 | 0.5 | 14 | | | | | |
| | 17 | 36.3 | 0.2 | 37.4 | 0.3 | 1.1 | 0.4 | 6 | | | | | |
| | 23 | 36.5 | 0.3 | 37.2 | 0.2 | 0.7 | 0.4 | 6 | | | | | |
| | 52 | 36.3 | 0.2 | 37.6 | 0.3 | 1.3 | 0.4 | 6 | | | | | |
| | 86 | 36.2 | 0.2 | 37.5 | 0.2 | 1.3 | 0.3 | 6 | | | | | |
| | 115 | 36.5 | 0.3 | 37.6 | 0.2 | 1.1 | 0.4 | 6 | | | | | |
| AZD1386 | 225 | 36.8 | 0.3 | 37.2 | 0.3 | 0.4 | 0.4 | 40 | Quiding, et al., 2013 | 100 | 79 | 7.9 | Chiche, Brown, & Walker, 2016** |
| NEO6860 | 1,149 | 36.6 | 0.3 | 36.4 | 0.3 | -0.2 | 0.4 | 52 | Arsenault, et al., 2018 | > 10,000 | > 10,000 | 31.62 | Chiche, et al., 2016** |
| V116517 | 68 | 37.0 | 0.2 | 37.1 | 0.3 | 0.1 | 0.3 | 4 | Unpublished*** | | 40 | 35 | Tafesse, et al., 2014 |
| | 226 | 36.9 | 0.3 | 37.1 | 0.3 | 0.2 | 0.4 | 4 | | | | | |
| | 678 | 36.8 | 0.1 | 37.0 | 0.2 | 0.2 | 0.2 | 4 | | | | | |
| | 1,357 | 36.8 | 0.2 | 37.2 | 0.4 | 0.4 | 0.4 | 4 | | | | | |
| | 2,261 | 36.9 | 0.2 | 37.4 | 0.4 | 0.5 | 0.5 | 4 | | | | | |

*These values are used as the hyperthermic index *H* values (see *Mathematical model description* in *Supplementary Information*). **The applied temperature, pH, and concentration of CAP to activate human TRPV1 were not reported. ***Patient-level $T_b$ data were provided by Purdue Pharma (see Table S8).

# TABLE S4

## *PRISMA checklist*

| Section/topic | # | Checklist item | Reported |
|---|---|---|---|
| **TITLE** | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | Page 1 |
| **ABSTRACT** | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | Page 1 |
| **INTRODUCTION** | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | Section 1 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | Page 3 in Supplementary Information |
| **METHODS** | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (*e.g.*, Web address), and, if available, provide registration information, including registration number. | Section 3.3 |
| Eligibility criteria | 6 | Specify study characteristics (*e.g.*, PICOS, length of follow-up) and report characteristics (*e.g.*, years considered, language, publication status) used as criteria for eligibility, giving rationale. | Section 3.3 |
| Information sources | 7 | Describe all information sources (*e.g.*, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | Pages 3-4 in Supplementary Information |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Page 3 in Supplementary Information |
| Study selection | 9 | State the process for selecting studies (*i.e.*, screening) and list the inclusion and exclusion criteria. | Page 4 in Supplementary Information |
| Data collection process | 10 | Describe method of data extraction from reports (*e.g.*, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | Page 4 in Supplementary Information |
| Data items | 11 | List and define all variables for which data were sought (*e.g.*, PICOS, funding sources) and any assumptions and simplifications made. | Page 4 in Supplementary Information and Table S5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | Page 4 in Supplementary Information |
| Summary measures | 13 | State the principal summary measures (*e.g.*, risk ratio, difference in means). | Section 3.3; Pages 4-5 in Supplementary Information |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency for each meta-analysis. | Section 3.3; Pages 4-5 in Supplementary Information |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (*e.g.*, publication bias, selective reporting within studies). | Page 5 in Supplementary Information |

| | | | |
|---|---|---|---|
| Additional analyses | 16 | Describe methods of additional analyses (*e.g.*, sensitivity or subgroup analyses, meta-regression), if done, indicating which were prespecified. | Section 3.3 |
| **RESULTS** | | | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusion at each stage, ideally with a flow diagram. | Section 3.2; Fig. S1 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (*e.g.*, study size, PICOS, follow-up period) and provide the citations. | Tables S3 and S6 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | Table S7 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a "forest plot". | Section 3.3; Fig. 11 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | Section 3.3; Fig. 11 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | Fig. S2 |
| Additional analysis | 23 | Give results of additional analyses, if done [(*e.g.*, sensitivity or subgroup analyses, meta-regression (see Item 16)]. | Section 3.3; Fig. 11 |
| **DISCUSSION** | | | |
| Summary of evidence | 24 | Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (*e.g.*, healthcare providers, users, and policy makers). | Section 5 |
| Limitations | 25 | Discuss limitations at study and outcome level (*e.g.*, risk of bias), and at review-level (*e.g.*, incomplete retrieval of identified research, reporting bias). | Sections 3.2 and 3.3 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | Section 5 |
| **FUNDING** | | | |
| Funding | 27 | Describe sources of funding for the systematic review and other support (*e.g.*, supply of data); role of funders for the systematic review. | Acknowledgements |

**TABLE S5**

*Assumptions and simplifications used in the modeling analysis*

| TRPV1 antagonist | Problem | Solution |
|---|---|---|
| ABT-102 | Of the three trials reported by Othman et al. (2013) and Rowbotham et al. (2011), oral $T_b$ was measured in two and gastrointestinal $T_b$ (with an ingested transmitter) in the third one. | Oral and gastrointestinal $T_b$s were considered equivalent. |
| | In Othman et al. (2013), $T_b$ was reported as a median with percentiles. | SD values were calculated from percentiles; when only the median was reported, it was considered to equal the mean. |
| | Two treatments, *viz.*, 2 mg of ABT-102 and placebo were studied in three trials; 4 mg of ABT-102 was studied in two trials (Othman et al., 2013; Rowbotham et al., 2011). | For each treatment, the data were pooled. |
| AZD1386 | Neither standard error (SE) nor SD values for the mean $T_b$ were reported by Quiding et al. (2013). | SD for $T_b$ was calculated based on the SD for the pain intensity difference, as estimated by Quiding et al. (2013). |
| V116517 | Neither the molecular mass of V116517 nor $T_b$ data were reported by Arendt-Nielsen et al. (2016). | The molecular mass (442 g/mol) and the $T_b$ data (Table S8) were provided by Purdue Pharma. |
| NEO6860 | The molecular mass was reported by neither Arsenault et al. (2018) nor Brown et al. (2017). | Molecular mass values for small-molecule TRPV1 antagonists fall in a narrow range. For this analysis, the molecular mass of NEO6860 was assumed to be 435 g/mol, which is the mean value for all antagonists presented in Tables S1 and S2. |
| | For both the proton and heat mode, $IC_{50} > 10$ μM. | For the analysis, both values were considered to be 10 μM. |

# TABLE S6

*Demographic characteristics of the analyzed studies*

| Study report | TRPV1 antagonist | Subject population | Age (year) | | Gender | | Body mass (kg) | | Body mass index (kg/m$^2$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Mean | SD | Male | Female | Mean | SD | Mean | SD |
| Arsenault, et al., 2018 | NEO6860 | With knee osteoarthritis | 61 | 9 | 20 | 34 | 79 | 14 | 29 | 4 |
| Arendt-Nielsen, et al., 2016 | V116517 | Healthy | 22 | 3 | 36 | 0 | 80 | 10 | 24 | 2 |
| | Placebo | | | | 35 | 0 | | | | |
| Othman, et al., 2013* | ABT-102 | Healthy | 38 | 10 | 35 | 10 | 76 | 11 | 25 | 2 |
| Othman, et al., 2013* | ABT-102 | Healthy | 43 | 10 | 23 | 4 | 79 | 11 | 25 | 2 |
| Rowbotham, et al., 2011* | ABT-102 | Healthy | 30 | 9 | 18 | 18 | 70 | 11 | 24 | 3 |
| Quiding, et al., 2013 | AZD1386 | Following molar extraction | 22 | 4 | 40 | 0 | 76 | 11 | 24 | 4 |
| | Placebo | | 22 | 5 | 40 | 0 | 77 | 12 | 25 | 3 |

*The demographic data for this study are reported by Othman, Nothaft, Awni, & Dutta (2012).

**TABLE S7**

*Risk of bias assessment*

| | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|---|---|---|---|---|---|---|---|
| Arsenault, et al., 2018 | ? | ? | ✓ | ? | ✓ | ✓ | ✓ |
| Arendt-Nielsen, et al., 2016 | ? | ? | ✓ | ? | ✓ | ✓ | ✗ |
| Othman, et al., 2013 | ? | ? | ? | ? | ✓ | ✓ | ✗ |
| Rowbotham, et al., 2011 | ✓ | ✓ | ✓ | ? | ✓ | ✓ | ✓ |
| Quiding, et al., 2013 | ✓ | ? | ? | ? | ✓ | ✓ | ✓ |

**TABLE S8**

*The thermal effect of V116517 in healthy male volunteers (trial NCT02695745)*

| Treatment | Dose (mg) | Oral $T_b$ at different times post-dosing (°C) | | | | | | | | | | | | Number of subjects |
| | | 0 h | | 3 h | | 6 h | | 8 h | | 12 h | | 24 h | | |
| | | Mean | SE | Mean | SE | Mean | SE | Mean | SE | Mean | SE | Mean | SE | |
| V116517 | 30 | 37.0 | 0.1 | 37.1 | 0.1 | 37.3 | 0.2 | 37.1 | 0.1 | 37.0 | 0.1 | 36.9 | 0.1 | 4 |
| | 100 | 36.9 | 0.1 | 37.1 | 0.2 | 37.2 | 0.1 | 37.1 | 0.1 | 37.2 | 0.1 | 36.9 | 0.1 | 4 |
| | 300 | 36.8 | 0.1 | 37.0 | 0.1 | 37.4 | 0.2 | 37.1 | 0.2 | 37.3 | 0.2 | 36.8 | 0.1 | 4 |
| | 600 | 36.8 | 0.1 | 37.2 | 0.2 | 37.4 | 0.2 | 37.7 | 0.2 | 37.5 | 0.3 | 36.9 | 0.1 | 4 |
| | 1,000 | 36.9 | 0.1 | 37.4 | 0.2 | 37.6 | 0.2 | 37.5 | 0.1 | 37.5 | 0.1 | 37.0 | 0.0 | 4 |
| Placebo | | 36.8 | 0.0 | 36.8 | 0.1 | 36.9 | 0.1 | 36.9 | 0.1 | 37.0 | 0.1 | 36.8 | 0.0 | 10 |

**FIGURE S1.** PRISMA Flow Diagram

**FIGURE S2.** "Funnel plot" of the studies with mode-nonselective antagonists. Each circle represents a group treated with a single dose a TRPV1 antagonist; the same groups are shown in Figure 11. The "funnel sides" (slotted blue lines) form a triangular area that is expected, in the absence of publication bias, to harbor 95% of data. The average SDM for all doses of all antagonists corresponds to the "funnel axis" (vertical black line) and also to the vertical diagonal of the rhombus; the horizontal diagonal of the rhombus represents the 95% confidence interval. A high degree of symmetry in the distribution of data relative to the funnel axis (as in this plot) indicates that the results are unlikely to be affected by a bias.

## Supplementary References

Arendt-Nielsen, L., Harris, S., Whiteside, G. T., Hummel, M., Knappenberger, T., O'Keefe, S., et al. (2016). A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile. *Pain 157*, 2057-2067.

Arsenault, P., Chiche, D., Brown, W., Miller, J., Treister, R., Leff, R., et al. (2018). NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain. *Pain Reports 3*, e696.

Brown, W., Leff, R. L., Griffin, A., Hossack, S., Aubray, R., Walker, P., et al. (2017). Safety, pharmacokinetics, and pharmacodynamics study in healthy subjects of oral NEO6860, a modality selective transient receptor potential vanilloid subtype 1 antagonist. *The Journal of Pain 18*, 726-738.

Chiche, D., Brown, W., & Walker, P. (2016). NEO6860, a novel modality selective TRPV1 antagonist: results from phase I, double-blind, placebo-controlled study in healthy subjects. *The Journal of Pain 17*, S79 (conference poster).

DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. *Controlled Clinical Trials 7*, 177-188.

Di Veroli, G. Y., Fornari, C., Goldlust, I., Mills, G., Koh, S. B., Bramhall, J. L., et al. (2015). An automated fitting procedure and software for dose-response curves with multiphasic features. *Scientific Reports 5*, 14701.

Higgins, J. P., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ 343*, d5928.

Meddings, J. B., Scott, R. B., & Fick, G. H. (1989). Analysis and comparison of sigmoidal curves: application to dose-response data. *American Journal of Physiology 257*, G982-989.

Metropolis, N., & Ulam, S. (1949). The Monte Carlo method. *Journal of the American Statistical Association 44*, 335-341.

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine 6*, e1000097.

Othman, A. A., Nothaft, W., Awni, W. M., & Dutta, S. (2012). Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials. *The Journal of Clinical Pharmacology 52*, 1028-1041.

Othman, A. A., Nothaft, W., Awni, W. M., & Dutta, S. (2013). Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials. *British Journal of Clinical Pharmacology 75*, 1029-1040.

Quiding, H., Jonzon, B., Svensson, O., Webster, L., Reimfelt, A., Karin, A., et al. (2013). TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction. *Pain 154*, 808-812.

Rowbotham, M. C., Nothaft, W., Duan, W. R., Wang, Y., Faltynek, C., McGaraughty, S., et al. (2011). Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. *Pain 152*, 1192-1200.

Surowy, C. S., Neelands, T. R., Bianchi, B. R., McGaraughty, S., El Kouhen, R., Han, P., et al. (2008). (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. *The Journal of Pharmacology and Experimental Therapeutics 326*, 879-888.

Tafesse, L., Kanemasa, T., Kurose, N., Yu, J., Asaki, T., Wu, G., et al. (2014). Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-

5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyrid    yl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain management. *Journal of Medicinal Chemistry* *57*, 6781-6794.

Wolberg, J. (2006). *Data analysis using the method of least squares: extracting the most information from experiments*. Berlin: Springer.

# Ammonium chloride-induced hypothermia is attenuated by transient receptor potential channel vanilloid-1, but augmented by ankyrin-1 in rodents

Zoltan Rumbus [a], Kata Fekete [a], Leonardo Kelava [a], Bibor Gardos [a], Krisztian Klonfar [a], Patrik Keringer [a], Erika Pinter [b], Eszter Pakai [a], Andras Garami [a,*]

[a] *Department of Thermophysiology, Institute for Translational Medicine, Medical School, University of Pecs, Pecs H-7624, Hungary*
[b] *Department of Pharmacology and Pharmacotherapy, Medical School, University of Pecs, Pecs H-7624, Hungary*

ABSTRACT

*Aims:* Systemic administration of ammonium chloride ($NH_4Cl$), an acidifying agent used in human patients and experimental conditions, causes hypothermia in mice, however, the mechanisms of the thermoregulatory response to $NH_4Cl$ and whether it develops in other species remained unknown.

*Main methods:* We studied body temperature ($T_b$) changes in rats and mice induced by intraperitoneal administration of $NH_4Cl$ after blockade of transient receptor potential vanilloid-1 (TRPV1) or ankyrin-1 (TRPA1) channels.

*Key findings:* In rats, $NH_4Cl$ decreased $T_b$ by 0.4–0.8°C ($p < 0.05$). The $NH_4Cl$-induced hypothermia also developed in *Trpv1* knockout (*Trpv1*$^{-/-}$) and wild-type (*Trpv1*$^{+/+}$) mice, however, the $T_b$ drop was exaggerated in *Trpv1*$^{-/-}$ mice compared to *Trpv1*$^{+/+}$ controls with maximal decreases of 4.0 vs. 2.1°C, respectively ($p < 0.05$). Pharmacological blockade of TRPV1 channels with AMG 517 augmented the hypothermic response to $NH_4Cl$ in genetically unmodified mice and rats ($p < 0.05$ for both). In contrast, when $NH_4Cl$ was infused to mice genetically lacking the TRPA1 channel, the hypothermic response was significantly attenuated compared to wild-type controls with maximal mean $T_b$ difference of 1.0°C between the genotypes ($p = 0.008$). Pretreatment of rats with a TRPA1 antagonist (A967079) also attenuated the $NH_4Cl$-induced $T_b$ drop with a maximal difference of 0.7°C between the pretreatment groups ($p = 0.003$).

*Significance:* TRPV1 channels limit, whereas TRPA1 channels exaggerate the development of $NH_4Cl$-induced hypothermia in rats and mice, but other mechanisms are also involved. Our results warrant for regular $T_b$ control and careful consideration of $NH_4Cl$ treatment in patients with TRPA1 and TRPV1 channel dysfunctions.

## 1. Introduction

Ammonium chloride ($NH_4Cl$) is a systemic and urinary acidifying agent that can be used in the treatment of metabolic alkalosis [1–3]. As an expectorant, it is a common ingredient of many cough mixtures, which explains why the excessive consumption of such over-the-counter medications can lead to metabolic acidosis [4,5] that was also observed in subjects receiving $NH_4Cl$ in other types of medicines [6–8]. Extending its application areas, more recently, the use of $NH_4Cl$ was implicated in COVID-19 [9,10].

The oral and/or parenteral administration of $NH_4Cl$ is often used to induce systemic (extracellular) acidosis in animal models [11–15] and in

human studies [16–19]. Although interspecies differences, for example, between rats and mice, were demonstrated in the response to the same $NH_4Cl$-loading protocol [13,20], $NH_4Cl$ administration has been widely used to study the effect of acidosis associated with different conditions, such as physical exercise [16,21], kidney functions [22,23], iron metabolism [24], or parathyroid functions [25].

In 1988, Gordon showed that the systemic administration of $NH_4Cl$ leads to hypothermia in mice [26]. This finding can explain why its overconsumption was also associated with hypothermia in case of a human patient [5]. However, the molecular mediators of the $NH_4Cl$-induced hypothermia have remained largely unknown. Our literature search did not reveal any studies that aimed to clarify the underlying

mechanisms of this thermoregulatory phenomenon.

Transient receptor potential (TRP) vanilloid-1 (V1) and ankyrin-1 (A1) channels are temperature-sensitive members of the TRP channel family, for the reason that *in vitro* they can be activated by noxious heat and cold, respectively [27,28]. In addition to thermal signals, they can be both activated by ligand agonists and by changes in pH, hence they function as polymodal receptors [29,30], especially on primary afferent neurons where they are often co-expressed [31,32]. Their thermosensor function has been well established in pain sensation [29,33,34], however, neither of them was found to serve as a thermosensor for the thermoregulation system in rodents [35,36]. It was proposed that their activation by agonists other than temperature (by protons for TRPV1 and by sulfides for TRPA1) contributes to the regulation of deep body temperature ($T_b$) [37,38]. Interestingly, both channels can be activated by $NH_4Cl$ [39,40], and also by low pH [41–44]. However, to our best knowledge, the contribution of the TRPV1 or TRPA1 channel to the thermal response to $NH_4Cl$ has not been investigated yet.

In the present work, we studied whether $NH_4Cl$ induces hypothermia also in rats in addition to mice to exclude the possibility of a mouse-specific effect, and whether the blockade of TRPV1 and TRPA1 channels influences the $NH_4Cl$-induced hypothermia by using genetic deletion of the channels. To avoid chronic compensatory mechanisms, which may develop for the function of a knocked out gene, we also used pharmacological inhibition of TRPV1 and TRPA1 in genetically unaltered animals.

## 2. Methods

### 2.1. Animals

Experiments were conducted in adult male rats and mice under protocols approved by the Institutional Animal Use and Care Committee of the University of Pecs (registration no.: BA02/2000–13/2021) and in accordance with the directives of the National Ethical Council for Animal Research and those of the European Communities Council (86/609/EEC). One hundred and ten Wistar rats and thirty-seven C57BL/6 mice were obtained from the Laboratory Animal Centre of the University of Pecs. In addition, mice with ($^{-/-}$ aka knockout, KO) or without ($^{+/+}$ aka wild type, WT) a homozygous targeted mutation in the *Trpv1* gene (*Trpv1* KO: n = 21; *Trpv1* WT: n = 14) or in the *Trpa1* gene (*Trpa1* KO: n = 24; *Trpa1* WT: n = 16) were also obtained from the Laboratory Animal Centre of the University of Pecs, where they were bred and kept as described in details elsewhere [35,45]. Mice from these strains were also used in previous studies aiming to investigate the thermoregulatory function of TRPA1 [35,37] and TRPV1 [38,46]. The animals were housed in polycarbonate cages kept in temperature-controlled rooms on a 12 h light/dark cycle (lights on at 5:00 A.M.). The ambient temperature was maintained at 24–25°C and humidity at 30–40%. Standard rodent chow and tap water were available *ad libitum*. Animals were extensively habituated to the experimental setup, as described elsewhere [47,48]. At the time of the experiments, the mice and rats weighed 25 ± 1 and 328 ± 3 g, respectively.

### 2.2. Surgeries

#### 2.2.1. Anesthesia and perioperative care

Animals were anesthetized with intraperitoneal (i.p.) administration of a ketamine–xylazine cocktail (81.7 and 9.3 mg/kg for mice, 55.6 and 5.5 mg/kg for rats, respectively), and they received antibiotic protection intramuscularly (gentamycin, 6 mg/kg). To prevent intra- and post-operative hypothermia, during the surgery mice were kept on a heating pad (PECO Services Ltd., Brough, United Kingdom), and then they were allowed to recover from anesthesia in a temperature-controlled chamber (model MIDI F230S; PL Maschine Ltd., Tarnok, Hungary) set to 31°C. Each rat and mouse was implanted with an i.p. catheter, additionally rats assigned to experiments with pharmacological antagonists were

also implanted with an intravenous (i.v.) catheter during the same surgery. The i.p. and i.v. catheter implantations have been widely used in thermoregulation experiments, and the animals tolerated these interventions well [37,38,46,49]. These preimplanted catheters were used for the non-stressful administration of substances to conscious animals in our experiments. In case of a bolus injection (i.p. or i.v.), the handling of the animal and the puncture of the abdominal wall with the needle would have resulted in pain and stress-induced hyperthermia (for review, see [50]), which could interfere with our results. All experiments were performed 3–5 days after the surgery.

#### 2.2.2. I.p. catheter implantation

For the non-stressful i.p. administration of the substances during the experiment, a polyethylene (PE)-50 catheter filled with pyrogen-free saline was implanted into the peritoneal cavity of each mouse and rat, similarly as in previous studies [38,46]. In brief, through a small midline incision on the abdomen, the internal end of the catheter was fixed to the left side of the abdominal wall with a suture, while the external end of the catheter was tunneled under the skin to the nape, where it was exteriorized and heat-sealed. The surgical wound was sutured in layers. The catheter was flushed with 0.1 ml of saline on the day after the surgery and every other day thereafter.

#### 2.2.3. I.v. catheter implantation

This procedure was performed in rats assigned to treatment with a TRPV1 or a TRPA1 antagonist. As described before [46], the i.v. catheter was implanted during the same surgery as the i.p. catheter. A small longitudinal incision was made on the ventral surface of the neck, left of the trachea. The left jugular vein was exposed, freed from its surrounding connective tissue, and ligated. A silicone catheter (with inner and outer diameter of 0.5 and 0.9 mm, respectively) was filled with heparinized (10 U/ml) saline, then it was inserted into the left jugular vein, passed into the superior vena cava, and secured in place with ligatures. The free end of the catheter was knotted and exteriorized at the nape. The skin wound was sutured. The catheter was flushed with heparinized saline on the day following the surgery and every other day thereafter.

### 2.3. Thermocouple thermometry

The mice and the rats were placed in cylindrical confiners and equipped with copper-constantan thermocouples (Omega Engineering, Stamford, CT, USA) to measure colonic temperature (a form of deep $T_b$). The colonic thermocouple was inserted beyond the anal sphincter (10 and 3 cm deep for rats and mice, respectively); fixed to the base of the tail with adhesive tape; and plugged into a data logger device (Cole-Palmer, Vernon Hills, IL, USA) connected to a computer. Animals in their confiners were then placed into a biochemistry incubator (model BJPX-Newark; Biobase; Jinan, China). As the expected $T_b$ change was hypothermia, the ambient temperature was set to 25°C, which is slightly subneutral for rats and mice in this setup. The preimplanted i.p. and i.v. catheter (when present) was connected to a PE-50 extension, which was prefilled with the substance of interest and connected to a syringe placed in an infusion pump (model 975; Harvard Apparatus Inc., Holliston, MA, USA).

### 2.4. Drugs and drug administration

#### 2.4.1. I.p. $NH_4Cl$ to mice and rats

$NH_4Cl$ was purchased from VWR Chemicals (Leuven, Belgium). On the day of an experiment, $NH_4Cl$ was freshly dissolved in sterile water to achieve final concentrations of 32.1, 220 or 280 mg/ml. For the i.p. administration of $NH_4Cl$ to mice, the working solution (32.1 mg/ml) was infused (10 ml/kg) over 16 min to deliver $NH_4Cl$ at 321 mg/kg (~6 mmol/kg). In rats, the working solutions (220 and 280 mg/ml) were infused (1 ml/kg) over 5 min to deliver $NH_4Cl$ at 220 and 280 mg/kg (ca.

4 and 5 mmol/kg), respectively. The decreased dose of $NH_4Cl$ in the rats compared to mice was necessary, because rats were more sensitive to the effect of the same $NH_4Cl$-loading protocol on protein expression than mice [13]. Control animals were infused with sterile water. All infusion rates and volumes were selected with the goal to minimize the stress and discomfort of the animals that may originate from the substance administration procedure itself. Similar i.p. infusion rates as in the present experiments were successfully applied in our previous studies for non-stressful administration of substances to mice [51] and rats [46].

### 2.4.2. I.v. AMG 517 and A967079 to rats

AMG 517, a highly potent TRPV1 antagonist [52], and A967079, a highly potent TRPA1 antagonist [53], were purchased from Tocris (Bristol, UK). A stock solution of AMG 517 (1 mg/ml) was prepared with 10% dimethyl sulfoxide (DMSO) and 10% Tween-80 in saline, aliquoted, and stored at $-80°C$. On the day of the experiment, the stock was diluted to give a working solution of AMG 517 at 210 µg/ml in 10% DMSO and 10% Tween-80 in saline. A stock solution of A967079 (10 mg/ml) was prepared with polyethylene glycol 400 (PEG 400), aliquoted, and stored at $-80°C$. On the day of the experiment, the stock was diluted with PEG 400 and saline to give a working solution of A967079 at 5 mg/ml in 80% PEG 400 in saline. For the i.v. administration, the working solution of AMG 517 or A967079 (210 µg/ml or 5 mg/ml, respectively) was infused (1 ml/kg) over 10 min to deliver AMG 517 and A967079 at 210 µg/kg and 5 mg/kg, respectively. Both antagonists were infused i.v. to the rats 20 min before the i.p. infusion of $NH_4Cl$. Control rats were infused with the vehicle of the antagonist of interest. The efficacies of AMG 517 and A967079 administered i.v. at similar doses and rates as in the present experiments were shown in previous studies [54,55].

### 2.4.3. Subcutaneous (s.c.) AMG 517 to mice

To study the effect of AMG 517 on $NH_4Cl$-induced hypothermia in mice, we used a drug dose and administration model that was successfully applied earlier [56]. The stock and working solutions of AMG 517 were prepared as described above. The working solution (or its vehicle) was injected s.c. as a bolus to deliver AMG 517 at a dose of 210 µg/kg just before setting up the mice for the experiment (i.e., ~120 min before the administration of $NH_4Cl$). Then, the mice were allowed to accommodate to the experimental conditions for ~2 h before they received the non-stressful, i.p. infusion of $NH_4Cl$ (321 mg/kg) through a pre-implanted catheter. The 2-h latency until the $NH_4Cl$ infusion was needed to reduce the stress-induced hyperthermia resulting from the needle prick associated with the s.c. injection of AMG 517 (or its vehicle). Because of the long (31h) half-life of AMG 517 in rodents [57], the effect of the drug could be reasonably expected at the time of $NH_4Cl$ infusion even with this latency.

The drug administration procedures in the different experiments are summarized in Table 1.

### 2.5. Blood pH measurements

One hour after the i.p. administration of $NH_4Cl$, the animals were anesthetized with a ketamine-xylazine cocktail, and then blood samples were collected by cardiac puncture with a heparinized syringe. The pH of the blood samples was measured by a pH meter (model OP-211/2; Radelkis Ltd., Budapest, Hungary) within 1 min after collection. After the blood withdrawal, the animals were euthanized with sodium pentobarbital (100 mg/kg, i.p.).

### 2.6. Data processing and analysis

Data on deep $T_b$ and on blood pH were compared by ANOVA, as appropriate. ANOVA was followed by the Student-Newman-Keuls *post hoc* test as in our earlier study [49]. Sigmaplot 11.0 (Systat Software, San Jose, CA, USA) software was used for statistical analyses. Differences were considered significant when $p < 0.05$. Data are presented as mean $\pm$ SE.

## 3. Results

### 3.1. Systemic administration of $NH_4Cl$ causes hypothermia in rats

First, we studied the thermal effect of $NH_4Cl$ administered systemically (i.p.) to rats in order to exclude the possibility that the $NH_4Cl$-induced hypothermic response is specific only for mice. We found that the i.p. injection of $NH_4Cl$ to the rats caused hypothermia, which was more pronounced at the higher dose (Fig. 1). The colonic temperature of the rats started to drop promptly, already at 10 min after the injection of $NH_4Cl$ at both doses. Compared to the baseline, the $NH_4Cl$-induced maximal mean ($\pm$ SE) decrease in deep $T_b$ was $-0.4 \pm 0.1°C$ at 20 min in case of 220 mg/kg and $-0.8 \pm 0.2°C$ at 30 min in case of 280 mg/kg. From that timepoint, the $T_b$ of the $NH_4Cl$-treated rats gradually increased and reached the $T_b$ level of the control (sterile water-treated) group by the end of the experiment. The $T_b$ of the sterile water-treated rats tended to increase, and then to decrease during the experiment after the i.p. infusion, but it did not differ significantly from the baseline at any timepoints. The initial increase in the $T_b$ could be caused by an unwanted stress response to sterile water infusion despite all of our efforts to minimize the discomfort associated with substance administration, while the gradual fall might have reflected ultradian body temperature rhythms in rats maintained at an ambient temperature of ~25°C, which is below the thermoneutral zone. Statistically, both doses of $NH_4Cl$ had a significant effect as compared to controls ($p < 0.001$ for both), and a statistical difference was also present between the lower and the higher dose groups ($p < 0.001$). At 220 mg/kg, the $NH_4Cl$-induced decrease in deep $T_b$ was significant compared to the control group between 20 and 50 min, while at 280 mg/kg, the $T_b$ was significantly lower than in controls between 20 and 90 min. The development of hypothermia in response to $NH_4Cl$ in rats is a novel finding of our study, especially considering that the effect occurred already at an i.p. dose of 220 mg/kg, which is almost 50% smaller than the threshold dose predicted earlier in mice [26].

**Table 1**
Summary of drug administration procedures in the experiments.

| Species (strain) | Pretreatment | | | $NH_4Cl$ | Figure number |
|---|---|---|---|---|---|
| | Drug | Dose (mg/kg) and route | Time prior $NH_4Cl$ (min) | I.p. dose (mg/kg) | |
| Rat (Wistar) | N/A | | | 220; 280 | 1 |
| Mouse ($Trpv1^{-/-}$ and $^{+/+}$) | N/A | | | 321 | 2 |
| Mouse (C57BL/6) | AMG 517 | 0.21 s.c. | $-120$ | 321 | 3 |
| Rat (Wistar) | AMG 517 | 0.21 i.v. | $-20$ | 280 | 4 |
| Mouse ($Trpa1^{-/-}$ and $^{+/+}$) | N/A | | | 321 | 5 |
| Rat (Wistar) | A967079 | 5 i.v. | $-20$ | 280 | 6 |

N/A, not applicable.

**Fig. 1.** Changes in deep (colonic) $T_b$ in response to i.p. administration of $NH_4Cl$ (doses indicated) or sterile water in rats. Here and in Figs. 2–6, n is the number of animals in each experimental group. *$p < 0.05$, 220 mg/kg $NH_4Cl$ vs. sterile water difference; #$p < 0.05$, 280 mg/kg $NH_4Cl$ vs. sterile water difference; $$p < 0.05$, 220 vs. 280 mg/kg $NH_4Cl$ difference.

### 3.2. NH4Cl-induced hypothermia is augmented in mice genetically lacking the TRPV1 channel

After we showed that the hypothermic response to $NH_4Cl$ is not specific to mice only, we wanted to know if two of the most studied thermo-TRP channels, TRPV1 or TRPA1, are involved in this thermoregulatory response. In our first approach, we compared the hypothermic response to $NH_4Cl$ between *Trpv1*$^{-/-}$ and *Trpv1*$^{+/+}$ mice. Since the threshold i.p. dose of $NH_4Cl$ to trigger hypothermia in mice was above 300 mg/kg according to Gordon [26], in our experiments we infused the mice i.p. with 321 mg/kg of $NH_4Cl$. As expected, $NH_4Cl$ at this dose caused a sudden drop in the colonic temperature of *Trpv1*$^{+/+}$ mice, which reached the biggest mean decrease of $-2.1 \pm 0.5°C$ at 30 min post-injection (Fig. 2). Compared to the vehicle (sterile water), the deep $T_b$ of $NH_4Cl$-treated *Trpv1*$^{+/+}$ mice was markedly lower between 20 and 50 min post-injection ($p < 0.05$). In *Trpv1*$^{-/-}$ mice, $NH_4Cl$ also caused hypothermia compared to sterile water, which was significant between 20 and 70 min ($p < 0.05$) with a maximal mean decrease of $-4.0 \pm 0.4°C$ ($p < 0.001$). Interestingly, however, the hypothermic response to $NH_4Cl$ was much more pronounced in the *Trpv1*$^{-/-}$ mice than in their *Trpv1*$^{+/+}$ littermates (Fig. 2). The intergenotype difference was significant ($p < 0.05$) between 20 and 60 min post-$NH_4Cl$ administration with a maximum of ~2.0°C difference between the groups at 40 min ($p < 0.001$).

Nevertheless, it should be noted that the $NH_4Cl$-induced hypothermia developed in both genotypes of the mice (though to a different extent), which suggests that it also involves TRPV1-independent mechanisms.

### 3.3. Pharmacological blockade of the TRPV1 channel exaggerates NH4Cl-induced hypothermia in mice and rats

Our findings in the genetically modified mouse model clearly indicated a bigger hypothermic response in *Trpv1*$^{-/-}$ mice. However, it could not be excluded that the *Trpv1*$^{-/-}$ mice had developed chronic compensatory mechanisms for the absence of TRPV1, which could have influenced the results. To avoid the potential development of chronic compensation, we decided to use genetically unaltered animals (*viz.*, C57BL/6 mice and Wistar rats) and block their TRPV1 channels acutely by a pharmacological antagonist, AMG 517.

AMG 517 is a highly potent and selective, in itself hyperthermia-inducing TRPV1 antagonist [52], which has been tested in hypothermic conditions associated with severe systemic inflammation and with general anesthesia [46,56]. Similarly as in our earlier study [56], in the present experiments the efficacy of AMG 517 could be confirmed by the higher deep $T_b$ of the AMG 517-treated mice compared to vehicle-treated controls before $NH_4Cl$ administration (Fig. 3a). As it could be expected based on our results obtained in *Trpv1*$^{+/+}$ mice, in the vehicle-pretreated C57BL/6 mice the hypothermic response to $NH_4Cl$ developed rapidly and it reached the biggest mean decrease of $-2.4 \pm 0.4°C$ at 30 min ($p < 0.001$ compared to sterile water) (Fig. 3b). In the vehicle-pretreated mice, the $NH_4Cl$-induced decrease in deep $T_b$ was significant ($p < 0.05$) compared to the sterile water-treated group between 20 and 70 min post-injection. Pretreatment with AMG 517 exaggerated the hypothermic effect of $NH_4Cl$ to a maximal mean $T_b$ decrease of $-3.5 \pm 0.6°C$ at 40 min ($p < 0.001$ compared to vehicle pretreatment) (Fig. 3b). The biggest difference between the mean $T_b$ of the pretreatment groups was 1.6°C at 50 min post-$NH_4Cl$ injection ($p < 0.001$). In response to $NH_4Cl$, the deep $T_b$ of the AMG 517-pretreated mice was significantly

**Fig. 2.** Deep $T_b$ responses of $Trpv1^{+/+}$ and $Trpv1^{-/-}$ mice to i.p. administration of $NH_4Cl$ (dose indicated) or sterile water. $^*p < 0.05$, $NH_4Cl$ vs. sterile water difference in $Trpv1^{+/+}$ mice; $^\#p < 0.05$, $NH_4Cl$ vs. sterile water difference in $Trpv1^{-/-}$ mice; $^\$p < 0.05$, intergenotype difference in response to $NH_4Cl$.

lower than that of the vehicle-pretreated mice between 30 and 70 min ($p < 0.05$).

We also wanted to confirm that the blockade of TRPV1 leads to the augmentation of $NH_4Cl$-induced hypothermia not only in mice, but also in rats. We administered the same dose (210 μg/kg) of AMG 517 to rats i. v. 20 min before the i.p. injection of $NH_4Cl$. As expected, AMG 517 caused prompt hyperthermia, which was present also at the time of the i. p $NH_4Cl$ injection (Fig. 4a). After the injection of $NH_4Cl$, the deep $T_b$ of vehicle-pretreated rats started to decrease immediately and reached a mean maximal decrease of $-1.2 \pm 0.2°C$ at 30 min ($p < 0.001$ compared to sterile water injection); it was significantly ($p < 0.05$) different between the two i.p. treatment groups ($NH_4Cl$ vs. sterile water) between 20 and 100 min (Fig. 4b). Importantly, in AMG 517-pretreated rats both the magnitude and the duration of the $NH_4Cl$-induced hypothermia was markedly exaggerated. The maximal mean $T_b$ fall of $-1.7 \pm 0.2°C$ developed at 40 min, and the $T_b$ of the $NH_4Cl$-treated rats remained lower than the $T_b$ of the sterile water-treated rats between 20 and 130 min ($p < 0.05$). Accordingly, the effect of $NH_4Cl$ on $T_b$ was significantly different between the i.v. pretreatment groups (AMG 517 vs. vehicle) from 40 to 70 and at 110 min post-$NH_4Cl$ injection (Fig. 4b).

Similarly to our results with the genetic blockade of TRPV1, the $NH_4Cl$-induced hypothermia developed both with and without the pharmacological blockade of the TRPV1 channel (though to a different extent), which suggests the involvement of TRPV1-independent mechanisms.

### 3.4. The hypothermic response to $NH_4Cl$ is attenuated in the absence of the TRPA1 channel in mice

Because TRPV1 and TRPA1 channels are often co-expressed [31,32,58] and crosstalk between them was also reported [59,60],

after discovering the exaggeration of $NH_4Cl$-induced hypothermia in different models of TRPV1 blockade, we studied whether the TRPA1 channel also plays a role in this thermal response. Similarly as in the case of TRPV1, in our first approach we used mice genetically lacking the channel ($Trpa1^{-/-}$) and their WT littermates ($Trpa1^{+/+}$). As expected, the injection of $NH_4Cl$ (321 mg/kg, i.p.) caused marked hypothermia in $Trpa1^{+/+}$ mice as compared to sterile water (Fig. 5). In $Trpa1^{+/+}$ mice, the biggest $NH_4Cl$-induced drop in $T_b$ ($-2.8 \pm 0.3°C$) developed 30 min after the injection ($p < 0.001$), and the $T_b$ of $NH_4Cl$-tretaed mice was significantly lower than the $T_b$ of the sterile water-treated group from 20 to 110 min post-injection ($p < 0.05$). In the $Trpa1^{-/-}$ mice, however, the hypothermic response to $NH_4Cl$ was greatly attenuated: the biggest mean $T_b$ decrease was $-2.5 \pm 0.2°C$ at 20 min, and it was significantly ($p < 0.05$) lower than that of sterile water-treated mice only between 20 and 50 min (Fig. 5). With regards to intergenotype difference, $Trpa1^{+/+}$ mice had significantly lower deep $T_b$ than $Trpa1^{-/-}$ mice between 40 and 100 min after the administration of $NH_4Cl$ with a maximal mean $T_b$ difference of $1.0°C$ at 70 min ($p = 0.008$).

It should be noted that although the $NH_4Cl$-induced hypothermia was markedly attenuated in the genetic absence of the TRPA1 channel, it was still present in the KO mice suggesting the contribution of TRPA1-independent mechanisms to the response.

### 3.5. The hypothermic response to $NH_4Cl$ is attenuated by the pharmacological blockade of the TRPA1 channel in rats

Similarly as in the case of TRPV1, it was important to exclude the potential presence of chronic compensatory mechanisms that may have developed in the absence of the TRPA1 channel in the $Trpa1^{-/-}$ mice. For that, we used pharmacological blockade of the channel with a highly potent and selective TRPA1 antagonist, A967079 [53]. However, we

**Fig. 3.** (a) Colonic temperature responses to s.c. administration of the TRPV1 antagonist AMG 517 (dose indicated) or vehicle in C57BL/6 mice. (b) Changes in deep $T_b$ of the mice in response to i.p. administration of $NH_4Cl$ (dose indicated) or sterile water after s.c. pretreatment at $-120$ min with AMG 517 (dose indicated) or vehicle. *$p < 0.05$, $NH_4Cl$ vs. sterile water difference in vehicle-pretreated mice; #$p < 0.05$, $NH_4Cl$ vs. sterile water difference in AMG 517-pretreated mice; $$p < 0.05$, AMG 517 vs. vehicle pretreatment difference in response to $NH_4Cl$.

**Fig. 4.** (a) Colonic temperature responses to i.v. administration of the TRPV1 antagonist AMG517 (dose indicated) or vehicle in rats. $^\$ p < 0.05$, AMG 517 vs. vehicle pretreatment difference. (b) Changes in deep $T_b$ of the mice in response to i.p. administration of $NH_4Cl$ (dose indicated) or sterile water after i.v. pretreatment at $-20$ min with AMG 517 (dose indicated) or vehicle. $^* p < 0.05$, $NH_4Cl$ vs. sterile water difference in vehicle-pretreated rats; $^\# p < 0.05$, $NH_4Cl$ vs. sterile water difference in AMG 517-pretreated rats; $^\$ p < 0.05$, AMG 517 vs. vehicle pretreatment difference in response to $NH_4Cl$.

could not use the mouse experimental model that was applied in case of AMG 517, because the half-life of A967079 is relatively short, ca. 49 min [53], thus the efficacy of the drug could have been questionable 2 h after its s.c. administration, when $NH_4Cl$ could be injected to mice (for details,

see Table 1). In addition, it was of crucial importance to test the contribution of the TRPA1 channel in another species than mice, because interspecies differences were demonstrated in the temperature-sensitivity of the channel as well as in its response to pharmacological

**Fig. 5.** Deep $T_b$ responses of *Trpa1*$^{+/+}$ and *Trpa1*$^{-/-}$ mice to i.p. administration of $NH_4Cl$ (dose indicated) or sterile water. *$p < 0.05$, $NH_4Cl$ vs. sterile water difference in *Trpa1*$^{+/+}$ mice; #$p < 0.05$, $NH_4Cl$ vs. sterile water difference in *Trpa1*$^{-/-}$ mice; $$p < 0.05$, intergenotype difference in response to $NH_4Cl$.

agents (for review, see [61]). Therefore, we studied the effects of i.v. administered A967079 on $NH_4Cl$-induced hypothermia in rats with a similar experimental design as in the case of AMG 517 (for details, Table 1). In accordance with previous studies [35,53], A967079 did not have any meaningful effect on the colonic temperature of the rats before the i.p injection of $NH_4Cl$ or sterile water (Fig. 6). On the contrary, when the same dose (5 mg/kg) of A967079 was infused 20 min before the i.p. injection of $NH_4Cl$, it markedly attenuated the hypothermic response. While the $T_b$ of $NH_4Cl$-treated rats was significantly ($p < 0.05$) lower at 20–150 min compared to sterile water injection after pretreatment with vehicle, in the A967079-pretreated rats the $NH_4Cl$-induced hypothermia was significant only between 10 and 90 min (Fig. 6). In accordance, a statistically significant difference was also present between the two pretreatments in the $NH_4Cl$-treated rats between 40 and 120 min with a maximal difference of 0.7°C at 50 min ($p = 0.003$).

In line with our results with the genetic blockade of TRPA1, the $NH_4Cl$-induced hypothermia was substantially attenuated, but still present after the pharmacological inhibition of the TRPA1 channel suggesting the contribution of TRPA1-independent mediators to the response.

### 3.6. I.p. administration of $NH_4Cl$ decreases the blood pH in rats and mice

Last, we wanted to know how the applied doses of $NH_4Cl$ affected the blood pH of the rats and the mice. In rats, the blood pH after i.p. administration of $NH_4Cl$ was decreased at both doses (to 7.47 and 7.24) compared to sterile water treatment (pH = 7.51), however, the difference was significant only at the higher (280 mg/kg) dose ($p < 0.001$) (Fig. 7). The blood pH was also statistically different between two doses of $NH_4Cl$ ($p < 0.001$). In mice, the i.p. injection of $NH_4Cl$ (321 mg/kg) resulted in substantial drop in blood pH in all genotypes compared to sterile water injection (Fig. 7). The fall in the blood pH of the mice reached a similar extent in all genotypes ranging between 7.23 and 7.30

after the i.p. injection of $NH_4Cl$.

## 4. Discussion

In the present study, we show that the i.p. administration of $NH_4Cl$ decreases deep $T_b$ in rats and mice. The genetic and pharmacological blockade of the TRPV1 channel exaggerates the hypothermic effect of $NH_4Cl$. On the contrary, the hypothermic response to $NH_4Cl$ is attenuated by the genetic ablation and pharmacological inhibition of the TRPA1 channel. Nevertheless, the hypothermic response occurred (to a different extent) in all of our experimental models, indicating that *per se* neither TRPA1 nor TRPV1 is essential for $NH_4Cl$-induced hypothermia. These findings suggest that TRPV1 channels are limiting regulators, whereas TRPA1 channels are potentiating signaling molecules of $NH_4Cl$-induced hypothermia.

The hypothermic effect of i.p. administered $NH_4Cl$ has been shown in mice long time ago [26]. However, it has remained unknown whether it also develops in other species and which receptors are involved in the $NH_4Cl$-induced hypothermic response. $NH_4Cl$ administration is often used to induce metabolic acidosis in rodents [12–15]. The mechanism of $NH_4Cl$-induced metabolic acidosis is consumption of bicarbonate during conversion of ammonia to urea nitrogen via the urea cycle [62]. In severe cases of the $NH_4Cl$-induced metabolic acidosis, a fall in intracellular pH also developed [19], although the intra- and extracellular pH levels did not always correlate in milder cases of acidosis (extracellular pH drop of 0.11–0.19) [14,19,63]. The different effects on pH can originate from the used species (rat vs. mouse), experimental model (*in vitro* vs. *in vivo*), and acid loading protocol (acute vs. chronic). In our experiments, $NH_4Cl$ decreased the blood pH to ~7.25 in rats and mice, which was markedly lower than in the control animals, however, in this *in vivo* experimental design the intracellular pH could not be measured. The decreased blood pH could potentially serve as a direct mechanism for the development of the hypothermia, for example, through the

**Fig. 6.** Changes in deep $T_b$ of rats in response to i.p. administration of $NH_4Cl$ (dose indicated) or sterile water after i.v. pretreatment at $-20$ min with A967079 (dose indicated) or vehicle. *$p < 0.05$, $NH_4Cl$ vs. sterile water difference in vehicle-pretreated rats; [#]$p < 0.05$, $NH_4Cl$ vs. sterile water difference in A967079-pretreated rats; [\$]$p < 0.05$, A967079 vs. vehicle pretreatment difference in response to $NH_4Cl$.

stimulation of the TRPV1-mediated acido-antithermogenic and acido-antivasoconstrictor reflexes that originate from trunk muscles and limit the increase in deep $T_b$ during physical exercise (for review, see [64]). However, since the $NH_4Cl$-induced hypothermia was still detectable after genetic and pharmacological blockade of both the TRPV1 and the TRPA1 channels, it cannot be excluded that the hypothermic response to the decreased blood pH involved TRPV1- and TRPA1-independent mechanisms. Several acid-sensitive ion channels, other than TRPV1 and TRPA1, are expressed on primary sensory neurons, which are involved in a number of physiological and pathophysiological reactions to acidosis (for review, see [65]). Whether any of these acid sensors contribute to the development of $NH_4Cl$-induced hypothermia remains subject for future studies.

It is also possible, however, that the hypothermic effect of $NH_4Cl$ was triggered by mechanisms that are not related solely to the decreased blood pH, because the lower dose of $NH_4Cl$ caused hypothermia in rats, but it did not influence the blood pH significantly, which argues against a direct acid-induced effect. Unfortunately, the pH of the mice was not reported in the study by Gordon [26]. It should be also noted that although the acidosis clearly developed in the rats (at the higher dose) as well as in the mice of all genotypes in our experiments, the extent of decrease in blood pH was not very severe. The drop in blood pH was probably not sufficient to reach the proton activation threshold of the TRPV1 channel, because the half-maximal response of the rat TRPV1 channel to protons occurs at a pH of ~5.78 *in vitro* [66]. However, the elevated proton concentrations could potentiate responses evoked by other agonists, resulting in increased activity of the channel [43].

With regards to the TRPA1 channel, the pH activation is complex. It

was demonstrated that weak acids activate rodent TRPA1, but this was due to intracellular acidosis and direct proton activation of the channel from the cytosolic side [44,67]. Although protons can rapidly permeate through the membrane to induce an intracellular acidosis when the extracellular $H^+$ concentration is increased [68], rodent TRPA1 failed to respond to extracellular acidosis, and protons even inhibited the channel in a later study [41]. Nevertheless, exclusively in humans, TRPA1 is an important (nociceptive) proton sensor [41], which complicates the translation of results from animal experiments to humans. Moreover, in case of $NH_4Cl$ administration the intracellular pH level does not always correlate with the extracellular pH and an increased pH within the cell was also described instead of acidosis (for review, see [69]). Ammonia and intracellular alkalization were shown to activate both the TRPV1 and the TRPA1 channels [39,40]. Hence, the rapid inward diffusion of gaseous ammonia and the resulting intracellular alkalization could have also contributed to our results. It is known that systemic (i.v.) administration of $NH_4Cl$ leads to formation of ammonia, which can readily cross the blood-brain barrier [70]. This raises the possibility that activation of TRPA1 channels in thermoregulatory neurons in the brain triggered the hypothermic response, as shown earlier in case of another gasotransmitter, hydrogen sulfide [37], but the investigation of the exact molecular interaction between $NH_4Cl$ and TRP channels, as well as finding the site of the thermoregulatory action of $NH_4Cl$ were beyond the scope of the present study and remain subjects for future research.

The exaggeration of $NH_4Cl$-induced hypothermia by the blockade of TRPV1 channels was an unexpected novel finding. However, it should be mentioned that it was shown earlier that inhibition of TRPV1 channels potentiated the neuronal responses to $NH_4^+$ [71]. We can only speculate

**Fig. 7.** Blood pH of rats and mice of different genotypes ($Trpv1^{+/+}$, $Trpv1^{-/-}$, $Trpa1^{+/+}$, and $Trpa1^{-/-}$) one hour after the i.p. administration of $NH_4Cl$ (doses indicated) or sterile water. Numbers in parentheses indicate the number of animals in the corresponding groups. *$p < 0.05$, $NH_4Cl$ vs. sterile water difference within the same genotype.

that $NH_4^+$ ions could inhibit TRPV1 channels located in the abdominal wall, which were shown to tonically suppress skin vasoconstriction and thermogenesis [72]. When these TRPV1 channels are blocked with genetic or pharmacological tools the hypothermia-counteracting effect is absent, hence the thermal response to $NH_4Cl$ becomes augmented. In support of this assumption, it was found that different quaternary ammonium ions blocked the TRPV1 channel from the intracellular surface with the bigger molecules becoming slower blockers [73]. As an alternative theory, we showed earlier that acidosis-induced vasodilation of rat and mouse tail arteries are limited by non-neuronal TRPV1 channels in the vascular wall [74], thus it can be assumed that the blockade of these vasodilation-limiting TRPV1 channels could result in higher heat loss and exaggerated hypothermic response to $NH_4Cl$. It has to be noted, however, that the abovementioned action mechanisms of $NH_4Cl$ on TRPV1 channels remain hypothetical until directly tested in future experiments. As another limitation of our study, it should be mentioned that we used only male animals in our experiments, hence sex differences in the thermal response to $NH_4Cl$ could not be investigated. Nevertheless, our results can also serve as an encouraging basis for designing future studies, which are required to determine the potential presence of sex differences in the development of $NH_4Cl$-induced hypothermia and its relation to TRPA1 and TRPV1 channels.

In conclusion, TRPA1 channels contribute to the development of $NH_4Cl$-induced hypothermia in mice and rats, whereas TRPV1 channels play a limiting function, although in itself neither of them is essential for the occurrence of the response. It can be hypothesized that activation of TRPA1 channels in thermoregulation-related brain nuclei are responsible for the induction of $NH_4Cl$-induced hypothermia, while TRPV1 channels on the periphery, possibly in abdominal muscles or vascular smooth muscle exert a limiting effect on the response. Our findings highlight the importance of the nonthermal activation of TRPV1 and TRPA1 channels in thermoregulation. Since $NH_4Cl$ is still used in clinical practice (*e.g.*, as a diuretic, expectorant, and perhaps COVID-19 treatment), the present results warrant for regular $T_b$ control and careful

consideration of the treatment, especially in patients with TRPA1 and TRPV1 channel function disorders.

**CRediT authorship contribution statement**

**Zoltan Rumbus:** Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Kata Fekete:** Writing – review & editing, Investigation, Formal analysis, Data curation. **Leonardo Kelava:** Writing – review & editing, Methodology, Investigation, Formal analysis. **Bibor Gardos:** Writing – review & editing, Investigation, Formal analysis. **Krisztian Klonfar:** Formal analysis, Investigation, Writing – review & editing. **Patrik Keringer:** Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing. **Erika Pinter:** Conceptualization, Formal analysis, Funding acquisition, Project administration, Resources, Writing – review & editing. **Eszter Pakai:** Writing – review & editing, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation. **Andras Garami:** Investigation, Funding acquisition, Formal analysis, Conceptualization, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing.

**Declaration of competing interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Data availability**

All data generated or analyzed during this study are included in this published article.

**References**

[1] A.L. Sellers, E.C. Kast, The treatment of alkalosis with intravenous ammonium chloride solution, Perm. Found. Med. Bull. 3 (1945) 171–174.

[2] W.J. Martin, G.R. Matzke, Treating severe metabolic alkalosis, Clin. Pharm. 1 (1982) 42–48.

[3] S.A. Doxiadis, M.K. Goldfinch, K.S. Holt, Alkalosis in infants; treatment by intravenous infusion of ammonium chloride, Lancet 265 (1953) 801–804.

[4] K.M. Wong, W.L. Chak, C.Y. Cheung, Y.H. Chan, K.S. Choi, K.F. Chau, et al., Hypokalemic metabolic acidosis attributed to cough mixture abuse, Am. J. Kidney Dis. 38 (2001) 390–394.

[5] S. MacRury, R. Neilson, K. Goodwin, Benylin dependence, metabolic acidosis and hyperglycaemia, Postgrad. Med. J. 63 (1987) 587–588.

[6] F.J. Wood, Ammonium chloride acidosis, Clin. Sci. 14 (1955) 81–89.

[7] A.S. Relman, P.F. Shelburne, A. Talman, Profound acidosis resulting from excessive ammonium chloride in previously healthy subjects. A study of two cases, N. Engl. J. Med. 264 (1961) 848–852.

[8] M.H. Sleisenger, A.S. Freedberg, Ammonium chloride acidosis; a report of six cases, Circulation 3 (1951) 837–845.

[9] Z. Siami, S. Aghajanian, S. Mansouri, Z. Mokhames, R. Pakzad, K. Kabir, et al., Effect of ammonium chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: a randomized clinical trial, Int. J. Infect. Dis. 108 (2021) 306–308.

[10] N. Baker, A.J. Williams, A. Tropsha, S. Ekins, Repurposing quaternary ammonium compounds as potential treatments for COVID-19, Pharm. Res. 37 (2020) 104.

[11] A.C. Celotto, L.G. Ferreira, V.K. Capellini, A.A. Albuquerque, A.J. Rodrigues, P. R. Evora, Acute but not chronic metabolic acidosis potentiates the acetylcholine-induced reduction in blood pressure: an endothelium-dependent effect, Braz. J. Med. Biol. Res. 49 (2016) e5007.

[12] J. Galicek, F. Seow, J.M. Lingard, The effect of chronic acid/base disturbances on renal amino acid clearances in the rat, Aust. J. Exp. Biol. Med. Sci. 59 (1981) 383–391.

[13] M. Nowik, N.B. Kampik, M. Mihailova, D. Eladari, C.A. Wagner, Induction of metabolic acidosis with ammonium chloride (NH4Cl) in mice and rats—species differences and technical considerations, Cell. Physiol. Biochem. 26 (2010) 1059–1072.

[14] K.F. Rothe, F. Schimek, New aspects of acid-base balance influences of NH4Cl on intra- and extracellular acid-base equilibrium studies in the rat, J. Med. 15 (1984) 135–148.

[15] Z. Rumbus, E. Toth, L. Poto, A. Vincze, G. Veres, L. Czako, et al., Bidirectional relationship between reduced blood pH and acute pancreatitis: a translational study of their noxious combination, Front. Physiol. 9 (2018) 1360.

[16] J. Edge, T. Mundel, H. Pilegaard, E. Hawke, M. Leikis, N. Lopez-Villalobos, et al., Ammonium chloride ingestion attenuates exercise-induced mRNA levels in human muscle, PloS One 10 (2015) e0141317.

[17] G.R. Kleger, M. Turgay, R. Imoberdorf, M.A. McNurlan, P.J. Garlick, P.E. Ballmer, Acute metabolic acidosis decreases muscle protein synthesis but not albumin synthesis in humans, Am. J. Kidney Dis. 38 (2001) 1199–1207.

[18] D. Reaich, S.M. Channon, C.M. Scrimgeour, T.H. Goodship, Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans, Am. J. Physiol. 263 (1992) E735–E739.

[19] A. Tizianello, G. De Ferrari, G. Gurreri, N. Acquarone, Effects of metabolic alkalosis, metabolic acidosis and uraemia on whole-body intracellular pH in man, Clin. Sci. Mol. Med. 52 (1977) 125–135.

[20] A. Stauber, T. Radanovic, G. Stange, H. Murer, C.A. Wagner, J. Biber, Regulation of intestinal phosphate transport. II. Metabolic acidosis stimulates Na(+)-dependent phosphate absorption and expression of the Na(+)-P(i) cotransporter NaPi-IIb in small intestine, Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G501–G506.

[21] R. Lane, L. Adams, Metabolic acidosis and breathlessness during exercise and hypercapnia in man, J. Physiol. 461 (1993) 47–61.

[22] L.M. Bento, M.M. Fagian, A.E. Vercesi, J.A. Gontijo, Effects of NH4Cl-induced systemic metabolic acidosis on kidney mitochondrial coupling and calcium transport in rats, Nephrol. Dial. Transplant. 22 (2007) 2817–2823.

[23] A. Jara, A.J. Felsenfeld, J. Bover, C.R. Kleeman, Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease, Kidney Int. 58 (2000) 1023–1032.

[24] R. Daher, N. Ducrot, T. Lefebvre, S. Zineeddine, J. Ausseil, H. Puy, et al., Crosstalk between acidosis and iron metabolism: data from in vivo studies, Metabolites 12 (2022) 89.

[25] F.L. Coe, J.J. Firpo Jr., D.L. Hollandsworth, L. Segil, J.M. Canterbury, E. Reiss, Effect of acute and chronic metabolic acidosis on serum immunoreactive parathyroid hormone in man, Kidney Int. 8 (1975) 263–273.

[26] C.J. Gordon, Thermoregulatory responses in mice following acute administration of principal nitrogenous excretory substances, Pharmacol. Biochem. Behav. 31 (1988) 699–703.

[27] A.A. Romanovsky, M.C. Almeida, A. Garami, A.A. Steiner, M.H. Norman, S. F. Morrison, et al., The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not, Pharmacol. Rev. 61 (2009) 228–261.

[28] H. Wang, J. Siemens, TRP ion channels in thermosensation, thermoregulation and metabolism, Temperature (Austin) 2 (2015) 178–187.

[29] D. Bamps, J. Vriens, J. de Hoon, T. Voets, TRP channel cooperation for nociception: therapeutic opportunities, Annu. Rev. Pharmacol. Toxicol. 61 (2021) 655–677.

[30] P. Holzer, Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system, Pharmacol. Ther. 131 (2011) 142–170.

[31] D. Huang, S. Li, A. Dhaka, G.M. Story, Y.Q. Cao, Expression of the transient receptor potential channels TRPV1, TRPA1 and TRPM8 in mouse trigeminal primary afferent neurons innervating the dura, Mol. Pain 8 (2012) 66.

[32] K. Kobayashi, T. Fukuoka, K. Obata, H. Yamanaka, Y. Dai, A. Tokunaga, et al., Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors, J. Comp. Neurol. 493 (2005) 596–606.

[33] D. Julius, TRP channels and pain, Annu. Rev. Cell Dev. Biol. 29 (2013) 355–384.

[34] M. Kashio, M. Tominaga, TRP channels in thermosensation, Curr. Opin. Neurobiol. 75 (2022) 102591.

[35] C. de Oliveira, A. Garami, S.G. Lehto, E. Pakai, V. Tekus, K. Pohoczky, et al., Transient receptor potential ankyrin-1 is not a cold sensor for autonomic thermoregulation in rodents, J. Neurosci. 34 (2014) 4445–4452.

[36] A.A. Steiner, V.F. Turek, M.C. Almeida, J.J. Burmeister, D.L. Oliveira, J.L. Roberts, et al., Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors, J. Neurosci. 27 (2007) 7459–7468.

[37] E. Olah, Z. Rumbus, V. Kormos, V. Tekus, E. Pakai, H.V. Wilson, et al., The hypothermic effect of hydrogen sulfide is mediated by the transient receptor potential ankyrin-1 channel in mice, Pharmaceuticals (Basel) 14 (2021) 992.

[38] A. Garami, E. Pakai, H.A. McDonald, R.M. Reilly, A. Gomtsyan, J.J. Corrigan, et al., TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development, Acta Physiol. (Oxf.) 223 (2018) e13038.

[39] A. Dhaka, V. Uzzell, A.E. Dubin, J. Mathur, M. Petrus, M. Bandell, et al., TRPV1 is activated by both acidic and basic pH, J. Neurosci. 29 (2009) 153–158.

[40] F. Fujita, K. Uchida, T. Moriyama, A. Shima, K. Shibasaki, H. Inada, et al., Intracellular alkalization causes pain sensation through activation of TRPA1 in mice, J. Clin. Invest. 118 (2008) 4049–4057.

[41] J. de la Roche, M.J. Eberhardt, A.B. Klinger, N. Stanslowsky, F. Wegner, W. Koppert, et al., The molecular basis for species-specific activation of human TRPA1 protein by protons involves poorly conserved residues within transmembrane domains 5 and 6, J. Biol. Chem. 288 (2013) 20280–20292.

[42] S.E. Jordt, M. Tominaga, D. Julius, Acid potentiation of the capsaicin receptor determined by a key extracellular site, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8134–8139.

[43] M. Tominaga, M.J. Caterina, A.B. Malmberg, T.A. Rosen, H. Gilbert, K. Skinner, et al., The cloned capsaicin receptor integrates multiple pain-producing stimuli, Neuron 21 (1998) 531–543.

[44] Y.Y. Wang, R.B. Chang, S.D. Allgood, W.L. Silver, E.R. Liman, A TRPA1-dependent mechanism for the pungent sensation of weak acids, J. Gen. Physiol. 137 (2011) 493–505.

[45] K. Bolcskei, Z. Helyes, A. Szabo, K. Sandor, K. Elekes, J. Nemeth, et al., Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice, Pain 117 (2005) 368–376.

[46] A. Garami, M. Ibrahim, K. Gilbraith, R. Khanna, E. Pakai, A. Miko, et al., Transient receptor potential vanilloid 1 antagonists prevent anesthesia-induced hypothermia and decrease postincisional opioid dose requirements in rodents, Anesthesiology 127 (2017) 813–823.

[47] A. Garami, E. Pakai, D.L. Oliveira, A.A. Steiner, S.P. Wanner, M.C. Almeida, et al., Thermoregulatory phenotype of the Trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis, J. Neurosci. 31 (2011) 1721–1733.

[48] A.A. Romanovsky, A.I. Ivanov, Y.P. Shimansky, Selected contribution: ambient temperature for experiments in rats: a new method for determining the zone of thermal neutrality, J. Appl. Physiol. 2002 (92) (1985) 2667–2679.

[49] P. Keringer, N. Furedi, B. Gaszner, A. Miko, E. Pakai, K. Fekete, et al., The hyperthermic effect of central cholecystokinin is mediated by the cyclooxygenase-2 pathway, Am. J. Physiol. Endocrinol. Metab. 322 (2022) E10–E23.

[50] A.A. Romanovsky, M.C. Almeida, D.M. Aronoff, A.I. Ivanov, J.P. Konsman, A. Steiner, et al., Fever and hypothermia in systemic inflammation: recent discoveries and revisions, Front. Biosci. 10 (2005) 2193–2216.

[51] E. Pakai, V. Tekus, C. Zsiboras, Z. Rumbus, E. Olah, P. Keringer, et al., The neurokinin-1 receptor contributes to the early phase of lipopolysaccharide-induced fever via stimulation of peripheral cyclooxygenase-2 protein expression in mice, Front. Immunol. 9 (2018) 166.

[52] N.R. Gavva, J.J. Treanor, A. Garami, L. Fang, S. Surapaneni, A. Akrami, et al., Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans, Pain 136 (2008) 202–210.

[53] J. Chen, S.K. Joshi, S. DiDomenico, R.J. Perner, J.P. Mikusa, D.M. Gauvin, et al., Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation, Pain 152 (2011) 1165–1172.

[54] A. Garami, Y.P. Shimansky, E. Pakai, D.L. Oliveira, N.R. Gavva, A.A. Romanovsky, Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia, J. Neurosci. 30 (2010) 1435–1440.

[55] S. McGaraughty, K.L. Chu, R.J. Perner, S. Didomenico, M.E. Kort, P.R. Kym, TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats, Mol. Pain 6 (2010) 14.

[56] S.P. Wanner, A. Garami, E. Pakai, D.L. Oliveira, N.R. Gavva, C.C. Coimbra, et al., Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory, Cell Cycle 11 (2012) 343–349.

[57] E.M. Doherty, C. Fotsch, A.W. Bannon, Y. Bo, N. Chen, C. Dominguez, et al., Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyri-midines leading to the selection of a clinical candidate, J. Med. Chem. 50 (2007) 3515–3527.

[58] E.S. Fernandes, M.A. Fernandes, J.E. Keeble, The functions of TRPA1 and TRPV1: moving away from sensory nerves, Br. J. Pharmacol. 166 (2012) 510–521.

[59] M.J. Patil, N.A. Jeske, A.N. Akopian, Transient receptor potential V1 regulates activation and modulation of transient receptor potential A1 by Ca2+, Neuroscience 171 (2010) 1109–1119.

[60] A. Staruschenko, N.A. Jeske, A.N. Akopian, Contribution of TRPV1-TRPA1 interaction to the single channel properties of the TRPA1 channel, J. Biol. Chem. 285 (2010) 15167–15177.

[61] J. Chen, D.H. Hackos, TRPA1 as a drug target—promise and challenges, Naunyn Schmiedebergs Arch. Pharmacol. 388 (2015) 451–463.

[62] S. Matsumoto, J. Haberle, J. Kido, H. Mitsubuchi, F. Endo, K. Nakamura, Urea cycle disorders-update, J. Hum. Genet. 64 (2019) 833–847.

[63] J.I. Shapiro, M. Whalen, R. Kucera, N. Kindig, G. Filley, L. Chan, Brain pH responses to sodium bicarbonate and Carbicarb during systemic acidosis, Am. J. Physiol. 256 (1989) H1316–H1321.

[64] A. Garami, Y.P. Shimansky, Z. Rumbus, R.C.L. Vizin, N. Farkas, J. Hegyi, et al., Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis, Pharmacol. Ther. 208 (2020) 107474.

[65] P. Holzer, Acid-sensitive ion channels and receptors, Handb. Exp. Pharmacol. (2009) 283–332.

[66] P. McIntyre, L.M. McLatchie, A. Chambers, E. Phillips, M. Clarke, J. Savidge, et al., Pharmacological differences between the human and rat vanilloid receptor 1 (VR1), Br. J. Pharmacol. 132 (2001) 1084–1094.

[67] Y.Y. Wang, R.B. Chang, E.R. Liman, TRPA1 is a component of the nociceptive response to CO2, J. Neurosci. 30 (2010) 12958–12963.

[68] D.A. Andersson, H.W. Chase, S. Bevan, TRPM8 activation by menthol, icilin, and cold is differentially modulated by intracellular pH, J. Neurosci. 24 (2004) 5364–5369.

[69] A. Roos, W.F. Boron, Intracellular pH, Physiol. Rev. 61 (1981) 296–434.

[70] S.I. Rapoport, H.K. Thompson, Effect of intravenous NH4Cl and NaHCO3 on the pH of the brain surface, as related to respiration and the blood-brain barrier, Exp. Neurol. 42 (1974) 320–333.

[71] S. Balakrishnan, S.L. Mironov, Instant activation of TRP channels by NH(4) (+) promotes neuronal bursting and glutamate spikes in CA1 neurons, Curr Res Physiol 3 (2020) 20–29.

[72] A. Garami, A.A. Steiner, E. Pakai, S.P. Wanner, M.C. Almeida, P. Keringer, et al., The neural pathway of the hyperthermic response to antagonists of the transient receptor potential vanilloid-1 channel, Temperature (Austin) 10 (2023) 136–154.

[73] A. Jara-Oseguera, I. Llorente, T. Rosenbaum, L.D. Islas, Properties of the inner pore region of TRPV1 channels revealed by block with quaternary ammoniums, J. Gen. Physiol. 132 (2008) 547–562.

[74] I. Ivic, M. Solymar, E. Pakai, Z. Rumbus, E. Pinter, A. Koller, et al., Transient receptor potential vanilloid-1 channels contribute to the regulation of acid- and base-induced vasomotor responses, J. Vasc. Res. 53 (2016) 279–290.

Taylor & Francis
Taylor & Francis Group

Check for updates

# Fever, hypothermia, and mortality in sepsis[*]

## Comment on: Rumbus Z, Matics R, Hegyi P, Zsiboras C, Szabo I, Illes A, Petervari E, Balasko M, Marta K, Miko A, Parniczky A, Tenk J, Rostas I, Solymar M, Garami A. Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials. PLoS One. 2017;12(1):e0170152. DOI: 10.1371/journal.pone.0170152

Sepsis presents a major challenge for critical care and the society worldwide. Despite the ample research interest in understanding the underlying mechanisms, mortality rate remains considerably high in sepsis even nowadays. In order to assess the prognosis and the severity of the disease, thus to initiate the most optimal treatment, it is necessary to identify vital signs and biomarkers, which can predict the outcome. As a manifestation of systemic inflammation, sepsis is often accompanied by changes in body temperature ($T_b$): fever or hypothermia. Our understanding of the thermoregulatory manifestations of systemic inflammation has advanced in the past decades, but it has remained unanswered whether fever and hypothermia can serve as predictors of the outcome in sepsis. In the highlighted study, we investigated the association between the alterations of $T_b$ and the rate of mortality in septic patients [1].

By conducting a meta-analysis of clinical trials, we studied the association between changes in $T_b$ and mortality in a big number (> 10,000) of septic patients [1]. We found that in septic patients with fever the estimated mortality rate was ~ 22%, which was higher (~ 31%) in normothermic patients, while it was the highest (~ 47%) in hypothermic patients [1]. When we compared the $T_b$ data of all septic patients divided into mortality quartiles, we found that $T_b$ was by 1°C higher in patients with the lowest (< 25%) mortality than in patients with the highest rate of death (> 75%). The results of our meta-analyses clearly demonstrate a negative correlation between $T_b$ and mortality in sepsis: fever is associated with decreased, whereas hypothermia with increased rate of death. However, this association does not automatically imply that fever is always beneficial and hypothermia is harmful in sepsis (Table 1). The causative relationship between the thermoregulatory manifestations and the outcome in systemic inflammation could not be assessed in our study and it deserves discussion.

The beneficial versus harmful effect of fever has been debated since the time of Hippocrates. Despite the advancements in our understanding of the molecular, cellular, and physiological mechanisms of the fever response, the question of whether it is a friend or foe is asked even in recent days. The controversies between the findings on beneficial versus harmful effects of fever can be mitigated by focusing on the question of when instead of whether fever is a friend or a foe as suggested by Romanovsky and Szekely [2]. It was proposed that the thermoregulatory manifestations of systemic inflammation can be regarded as adaptations in constellation of the sickness syndrome. Two sickness patterns can be distinguished as part of the syndrome, which represent sequential stages of the body's response to systemic inflammation and constitute two different adaptive strategies to infection [2]. The two distinguished patterns of the syndrome, the early and the late phase syndrome, correspond to mild and severe forms of systemic inflammation. Romanovsky and Szekely [2] proposed that fever, as part of the early phase syndrome, should be regarded as an adaptive strategy of the organism, which occurs at the onset of the infection and constitutes a response of the healthy organism to the forthcoming disease. In this regard, the biological purpose of the early phase syndrome is to engage active defense mechanisms (fever), notify the host about the pathogenic insult (hyperalgesia), and secure the means (vigilance, hyperactivity, hypertension, and anorexia), which can empower the active search for optimal environment (warmth seeking, adequate water supply, protection from external stressors) for fighting the disease. This type of adaptation to

---

*This article was commissioned by Samuel P. Wanner, Discovery Editor.

**Table 1.** Disease coping strategies in different premorbid conditions, thermoregulatory manifestations, and potential outcomes in different severities of sepsis.

| Infection severity | Premorbid condition | Coping strategy | Deep body temperature | Predicted outcome | Effect on mortality |
|---|---|---|---|---|---|
| Mild | Healthy | Disease fighting | Fever | Pathogen clearance | Not applicable |
| Moderate | Healthy | Disease fighting | Fever | Pathogen clearance | ↓ |
| | | | Extreme fever | Organ failure, energy depletion | ↑ |
| | Comorbidities* or exhaustion† | Disease fighting | Fever | Organ failure, energy depletion | ↑ |
| | | Energy saving | Hypothermia | Disease tolerance†† | ↓ |
| Severe (e.g., septic shock) | Healthy | Energy saving | Hypothermia | Disease tolerance | ↓ |
| | Comorbidities or exhaustion | | Extreme hypothermia | Organ failure | ↑ |

Effects on mortality are marked as: ↓, decrease; ↑, increase. *E.g., pre-existing cardiovascular, pulmonary, neurological disease. †E.g., because of old age, starvation, prolonged systemic inflammation. ††The host's ability to tolerate the presence of the pathogen; for details, see Garami et al. [3].

infections develops at a high energy cost. A short-lasting, mild infectious challenge (common cold or influenza) is often characterized by the early phase syndrome only. In a previously fit and healthy patient, fever will be likely beneficial (Table 1). On the contrary, the beneficial value of fever can be compromised by an already existing or forthcoming energy deficiency, for example, in moderate-to-severe infections of patients with different (e.g., nutritional, cardiovascular, and respiratory) comorbidities, who lack adequate protection from external stressors. The energy resources are depleted more rapidly in extremely high fevers, resulting in the worsening of the outcome of the disease. In such situations, the beneficial value of fever diminishes and its harmful consequences emerge (Table 1). It has to be noted that because of data unavailability, extreme fever responses ($T_b$ above 39.9°C), which could have detrimental consequences, were not included in the meta-analysis in focus [1].

In contrast to fever, the biological significance of hypothermia has been almost completely ignored in systemic inflammation. The possible reasons for this inattention include the lower incidence rate of hypothermia compared to fever, improper $T_b$-measuring techniques that result in cases that go undetected, and the low priority of decreased $T_b$ in critically ill patients who are often in extremely poor conditions when presented to the physician. From a physiological perspective, hypothermia can be regarded as a part of the late phase syndrome, which represents the systemic response to infection when the disease has already progressed, thus damaged and weakened the organism [2]. The pain has lost its warning function, resulting in hypoalgesia. High energy-consuming responses are not affordable; consequently, somnolence, motor depression, and normo- or hypotension are characteristic. In severe clinical cases (e.g., septic shock), the late phase syndrome becomes predominant and it can completely replace the early phase syndrome. As a general rule, hypothermia is a beneficial response when the damage is severe enough to cause or facilitate energy depletion (Table 1). In severe forms of inflammation, the energy resources can be reduced by the overwhelming inflammatory response, involving pathological energy expenditure and increased oxygen demand of damaged tissues. At the same time, the energy supply is commonly decreased or completely absent due to the compromised ability to get food and the development of adaptive anorexia. Because of the dependence of biochemical rates on temperature (van't Hoff's rule), tissue metabolic requirements decrease by more than 10% for every 1°C drop in $T_b$. Direct experiments have shown that spontaneous hypothermia is more advantageous than fever in rats with severe forms of aseptic (lipopolysaccharide-induced) or septic (Escherichia coli-induced) systemic inflammation [reviewed in ref. 3]. In these studies, the development of hypothermia (vs fever) exerted a pronounced influence on survival rates of the rats with systemic inflammation: the survival rate of hypothermic rats was markedly higher than that of the febrile rats in both aseptic and

septic models of severe systemic inflammation. Further advantages of hypothermia over fever included the suppression of endotoxemia and reduced lung infiltration by neutrophil leukocytes. The more severe the pathogenic challenge, premorbid pathology, and actual conditions, the more likely that hypothermia and its energy-saving actions will be advantageous for the host (Table 1). If the patient is sleepy, depressed, hypoactive, hypotensive, and hypoalgesia occurs, the energy-saving strategy of hypothermia is likely to be protective [2]. It should be also noted that in severe cases of sepsis, particularly in patients with pre-existing energy exhaustion or comorbidities, $T_b$ may fall to critical levels and the adverse consequences of the extreme hypothermia (e.g., cardiac arrhythmias, neurological dysfunctions) can overcome its adaptive value (Table 1).

Despite the growing body of evidence for the adaptive value of hypothermia in systemic inflammation, hypothermia is generally perceived in clinical settings as something dysregulated and accidental, and prompt rewarming is regularly considered for those septic patients who display a fall in $T_b$. The first effort to reconcile experimental and clinical evidence in septic hypothermia was made only recently; it was revealed that hypothermia is predominantly transient, self-limiting, and nonterminal response, which naturally occurs in human sepsis [4]. Consequently, it can be questioned whether rewarming is at all necessary in the subset of septic patients who naturally develop hypothermia. To answer the question, well-designed, interventional clinical studies are warranted, in which spontaneous hypothermia is allowed or prevented within the hypothermic subset of septic patients.

As a perspective approach, the utilization of controlled, targeted modulation of $T_b$ by pharmacological tools could also be studied in systemic inflammation; new hypo- and hyperthermia-inducing drugs may be used one day, like the antagonists of the transient receptor potential vanilloid-1 channel [5]. Such and similar studies with targeted modulation of $T_b$ in systemic inflammation could unequivocally determine the cause-effect relationship between the thermoregulatory manifestations and the outcome in sepsis, thus further advance our understanding of the association between $T_b$ and mortality observed in the highlighted article [1].

## References

[1] Rumbus Z, Matics R, Hegyi P, et al. Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials. PLoS One. 2017;12(1):e0170152.

[2] Romanovsky AA, Szekely M. Fever and hypothermia: two adaptive thermoregulatory responses to systemic inflammation. Med Hypothesis. 1998;50(3):219–226.

[3] Garami A, Steiner AA, Romanovsky AA. Fever and hypothermia in systemic inflammation. In: Thermoregulation, Part II: from basic neuroscience to clinical neurology. Romanovsky AA, editor. Handb Clin Neurol. Aminoff MJ, Boller F, Swaab DF, Series editors. Oxford, UK: Elsevier, 2018:157: in press.

[4] Fonseca MT, Rodrigues AC, Cezar LC, et al. Spontaneous hypothermia in human sepsis is a transient, self-limiting, and nonterminal response. J Appl Physiol. 2016;120(12):1394–1401.

[5] Garami A, Pakai E, McDonald HA, et al. TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited, and implications for drug development. Acta Physiol (Oxf). 2018;223(3):e13038.

Zoltan Rumbus
*Institute for Translational Medicine, Medical School, University of Pecs, Pecs, Hungary*

Andras Garami
*Institute for Translational Medicine, Medical School, University of Pecs, Pecs, Hungary*
✉ andras.garami@aok.pte.hu  http://orcid.org/0000-0003-2493-0571